Synthesis and structure-activity relationships of NG-acylated arylalkylguanidines and related compounds as histamine receptor ligands: searching for selective H4R agonists by Igel, Patrick
Synthesis and structure-activity relationships 
of NG-acylated arylalkylguanidines and related 
compounds as histamine receptor ligands: 
Searching for selective H4R agonists 
 
 
 
 
 
Dissertation 
zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) der 
Naturwissenschaftlichen Fakultät IV – Chemie und Pharmazie – 
der Universität Regensburg 
 
 
 
 
 
 
 
 
 
vorgelegt von 
Patrick Igel 
aus Plattling 
2008 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Die vorliegende Arbeit entstand in der Zeit von Januar 2005 bis November 2008 unter der 
Anleitung von Herrn Prof. Dr. Armin Buschauer am Institut für Pharmazie der 
Naturwissenschaftlichen Fakultät IV – Chemie und Pharmazie – der Universität Regensburg. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Das Promotionsgesuch wurde eingereicht im November 2008. 
 
Tag der mündlichen Prüfung: 15. Dezember 2008 
 
Prüfungsausschuss: Prof. Dr. J. Wegener  (Vorsitzender) 
   Prof. Dr. A. Buschauer (Erstgutachter) 
   Prof. Dr. S. Elz  (Zweitgutachter) 
   Prof. Dr. A. Göpferich  (Drittprüfer) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Everything should be made as simple as possible, but not simpler. 
Albert Einstein (1879 – 1955) 
Danksagungen 
 
An dieser Stelle möchte ich mich bedanken bei: 
 
Herrn Prof. Dr. Armin Buschauer für die interessante und herausfordernde Aufgabenstellung, 
seine wissenschaftlichen Anregungen und intensive Förderungen sowie seine konstruktive 
Kritik bei der Durchsicht der Arbeit, 
 
Herrn Prof. Dr. Sigurd Elz für die Ratschläge und wissenschaftlichen Diskussionen bei 
chemischen und pharmakologischen Fragestellungen, die Bereitstellung von 3-(1-Trityl-1H-
imidazol-4-yl)propan-1-ol, die Durchführung von organpharmakologischen Untersuchungen 
sowie für die Erstellung des Zweitgutachtens, 
 
Herrn Prof. Dr. Roland Seifert für die Möglichkeit zur Durchführung der GTPase Assays und 
Radioligand-Bindungsstudien an seinem Lehrstuhl, für die fachliche Anleitung und die 
wissenschaftlichen Anregungen und Diskussionen sowie für die Durchsicht der Kapitel 6 
und 7, 
 
Herrn Prof. Dr. Günther Bernhardt für seine stete Hilfsbereitschaft und fachliche 
Unterstützung insbesondere bei der Charakterisierung des neuen Radioliganden sowie die 
konstruktive Kritik beim Verfassen des Kapitels 7,  
 
Herrn David Schnell und Herrn Dr. Erich Schneider für die Entwicklung und Bereitstellung 
der H3R und H4R Testsysteme sowie für deren Hilfsbereitschaft bei allen pharmakologischen 
Fragestellungen und für die vielen anregenden wissenschaftlichen und nicht-
wissenschaftlichen Diskussionen, 
 
Herrn Max Keller für die vielen interessanten und anregenden Diskussionen sowie für die 
geopferte Zeit für die Einweisung in die HPLC-Anlagen und seine wertvolle Unterstützung bei 
der Generierung und Aufreinigung des Radioliganden, 
 
Herrn Dr. Marc Kunze und Frau Dr. Birgit Striegl für den ausgiebigen Austausch über 
Synthesemethoden von Histamin Rezeptor Liganden sowie die Bereitstellung von 2-Methyl-
1-trityl-1H-imidazol (Dr. Birgit Striegl), 
 
Frau Kerstin Fisch, Frau Karin Schadendorf und Frau Astrid Seefeld für die tatkräftige 
Unterstützung bei der Durchführung der GTPase Assays, 
 
Frau Gertraud Wilberg für die Hilfsbereitschaft bei den Membranpräparationen, 
 
Frau Christine Braun und Frau Kerstin Röhrl für die engagierte Durchführung der 
organpharmakologischen Testungen am isolierten Meerschweinchen-Ileum und 
Meerschweinchen-Atrium, 
 
Frau Silvia Heinrich und Martina Wechler für die stets freundliche Unterstützung bei allen 
organisatorischen Angelegenheiten, 
 
Herrn Peter Richthammer für seine stete Hilfsbereitschaft und Kompetenz bei allen 
technischen Herausforderungen sowie für die gute Zusammenarbeit bei der Durchführung 
der verschiedenen Praktika, 
 
allen Mitarbeitern der analytischen Abteilung der Universität Regensburg für die Aufnahme 
und Hilfestellung bei der Interpretation der NMR- und Massenspektren sowie für die 
Durchführung der Elementaranalysen, 
 
allen Mitgliedern der Histamin-Gruppe am Lehrstuhl (Herrn Tobias Birnkammer, Frau 
Daniela Erdmann, Herrn Roland Geyer, Frau Dr. Anja Kraus, Herrn Johannes Mosandl, 
Herrn Dr. Hendrik Preuß) für die engagierte Zusammenarbeit, 
 
allen Mitgliedern des Lehrstuhls für die stets gute Kollegialität, Arbeitsatmosphäre und 
Zusammenarbeit, 
 
der Deutschen Forschungsgemeinschaft für die finanzielle Förderung im Rahmen des 
Graduiertenkollegs GRK 760, 
 
meinen aktuellen und ehemaligen Kollegen Dr. Stephan Braun, Peter Höcherl, Dr. Edith 
Hofinger, Matthias Kühnle, Dr. Christine Müller, Dr. Hendrik Preuß und Dr. Ralf Ziemek für 
die schöne gemeinsame Zeit auch außerhalb der Universität, 
 
und insbesondere meinen Eltern, meinem Bruder sowie natürlich meiner Freundin Erika für 
die Unterstützung und Geduld während der Promotion. 
 
 
 
 
Contents 
1 Introduction 
1.1 G-protein coupled receptors 
1.1.1 GPCRs as drug targets and their classification 1
1.1.2 G-protein cycle and signal transduction 2
1.1.3 Receptor models of GPCR activation and ligand classification 5
1.1.4 GPCR oligomerization and “bivalent ligands” 6
1.2 Histamine and histamine receptor subtypes 
1.2.1  The biogenic amine histamine: An overview 9
1.2.2  The histamine H1 receptor 11
1.2.3  The histamine H2 receptor 13
1.2.4  The histamine H3 receptor 17
1.2.5  The histamine H4 receptor 19
1.3 References 24
 
2 Scope and objectives 39
  
3 Imidazolylbutylcyanoguanidines and analogs: Identification of 
potent and selective histamine H3R and H4R ligands 
3.1 Introduction 43
3.2 Chemistry 45
3.3 Pharmacological results and discussion 
3.3.1 Potencies and efficacies of the synthesized compounds at the hH1R, hH2R, 
hH3R and hH4R in the steady-state GTPase activity assay 49
3.3.2 Affinities of UR-PI376 (3.66) for the hH1R, hH2R, hH3R and hH4R subtypes in 
radioligand binding experiments 60
3.3.3 Inhibition of the UR-PI376 (3.66) stimulated GTP hydrolysis at the hH4R by 
standard H4R antagonists 61
3.3.4 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 62
3.3.5 Summary and Conclusion 63
3.4 Experimental section 
3.4.1 Chemistry 
3.4.1.1 General conditions 65
3.4.1.2 Preparation of the isoureas 3.24-3.40 66
3.4.1.3 Preparation of the cyanoguanidines 3.42-3.48, 3.52-3.58, 3.61-3.77, 3.80 
and 3.81 
72
Contents II 
3.4.1.4 Preparation of the carbamoylguanidines 3.49, 3.50, 3.59 and 3.78 88
3.4.1.5 Preparation of the diamine 3.84 90
3.4.1.6 Preparation of the bivalent isourea precursors 3.88-3.91 91
3.4.1.7 Preparation of the bivalent cyanoguanidines 3.92-3.95 93
3.4.1.8 Preparation of the trityl-protected sulfonylguanidines 3.100 and 3.101 95
3.4.1.9 Preparation of the sulfonylguanidines 3.102 and 3.103 95
3.4.1.10 Preparation of 3-(1H-imidazol-4-yl)propan-1-amine 3.41 96
3.4.1.11 Preparation of 4-(1H-imidazol-4-yl)butane-1-amine 3.60 97
3.4.1.12 Synthesis of the amines 3.11, 3.12 and 3.14-3.18 99
3.4.1.13 Preparation of 2-phenylethanesulfonic acid (3.125) and 2-phenylethane-
sulfonylchloride (3.99) 105
3.4.2 Pharmacological methods 
3.4.2.1 Materials 105
3.4.2.2 Steady-state GTPase activity assay 106
3.4.2.3 Radioligand binding assays 107
3.4.2.4 Histamine H1R assay on guinea pig ileum 107
3.4.2.5 Histamine H2R assay on the isolated spontaneously beating guinea pig right 
atrium 108
3.5 References 108
    
4  NG-Acylated imidazolylalkylguanidines: synthesis and structure-
activity relationsships at the histamine receptor subtypes 
4.1 Introduction 113
4.2 Chemistry 114
4.3 Pharmacological results and discussion 
4.3.1 Potencies and efficacies of the prepared compounds at the hH1R, hH2R, 
hH3R and hH4R in the steady-state GTPase assay 118
4.3.2 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 123
4.3.3 Summary and conclusion 125
4.4 Experimental section 
4.4.1 Chemistry 
4.4.1.1 General conditions 126
4.4.1.2 Preparation of the 2-(1-trityl-1H-imidazol-4-yl)ethanamines 4.13 and 4.14 127
4.4.1.3 Preparation of the 3-(1-trityl-1H-imidazol-4-yl)propan-1-ols 4.19 and 4.20 131
4.4.1.4 Preparation of 4-(1-trityl-1H-imidazol-4-yl)butan-1-amine 4.23 133
4.4.1.5 Preparation of N-methyl-3-(1-trityl-1H-imidazol-4-yl)propan-1-amine 4.25 135
4.4.1.6 Preparation of the guanidinylation reagents 4.26-4.29 136
  
Contents III
4.4.1.7 Preparation of the diurethane-protected 1-trityl-1H-imidazol-4-ylalkyl-
guanidines 4.30-4.33 137
4.4.1.8 Preparation of the diurethane-protected 3-(1-trityl-1H-imidazol-4-yl)propyl-
guanidines 4.38 and 4.40 139
4.4.1.9 Preparation of the trityl-protected imidazolylalkylguanidines 4.34-4.37, 4.39 
and 4.41 140
4.4.1.10 Preparation of the trityl-protected NG-acylated imidazolylalkylguanidines 
4.42-4.52 and 4.57-4.62 142
4.4.1.11 Preparation of the Boc/trityl-protected NG-acylated imidazolylpropyl-
guanidines 4.53-4.56 148
4.4.1.12 Preparation of the NG-acylated imidazolylpropylguanidines 4.63-4.83 150
4.4.2 Pharmacological methods 
4.4.2.1 Materials 159
4.4.2.2 Steady-state GTPase activity assay 160
4.4.2.3 Histamine H1R assay on guinea pig ileum 160
4.4.2.4 Histamine H2R assay on the isolated spontaneously beating guinea pig right 
atrium 160
4.5 References 160
    
5 Synthesis and structure-activity relationsships of NG-acylated 
arylpropylguanidines at the histamine receptor subtypes 
5.1 Introduction 165
5.2 Chemistry 166
5.3 Pharmacological results and discussion 
5.3.1 Potencies and efficacies of the prepared compounds at the hH1R, hH2R, 
hH3R and hH4R in the steady-state GTPase assay 170
5.3.2 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 174
5.3.3 Summary and conclusion 175
5.4 Experimental section 
5.4.1 Chemistry 
5.4.1.1 General conditions 177
5.4.1.2 Preparation of the arylpropylalcohols 5.10, 5.12, 5.16 and 5.22, and 
arylpropylamines 5.29-5.31 178
5.4.1.3 Preparation of the guanidinylation reagents 5.35 and 5.36 183
5.4.1.4 Preparation of the di-Cbz-protected arylpropylguanidines 5.37-5.40 183
5.4.1.5 Preparation of the di-Cbz-protected arylpropylguanidines 5.41-5.45 185
5.4.1.6 Preparation of the arylpropylguanidines 5.46-5.54 187
5.4.1.7 Preparation of the NG-acylated arylpropylguanidines 5.59-5.80 191
5.4.1.8 Preparation of the NG-acylated arylpropylguanidines 5.81-5.88 201
  
Contents IV 
5.4.2 Pharmacological methods 
5.4.2.1 Materials 204
5.4.2.2 Steady-state GTPase activity assay 205
5.4.2.3 Histamine H1R assay on guinea pig ileum 205
5.4.2.4 Histamine H2R assay on the isolated spontaneously beating guinea pig right
atrium 205
5.5 References 205
  
6 NG-Acylated imidazolylpropylguanidines as potent histamine H4 
receptor agonists: selectivity by variation of the NG-substituent 
6.1 Introduction 209
6.2 Chemistry 210
6.3 Pharmacological results and discussion 
6.3.1 Potencies and efficacies of the prepared compounds at the hH1R, hH2R, 
hH3R and hH4R in the steady-state GTPase activity assay 214
6.3.2 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 218
6.3.3 Summary and conclusion 219
6.4 Experimental section 
6.4.1 Chemistry 
6.4.1.1 General conditions 220
6.4.1.2 Preparation of 1-(3-(1H-imidazol-4-yl)propyl)guanidine 6.2 (SK&F 91486) 221
6.4.1.3 Preparation of the trityl-protected NG-acylated imidazolylpropylguanidines 
6.4, 6.6 and 6.8 222
6.4.1.4 Preparation of the Boc/trityl-protected NG-acylated imidazolylpropyl-
guanidines 6.5, 6.7 and 6.9-6.14 223
6.4.1.5 Preparation of the NG-acylated imidazolylpropylguanidines 6.15-6.25 226
6.4.1.6 Preparation of the diurethane-protected 3-(1-trityl-1H-imidazol-4-yl)propyl-
guanidines 6.27 and 6.28 231
6.4.1.7 Preparation of the diurethane-protected 3-(1-trityl-1H-imidazol-4-yl)propyl-
guanidine 6.33 232
6.4.1.8 Preparation of the trityl protected imidazolylpropylguanidines 6.29, 6.30 and 
6.34 234
6.4.1.9 Preparation of the guanidinylation reagents 6.35-6.38 235
6.4.1.10 Preparation of methyl 3-(methylamino)propanoate 6.41 236
6.4.1.11 Preparation of the methyl esters 6.43-6.46 236
6.4.1.12 Preparation of the carboxylic acids 6.47-6.50 238
6.4.2 Pharmacological methods 
6.4.2.1 Materials 240
6.4.2.2 Steady-state GTPase activity assay 240
Contents V
6.4.2.3 Histamine H1R assay on guinea pig ileum 240
6.4.2.4 Histamine H2R assay on the spontaneously beating guinea pig right atrium 240
6.5 References 241
  
7 Tritium-labeled N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionyl-
guanidine ([3H]UR-PI294), a high affinity histamine H3 and H4 
receptor radioligand 
7.1 Introduction 245
7.2 Chemistry 246
7.3 Results and discussion 
7.3.1 Saturation binding analysis of [3H]UR-PI294 at the hH3R and hH4R 247
7.3.2 Analysis of the association and dissociation kinetic of [3H]UR-PI294 at the 
hH3R and hH4R 249
7.3.3 Competition binding experiments of [3H]UR-PI294 with reference ligands at 
the hH3R and hH4R 250
7.3.4 Summary and conclusions 252
7.4 Experimental section 
7.4.1 Synthesis 
7.4.1.1 General conditions 253
7.4.1.2 Preparation of N1-[3-(1H-imidazol-4-yl)propyl]-N2-[2,3-3H2]propionylguanidine 
7.10 ([3H]UR-PI294) 253
7.4.2 Pharmacological methods 
7.4.2.1 General 254
7.4.2.2 [3H]UR-PI294 binding assay 254
7.4.2.3 [3H]UR-PI294 kinetic studies 255
7.5 References 255
  
8 Summary 259
  
9 Appendix 
9.1 Data analysis and pharmacological parameters 261
9.2 Elemental analysis data 262
9.3 HPLC purity data 268
9.4 Short lectures and poster presentations 269
9.5 Publications 270
9.6 References 270
 
Abbreviations 
 
abs absolute 
Anal. analysis 
aq. aqueous 
Ar aromatic 
ATP adenosine triphosphate 
Boc tert-butoxycarbonyl 
Bmax the maximal specific binding of a ligand 
bp boiling point 
BRET bioluminescence resonance energy transfer 
n-BuLi n-butyl lithium 
cAMP cyclic 3’, 5’-adenosine monophosphate 
cat. catalytical amounts 
Cbz benzyloxycarbonyl 
CDI N,N’-carbonyldiimidazole 
cHex cyclohexyl 
CI chemical ionization 
CNS central nervous system 
COSY correlated spectroscopy 
Cquat quaternary carbon atom 
CREB cAMP response element binding protein 
d day(s) or doublet 
DAG diacylglycerol 
DCM dichloromethane 
dec. decomposition 
DIAD diisopropyl azodicarboxylate 
DIEA diisopropylethylamine 
DMAP 4-dimethylaminopyridine 
DMF N, N-dimethylformamide 
DMSO dimethylsulfoxide 
DMSO-d6 per-deuterated DMSO 
DNABP DNA binding protein 
E1, E2 1st and 2nd extracellular loop of a GPCR 
EDC N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide 
EC50  molar concentration of the agonist causing 50 % of the maximal 
response 
Abbreviations VII
EDTA ethylendiaminetetraacetic acid 
EI electron impact ionization 
Emax maximal response relative to histamine (1.00) 
eq equivalents 
ES electrospray ionization 
FRET fluorescence resonance energy transfer 
Fur furanyl 
G G-protein 
GDP guanosine diphosphate 
GPCR G-protein coupled receptor 
gp guinea pig 
gpH1R guinea pig histamine H1 receptor 
gpH2R guinea pig histamine H2 receptor 
GTP guanosine triphosphate 
h hour(s) or human 
HR histamine receptor 
hH1R human histamine H1 receptor 
hH2R human histamine H2 receptor 
hH2R-GsαS fusion protein between the hH2R and short splice variant of Gsα 
hH3R human histamine H3 receptor 
hH4R human histamine H4 receptor 
hH4R-RGS19 fusion protein between the hH4R and RGS19 
HMBC heteronulcear multiple bond correlation 
HPLC high performance (pressure) liquid chromatography 
HR-MS high resolution mass spectroscopy 
H1R, H2R, H3R, H4R histamine receptor subtypes 
HSQC heteronuclear single quantum coherence 
IC50 functional assay: antagonist (inverse agonist) concentration 
suppressing 50 % of an agonist induced effect 
 radioligand binding assay: ligand concentration inhibiting the 
binding of a radioligand by 50 % 
IgE immunoglobuline E 
Im imidazolyl 
IP3 inositol-1,4,5-trisphosphate 
IP3R inositol trisphosphate receptor 
IR infrared spectroscopy 
J coupling constant 
Abbreviations VIII 
k’ capacity factor 
KB  dissociation constant (functional assay) 
KD dissociation constant (saturation binding) 
KI dissociation constant (competition binding) 
kob observed rate constant 
kon association rate constant 
koff dissociation rate constant 
LSI liquid secondary ion 
m multiplet 
MAPK mitogen-activated proteine kinase 
min minute(s) 
mp melting point 
MS mass spectrometry 
NG guanidino-nitrogen 
NMR nuclear magnetic resonance 
NOESY nuclear overhauser enhancement spectroscopy 
PE petroleum ether 
Ph phenyl 
Pi inorganic phosphate 
PIP2 phosphatidylinositol-4,5-bisphosphate 
PKA protein kinase A 
PKC protein kinase C 
PLCβ phospholipase Cβ 
ppm part per million 
Pyr pyridyl 
Pyraz pyrazolyl 
Phth phthalimide 
pEC50 negative decadic logarithm of the molar concentration of the 
agonist causing 50 % of the maximal response 
q quartet 
quin quintet 
r2 coefficient of determination 
R inactive state of a GPCR 
R* active state of a GPCR 
RGS regulator of G-protein signaling  
RP reversed phase 
rt room temperature 
Abbreviations IX
rpm revolutions per minute 
s singlet 
SEM standard error of the mean 
sep septet 
Sf9 Spodoptera frugiperda insect cell line 
t triplet 
t0 dead time 
TBME tert-butylmethylether 
TFA trifluoroacetic acid 
THF tetrahydrofuran 
Thio thiophenyl 
Thiaz thiazolyl 
TLC thin layer chromatography 
TM transmembrane 
TMEDA N1,N1,N2,N2-tetramethylethane-1,2-diamine 
tR retention time 
Triaz 1H-1,2,4-triazolyl 
Tris tris(hydroxymethyl)aminomethane 
 
 
Chapter 1  
 
Introduction 
 
1.1 G-protein coupled receptors 
1.1.1 GPCRs as drug targets and their classification 
G-protein coupled receptors (GPCRs) represent the largest group of integral membrane 
receptors.1-6 About 800 identified GPCRs correspond to about 2 % of the human genome.1 
Due to the multitude of important physiological functions influenced by GPCRs, these 
receptors are also involved in a variety of diseases including pain, asthma, inflammation, 
obesity, cancer, as well as cardiovascular, metabolic, gastrointestinal and CNS diseases.7 
This makes GPCRs one of the most important class of drug targets. Approximately 30 % of 
the currently marketed drugs address about 40 GPCRs.1,5 This offers a large space for the 
further development of new drugs targeting this class of receptors. 
A protein has to fulfill two requirements to be classified as a GPCR. One requirement is the 
existence of seven α-helical transmembrane (TM) domains, each consisting of about 25 to 
35 amino acids. Besides this structural requirement, the receptor has to interact with 
intracellular heterotrimeric G-proteins. The GPCR is able to bind an extracellular ligand and 
transduce the signal via the G-protein into the cell.2 
GPCRs can be divided in two groups: “endoGPCRs” (≈ 400 GPCRs) that are addressed by 
endogenous ligands like peptides, lipids, prostanoids, neurotransmitters, nucleosides and 
nucleotides and “csGPCRs” (chemosensory GPCRs, ≈ 400 GPCRs) that respond to external 
signals like odors, tastes, photons or pheromones.8, 9 Endogenous ligands have been 
identified for more than 260 endoGPCRs. The remaining GPCRs are so-called “orphan” 
receptors as their endogenous ligands are not known to date. Based on structural 
differences, mammalian GPCRs can be grouped in following receptor families: rhodopsin, 
secretin, adhesion, glutamate and frizzled/taste2 receptor families.5 All families share a 
common architecture: an extracellular N-terminus and intracellular C-terminus and seven 
transmembrane α-helices that are connected by three extracellular and three intracellular 
loops. The rhodopsin receptor family (class A) represents the largest subfamily comprising 
672 GPCRs (including 388 csGPCRs). Opsins, olfactory GPCRs, small-molecule/peptide 
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hormone GPCRs and glycoprotein hormone GPCRs belong to this class. Numerous highly 
conserved amino acids in the seven TM domains, a short N-terminal tail and a disulfide 
bridge linking the extracellular loops E1 and E2 are characteristic features of the class A 
GPCRs. Small molecules bind to these receptors within the seven TM domains, whereas 
more space filling ligands like peptides and glycoproteins interact with the N-terminus, extra-
cellular loops and amino acids located at the top of the TM helices. The secretin-like receptor 
family (class B) includes GPCRs for peptides like secretin, calcitonin and parathyroid 
hormone. This class of GPCRs has 15 members and is characterized by a N-terminus that 
contains a network of three disulfide bridges forming a globular domain structure. Activation 
of the receptor obviously occurs by bridging the N-terminus with extracellular loops and TM 
segments via the ligand. The 33 members of the adhesion GPCR family usually possess 
long and highly glycosylated N-termini and are thought to participate in cell adhesion. The 
metabotropic glutamate receptors (mGluRs), the γ-aminobutyric acid type B receptors 
(GABABRs) and Ca2+-sensing receptors (CaRs) belong to the glutamate receptor family 
(class C). The 22 members of this GPCR-family are usually characterized by very large N- 
and C-terminal tails, a disulfide bridge connecting E1 and E2 and a very short third intra-
cellular loop. The N-terminus, containing a Venus flytrap module, forms the ligand binding 
site. The 11 frizzled and smoothened receptors play a role in cell development and 
proliferation. The taste2 receptor family comprises 25 members that are crucial for the 
detection of the bitter taste of compounds.1, 2, 5, 9    
A milestone in GPCR research was the determination of the crystal structure of bovine 
rhodopsin by Palczewski in 2000 which provided first insight into the three dimensional 
arrangement of a mammalian class A GPCR. This structure served as template for the 
generation of numerous GPCR homology models. Such homology models are powerful tools 
to study GPCR conformations and ligand-receptor interaction on the molecular level and for 
virtual screening of compound libraries. The recently solved crystal structures of the human 
β2-adrenergic receptor10-12 and the turkey β1-adrenergic receptor13 revealed some 
unexpected differences relative to bovine rhodopsin. In contrast to bovine rhodopsin in both 
aminergic GPCRs the ionic-lock (salt bridge between Arg3.50 and Glu6.30 stabilizing the 
inactive state of rhodopsin) is absent and the E2 contains an α-helix.11, 12 The recent crystal 
structures and the resulting improved homology models will facilitate the target-based drug 
design for many GPCRs. 
 
1.1.2 G-protein cycle and signal transduction 
GPCRs in the active conformation (can be agonist-free considering constitutively active 
GPCRs or stabilized by an agonist) are able to activate heterotrimeric G-proteins which 
transduce the external signal into the cell. These G-proteins consist of a Gα-subunit and a 
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Gβγ-complex (Figure 1.1).14, 15 Binding of the G-protein to the GPCR induces a conformational 
change of the G-protein and results in the release of GDP from the Gα-subunit and the 
formation of the ternary complex. The ternary complex consisting of the agonist, the receptor 
and the nucleotide free G-protein is characterized by high affinity for agonists. Binding of 
GTP to the Gα-subunit causes a conformational change of the G-protein and disrupts the 
ternary complex. The Gα-GTP-subunit and the Gβγ-complex dissociate from the receptor and 
from each other and interact with effector proteins like enzymes or ion-channels resulting in 
cellular biological responses. After a certain period of time, the Gα-induced effector 
modulation is terminated due to the intrinsic GTPase activity of Gα. GTP bound to Gα is 
hydrolyzed to GDP and phosphate, and the GDP-bound Gα-subunit re-associates with the 
Gβγ-subunit allowing the next G-protein cycle.16 Besides the GPCRs, the activity of 
G-proteins is also receptor independently modulated by a family of proteins named 
regulators of G-protein signaling (RGS). These proteins stimulate the GTPase activity of the 
α-subunit.17-19 
 
 
 
Figure 1.1. The G-protein cycle. 
 
The 16 genes encoding for α-subunits of G-proteins result in minimum 28 distinct subunits 
that are divided in four subfamilies, termed Gs, Gi/o, Gq/11, G12/139, 20, based on their structure 
and signaling pathway. While some α-subunits are very restrictedly expressed, others are 
localized in numerous tissues or are more or less ubiquitously found.15 Five different β- and 
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12 different γ-subunits have been reported (splice variants are not included).20 All α- and 
γ-subunits hold lipid anchors keeping the G-proteins in proximity to the membrane and 
therefore facilitate interactions with membrane proteins such as GPCRs.21, 22 
Members of the Gαs-subfamiliy activate adenylyl cyclases (AC 1 – 9) resulting in increased 
cellular cAMP turnover (Figure 1.2). In contrast, Gαi inhibits AC (5 and 6) activity.9 The 
second messenger cAMP exerts various effects on effector proteins as activation of the 
protein kinase A (PKA) or the mitogen-activated protein kinase (MAPK) pathway both 
modulating gene expression.23 Phosphodiesterases inactivate cAMP and terminate the 
signal transduction. Gαo-proteins for example inhibit voltage dependent Ca2+-channels.24 
Activated Gαq/11-subunits stimulate the phospholipase Cβ (PLCβ) resulting in hydrolysis of 
phosphatidylinositol-4,5-bisphosphate (PIP2) and formation of the second messengers 
inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to the IP3 receptor 
(ligand-gated Ca2+-ion channel) which is located in the membrane of the endoplasmatic 
reticulum and promotes the release of Ca2+-ions from this intracellular store into the 
cytoplasm.25 DAG activates the protein kinase C (PKC) and modulates the function of cellular 
proteins by phosphorylation. IP3 is inactivated by dephosphorylation, whereas DAG is 
degraded by lipases or inactivated by phosphorylation.26, 27 Finally, the Gα12/13-proteins have 
been shown to interact with Ras homology guanine nucleotide exchange factors 
(RhoGEFs).9 Besides the Gα-subunit, also the Gβγ-complex has been shown to be involved in 
signal transduction. Examples for Gβγ-regulated effectors are the G-protein regulated 
inwardly rectifying K+-channels28, isoforms of the adenylyl cyclase29 and the PLC30. 
Meanwhile also G-protein independent signaling pathways of GPCRs have been reported.23 
However, GPCR signal transduction is much more complex than the presented classical 
pathways and the insight into these networks rapidly increases. 
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Figure 1.2. Classical signal transduction pathways of G-protein coupled receptors. Adapted from 
Jacoby et al.1 (DNABP: DNA binding protein, PKA/PKC: protein kinase A/C, DAG: diacylglycerol, IP3: 
inositol-1,4,5-trisphosphate, PIP2: phosphatidylinositol-4,5-bisphosphate, PLCβ: phospholipase Cβ, 
IP3R: IP3 receptor). 
 
 
1.1.3 Receptor models of GPCR activation and ligand classification 
Different models have been developed to describe the interaction between a GPCR, the 
G-protein and the ligand. The most simple one is the ternary complex model (Figure 1.3).31 
However, in this model agonist binding to the receptor is condition to activate the G-protein 
and therefore, constitutive activity and inverse agonistic activity of ligands can not be 
explained. This resulted in the extended ternary complex model which describes an 
equilibrium between two distinct receptor states: an inactive and an active receptor state.32, 33 
The inactive receptor (R) state is allowed to isomerize to an active receptor state (R*) 
independently from agonist binding. The ratio between [R*] and [R] describes the degree of 
constitutive activity of a GPCR. The active state of the receptor is able to bind G-proteins and 
promote GDP/GTP exchange resulting in signal transduction. In contrast to the extended 
ternary complex model, the thermodynamically more complete cubic ternary model 
additionally includes the formation of non-signaling complexes (RG and ARG) between the 
G-protein and the inactive state of the receptor.34-36  
Full agonists preferentially bind to and stabilize the active state of the receptor and produce a 
maximal biological response (efficacy). Inverse agonists particularly bind and stabilize the 
inactive state of the receptor and reduce the basal G-protein activity. Partial agonists and 
partial inverse agonists are less effective in stabilizing the active and the inactive state of the 
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receptor, respectively. Neutral antagonists do not distinguish between the different receptor 
states and do not affect the equilibrium.37 
However, the two-state model of GPCR activation can not sufficiently describe all observed 
experimental findings. GPCRs are assumed to exist not just in one active conformation, but 
to form multiple active state receptor conformations. There is increasing evidence that 
structurally different agonists stabilize distinct receptor conformations which can result in 
diverse biological responses.38 Development of such ligands acting on one and the same 
GPCR but modulating different signal transduction pathways may become promising for the 
fine-tuning of drug action. However, further studies are required to elaborate the potential 
therapeutic relevance of distinct GPCR phenotypes.9, 39-42 
 
 
Figure 1.3. Models describing the interaction between GPCR, agonist and G-protein (R: inactive state 
of the receptor; R*: active state of the receptor; G: G-protein; A: agonist). A, Ternary complex model: 
This model allows no discrimination between R and R*; B, Extended ternary complex model: This 
model accounts for R and R*; C, Cubic ternary complex model: This model permits the interaction of G 
with R resulting in non-signaling complexes. Signaling complexes mediating GDP/GTP exchange are 
highlighted in red. 
 
 
1.1.4 GPCR oligomerization and “bivalent ligands” 
Over a long period of time GPCRs were considered to act as monomeric entities in a 1:1:1 
stoichiometry with the G-protein and the ligand.43 However, experiments employing different 
techniques like cross-linking, immunoblotting and co-immunoprecipitation as well as FRET 
(fluorescence resonance energy transfer) and BRET (bioluminescence resonance energy 
transfer) investigations in living cells provided convincing evidence for GPCRs to form dimers 
or higher order oligomers.1, 44, 45 The existence of homodimers has been demonstrated for 
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several class A and C GPCRs including the dopamine D2 and D3 receptors,46, 47 the 
β2-adrenoceptor,48 the H1Rs, H2Rs and H4Rs,49-51 opioid receptors52-54, the mGluRs55, 56 and 
CaRs57. Besides homodimers also heterodimers like the δ/κ-opioid receptors,53 the 
somatostatine SSTR1B/dopamine D2 receptors58 and the GABAB1/GABAB2 receptors59 have 
been identified. The GPCRs are believed to interact via their extracellular loops, trans-
membrane helices and intracellular loops, forming covalent or non-covalent interactions.44 
Examples for covalently linked receptors are the mGluRs and CaRs providing dimers via 
disulfide bonds. Conversely, the GABAB1R/GABAB2R heterodimer forms non-covalent inter-
actions through a C-terminal coiled-coil domain.9 Although, few is known about the 
physiological role of GPCR dimerization, several investigations suggest a crucial role in 
GPCR trafficking, folding, activation and internalization.44 The GABAB1R/GABAB2R hetero-
dimer is a demonstrative example: The presence of GABAB2R is prerequisite for a proper 
transfer of GABAB1R to the cell surface. Moreover, the GABAB1R binds its agonist but does 
not couple to the G-protein, whereas the GABAB2R stimulates G-protein signaling but does 
not bind the ligand.59-61 There is growing evidence that GPCR dimerization, in particular 
heterodimerization, results in complexes with modified ligand binding and signal transduction 
properties relative to the individual receptors.9, 54 Distinct characteristics arising from hetero-
dimerization have been shown for the κ- and δ-opioid receptors53, the μ- and δ-opioid 
receptors54 or the angiotensin AT1 and bradykinin B2 receptors62. However, as many 
experiments have been performed in recombinant cell systems, the physiological relevance 
of GPCR oligomerization has to be further elucidated in ongoing studies.  
The bivalent ligand approach in the design of ligands targeting GPCRs has proven to be 
promising to improve not only potency and selectivity but also the pharmacokinetic profile of 
compounds.63 Usually bivalent ligands are characterized by a molecule containing two sets 
of pharmacophoric entities linked through a spacer. However, in the broader sense bivalent 
ligands can be divided in molecules comprising two sets of pharmacophoric groups or a 
single pharmacophore connected to a non-pharmacophoric recognition unit.64, 65 Two 
different binding modes for bivalent ligands at the receptor(s) are imaginable (Figure 1.4). If 
the spacer is of sufficient length the bivalent ligand may bridge two neighboring receptors, 
each pharmacophoric entitiy interacting with the binding site of one receptor. Molecular 
modeling studies with μ-opioid receptor dimers estimate a distance between the binding sites 
of approximately 27 Å.65 For bivalent ligands with shorter linkers, next to the binding site an 
accessory recognition site at a single receptor is probable. The existence of accessory 
binding sites has been demonstrated for bivalent opioid receptor antagonists and explains 
increased affinities of bivalent ligands, that are not capable to link two receptors, relative to 
the monovalent counterparts.63-66 According to Portoghese,64 such bivalent ligands containing 
spacers of insufficient length for bridging two receptors fit to the “message-address” concept 
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proposed by Schwyzer67. The pharmacophore can be considered as the “message” which is 
recognized by a family of receptors and, in case of agonists, is responsible for receptor 
activation, whereas the second pharmacophoric or non-pharmacophoric entity is considered 
as the “address” conferring additional affinity. 
The increase in affinity of bivalent ligands relative to their monovalent analogs can be 
explained by the assumption that the bivalent ligands first bind in a univalent manner to the 
receptor (Figure 1.4). Thereby, the second recognition unit of the bivalent ligand achieves 
closer proximity to the second binding site (neighboring receptor or accessory binding site) 
corresponding to a high local concentration of the second recognition unit. This should afford 
an increase in affinity greater than expected from the sum of its two monovalent pharma-
cophores.64, 65 The spacer length of the bivalent ligands plays a crucial role with respect to 
affinity as too short spacers prevent bridging of the binding sites, whereas too long linkers 
reduce the residence time of the recognition unit in vicinity to the binding site. Moreover, 
immobilization of the flexible linker of the bivalent ligand upon receptor binding results in a 
decrease in entropy. That means, the improved affinity of a bivalent ligand is enthalpy driven 
and to some extent compensated through the loss of entropy (ignoring a possible increase in 
entropy due to linker-mediated dehydration of a receptor surface).68, 69  For many bivalent 
ligands containing a linker of insufficient length to bridge neighboring receptors an increase 
in selectivity relative to the monovalent counterparts is observed.63 This can be explained 
with an accessory binding site for the second pharmacophore (Figure 1.4 A) present only on 
one receptor subtype. The affinity of bivalent ligands can also be influenced by cooperativity 
effects.64, 65  
 
 
Figure 1.4. Bivalent ligand binding to A, a GPCR with an accessory binding site, or to B, a GPCR 
dimer. The bivalent ligand is believed to bind first in a univalent manner before addressing the second 
binding site. Concerning the receptor dimer (B) univalent binding of a second bivalent ligand is 
possible. However, bridging neighboring receptors via the bivalent ligand is favored. Adapted from 
Portoghese et al.65 
bivalent 
ligand 
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Taken together, the bivalent ligand approach is a promising way not just to design highly 
potent and selective compounds. The recent advances in studying GPCR dimerization and 
the rising evidence for heterodimers to form a kind of new receptor subtypes with modified 
pharmacological behavior will promote the demand for molecules addressing neighboring 
receptors simultaneously.9, 43 Such bivalent ligands are required as pharmacological tools to 
study receptor dimerization and the potential of GPCR dimers and higher order oligomers as 
drug targets. 
 
1.2 Histamine and histamine receptor subtypes 
1.2.1 The biogenic amine histamine: An overview 
The first synthesis of the biogenic amine histamine (1.1, 2-(1H-imidazol-4-yl)ethanamine) has 
been reported by Windaus and Vogt in 1907.70 Three years later, Sir Henry Dale and his 
colleagues at the Wellcome Laboratories were able to isolate this amine from Secale 
cornutum.71, 72   
Histamine contains an imidazole ring that forms the two possible tautomers, 1.1a and 1.1b 
(Figure 1.5). The monocation of histamine preferentially forms the Nτ-tautomer (τ from the 
Greek telos) in aqueous solution (≈ 80 %)73, 74 and in the crystal (100 %)75, whereas the 
histamine base crystallizes in the Nπ-tautomeric (π from the Greek pros) form (100 %)76. With 
the imidazole ring (pKa = 5.8) and the primary amino group (pKa = 9.4) histamine contains 
two basic centers77 with the monocation predominating at physiological pH.78 
  
 
 
Figure 1.5. Tautomeric forms of the histamine monocation. 
 
Histamine is formed in the body by decarboxylation of the amino acid L-histidine (1.2) 
catalyzed by the enzyme L-histidine-decarboxylase (HDC) or L-aromatic amino acid 
decarboxylase under participation of the cofactor pyridoxalphosphate (Figure 1.6).79, 80 
Released histamine is rapidly inactivated by two pathways. In one route the primary amino 
group is oxidized in two steps catalyzed by the enzymes diamine oxidase and xanthine 
oxidase to imidazole-4-acetic acid (1.7). This acid is further metabolized by ribosylation of the 
imidazole ring. The major metabolic pathway in humans starts with the histamine 
N-methyltransferase (HNMT) catalyzed methylation (cofactor S-adenosyl-methionin) of the 
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imidazole Nτ-nitrogen followed by subsequent oxidation of the primary amine to the 
corresponding carboxylic acid.81 Two possible models for the inactivation of released 
histamine via the HNMT are discussed. According to the plasma membrane hypothesis the 
HNMT can be translocated from the cytosol to the cell membrane and act on the cell surface. 
The transporter hypothesis considers histamine to enter the cell by using organic cation 
transporters (OCTs) before being inactivated in the cytosol by the HNMT.82 The half-life of 
histamine is very short with less than 10 s in the rat and 20 – 30 s in the dog.72 
 
 
Figure 1.6. Biosynthesis and biotransformation of histamine.   
 
High tissue concentrations of histamine are found in particular in the lungs, the skin, 
connective tissues and gastrointestinal tract.72 From the cellular point of view histamine is 
located in mast cells83, blood basophils84, blood platelets85, enterochromaffin-like (ECL) cells 
of the stochmach86, endothelial cells87 and also in neurons88. In mast cells and basophils 
histamine is stored in secretory granules and released during allergic conditions resulting in 
smooth muscle contraction, vasodilatation and an increase in vascular permeability.89 
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Besides the IgE-mediated histamine liberation, also peptides, drugs, toxins or chemicals like 
substance P, mastoparan, morphine or compound 48/80 can trigger histamine release from 
mast cells and basophils.90-92 Histamine released from ECL cells controls gastric acid 
secretion from parietal cells.93 In histaminergic neurons that are mainly located in the tubero-
mamillary nucleus of the posterior hypothalamus, histamine acts as a neurotransmitter 
playing a crucial role in sleep/waking cycle, learning and memory, anxiety, locomotion, 
feeding and drinking and neuroendocrine regulation.94 Certain cells like macrophages, 
dendritic cells, neutrophils and T-cells also have been found to release histamine after de-
novo synthesis without prior storage in granules.89 
The mentioned effects of histamine are all mediated by four histamine receptor (HR) 
subtypes: the H1R, H2R, H3R and H4R. All these receptors are members of class A or 
rhodopsin-like GPCRs.95, 96 
 
1.2.2 The histamine H1 receptor 
The H1R mediates typical pathophysiological histamine effects that have been known for 
almost 100 years. Even if not aware of the target, the first classical “antihistamines” 
addressing this HR subtype were developed in the 1930s and 1940s and employed for the 
treatment of allergic conditions.97 However, these antihistamines could not antagonize all 
effects provoked by histamine and, therefore, Ash and Schild introduced in 1966 for the first 
time the denotation of the H1R.98 In 1991 Yamashita and colleagues were able to clone the 
bovine H1R99,two years later the cloning of the human H1R was reported100. 
The human H1R represents a 487 amino acid protein that preferentially couples to a 
pertussis-toxin insensitive Gq/11-protein.101 The receptor is expressed in numerous tissues like 
the brain, smooth muscles from airways, blood vessels and gastrointestinal tract, the cardio-
vascular system, endothelial cells and lymphocytes. H1R receptor activation in smooth 
muscle cells results in a contraction due to calcium mobilization from intracellular stores.102, 
103 Vascular permeability increases upon H1R stimulation as a result of endothelial cell 
contraction.104-106 Furthermore, the H1R triggers the release of nitric oxide from endothelial 
cells which induces dilatation of vascular smooth muscles.107, 108 The aforementioned H1R 
mediated histamine effects promote the typical allergic reactions as urticaria, broncho-
constriction and decrease in blood pressure. In the CNS the H1R is involved in the 
modulation of a multitude of functions like the circadian rhythm of sleep and wakefulness109, 
110, cognitive processes111, 112, thermoregulation113 and pain114. 
The histamine H1R is characterized by a large third intracellular loop and a relatively short 
C-terminal tail.95 Molecular modeling investigations and site-directed mutagenesis suggest 
histamine to bind to the hH1R by forming an ionic interaction between its protonated amino 
group and the conserved Asp-107 of TM3. Lys-191 in TM5 is considered to interact with Nπ 
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of the imidazole ring, whereas the Asn-198 is supposed to form a hydrogen bond with Nτ-H. 
In place of Asn-198, Nτ-H may interact with Thr-194 (Figure 1.7).115-118 
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Figure 1.7. Proposed binding mode of histamine at the hH1R. 
 
Many efforts have been spent to obtain H1R subtype selective agonists. The first H1R 
agonists displaying some selectivity over the H2R were betahistine (1.9) and 2-methyl-
histamine (1.10). However, the potencies of these histamine analogs were rather poor (5 – 
20 % relative to histamine).119, 120 Potencies similar and even superior to histamine were 
achieved in the series of the 2-phenylhistamines, in particular when a halogen or a halogen-
substituted group was introduced in the meta position of the phenyl ring (1.11).121, 122 The 
most successful approach in this field led to the histaprodifens (1.12) and especially the 
suprahistaprodifens (1.13) which are about 36 times more potent H1R agonists than 
histamine118, 123 and are highly interesting pharmacological tools. The only H1R agonist used 
in therapy is betahistine (Aequamen®) which has some relevance for the therapy of 
Menière’s disease.124 
The first generation H1R antagonists like mepyramine (1.14, Pyrilamine®) or diphen-
hydramine (1.15, Dolestan®) have already been developed more than 50 years ago. 
Drawback of these antiallergic drugs is their high lipophilicity that enables penetration 
through the blood-brain barrier and causes sedation. To reduce this side effect more polar 
H1R antagonists such as cetirizine (1.16, Zyrtec®) and fexofenadine (1.17, Telfast®) have 
been developed which belong to top selling blockbuster drugs.95 The most commonly used 
radioligand to label the H1R is the high affinity antagonist [3H]mepyramine.125 
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Figure 1.8. Structures of H1R ligands. 
 
1.2.3 The histamine H2 receptor 
Ash and Schild had suggested the existence of an additional HR subtype in 1966.98 In 1972 
Black and colleagues confirmed this prediction by pharmacological characterization of the 
second histamine receptor using the first H2R antagonist burimamide. Contrary to the 
classical antihistamines, burimamide was able to block the histamine mediated gastric acid 
secretion and positive chronotropic effect on the heart.126 In 1991, Gantz and co-workers 
were able to clone the intronless canine and humane H2Rs.127, 128  
The human H2R consists of 359 amino acids and couples to a Gs-protein resulting in an 
increase in cAMP turnover.128-130 High expression levels of the receptor are found in the 
heart131, in gastric parietal cells132, neurons133, vascular134, 135, airway136 and uterine137 smooth 
muscle cells and immune cells89. Activation of cardiac H2Rs results in a positive chronotropic 
and inotropic response.126, 138, 139 An essential physiological function of the H2R is the control 
of gastric acid secretion from parietal cells.126, 140 Moreover, histamine mediates smooth 
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muscle relaxation in airway, uterine and blood vessels via the H2R.126, 134, 136, 137 H2Rs have 
numerous functions in the immune system. For example H2Rs have been shown to inhibit 
T-cell proliferation141-143, to block the histamine release from mast cells and to modulate 
cytokine production144-146. Additionally, stimulation of H2Rs expressed on promyelocytic 
leukemic cells triggers the functional differentiation to mature granulocytes.147 In the CNS, 
H2Rs inhibit the long-lasting afterhyperpolarization after Ca2+ influx and block the 
accommodation of action potential after firing.133 
In contrast to the H1R, the H2R possesses a substantially shorter third intracellular loop and a 
longer palmitoylated C-terminus.95 The endogenous ligand histamine is assumed to bind in 
its Nπ-tautomeric form to amino acids located in TM3 and TM5 of the hH2R. The protonated 
amino group interacts with the conserved Asp-98 of TM3 and the imidazole Nπ-H forms a 
hydrogen bond with Asp-186 of TM5. Imidazole Nτ interacts with Tyr-182 likewise located in 
TM5 (Figure 1.9).148, 149 Alternatively to Tyr-182, Thr-190 may participate in histamine 
binding.150  
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Figure 1.9. Proposed binding mode of histamine at the hH2R. 
 
H2R agonists can be roughly divided in amine-type H2R agonists and guanidine-type H2R 
agonists (Figure 1.10). The first amine-type H2R agonist showing selectivity over the H1R 
was 5-methylhistamine (1.18, former nomenclature: 4-methylhistamine).120 However, very 
recently this compound turned out to be selective for the H4R.151 Further examples of amine-
type H2R agonists are the non-imidazoles amthamine (1.19) and dimaprit (1.20).152-154 
Contrary to 5-methylhistamine and dimaprit, the aminothiazole analog amthamine is devoid 
of agonistic activity at the H3R and H4R.151 The first guanidine-type H2R agonist was 
imidazolylpropylguanidine (1.21, SK&F 91486), exerting just poor partial agonistic activity at 
the guinea pig (gp) right atrium.155 Introduction of a cimetidine-like substituent at the 
guanidine group resulted in impromidine (1.22) which displays a drastically increased 
potency at the gpH2R (50 times the potency of histamine at the gpH2R).156, 157 The imidazolyl-
propylguanidine moiety is considered to be crucial for H2R agonistic activity, whereas the 
additional substituent is regarded as affinity conferring group.158 Exchanging the cimetidine-
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like portion with pheniramine-like moieties led to arpromidine (1.23) and analogs, which 
belong to the most potent guanidine-type H2R agonists (up to 400 times the potency of 
histamine at the gpH2R).159, 160 The chiral impromidine isomer sopromidine is of special 
interest as the (R)-configurated compound (1.24, sopromidine) behaves as gpH2R agonist, 
whereas the (S)-configurated counterpart is devoid of agonist activity.161 Due to the positive 
inotropic and chronotropic activity of H2R agonists, impromidine has been investigated in the 
clinic for the therapy of patients suffering from severe catcholamine-insensitive congestive 
heart failure.162, 163 However, the strong basic guanidine moiety of these compounds is 
responsible for pharmacokinetic drawbacks. The guanidine group is nearly quantitatively 
protonated under physiological conditions, which results in a lack of oral bioavailability and 
CNS penetration.164 To overcome the unfavorable pharmacokinetic properties of arpromidine 
the strong basic guanidine group was replaced with an acylguanidine group which is by 
approximately five orders of magnitude less basic (pKa ≈ 13  pKa ≈ 8).164 The obtained 
NG-acylated imidazolylpropylguanidines turned out to be very potent H2R agonists with 
slightly reduced potencies relative to their guanidine analogs.164 Moreover, acylguanidine-
type H2R agonists like UR-AK24 (1.25) proved to be orally bioavailable and brain-penetrating 
compounds.164 H2R agonists capable to pass the blood brain barrier are considered as 
promising pharmacological tools to evaluate the function of H2Rs in the CNS. Though, more 
detailed pharmacological investigations of these acylguanidine-type H2R agonists revealed 
these compounds to be even more potent at the hH3R and hH4R. Obviously, the imidazolyl-
propylguanidine portion is a “privileged structural motif” for HR binding, and replacing this 
moiety may be a promising initial point for the development of subtype selective 
compounds.164 In terms of the H2R, selective acylguanidine-type compounds like UR-PG267 
(1.26) could be generated by replacing the imidazole with a 2-aminothiazole ring.165  
For more than three decades H2R antagonists have been successfully used in the clinic for 
the treatment of gastroduodenal ulcer and gastroesophageal reflux disease. After the 
discovery of burimamide126 a structural analog, cimetidine (1.27, Tagamet®), became the first 
marketed drug, before other H2R antagonists such as ranitidine (1.28, Zantic®) and 
famotidine (1.29, Pepdul®) were introduced in therapy.166, 167 [3H]Tiotidine and [125I]iodoamino-
potentidine are the most commonly used H2R ligands for radioligand binding assays.166 
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Figure 1.10. Structures of H2R ligands. 
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1.2.4 The histamine H3 receptor 
In 1983 Schwartz and his co-workers evaluated the liberation of histamine from neurons of 
the rat cortex and showed histamine to inhibit its own release.168 Unexpectedly, the H2R 
antagonist burimamide suppressed the histamine release at nanomolar concentrations which 
was far below the concentration necessary for blocking the H2R. This observation prompted 
Arrang and colleagues to conclude the existence of a third HR subtype.169 The development 
of the selective H3R agonist (R)-α-methylhistamine and of the selective H3R antagonist 
thioperamide in 1987 further confirmed the third HR subtype.170 Finally, after numerous 
homology-based (relative to the H1/2Rs) cloning approaches failed, Lovenberg and co-
workers were able to clone the hH3R in 1999.171 The cloned receptor displays only low 
sequence homology with the H1/2Rs of about 20 % which is comparable to its homology with 
other aminergic GPCRs.171 This explains the failure of cloning this receptor based on the 
sequence homology of the known HR subtypes. In contrast to the H1R and H2R, the gene 
encoding the H3R contains two172 or perhaps three173 introns resulting in at least 20 hH3R 
isoforms.174 The best characterized isoform is the 445 amino acids containing hH3R 
described by Lovenberg et al.171 The H3R has been shown to display constitutive activity in 
recombinant systems as well as in brain membranes of the rat.175 The H3R couples to 
Gi/o-proteins176 and has been demonstrated to influence several signal transduction 
pathways. For instance, inhibition of adenylyl cyclase (AC), activation of mitogen-activated 
protein kinase (MAPK), activation of phospholipase A2 (PLA2), lowering of intracellular Ca2+-
levels and inhibition of the Na+/H+ exchanger are reported.174 
The H3R is preferentially localized in the CNS and acts as an autoreceptor regulating the 
synthesis and release of histamine from histaminergic neurons.177, 178 In addition, as a 
presynaptic heteroreceptor the H3R controls the neuronal release of dopamine179, 
serotonin180, noradrenaline181, acetylcholine182 and γ-amino butyric acid183. The H3R is 
supposed to be involved in a multitude of CNS functions like wakefulness, locomotor activity, 
thermoregulation, food intake and memory.184 
According to Yao and coworkers histamine is assumed to interact with the conserved 
Asp-114 of TM3 via the protonated amino group. Asp-80 in TM2 obviously forms a hydrogen 
bridge with Nτ-H, which is crucial for receptor activation. The imidazole Nπ is likely to interact 
with Asn-404 in TM7 (Figure 1.11).185 In contrast, Uveges and colleagues suggest the 
imidazole ring to interact with Glu-206 in TM5.186 
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Typical H3R agonists are Nα-methylhistamine (1.32) and the highly selective 
(R)-α-methylhistamine (1.33, Figure 1.12).170 Structurally less related to histamine are the 
H3R agonists imetit (1.34)187 and methimepip (1.35)188. The latter shows high selectivity for 
the H3R188. An interesting approach to increase bioavailability and CNS penetration of the 
very polar (R)-α-methylhistamine was achieved by generation of more lipophilic azomethine 
prodrugs such as BP 2-94 (1.36) and analogs.189 H3R agonists may be of therapeutic value 
for the treatment of insomnia190, pain191, inflammation192, 193 or migraine194.  
However, it has to be considered that due to the high sequence homology of the H3R and 
H4R many imidazole-containing H3R ligands are also active at the H4R.151 For example the 
classical H3R antagonist (inverse agonist) thioperamide (1.37) displays similar affinity for 
both HR subtypes.151 Further examples of imidazole-containing H3R antagonists are 
clobenpropit (1.38) or iodophenpropit (1.39), which are active at the H4R as well.151 
Meanwhile, several non-imidazole H3R antagonists such as A-349821 (1.40)195 or 
JNJ 10181457 (1.41)196 have been developed. Contrary to the imidazoles, these compounds 
are inactive at the H4R and do not bind to off-targets like cytochrome P450 and therefore 
have improved drug-like properties. H3R antagonists have been extensively studied by 
several pharmaceutical companies as drug candidates for the treatment of obesity197, 
schizophrenia198, attention-deficit hyperactivity disorder199, narcolepsy200 or Alzheimer’s 
disease201, 202. In addition, H3R antagonists may be of interest to relieve nasal congestion, 
since H3R activation blocks noradrenalin release from sympathetic nerve ends.203 For radio-
ligand binding studies particularly the high affinity H3R agonists [3H]Nα-methylhistamine and 
[3H](R)-α-methylhistamine or the inverse agonist [125I]iodophenpropit have been used.166 
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1.2.5 The histamine H4 receptor 
Already in 1994 Raible and colleagues predicted the existence of an additional HR subtype. 
They observed that the histamine triggered calcium mobilization in human eosinophils could 
not be blocked by H1R and H2R antagonists, but with the H3R antagonist thioperamide. 
However, the potent H3R agonist (R)-α-methylhistamine was less potent than histamine in 
inducing calcium mobilization, which disagrees with an H3R mediated effect. Therefore, 
Raible and co-workers suggested a novel HR subtype on human eosinophils.204, 205 After 
cloning of the hH3R by Lovenberg and co-workers171, in the years 2000 and 2001 several 
research groups were able to identify and clone a gene encoding for a new HR subtype due 
to the high sequence homology with the H3R (58 % sequence identity within the TM 
domains).206-212 This new hH4R consists of 390 amino acids and – like the H3R – displays a 
rather high constitutive activity.210 The gene encoding the receptor consists of two introns 
and three exons207. Very recently, the existence of two splice variants of the H4R has been 
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reported. These H4R isoforms were mainly localized intracellularly, failed ligand binding and 
prevented the translocation of the coexpressed full-length H4R to the cell membrane.213 Like 
the H3R, the H4R couples to pertussis toxin sensitive Gi/o-proteins resulting in AC inhibition as 
well as in activation of the MAPK pathway.207, 210 Furthermore, H4R activation in mast cells 
results in Ca2+-mobilization which is sensitive to pertussis-toxin and the PLCβ inhibitor 
U73122. Most likely, the Gβγ-subunits of the Gi/o-proteins are involved in PLCβ-activation 
(Figure 1.13).214, 215 
 
 
Figure 1.13. Signal transduction pathways of the H4R. 1, Inhibition of the adenylyl cyclase via the α-subunit of the G-protein resulting in decreased cAMP turnover. cAMP stimulates PKA activity 
resulting in phosphorylation of CREB and modulation of gene expression. 2, Activation of Gαi/o is also 
considered to stimulate the MAPK activity. 3, The Gβγ-subunit of the G-protein obviously activates the 
PLCβ causing hydrolysis of PIP2 to IP3 and DAG and Ca2+-mobilization from intracellular stores. 
(CREB: cAMP-responsive element binding protein, MAPK: mitogen-activated protein kinase, 
PKA/PKC: protein kinase A/C, DAG: diacylglycerol, IP3: inositol-1,4,5-trisphosphate, PIP2: 
phosphatidylinositol-4,5-bisphosphate, PLCβ: phospholipase Cβ, IP3R: IP3 receptor). 
 
High expression levels of the H4R have been described in immune cells like eosinophils, 
T-cells, dendritic cells, mast cells and basophils.207, 209, 210, 212, 214, 216 In addition, H4Rs have 
been shown to be localized on neurons together with H1Rs and H3Rs.217 Little is known about 
the exact physiological and pathophysiological roles of the H4R. The H4R has been shown to 
trigger chemotaxis of mast cells and eosinophils214, 218 and to induce Ca2+-mobilization in 
mast cells214, monocytes219 and eosinophils220. Furthermore, stimulation of the H4R results in 
actin polymerization, shape change and upregulation of adhesion proteins in eosinophils.218, 
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220 The release of inflammatory mediators like interleukin-16216, leukotriene B4221 and 
chemokine ligand 2219 is modulated via this HR subtype. Expression levels of the H4R in 
monocytes have been demonstrated to depend on interferon-γ, interleukin-10 and 
interleukin-13.210, 219 Besides the listed in vitro evaluations, the role of the H4R has been 
investigated in several animal models. H4R-deficient mice as well as mice treated with H4R 
antagonists displayed a reduced allergic airway inflammation.222 Moreover, H4R antagonists 
proved to be beneficial in the mouse zymosan-induced peritonitis model.223 Inhibition of the 
H4R turned out to be beneficial in the carrageenan-induced paw edema in rats224, 225 and had 
a protective effect in the rat colitis model.226 In mice, H4R antagonists were superior to H1R 
antagonists in attenuation of experimental pruritus.227 Additionally, the H4R was found to be 
expressed in synovial cells of patients suffering from rheumatoid arthritis. The observed 
variations in the expression levels of the H4R may be related to severity and duration of the 
rheumatoid arthritis.217 These findings as well as the expression pattern of the H4R suggest 
this HR subtype to play a crucial role in inflammatory and immunological processes. 
Like all other HR subtypes, the H4R is a class A GPCR which contains typical motifs of 
biogenic amine receptors: a conserved Asp in TM3, a DRY-motif at the end of TM3, a 
disulfide bridge linking the extracellular loops E1 and E2 and a possible palmitoylation site in 
the C-terminal tail.206 Molecular modeling and site-directed mutagenesis performed by Shin 
et al.228 and Jongejan et al.229 assume histamine to interact with the hH4R via its protonated 
amino group with Asp-94 of TM3, whereas the imidazole ring is considered to mainly interact 
with Glu-182 of TM5. Jongejan et al. propose the imidazole Nπ to form a hydrogen bond with 
the protonated Glu-182 and the imidazole Nτ-H to interact with Ser-320 of TM6 (Figure 1.14 
A). In contrast, Kiss and colleagues suggest a reversed binding mode of histamine at the 
hH4R to be more favorable.230 They expect the protonated amino group to interact with 
Glu-182. Asp-94 is presumed to form a hydrogen bond with the imidazole Nτ-H and Thr-323 
of TM6 to interact with the imidazole Nπ (Figure 1.14 B). Moreover, the authors describe a 
possible binding mode of the cyanoguanidine-type H4R agonist OUP-16 at the hH4R. The 
imidazole Nτ-H of this compound is considered to interact like histamine with Asp-94, 
whereas an N-H group of the cyanoguanidine moiety presumably forms a hydrogen bond 
with Glu-182. In addition, a hydrogen bond between the nitrile group and Thr-323 is expected 
(Figure 1.14 C). Furthermore, very recently the importance of Phe-169 in the second extra-
cellular loop of the hH4R for agonist binding has been demonstrated.231  
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Figure 1.14. Proposed binding modes of histamine (A, B) and OUP-16 (C) at the hH4R according to A, 
Jongejan et al.229 (A) and Kiss et al.230 (B, C) 
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The successful cloning and expression of the H4R stimulated the search for selective 
agonists and antagonists. Numerous known GPCR ligands were pharmacologically studied 
on the new HR. Several H2R and H3R ligands in particular imidazole-containing compounds 
such as clobenpropit (1.38) or imetit (1.34) as well as the isothiourea dimaprit (1.20) proved 
to exert agonistic activity at the H4R.151 Even the antipsychotic drug clozapine (1.43) was 
active as an agonist at H4R (Figure 1.15).207 The first reported selective H4R agonist was the 
chiral tetrahydrofuran analog OUP-16 (1.42) which was derived from the H3R agonist 
imifuramine.232 Thereafter, 5-methylhistamine (1.18), originally considered a H2R selective 
agonist, turned out to be a more potent and selective agonist at the H4R.151 The H4R agonist 
VUF8430 (1.44) was developed based on the H2R agonist dimaprit.233 In addition, 
NG-acylated imidazolylpropylguanidines like UR-AK24 (1.25) – originally designed as H2R 
agonists – turned out to be highly potent and almost full H4R agonists. However, the residual 
agonistic activities of these compounds at the H2R and H3R compromise their use as H4R 
agonists. Selective H4R agonists are required as pharmacological tools for further studies on 
the biological role of this new HR subtype. 
The H3R inverse agonists thioperamide (1.37) and iodophenpropit (1.39) were identified as 
potent H4R inverse agonist and neutral antagonist, respectively. Meanwhile, highly selective 
H4R antagonists such as the indole-2-carboxamide JNJ 7777120 (1.45)234, the quinoxaline 
analog 1.46225 and the 2-aminopyrimidines 1.47235 and 1.48236 have been developed. With 
the conformationally constrained compound 1.48 the lack of selectivity of 1.47 toward the 
5-HT1A and 5-HT1D receptors could be overcome.236 In particular, JNJ 7777120 is a valuable 
pharmacological tool and has already been employed in several animal models to study the 
biological function of the H4R.222-224, 227 Encouraged by the promising results from animal 
models, H4R antagonists are discussed as potential drugs for the treatment of inflammatory 
and autoimmune diseases like allergic rhinitis, asthma bronchiale, rheumatoid arthritis or 
pruritus.237 For radioligand binding studies [3H]histamine and [3H]JNJ 7777120 as well the 
iodinated H3R ligand [125I]iodophenpropit have been employed.151 
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Figure 1.15. Structures of H4R ligands. 
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Chapter 2  
 
Scope and objectives 
 
Arpromidine belongs to the most potent guanidine-type histamine H2 receptor (H2R) agonists 
reported in literature.1 However, drawbacks of this class of compounds are the very poor bio-
availability after oral administration and lack of CNS penetration. This resulted in the 
development of NG-acylated imidazolylpropylguanidines with substantially reduced basicity 
relative to the guanidines. Depending on the acyl residue, these compounds show a 
comparable or just slight reduction in H2R agonistic activity relative to the guanidine-type H2R 
agonists which demonstrates the alkylguanidines and acylguanidines to conduct as bio-
isosteres.2-4  
Surprisingly, more detailed pharmacological investigations of the acylguanidine-type H2R 
agonists at other HR subtypes revealed these compounds to be also active at the hH3R and 
hH4R. In general, the compounds displayed high potencies at both HR subtypes along with 
rather low efficacies at the hH3R but high efficacies at the hH4R. 
The aim of this thesis was the design, synthesis and pharmacological characterization of 
novel NG-acylated imidazolylpropylguanidines and related compounds to elucidate structure-
activity and structure-selectivity relationships at the different HR subtypes and to obtain HR 
subtype selective compounds. As the biological role of the recently reported H4R is far from 
being understood,5-11 a major goal was the development of potent and selective H4R agonists 
as pharmacological tools. Therefore, the structural components of the NG-acylated 
imidazolylpropylguanidines should be systematically modified resulting in four series of 
compounds (Figure 2.1).  
Cyanoguanidines like OUP-1612 display agonistic potency at the H4R, whereas in the series 
of guanidine-type H2R agonists the introduction of a cyanoguanidine group was not tolerated 
in terms of H2R activation.13 Therefore, in the first series of compounds the basic acyl-
guanidine group should be replaced by a non-basic cyanoguanidine group with the intent to 
dispose agonistic activity at the H2R and retain agonistic potency at the H4R. In addition, the 
acylguanidine group should be replaced with a basic carbamoylguanidine and a non-basic 
sulfonylguanidine moiety to obtain information about the structural and physicochemical 
requirements of the central group for HR activity. 
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Figure 2.1. Overview about the intended modifications of the NG-acylated imidazolylpropylguanidines 
resulting in four series of compounds. 
 
The second series of compounds should focus on the imidazolylpropylguanidine portion. A 
three membered carbon chain connecting the imidazole-ring with the (acyl)guanidine moiety 
has been demonstrated to be optimal for H2R agonistic activity.2, 14 To elucidate if this is also 
true for H3R and H4R activity, the chain length should be varied. As methylation in position 5 
of the imidazole ring in histamine substantially increased selectivity for the H4R relative to the 
H3R,15 the same strategy should be employed for the NG-acylated imidazolylpropyl-
guanidines. Methylation of the guanidine group in arpromidine was incompatible with high 
H2R agonistic potency.1 Therefore, NG-alkylation should be investigated with respect to 
shifting the selectivity towards the H3R or H4R at the expense of H2R agonistic activity. 
Replacing the imidazole ring in acylguanidine-type H2R agonists with aminothiazoles resulted 
in remarkably enhanced selectivity for the H2R relative to the H3R and H4R.16 To evaluate if 
this concept of improving HR subtype selectivity can be transferred to other heterocycles, in 
the third series the imidazole ring should be substituted with aromatic groups. 
The last series of compounds should focus on the acyl residue. Two strategies should be 
employed in order to achieve an increase in selectivity for the H4R: Structural moieties of the 
selective H4R antagonist JNJ 7777120 or small alkanoyl residues, respectively, were 
attached to the imidazolylpropylguanidine component. The latter approach was stimulated by 
the observation that high H2R potency is favored by more bulky NG-acyl residues in 
guanidine-type HR ligands,14 whereas the small endogenous ligand histamine is 
approximately 50 times more potent at the H3R and H4R than at the H2R. Obviously, an 
additional affinity conferring moiety is not required to obtain high potencies at the H3R and 
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H4R. Hence, small alkanoyl residues should be introduced with the aim to shift selectivity 
from the H2R toward the H3R and in particular H4R. 
Moreover, the prepared compounds should be evaluated for the potential to convert 
promising HR ligands to pharmacological tools with special qualities as for example 
radioligands. 
The synthesized compounds should be pharmacologically investigated for agonism and 
antagonism at the different HR subtypes in membrane steady-state GTPase activity assays. 
In addition, selected compounds should be investigated at the guinea-pig ileum for H1R 
activity and at the guinea-pig right atrium for H2R activity. 
In summary, the aim of this thesis was to design, synthesize and pharmacologically 
characterize new NG-acylated imidazolylpropylguanidines and related compounds to get 
more information about structure-activity and structure-selectivity relationships and to obtain 
HR subtype selective compounds – in particular H4R agonists – as pharmacological tools. 
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Chapter 3  
 
Imidazolylbutylcyanoguanidines and analogs: 
Identification of potent and selective histamine 
H3R and H4R ligands 
 
3.1 Introduction 
Among the HR subtypes, the H4R shows the highest 
degree of homology with the H3R. Therefore it is not 
surprising that many H3R ligands also exhibit high affinity 
for the H4R.1 Especially for imidazole containing 
compounds such as thioperamide or proxyfan an overlap 
in the pharmacological profiles is observed.1 At present, 
only a confined number of selective H4R agonists, 
including 5-methylhistamine,1 OUP-16 (3.2)2 or 
VUF 8430,3 has been reported. However, these 
compounds have limitations since they also activate other HR subtypes.  
Initial point for the design of new selective H4R agonists were NG-acylated imidazolylpropyl-
guanidines, originally developed as potent H2R agonists.4-6 More detailed pharmacological 
investigations revealed that several of these compounds are also active at the H3R and H4R. 
For example UR-AK51 (3.1)5 shows high potencies both at the H3R and H4R but exhibits 
lower efficacy at the H3R relative to the H4R (Figure 3.1). With the aim to increase selectivity 
for the H4R over the H2R and H3R, the presented study was focused on the central acyl-
 
Figure 3.1. The acylguanidine UR-
AK51 and its pharmacological 
profile at HRs. 
 
Figure 3.2. Cyanoguanidines described in literature and their pharmacological activities at HRs. 
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guanidine moiety. The first reported selective H4R agonist OUP-162 contains – compared to 
the NG-acylated imidazolylpropylguanidines (pKa ≈ 8.0)7 – a non-basic cyanoguanidine 
moiety (pKa ≈ -0.4)8. Obviously, for H4R activation a second basic component besides the 
imidazole ring is not essential. In contrast, when replacing the strongly basic guanidine group 
in the potent H2R agonist impromidine (3.3), H2R agonistic activity is abolished (Figure 3.2).9 
Moreover, the antinociceptive drug improgan (3.5) – as well containing a cyanoguanidine 
moiety – displays low affinity for the H4R and lacks affinity for other HRs.10 Therefore, cyano-
guanidine analogs of the NG-acylated imidazolylpropylguanidines were prepared with the 
goal to obtain compounds that still exhibit agonistic activity at the H4R but are devoid of 
agonistic activity at other HR subtypes. Besides the cyanoguanidines, a couple of 
compounds were synthesized containing a carbamoylguanidine (pKa ≈ 8.0)8 or a sulfonyl-
guanidine (pKa ≈ 0.7)7 moiety instead of the acylguanidine group (Figure 3.3). These central 
groups with different basicities may reveal more information about structure-activity 
relationships at the distinct HR subtypes. As acylguanidine-type H2R agonists containing two 
sets of pharmacophoric groups (bivalent ligands) turned out to be considerably more potent 
than the monovalent counterparts,11 this bivalent approach was also investigated in the 
cyanoguanidine series with respect to H4R activity. 
In this chapter the development of a new class of potent and selective hH4R agonists and the 
unexpected discovery of a highly potent and selective carbamoylguanidine-type hH3R 
inverse agonist is reported. 
 
 
 
Figure 3.3. Replacement of the central acylguanidine group with a non-basic cyanoguanidine or 
sulfonylguanidine group and a basic carbamoylguanidine group. 
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3.2 Chemistry 
 
 
 
Scheme 3.1. Synthesis of the isourea precursors 3.24-3.40, the cyanoguanidines 3.42-3.48, 3.52-
3.58, 3.61-3.77, 3.80 and 3.81, and the carbamoylguanidines 3.49, 3.50, 3.59 and 3.78. Reagents and 
conditions: (i) DCM, 1 h, rt; (ii) MeCN, overnight, reflux; (iii) HCl 1 M, 14 d, rt. 
 
 
No. R No. R 
3.7, 3.24, 3.42, 3.49, 3.52, 3.59, 
3.61, 3.78, 3.80 Ph-(CH2)3 3.16, 3.33, 3.70 Pyridin-3-yl-(CH2)3 
3.8, 3.25, 3.43, 3.53, 3.62 Ph-(CH2)2 3.17, 3.34, 3.71 Pyridin-4-yl-(CH2)3 
3.9, 3.26, 3.44, 3.50, 3.54, 3.63 Ph-(CH2)4 3.18, 3.35, 3.72 Ph-CH(CH3)-(CH2)2 
3.10, 3.27, 3.45, 3.55, 3.64, 3.81 Ph2CH-(CH2)2 3.19, 3.36, 3.73 H 
3.11, 3.28, 3.46, 3.56, 3.65 cHex-(CH2)3 3.20, 3.37, 3.74 CH3 
3.12, 3.29, 3.47, 3.57, 3.66 Ph-S-(CH2)2 3.21, 3.38, 3.75 CH2CH3 
3.13, 3.30, 3.48, 3.58, 3.67 1H-Indol-3-yl-(CH2)2 3.22, 3.39, 3.76 CH(CH3)2 
3.14, 3.31, 3.68 4-F-Ph-(CH2)3 3.23, 3.40, 3.77 CH2-CH(CH3)2 
3.15, 3.32, 3.69 Pyridin-2-yl-(CH2)3   
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The cyanoguanidines 3.42-3.48, 3.52-3.58, 3.61-3.77, 3.80 and 3.81 were synthesized 
according to a synthetic routine previously described by Buschauer and colleagues (Scheme 
3.1).12 Aminolysis of diphenyl cyanocarbonimidate (3.6)13, 14 with the primary amines 3.7-3.23 
at ambient temperature gave the isourea intermediates 3.24-3.40 that crystallized from 
diethylether. Conversion of the isoureas to the cyanoguanidines was performed by refluxing 
with histamine (3.51) or the analogous primary amines 3.41, 3.60 or 3.79 in acetonitrile. 
Acidic hydrolysis of the cyanoguanidines8 resulted in the carbamoylguanidines 3.49, 3.50, 
3.59 and 3.78. 
 
 
 
Scheme 3.2. Synthesis of the bivalent cyanoguanidines 3.92-3.95. Reagents and conditions: 
(i) 4-(benzyloxycarbonylamino)butanoic acid (2 eq), CDI (2.2 eq), THF, overnight, rt; (ii) H2, Pd/C (10 
%), MeOH, 12h, rt; (iii) DCM/MeOH, 1 h, rt; (iv) MeCN, 12 h, reflux. 
 
For the preparation of the bivalent cyanoguanidines 3.92-3.95 the diamine spacers 3.84-3.87 
were treated with 2 equivalents of 3.6 providing the bis-isoureas 3.88-3.91, followed by 
aminolysis of these intermediates with 3.60 (Scheme 3.2). The spacer 3.84 was formed by 
coupling of the diamine 3.82 with two equivalents of Cbz-protected γ-aminobutyric acid and 
subsequent catalytic hydrogenation. 
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Scheme 3.3. Synthesis of the NG-sulfonated imidazolylpropylguanidines 3.102 and 3.103. Reagents 
and conditions: (i) NaH (60 % dispersion in mineral oil) (2 eq), NEt3 (2 eq), THF, overnight, 0 °C  rt; 
(ii) DIEA (3 eq), THF, overnight, 0 °C  rt; (iii) TFA (20 %), DCM, 5h, rt. 
 
The sulfonylguanidines 3.102 and 3.103 were prepared employing two different synthetic 
pathways (Scheme 3.3). 3.102 was synthesized by reaction of imidazolylpropylguanidine 
3.964 with tosylchloride (3.98) followed by detritylation under acidic conditions. As several 
attempts to prepare 3.103 in the same manner failed, 3.96 was replaced with its less basic 
tert-butoxycarbonyl (Boc) protected analog 3.97. This method had already been employed 
for the preparation of NG-acylated imidazolylpropylguanidines (cf. Chapter 6) and turned out 
to be also appropriate for the preparation of 3.103. 
 
OHN
N
Ph3C
NN
N
Ph3C
O
O
NH2
N
N
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3.104 3.105 3.106
3.41
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Scheme 3.4. Synthesis of 3-(1H-imidazol-4-yl)propan-1-amine 3.41. Reagents and conditions: 
(i) phthalimide (1.5 eq), PPh3 (1.5 eq), DIAD (2 eq), THF, 1 h, 0 °C  rt; (ii) N2H4 · H2O (6.3 eq), 
n-BuOH, 1h, reflux; (iii) HCl 1N, 30 min, reflux. 
 
Amines not commercially available (3.11, 3.12, 3.14-3.18, 3.41 and 3.60) were synthesized 
as shown in Schemes 3.4 – 3.6. 3.41 was synthesized starting from the imidazolylpropanol 
3.1044, 15 (Scheme 3.4). Conversion of the alcohol to the primary amine 3.106 was carried 
out by introduction of a phthalimide group under Mitsunobu-conditions16 to give 3.105 
followed by hydrazinolysis.17 Acidic hydrolysis of the trityl protecting group produced 3.41. 
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Scheme 3.5. Synthesis of 4-(1H-imidazol-4-yl)butan-1-amine (3.60). Reagents and conditions: 
(i) phthalimide (1 eq), K2CO3 (1.5 eq), KI (cat.), 12 h, 100 °C; (ii) urea (1 eq), Br2 (1 eq), MeOH, 24h, rt; 
(iii) formamidine, 5 h, 160 °C; (iv) HCl 20 %, overnight, reflux. 
 
 
The higher homolog of 3.41, 4-(1H-imidazol-4-yl)butan-1-amine (3.60), was prepared as 
outlined in Scheme 3.5 by analogy with a synthetic pathway proposed by Buschauer and 
colleagues for the synthesis of homohistamine.18 6-Phthalimidohexan-2-one (3.108) was 
obtained from the reaction of 6-chlorohexan-2-one (3.107) with phthalimide.19 Regioselective 
bromination of 3.108 was achieved by employing methanol as solvent in the presence of 
urea according to Zav’yalov and Kravchenko.20 Cyclization of formamidine with the 
α-bromoketone 3.109 in a Bredereck synthesis21 gave the imidazole 3.110 which was 
converted to 3.60 by acidic hydrolysis of the phthalimide group. 
 
 
 
Scheme 3.6. Synthesis of the arylalkylamines and analogs 3.11, 3.12 and 3.14-3.18. Reagents and 
conditions: (i) diethyl cyanomethylphosphonate (1.2 eq), NaH (60 % dispersion in mineral oil) (1.2 eq), 
THF, 6 h, rt; (ii) H2, Pd/C (10 %) (cat.), MeOH, 6h, rt; (iii) LiAlH4 (2 eq), Et2O, 2 h, reflux; (iv) 
phthalimide (1.1 eq), PPh3 (1.1 eq), DIAD (1.1 eq.), THF, overnight, 0 °C  rt; (v) N2H4 · H2O (6 eq), 
EtOH, overnight, rt; (vi) bromoethylamine · HBr (1 eq), KtBuO (2 eq), MeOH, 48 h, rt; (vii) H2, Rh/C (5 
%) (cat.), EtOH, 75 bar, 24 h, rt. 
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The amines 3.11, 3.12 and 3.14-3.18 were synthesized as 
presented in Scheme 3.6. Starting from the aldehyde 3.111 
or ketone 3.114, the nitriles 3.112 and 3.115 were 
synthesized by chain elongation using a Horner-
Wadsworth-Emmons reaction.22 3.14 was obtained by 
hydrogenation of the double bond in 3.112 followed by 
reduction of the nitrile 3.113 with LiAlH4, whereas 3.18 was 
generated contrariwise. Starting from the pyridylpropyl-
alcohols 3.117-3.119, the pyridylpropylamine isomers 3.15-
3.17 were synthesized via conversion into the phthalimides 
3.120-3.122 under Mitsunobu conditions16 followed by 
hydrazinolysis.23 3.12 was obtained by nucleophilic 
substitution of bromoethylamine with thiophenol.24 
Hydrogenation of the phenyl ring in 3.7 over Rh/C gave 3.11. 
Phenylethylsulfonyl chloride 3.99 required for the synthesis of 3.103 was synthesized 
according to the procedure described by Hannedouche and co-workers (Scheme 3.7).25 
2-Phenylethanethiol (3.124) was oxidized to the sulfonic acid 3.125 by treatment with 
peracetic acid and transformed to the sulfonyl chloride 3.99 by employing thionyl chloride. 
 
3.3 Pharmacological results and discussion 
3.3.1 Potencies and efficacies of the synthesized compounds at the hH1R, 
hH2R, hH3R and hH4R in the steady-state GTPase activity assay 
The prepared compounds were investigated for agonism and antagonism at the four hHR 
subtypes in steady-state GTPase assays measuring the enzymatic hydrolysis of radioactively 
labeled [γ-32P]GTP after G-protein activation via the respective HR subtype. These 
investigations were performed using membrane preparations of Sf9 insect cells coexpressing 
the hH1R plus RGS4, expressing the hH2R-GsαS fusion protein, coexpressing the hH3R plus 
Giα2 plus Gβ1γ2 plus RGS4 or coexpressing the hH4R-RGS19 fusion protein plus Giα2 plus 
Gβ1γ2 (Table 3.1).4, 26, 27 
Cyanoguanidines 3.42-3.48, 3.52-3.58, 3.61-3.77, 3.80 and 3.81. The initial investigation 
focused on the replacement of the acylguanidine moiety in UR-AK51 with a cyanoguanidine 
group to evaluate if this modification is tolerated by the hH4R with respect to agonistic 
activity. Indeed, the resulting compound 3.42 displayed partial agonism at the hH4R (EC50 = 
760 nM, Emax = 0.53). Moreover, 3.42 was almost inactive at the hH1R and exhibited just 
weak partial agonism at the hH2R (EC50 = 14 µM). At the hH3R, 3.42 behaved as moderate 
inverse agonist (KB = 1,900 nM, Emax = -0.37). However, compared to the reference 
 
Scheme 3.7. Synthesis of 3.99. 
Reagents and conditions: (i) 
CH3CO3H (3 eq), DCM, 2 h, 0 
°C  rt; (ii) SOCl2 (20 eq), DMF 
(cat.), DCM, 16 h, 0  35 °C.
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compound UR-AK51 (hH4R: EC50 = 17 nM, Emax = 0.74), efficacy and in particular potency at 
the hH4R drastically decreased (almost 50-fold). The phenylpropyl portion was varied to 
investigate the influence of the substituent in the “eastern part” of the molecule on hH4R 
activity. Shortening (3.43) as well as elongation (3.44) of the carbon chain resulted in 
considerably reduced potencies and efficacies. The space filling diphenylpropyl residue in 
3.45 caused a complete loss of activity, and substitution of the phenyl with a cyclohexyl ring 
(3.46) was not tolerated concerning hH4R agonism (Emax = -0.20). Similar impact was 
observed for the indole 3.48. Only the imidazolylpropylcyanoguanidine 3.47, bearing a 
phenylthioethyl substituent, retained some hH4R agonistic activity (EC50 = 1,300 nM, Emax = 
0.33). 
Since an improvement of the hH4R agonistic potency was not achieved by modifying the 
N-substituent (the “eastern part”) of 3.42, the attention was turned on the carbon chain 
connecting the imidazole ring with the cyanoguanidine group. This connecting chain proved 
to be critical for hH4R agonism. The lower homologs of 3.42-3.48, the compounds 3.52-3.58, 
were substantially less potent. For instance, 3.52 was almost inactive (KB > 10 µM) 
compared to 3.42. By contrast, increasing the chain length turned out to be a key step in 
structural optimization. The higher homolog of 3.42 (3.61) displayed 5-fold higher potency 
and essentially improved efficacy at the hH4R (EC50 = 150 nM, Emax = 0.90). As expected 
from the impromidine analog 3.49 (cf. Figure 3.2), 3.61 showed only low potency and no 
significant efficacy at the hH2R (EC50 = 5,600 nM, Emax = 0.08). 3.61 was found to be almost 
inactive at the hH1R (KB > 10 µM) and only poorly active at the hH3R (KB = 2,300 nM, Emax = 
-0.03). Notably, 3.61 is a potent and selective hH4R agonist devoid of agonistic activity at 
other HRs. Further elongation to a five membered carbon chain was not tolerated with 
respect to potency and agonistic activity at the hH4R.28 
Assured from these results, 3.61 was used as new lead structure to further improve hH4R 
agonistic potency and selectivity. Keeping the imidazolylbutyl portion constant, structural 
modifications were again focused on the “eastern part” of the cyanoguanidine-type 
compounds. Besides the residues employed in the homohistamine (3.42-3.48) and histamine 
(3.52-3.58) series, additional groups were introduced. Modifying the carbon spacer 
separating the phenyl ring and the cyanoguanidine group was found to be critical. Reducing 
the chain length just by one methylene group (3.62) clearly reduced potency and efficacy 
(EC50 = 1,100 nM, Emax = 0.36). Elongation of the spacer (3.63) even caused a loss of 
efficacy (Emax = 0.05). Apparently, a definite distance between the cyanoguanidine moiety 
and the phenyl ring is required for hH4R activation. The “eastern part” also turned out to be 
sensitive towards steric effects. A bulky diphenylpropyl residue (3.64) generated a weak 
inverse agonist at the hH4R (KB = 2,500 nM, Emax = -0.43). By contrast, a less space filling 
methyl group in α-position to the phenyl ring (3.72) had no significant influence on potency 
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and efficacy relative to 3.61 (EC50 = 140 nM, Emax = 0.79). Replacing the phenyl with a 
cyclohexyl (3.65) or an indole ring (3.67) was not tolerated in terms of hH4R activity. Notably, 
3.67 was 10-fold more potent than 3.61 at the hH3R (KB = 170 nM). Surprisingly, a fluorine 
substituent in position 4 of the phenyl ring (3.68) was found to abolish hH4R agonistic efficacy 
(KB = 260 nM, Emax = -0.10). Since the van der Waals radii for fluorine and hydrogen are 
comparable, obviously the negative polarization of the fluorine avoids the stabilization of an 
active hH4R conformation. Replacement of the phenyl carbocycle with a 2-, 3- or 4-pyridyl 
ring (3.69-3.71) also resulted in lower potencies and efficacies at the hH4R compared to 3.61. 
Interestingly, potencies decreased in the rank order from the 2-pyridyl to the 4-pyridyl analog 
(EC50 = 580 nM  EC50 = 2,600 nM). The lone pair of the nitrogens in the pyridine rings 
cause a negative electrostatic potential that evidently is unfavorable for receptor binding, in 
particular for 3.71 with the nitrogen in position 4. In contrast, formation of a thioether in the 
chain connecting the phenyl ring and the cyanoguanidine group (3.66, laboratory code: 
UR-PI376) afforded a considerable increase in potency and retained high efficacy at the 
hH4R (EC50 = 34 nM, Emax = 0.93) relative to compound 3.61. Introduction of the sulfur atom 
in the chain slightly enlarges the distance between the phenyl carbocycle and the cyano-
guanidine group. As this chain length proved to be critical in terms of potency at the hH4R (cf. 
3.62 and 3.63), this fine tuning of the spacer length may be an explanation for the increased 
potency. At the hH3R, UR-PI376 showed no agonism but moderate antagonistic/inverse 
agonistic activity (KB = 990 nM, Emax = -0.30). Activities of UR-PI376 at the hH1R and hH2R 
were negligible (KB > 10 µM, Emax ≈ 0.07).  
Thus minor structural modifications in the “eastern part” of the imidazolylbutylcyano-
guanidines can drastically change potency and efficacy. To obtain additional information 
about the structural requirements for the substituent in this position, a number of analogs 
bearing small alkyl residues (3.74-3.77) as well as the unsubstituted parent compound (3.73) 
were prepared. Leaving out the substituent (3.73) was well tolerated in terms of hH4R 
agonistic activity. 3.73 was essentially equipotent and equiefficacious with 3.61 (EC50 = 170 
nM, Emax = 0.91). However, compound 3.73 possessed similar potency at the hH3R and in 
contrast to the other imidazolylbutylcyanoguanidines exhibited partial agonistic activity at this 
HR subtype (EC50 = 250 nM, Emax = 0.42). The residue in the “eastern part” appears to be 
indispensable to discriminate between the hH3R and hH4R. This assumption is supported by 
the data on the alkylated analogs 3.74-3.77. Introduction of a methyl group (3.74) resulted in 
10-fold lower potency at the hH3R (KB = 2,100 nM, Emax = 0.16) but also hH4R potency 
decreased (EC50 = 960 nM, Emax = 0.75). However, enlarging the alkyl substituent increased 
potency at the hH4R (Me < Et < iPr < iBu, EC50 = 960 nM  EC50 = 120 nM) without 
remarkably affecting efficacy (Emax = 0.75 – 0.90). By contrast, at the hH3R, with increasing 
alkyl residues partial agonistic activity was abolished and potency slightly decreased (KB = 
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2,100 nM  KB = 3,400 nM). Reason for the pharmacological behavior at the hH3/4Rs may be 
that the unsubstituted compound 3.73 is able to form interactions – possibly a hydrogen bond 
– with amino acid residues at both receptors. Presumably, introduction of alkyl residues may 
prevent this kind of interaction, which may be compensated at the hH4R by hydrophobic 
interactions with the alkyl residues of the compounds. Since compounds with lager alkyl 
substituents are less potent at the hH3R, apparently, hydrophobic interactions are not 
feasible or steric factors may disturb binding. Nevertheless, the pharmacological data show 
that larger alkyl substituents are required for hH4R selectivity over the hH3R and for high 
hH4R potencies. For example an almost 30-fold selectivity in combination with high potency 
and efficacy at the hH4R was achieved for compound 3.77, characterized by a bulky isobutyl 
residue (EC50 = 120 nM, Emax = 0.90). The activities of 3.73-3.77 at the hH1R and hH2R were 
negligible (very weak antagonism, KB > 10 µM). 
Recently, 5-methylhistamine was identified as a selective hH4R agonist (Table 6.1).1 Hence, 
two compounds (3.80 and 3.81) bearing a methyl group at position 5 of the imidazole ring 
were prepared to evaluate if this modification can also improve selectivity of cyanoguanidine-
type hH4R agonists. Due to the availability of the corresponding amine, the prepared 
compounds contain a sulfur atom in the chain separating the imidazole ring from the cyano-
guanidine group. Unfortunately, both synthesized compounds (3.80 and 3.81) including the 
analog of lead compound 3.61 were almost inactive at the hH4R (KB > 10 µM). Provided that 
the sulfur atom in the spacer does not substantially change the pharmacological properties of 
3.80 and 3.81, in contrast to histamine introduction of a methyl group at position 5 of the 
imidazole ring seems to be not tolerated in cyanoguanidine-type hH4R agonists. This finding 
suggests the imidazole rings of the imidazolylbutylcyanoguanidines and histamine to exhibit 
distinct binding modes at the hH4R. 
Bivalent cyanoguanidines 3.92-3.95. Acylguanidine-type H2R agonists containing two 
pharmacophores linked through a spacer (“bivalent ligands”) have been shown to be 
substantially more potent relative to the monovalent compounds.11 Hence, this bivalent 
ligand approach was applied to the imidazolylbutylcyanoguanidines, aiming at compounds 
with improved hH4R agonistic potencies. In the series of bivalent acylguanidines, spacers 
consisting of 4 to 20 methylene groups between the two pharmacophores were employed. In 
the case of bivalent acylguanidine-type hH2R agonists the optimal spacer length was around 
eight methylene groups.11 Therefore, 6, 8 and 10-membered carbon chains were selected for 
connecting the cyanoguanidine moieties (3.93-3.95). However, the length of these spacers is 
presumably insufficient to bridge neighboring GPCRs, since molecular modeling 
investigations for μ-opioid receptor homodimers predict a distance between the binding sites 
of around 27 Å for the TM 5,6 interface.29 In 3.92, the distance between the equivalent 
pharmacophoric groups (cyanoguanidines ≈ 25 Å , imidazoles ≈ 40 Å) probably holds an 
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adequate length for bridging two receptors which should result in a potency greater than that 
caused from the sum of its two monovalent pharmacophores.29 This may be of interest as 
homo-oligomerization has been reported for the hH4R.30 To increase hydrophilicity and 
thereby prevent unspecific membrane effects or micelle formation, ether and amide groups 
were inserted into the spacer (3.92).  
However, none of the prepared bivalent cyanoguanidines 3.92-3.95 had agonistic activity at 
the hH4R. The poor potency observed for 3.93 with the six-membered methylene spacer was 
slightly enhanced when the spacer length was extended as in 3.94 and 3.95 (KB = 1,800 nM 
 KB = 390 nM). 3.92 – containing the longest spacer – turned out to be virtually inactive at 
the hH4R (KB > 10 µM). As the potencies of the bivalent ligands 3.93-3.95 at the hH4R did not 
clearly exceed the potencies of the monovalent ligands 3.74 and 3.75 (EC50 = 960 nM, EC50 
= 700 nM), evidently the second pharmacophore was not able to address an additional 
binding site. Moreover, agonistic activities were abolished. Obviously, the spacer prevents an 
appropriate binding of the imidazolylbutylcyanoguanidine group to stabilize an active hH4R 
conformation. 
By contrast, at the hH3R the bivalent ligands 3.93-3.95 showed a significant increase in 
potency relative to the monovalent counterparts 3.74 and 3.75. Potencies peaked for the 
compounds with octamethylene (3.94) and decamethylene (3.95) chain (KB = 17 nM, KB = 16 
nM), corresponding to a more than 100-fold increase in potency compared to 3.74 and 3.75 
(KB = 2,100 nM, KB = 2,900 nM). The efficacies remained essentially unchanged. The strong 
enhancement of potency suggests one of the pharmacophores in the bivalent ligands 3.93-
3.95 to address the identical binding site as the corresponding monovalent ligands, and the 
second pharmacophore – as the spacer lengths presumably are too short for bridging vicinal 
receptors – to increase affinity by addressing a second binding site on the same hH3R 
molecule.31, 32 This putative accessory recognition site for the imidazolylbutylcyanoguanidine 
pharmacophore present at the hH3R, but not at the hH4R, would also explain the switch from 
hH4R to hH3R selective compounds. Such an additional binding site on GPCRs for bivalent 
ligands has been described for the κ-opioid receptor antagonist nor-BNI. Mutational studies 
revealed an additional interaction of this ligand with a glutamate residue located at the top of 
TM6 to be primarily responsible for the high affinity and selectivity toward the µ-opioid 
receptor.33 Moreover, many examples of bivalent GPCR-ligands with drastically increased 
activities relative to the monovalent parent compounds despite insufficient linker chain 
lengths for addressing neighboring receptors have been reported.29, 34-36 Likewise, the most 
potent bivalent acylguanidine-type H2R agonists contain linkers which are presumably too 
short for interacting with two receptors simultaneously.11  
The imidazolylbutylcyanoguanidine group seems to be a versatile structural motif to address 
an accessory recognition site at the hH3R. Therefore, the synthesis of bivalent ligands 
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containing an H3R pharmacophore linked via a spacer to an imidazolylbutylcyanoguanidine 
group may be an appropriate approach to improve selectivity and affinity of hH3R ligands. 
Furthermore, such compounds may be interesting pharmacological tools to study the 
accessory binding site of this HR subtype. For 3.92 a 10-fold higher potency at the hH3R 
compared to the monovalent compounds 3.74 and 3.75 was determined (KB = 250 nM). Due 
to sufficient spacer length in 3.92, in addition to addressing a possible accessory binding site 
on the same receptor, bridging of two hH3R is conceivable. 
Carbamoylguanidines 3.49, 3.50, 3.59 and 3.78. Although potent and selective hH4R 
agonists were obtained in the cyanoguanidine series, the potencies of these compounds at 
the hH4R were lower than those of the corresponding acylguanidine-type compounds (cf. 
Chapter 6). To study to which extent the lack of basicity of the cyanoguanidine group 
accounts for the differences in hH4R potencies, a handful of structurally related but basic 
carbamoylguanidine-type compounds were prepared (3.49, 3.50, 3.59 and 3.78; pKa ≈ 8.0)8. 
In analogy to the cyanoguanidine-series, compounds with a two- (3.59), three (3.49 and 
3.50) and four-membered (3.78) carbon chain separating the imidazole ring from the 
carbamoylguanidine group were investigated for their pharmacological activities at the hHRs. 
In contrast to the cyanoguanidine 3.42 that showed partial agonistic activity at the hH4R (Emax 
= 0.53), the carbamoylguanidine analog 3.49 exerted considerable inverse agonistic efficacy 
(Emax = -0.75). Potency of 3.49 at the hH4R was moderate (KB = 170 nM). The phenylbutyl 
analog 3.50 exhibited comparable potency and efficacy. Like at the hH4R, 3.49 and 3.50 
were moderately potent inverse agonists at the hH3R. Interestingly, both carbamoyl-
guanidines showed moderate partial agonistic activity at hH2R (Emax ≈ 0.60). As expected 
from 3.52, the histamine analog 3.59 (laboratory code: UR-PI97) exhibited weak inverse 
agonistic activity at the hH4R (KB = 1,300 nM, Emax = -0.51). Analogous to 3.49 and 3.50, 
UR-PI97 behaved as weak partial agonist at the hH2R, even though efficacy was remarkably 
reduced (EC50 = 2,000 nM, Emax = 0.26) and showed negligible activity at the hH1R (KB > 
10,000 nM). Surprisingly, this compound turned out to be a highly potent hH3R inverse 
agonist (KB = 3.8 nM, Emax = -0.97). Compared to the cyanoguanidine analog 3.52, 
introduction of the carbamoylguanidine moiety resulted in a more than 1,500-fold increase in 
potency. In addition, UR-PI97 is highly selective over the hH1R, hH2R and hH4R (> 2,500, > 
500 and > 300-fold selectivity, respectively). The high selectivity of UR-PI97 over the hH4R is 
untypical as many imidazole containing H3R ligands as thioperamide or iodophenpropit also 
have high affinity for the H4R.1 In the cyanoguanidine series highest hH4R agonistic potency 
resided in compounds having a tetramethylene chain connecting the imidazole ring and the 
cyanoguanidine group. By contrast, the imidazolylbutylcarbamoylguanidine 3.78 showed no 
agonistic activity at the hH4R and had similar pharmacological activities as the 
carbamoylguanidines 3.49 and 3.50 at the HR subtypes. 
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Substitution of the cyanoguanidine group with a carbamoylguanidine moiety resulted in 
reversed pharmacological activities concerning the hH2R and hH4R. All carbamoylguanidines 
exerted partial agonistic activity at the hH2R, whereas most cyanoguanidines showed very 
low efficacies at this HR subtype. Moreover, the carbamoylguanidines exhibited higher 
potencies at the hH2R than the corresponding cyanoguanidines. Concerning the hH4R, the 
exchange of the cyanoguanidine moiety with a carbamoylguanidine group resulted in a loss 
of agonistic potency and produced inverse agonists. Since the cyanoguanidine and 
carbamoylguanidine groups have closely related structures, the different physicochemical 
properties may be an explanation for the essential differences in the pharmacological profile 
at the HRs. In contrast to the cyanoguanidines the basicity of the carbamoylguanidines is 
high enough to allow protonation under physiological conditions. Obviously, when comparing 
the cyanoguanidines and carbamoylguanidines a charged central group is not compatible 
with hH4R agonistic activity, whereas for hH2R agonistic activity protonation is favorable. In 
the case of UR-PI97, the capability to form an ionic interaction between the positively 
charged carbamoylguanidine group and a negatively charged amino acid residue (possibly 
the conserved Asp114 of TM3 that is crucial for histamine binding at the hH3R)37 may be the 
reason for the high increase in potency at the hH3R. However, the discrepancies in the 
pharmacological activities at the HRs can not just be explained by differences in basicity. 
Compared to the likewise basic acylguanidines, the carbamoylguanidines exhibit 
considerably lower potencies at hH2/3/4Rs and have no agonistic activity at the hH4R. 
Obviously, the variations in the structural arrangements and sizes of the central groups also 
contribute to the observed differences in HR subtype activity. 
Sulfonylguanidines 3.102 and 3.103. Additional investigations were carried out to evaluate 
the influence of the basicity on HR subtype activity and selectivity using the sulfonyl-
guanidines 3.102 and 3.103. Unlike the acylguanidine group (pKa ≈ 8)7, the sulfonylguanidine 
group (pKa ≈ 0.4)7 is virtually uncharged at physiological pH. The sulfonylguanidine analog of 
UR-AK51 (3.103) showed a more than 50-fold decrease in potency at the hH4R (KB = 1,400 
nM) and, contrary to UR-AK51, had no agonistic activity. The same was observed for the 
sulfonylguanidine 3.102 (acylguanidine analog at the hH4R: EC50 = 6.1 nM, Emax = 0.40). 
3.102 and 3.103 acted as moderate inverse agonists at the hH3R and showed partial 
agonism at the hH2R (Emax ≈ 0.50). However, potencies were reduced by two orders of 
magnitude relative to the acylated guanidines at the H2R subtype (EC50 = 12,000 nM). These 
findings show that removing basicity from the acylguanidines is not tolerated at the different 
HR subtypes. In terms of hH2R activity, this can be well explained by the putative interaction 
hH2R model. An ionic interaction between the positively charged acylguanidine group and the 
highly conserved aspartate residue of helix 3 is assumed.38 Similar interactions can be 
expected for the other HR subtypes. Obviously, for the acylguanidines an ionic interaction is 
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crucial for potent hH2/3/4R binding since the structurally closely related, non-protonated 
sulfonylguanidine analogs 3.102 and 3.103 display drastically reduced potencies. In contrast, 
likewise non-basic cyanoguanidines such as UR-PI376 are able to potently activate the 
hH4R. Apparently, for these cyanoguanidine-type compounds an ionic interaction with the 
receptor is not required. Therefore, distinct binding modes for the acylguanidine-type and 
cyanoguanidine-type agonists at the hH4R can be presumed. Nevertheless, it has to be 
considered that next to the physicochemical differences of the acylguanidines and sulfonyl-
guanidines also steric factors, as for example the different orientation of the oxygen atoms, 
may play a role in altering the pharmacological activities at the HR subtypes.  
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3.3.2 Affinities of UR-PI376 (3.66) for the hH1R, hH2R, hH3R and hH4R subtypes 
in radioligand binding experiments 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Displacement of [3H]mepyramine (5 nM), [3H]tiotidine (10 nM), [3H]Nα-methylhistamine 
(3 nM) and [3H]histamine (10 nM) with UR-PI376 from Sf9 insect cell membranes expressing the hH1R 
+ RGS4, hH2R-GsαS fusion protein, hH3R + Giα2 + Gβ1γ2 + RGS4 or hH4R-RGS19 fusion protein + Giα2 + 
Gβ1γ2. Radioligand binding was determined as described under Pharmacological methods. Data were 
analyzed for best fit to one site (monophasic) competition curves. Data points shown are the means of 
n independent experiments each performed in duplicate. 
 
UR-PI376 (3.66) was identified as the most potent and selective hH4R agonist in the cyano-
guanidine series by using steady-state GTPase assays (EC50 = 34 nM, Emax = 0.93, ≈ 30-fold 
selectivity toward the hH3R). Nevertheless, agonist potencies determined in functional 
assays depend on different factors as for example the G-protein availability.6 This can cause 
deviations between potencies received from functional experiments and binding studies. For 
this reason dissociation constants (KI values) of UR-PI376 at the different hHR subtypes 
were determined. UR-PI376 was found to displace [3H]mepyramine from the hH1R, 
[3H]tiotidine from the hH2R, [3H]Nα-methylhistamine from the hH3R and [3H]histamine from the 
hH4R giving monophasic competition binding curves (Figure 3.4). In accordance with the 
results from the GTPase assay, UR-PI376 bound with the highest affinity to the hH4R (KI = 
58 nM) and, as expected, showed a remarkably lower affinity for the hH3R (KI = 530 nM). 
However, the affinity of UR-PI376 for the hH4R was slightly reduced compared to the EC50 
value determined in the GTPase activity assay, while the contrary was observed for the 
affinity of UR-PI376 to the hH3R. Therefore, selectivity of UR-PI376 for the hH4R over the 
hH3R is about three times lower than in the functional experiments. At the hH1R and hH2R, 
the compound displayed low affinity resulting in a 450- and 70-fold selectivity for the hH4R, 
 KI (UR-PI376) [nM] n 
hH1R 26,000 ± 6,600 2 
hH2R 4,100 ± 780 3 
hH3R 530 ± 43 3 
hH4R 58 ± 13 3 
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respectively. Overall, the determined KI values and their rank orders are in agreement with 
the potencies evaluated in the functional GTPase assays and confirm UR-PI376 to be a 
highly affine and selective ligand for hH4R. 
 
3.3.3 Inhibition of the UR-PI376 (3.66) stimulated GTP hydrolysis at the hH4R 
by standard H4R antagonists  
 
 
 
 
 
 
 
 
Figure 3.5. Inhibition of the UR-PI376 stimulated GTP hydrolysis at the hH4R by the H4R antagonists 
thioperamide, iodophenpropit and JNJ 7777120. Steady-state GTPase activity in Sf9 insect cell 
membranes expressing the hH4R-RGS19 fusion protein + Giα2 + Gβ1γ2 was determined as described 
under Pharmacological methods. Reaction mixtures contained 1 µM of UR-PI376. Data were analyzed 
by nonlinear regression and were best fit to sigmoid concentration/response curves. Data points 
shown are the means of two independent experiments each performed in duplicate.a KI values of the 
reference H4R antagonists were taken from Lim et al.1 
 
The functional pharmacological activities of all compounds were determined in steady-state 
GTPase activity assays using membranes of Sf9 insect cells expressing the respective HR 
subtype. When using membranes instead of intact cells, G-proteins are directly accessible to 
the evaluated compounds. Therefore, the possibility of direct, receptor independent G-protein 
activation has to be taken into account. For many compounds like peptides, local 
anesthetics, β-adrenoceptor antagonists but also for cationic-amphiphilic HR ligands, direct 
G-protein activation has been reported.41-43 UR-PI376 with its polar and basic imidazole ring 
and more lipophilic side chain somehow features cationic-amphiphilic properties. To exclude 
a direct G-protein activation, GTPase activity was stimulated with UR-PI376 (1 µM) and the 
effect of increasing concentrations of the H4R antagonists thioperamide, iodophenpropit and 
JNJ 7777120 was evaluated. As shown in Figure 3.5, all antagonists suppressed the 
UR-PI376 induced GTP hydrolysis in a dose-dependent manner. Thioperamide was more 
Compound KB [nM] KI [nM]a 
Thioperamide 62 ± 4.6 125 
Iodophenpropit 30 ± 2.4 13 
JNJ 7777120 12 ± 2.5 16 
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effective than the other standard H4R antagonists due to its pronounced inverse agonistic 
activity at the hH4R (Table 3.1). The KB values determined for thioperamide, iodophenpropit 
and JNJ 7777120 against UR-PI376 in the functional assay were in good accordance with KI 
values from binding studies reported in literature (Figure 3.5). These results indicate the H4R 
antagonists to compete with UR-PI376 for the same binding site at the hH4R and suggest the 
GTPase activation through UR-PI376 to be receptor mediated. Direct G-protein activation by 
HR receptor ligands was reported to occur at concentrations > 10 µM.41-43 By contrast, 
UR-PI376 stimulated GTPase activation in membranes expressing the hH4R was detectable 
at concentrations ≥ 10 nM. The inverse agonistic activity of UR-PI376 at the hH3R also 
supports a receptor dependent G-protein activation as both the hH3R and hH4R were 
coexpressed with Giα2. Finally, UR-PI376 was found to displace [3H]histamine from the hH4R 
(Figure 3.4). These data confirm UR-PI376 to act as a hH4R agonist in the GTPase assay, 
whereas direct G-protein stimulation can definitely be ruled out. 
 
3.3.4 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 
Selected compounds were investigated on the isolated guinea pig (gp) ileum for H1R activity 
and on the isolated spontaneously beating guinea pig right atrium for H2R activity using 
histamine as the reference agonist (Table 3.2). 
The sulfonylguanidines 3.102 and 3.103 both showed very poor activities at the gpH2R. 
Contrary to 3.102, which was a very weak antagonist, the sulfonyl analog of UR-AK51 
(3.103) exerted weak partial agonism (Emax = 0.38). As observed for the hH2R in the GTPase 
assay, replacing the basic acylguanidine moiety with a non-basic sulfonylguanidine group 
was not tolerated at gpH2R. The potent cyanoguanidine-type hH4R agonist UR-PI376 (3.66) 
was a very poor gpH2R antagonist. This result is consistent with the poor hH2R activity 
determined in the GTPase assay. At the guinea pig ileum, all evaluated compounds acted as 
weak gpH1R antagonists. 
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Table 3.2. Pharmacological activities of selected compounds at the guinea pig ileum (gpH1R) and the 
guinea pig right atrium (gpH2R). 
 
a number of experiments, b pEC50 were calculated from the mean shift ΔpEC50 of the agonist curve 
relative to the histamine reference curve by equation: pEC50 = 6.00 + 0.13 + ∆pEC50. Summand 0.13 
represents the mean desensitization observed for control organs when two successive curves for 
histamine were performed (0.13 ± 0.02, n = 16). The SEM given for pEC50 is the SEM calculated for ∆pEC50, c efficacy, maximal response (%), relative to the maximal increase in heart rate induced by the 
reference compound histamine; d Emax (histamine) at 50 µM 3.66: 0.80 ± 0.01; e Emax (histamine) at 
30 µM 3.102: 0.93 ± 0.02; n.d.: not determined.  
 
3.3.5 Summary and Conclusion 
Starting from the NG-acylated imidazolylpropylguanidine UR-AK51, which is lacking HR 
subtype selectivity and shows high activities at hH2/3/4Rs, several classes of compounds with 
structurally related polar central groups were prepared. The aim was to obtain potent hH4R 
agonists with improved selectivity compared to UR-AK51 and to acquire information about 
structure-activity and structure-selectivity relationships of the compounds at the distinct HR 
subtypes. 
Replacing the acylguanidine moiety in UR-AK51 with a cyanoguanidine group produced 3.42 
that exhibited moderate partial agonism at the hH4R. Altering the chain length between the 
imidazole ring and the cyanoguanidine group revealed a tetramethylene spacer to be optimal 
for high potency and efficacy at the hH4R. By contrast, two- and five-membered carbon 
chains were not tolerated with respect to hH4R agonistic activity. The residue in the “eastern 
part” of the imidazoylbutylcyanoguanidines was found to be sensitive toward variations. 
Minor modifications, for example altering the chain length or fluorine substitution of the 
phenyl ring, substantially reduced hH4R activity. Otherwise, introduction of small alkyl 
residues was well accepted and revealed that larger substituents in the “eastern part” of the 
compounds are required for selectivity over the hH3R. At the hH1R and hH2R, most cyano-
guanidines showed negligible efficacies and just low potencies. Compared to hH1R and hH2R 
higher activities were observed for the hH3R, but almost all imidazolylbutylcyanoguanidines 
were most potent at the hH4R. Introduction of a methyl group at position 5 of the imidazole 
ring resulted in nearly total loss of hH4R activity. The possibility of direct, receptor 
gpH1R  gpH2R Compound 
pA2 na  pEC50b (pA2) [pD2’] Emaxc na 
histamine - -  6.00 ± 0.10 1.00 ± 0.02 > 50 
UR-AK514 5.67 ± 0.14 5  6.78 ± 0.10 0.97 ± 0.05 3 
3.66 
(UR-PI376) n.d.   (4.24 ± 0.12)  
d 2 
3.102 4.97 ± 0.08 12  (< 4.5) [< 4.5] < 5
e 2 
3.103 < 4.5 12  4.42 0.38 ± 3 2 
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independent G-protein activation in the steady-state GTPase assay by these compounds 
could be excluded by investigating UR-PI376 in the presence of different hH4R antagonists.  
The application of the bivalent ligand approach to imidazolylbutylcyanoguanidines was 
unsuccessful with respect to hH4R agonism. However, a substantial increase in potency 
compared to the corresponding “monovalent” ligands was observed at the hH3R. As the 
distances between the pharmacophores of the bivalent ligands presumably are too short to 
enable simultaneous occupation of both (“orthosteric”) binding pockets of a receptor dimer, 
the interaction of the second pharmacophore with an accessory binding site at the same 
hH3R molecule can be assumed.31, 32 
Exchange of the cyanoguanidine with a carbamoylguanidine group drastically changed the 
pharmacological activities at the HRs. All compounds displayed inverse agonistic activity at 
the hH4R, whereas partial agonism was observed at the hH2R. Unexpectedly, with UR-PI97 a 
highly potent hH3R inverse agonist was identified. Compared to the acylguanidines, the 
sulfonylguanidine analogs suffered a considerable decrease in activity at all HR subtypes.  
Substitution of the acylguanidine component with a cyanoguanidine, carbamoylguanidine or 
sulfonylguanidine moiety had great impact on potency and efficacy at the HR subtypes. 
Basicity of the groups turned out to play a crucial role for the pharmacological properties as 
the structurally related basic acylguanidines and the non-basic sulfonylguanidine analogs as 
well as the basic carbamoylguanidines and non-basic cyanoguanidines had considerably 
different activities at the HR subtypes. However, great differences are also obvious when 
comparing the pharmacological profiles of the compounds with similar basicities 
(acylguanidines versus carbamoylguanidines and cyanoguanidines versus sulfonyl-
guanidines, respectively). Thus, next to the physicochemical differences, certainly, the 
varying structures of the central groups largely influence the biological activities at the distinct 
HR subtypes. 
In summary, with UR-PI97 unexpectedly a new highly potent carbamoylguanidine-type hH3R 
inverse agonist was discovered that is 25 times more potent than the standard H3R ligand 
thioperamide. In contrast to thioperamide, that is essentially equipotent at the hH3R and 
hH4R, for UR-PI97 a more than 300-fold selectivity over the hH4R was found. Since many 
reported imidazole containing H3R antagonists/inverse agonists also bind with high affinity to 
the H4R,1 UR-PI97 belongs to the most selective imidazole containing hH3R inverse agonists 
known so far. 
Furthermore, new potent and selective cyanoguanidine-type hH4R agonists were obtained. 
UR-PI376 turned out to be the most potent hH4R agonist in this series. Compared to the lead 
compound UR-AK51 (Figure 3.1), UR-PI376 is devoid of agonistic activities at the hH2R and 
hH3R, and the selectivity for the hH4R toward the hH2R and hH3R subtype considerably 
increased (approximately 300- and 30-fold selectivity in the GTPase assay, respectively). 
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Radioligand binding studies confirmed data from the functional GTPase assays. In contrast 
to UR-PI376 other selective hH4R agonists, such as 5-methylhistamine1 (Table 3.1), 
VUF 84303 or OUP-162 have agonistic activities at other HR subtypes. Therefore the new 
cyanoguanidine-type H4R agonist UR-PI376 will be a valuable additonal pharmacological tool 
to study the biological functions of the hH4R. 
 
3.4 Experimental section 
3.4.1 Chemistry 
3.4.1.1 General conditions 
Commercial reagents and chemicals were purchased from Acros Organics (Geel, Belgium), 
IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany), Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Munich, 
Germany), TCI Europe (Zwijndrecht, Belgium) and used without further purification. 
Deuterated solvents for NMR spectroscopy were from Deutero GmbH (Kastellaun, 
Germany). All solvents were of analytical grade or distilled prior to use. If moisture-free 
conditions were required, reactions were performed in dried glassware under inert 
atmosphere (argon or nitrogen). Anhydrous DMF was purchased from Sigma-Aldrich Chemie 
GmbH. 3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol (3.104) was a gift from Prof. Dr. Sigurd Elz, 
Department of Pharmaceutical/Medicinal Chemistry I, University of Regensburg. Flash 
chromatography was performed on silica gel (Merck silica gel 60, 40 - 63 µM). Reactions 
were monitored by TLC on aluminum plates coated with silica gel (Merck silica gel 60 F254, 
thickness 0.2 mm). The compounds were detected by UV light (254 nm), a 0.3 % solution of 
ninhydrine in n-butanol (amines) or a 1.0 % solution of Fast Blue B salt (imidazole containing 
compounds) in EtOH/H2O = 30/70 (v/v). All melting points are uncorrected and were 
measured on a Büchi 530 (Büchi GmbH, Essen, Germany) apparatus.  
Nuclear Magnetic Resonance spectra (1H-NMR and 13C-NMR) were recorded with Bruker 
Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz), Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz) 
or Bruker Avance 600 (1H: 600.1 MHz; 13C: 150.9 MHz) NMR spectrometers (Bruker BioSpin 
GmbH, Rheinstetten, Germany). Chemical shifts are given in δ (ppm) relative to external 
standards. Abbreviations for the multiplicities of the signals: s (singlet), d (doublet), t (triplet), 
q (quartet), quin (quintet), sep (septet), m (multiplet), brs (for broad singlet) and combinations 
thereof. The multiplicity of carbon atoms (13C-NMR) was determined by DEPT 135 
(distortionless enhancement by polarization transfer): “+” primary and tertiary carbon atom 
(positive DEPT 135 signal), “-“ secondary carbon atom (negative DEPT 135 signal), “quat” 
quaternary carbon atom. In certain cases 2D-NMR techniques (COSY, HMQC, HSQC, 
HMBC, NOESY) were used to assign 1H and 13C chemical shifts. Infrared spectra (IR) were 
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measured on a Bruker Tensor 27 spectrometer equipped with an ATR (attenuated total 
reflexion) unit from Harrick Scientific Products Inc. (Ossining/NY, US). Mass spectra (MS) 
were recorded on a Finnigan MAT 95 (EI-MS 70 eV, HR-MS), Finnigan SSQ 710A (CI-MS 
(NH3)) and on a Finnigan ThermoQuest TSQ 7000 (ES-MS) spectrometer. The peak-
intensity in % relative to the strongest signal is indicated in parenthesis. Elemental analysis 
(C, H, N, Heraeus Elementar Vario EL III) were performed by the Analytical Department of 
the University Regensburg and are within ± 0.4 % unless otherwise noted. 
Preparative HPLC was performed with a pump model K-1800 (Knauer, Berlin, Germany), the 
column was Eurosphere-100 (250 x 32 mm) (Knauer), which was attached to a UV-detector 
model K-2000 (Knauer). UV detection of the compounds was done at 210 nm. The 
temperature was 25 °C and the flow rate 37 ml/min. The mobile phase was 0.1 % TFA in 
millipore water and MeCN. Analytical HPLC was performed on a system from Thermo 
Separation Products (TSP, Egelsbach, Germany) equipped with a SN 400 controller, P4000 
pump, an AS3000 autosampler and a Spectra Focus UV/VIS detector. Stationary phase was 
a Eurosphere-100 C-18 (250 x 4.0 mm, 5 μm) column (Knauer) thermostated at 30 °C. The 
flow rate was 0.8 ml/min and the dead time (t0) was 3.32 min. For some compounds 
analytical HPLC was performed on a Merck-Hitachi system equipped with a L-5000 LC 
controller, 655A-12 LC pump, a 655A-40 autosampler and a L-4250 UV/VIS detector. 
Stationary phase was a Eurosphere-100 C-18 (250 x 4.0 mm, 5 μm) column (Knauer) 
thermostated at 25 °C. The flow rate was 0.7 ml/min and the dead time (t0) was 2.54 min. As 
mobile phase gradients of MeCN/0.05 % TFA (aq.) were used and the absorbance was 
detected at 210 nm. Compound purities were calculated as the percentage peak area of the 
analyzed compound by UV detection at 210 nm. HPLC conditions, retention times (tR), 
capacity factors (k’ = (tR – t0)/t0) and purities of the synthesized compounds are listed in the 
appendix (Chapter 9). 
 
3.4.1.2 Preparation of the isoureas 3.24-3.40 
General procedure 
 
A solution of the pertinent primary amine (1 eq) and diphenyl cyanocarbonimidate (3.6, 1 eq) 
in DCM was stirred for 1 h. After evaporation of the solvent, the product was crystallized from 
Et2O.  
 
1-Cyano-2-phenyl-3-(3-phenylpropyl)isourea (3.24) 
The title compound was prepared from 3.7 (0.68 g, 5.0 mmol) and 3.6 (1.19 g, 5.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.2 g, 86 %); mp 92 
– 95 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.91 – 2.10 (m, 2H, Ph-CH2-CH2), 2.73 (t, 2H, 
3J = 7.6 Hz, Ph-CH2), 3.39 – 3.54 (m, 2H, Ph-(CH2)2-CH2), 6.86 (t, 1H, 3J = 6.0 Hz, N-H), 7.00 
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– 7.51 (m, 10H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 30.97 (-, Ph-CH2-CH2), 32.88 (-, 
Ph-CH2), 42.27 (-, Ph-(CH2)2-CH2), 115.68 (Cquat, C≡N), 121.48 (+, 2 Ph-C), 126.30 (+, 1 Ph-
C), 126.67 (+, 1 Ph-C), 128.36 (+, 2 Ph-C), 128.64 (+, 2 Ph-C), 129.60 (+, 2 Ph-C), 140.66 
(Cquat, Ph-C), 151.04 (Cquat, 1 Ph-C), 164.05 (Cquat, C=N). IR (cm-1) = 3190 (N-H), 3061, 2942, 
2187 (C≡N), 1635 (C=N), 1598, 1419, 1203. CI-MS (NH3) m/z (%): 280 (100) [M + H]+. Anal. 
(C17H17N3O) C, H, N. C17H17N3O (279.34). 
 
1-Cyano-2-phenyl-3-phenethylisourea (3.25)13 
The title compound was prepared from 3.8 (0.97 g, 8.0 mmol) and 3.6 (1.91 g, 8.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.3 g, 85 %); mp 126 
– 128 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.96 (t, 2H, 3J = 7.1 Hz, Ph-CH2), 3.63 – 
3.78 (m, 2H, Ph-CH2-CH2), 6.90 (d, 2H, 3J = 7.8 Hz, Ph-H), 7.07 (t, 1H, 3J = 6.1 Hz, N-H), 
7.19 – 7.44 (m, 8H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 36.18 (-, Ph-CH2), 43.93 (-, 
Ph-CH2-CH2), 115.69 (Cquat, C≡N), 121.45 (+, 2 Ph-C), 126.63 (+, 1 Ph-C), 126.93 (+, 1 Ph-
C), 128.87 (+, 2 Ph-C), 128.97 (+, 2 Ph-C), 129.53 (+, 2 Ph-C), 137.81 (Cquat, 1 Ph-C), 
151.96 (Cquat, Ph-C), 164.03 (Cquat, C=N). IR (cm-1) = 3188 (N-H), 3063, 2189 (C≡N), 1646 
(C=N), 1448, 1419, 1196. CI-MS (NH3) m/z (%): 264 (100) [M – H+]-. Anal. (C16H15N3O) C, H, 
N. C16H15N3O (265.31). 
 
1-Cyano-2-phenyl-3-(4-phenylbutyl)isourea (3.26) 
The title compound was prepared from 3.9 (1.19 g, 8.0 mmol) and 3.6 (1.91 g, 8.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (2.0 g, 85 %); mp 134 
– 136 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.61 – 1.81 (m, 4H, Ph-CH2-(CH2)2, 2.67 (t, 
2H, 3J = 6.7 Hz, Ph-CH2), 3.38 – 3.50 (m, 2H, Ph-(CH2)3-CH2), 6.99 (t, 1H, 3J = 5.8 Hz, N-H), 
7.01 – 7.51 (m, 10H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 28.32, 29.06 (-, Ph-CH2-
(CH2)2), 35.34 (-, Ph-CH2), 42.56 (-, Ph-(CH2)3-CH2), 115.77 (Cquat, C≡N), 121.51 (+, 2 Ph-C), 
125.99 (+, 1 Ph-C), 126.63 (+, 1 Ph-C), 128.45 (+, 2 Ph-C), 128.47 (+, 2 Ph-C), 129.58 (+, 2 
Ph-C), 141.73 (Cquat, 1 Ph-C), 151.09 (Cquat, 1 Ph-C), 164.04 (Cquat, C=N). IR (cm-1) = 3190 
(N-H), 3057, 2934, 2187 (C≡N), 1644 (C=N), 1446, 1417, 1192. EI-MS (70 eV) m/z (%): 293 
(10) [M+•], 91 (100) [C7H7+]. Anal. (C18H19N3O) C, H, N. C18H19N3O (293.36). 
 
1-Cyano-3-(3,3-diphenylpropyl)-2-phenylisourea (3.27)44 
The title compound was prepared from 3.10 (1.06 g, 4.0 mmol) and 3.6 (0.95 g, 4.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.3 g, 91 %); mp 166 
– 168 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.37 – 2.52 (m, 2H, Ph2CH-CH2), 3.33 – 
3.46 (m, 2H, Ph2CH-CH2-CH2), 4.03 (t, 1H, 3J = 7.9 Hz, Ph2CH), 6.97 – 7.11 (m, 3H, 2 Ph-H 
+ N-H), 7.13 – 7.49 (m, 13H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 35.11 (-, Ph2CH-
Chapter 3 68
CH2-CH2), 41.48 (-, Ph2CH-CH2), 48.63 (+, Ph2CH), 115.62 (Cquat, C≡N), 121.46 (+, 2 Ph-C), 
126.66 (+, 3 Ph-C), 127.70 (+, 4 Ph-C), 128.78 (+, 4 Ph-C), 129.57 (+, 2 Ph-C), 143.61 (Cquat, 
2 Ph-C), 151.03 (Cquat, 1 Ph-C), 163.93 (Cquat, C=N). IR (cm-1) = 3184 (N-H), 3061, 2187 
(C≡N), 1641 (C=N), 1447, 1208. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 356 (100) [M + 
H]+. Anal. (C23H21N3O) C, H, N. C23H21N3O (355.43). 
 
1-Cyano-3-(3-cyclohexylpropyl)-2-phenylisourea (3.28) 
The title compound was prepared from 3.11 (1.13 g, 8.0 mmol) and 3.6 (1.91 g, 8.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.75 g, 77 %); mp 
101 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.76 – 1.03 (m, 2H), 1.04 – 1.42 (m, 6H), 1.54 
– 1.94 (m, 7H), 3.31 – 3.58 (m, 2H, cHex-(CH2)2-CH2), 6.80 (t, 1H, 3J = 5.8 Hz, N-H), 7.03 – 
7.61 (m, 5H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 26.33 (-, 2 CH2), 26.61 (-, CH2), 
26.98 (-, CH2), 33.30 (-, 2 CH2), 34.32 (-, CH2), 37.30 (+, CH), 43.13 (-, CH2), 115.77 (Cquat, 
C≡N), 121.49 (+, 2 Ph-C), 126.62 (+, 1 Ph-C), 129.59 (+, 2 Ph-C), 151.11 (Cquat, 1 Ph-C), 
164.05 (Cquat, C=N). IR (cm-1) = 3183 (N-H), 3063, 2918, 2851, 2189 (C≡N), 1640 (C=N), 
1446, 1416, 1207. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 286 (100) [M + H]+. Anal. 
(C17H23N3O) C, H, N. C17H23N3O (285.38). 
 
1-Cyano-2-phenyl-3-[2-(phenylthio)ethyl]isourea (3.29) 
The title compound was prepared from 3.12 (1.53 g, 10.0 mmol) and 3.6 (2.38 g, 10.0 mmol) 
in DCM (50 mL) according to the general procedure yielding a white solid (2.6 g, 86 %); mp 
110 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 3.18 (t, 2H, 3J = 7.0 Hz, Ph-S-CH2), 3.55 – 
3.69 (m, 2H, Ph-S-CH2-CH2), 7.05 (d, 2H, 3J = 7.8 Hz, Ph-H), 7.15 – 7.50 (m, 8H, Ph-H), 7.57 
(t, 1H, 3J = 6.1 Hz, N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 33.22 (-, Ph-S-CH2), 41.68 (-, 
Ph-S-CH2-CH2), 115.55 (Cquat, C≡N), 121.44 (+, 2 Ph-C), 126.71 (+, 1 Ph-C), 126.79 (+, 1 
Ph-C), 129.26 (+, 2 Ph-C), 128.62 (+, 2 Ph-C), 129.92 (+, 2 Ph-C), 134.60 (Cquat, 1 Ph-C), 
150.98 (Cquat, 1 Ph-C), 163.88 (Cquat, C=N). IR (cm-1) = 3252 (N-H), 3212, 3065, 2190 (C≡N), 
1635 (C=N), 1433, 1207. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 298 (100) [M + H]+. Anal. 
(C16H15N3OS) C, H, N. C16H15N3OS (297.37). 
 
1-Cyano-3-(1H-indol-3-yl)ethyl-2-phenylisourea (3.30) 
The title compound was prepared from 3.13 (1.28 g, 8.0 mmol) and 3.6 (1.91 g, 8.0 mmol) in 
DCM (50 mL) according to the general procedure. The obtained solid was recrystallized from 
Et2O/MeCN yielding a beige solid (2.1 g, 86 %); mp 167 – 168 °C. 1H-NMR (300 MHz, 
DMSO-d6) isomers: δ [ppm] = 2.95 (t, 0.8H, 3J = 7.4 Hz, indole-3-CH2), 3.03 (t, 1.2H, 3J = 
7.0 Hz, indole-3-CH2), 3.44 – 3.67 (m, 2H, indole-3-CH2-CH2), 6.77 – 7.62 (m, 10H, Ph-H + 
indole-H), 8.49 (t, 0.4H, 3J = 5.4 Hz, N-H), 8.88 (t, 0.6H, 3J = 5.7 Hz, N-H), 10.89 (s, 1H, 
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indole-N-H). 13C-NMR (75 MHz, DMSO-d6) isomers: δ [ppm] = 24.06, 25.44 (-, indole-3-CH2), 
42.81, 43.06 (-, CH2-NH), 110.66, 110.84 (Cquat, indole-C-3), 111.33 (+, indole-C-7), 114.77 
(Cquat, C≡N), 118.13, 118.27, 118.31, 119.84 (+, indole-C-4,5,6), 120.91, 121.46 (+, Ph-C), 
123.00, 123.07 (+, indole-C-2), 126.01, 126.04 (+, Ph-C), 127.05, 127.11 (Cquat, indole-C-3a), 
129.24, 130.14 (+, Ph-C), 136.15, 136.21 (Cquat, indole-C-7a), 150.97, 151.42 (Cquat, Ph-C), 
159.50, 162.62 (Cquat, C=N). IR (cm-1) = 3354 (N-H), 3205 (N-H), 3058, 2180 (C≡N), 1640 
(C=N), 1445, 1424, 1198. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 305 (100) [M + H]+. 
Anal. (C18H16N4O) C, H, N. C18H16N4O (304.35). 
 
1-Cyano-3-[3-(4-fluorophenyl)propyl]-2-phenylisourea (3.31) 
The title compound was prepared from 3.14 (0.92 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.2 g, 67 %); mp 104 
– 106 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.88 – 2.06 (m, 2H, Ph-CH2-CH2), 2.69 (t, 
2H, 3J = 7.6 Hz, Ph-CH2), 3.37 – 3.53 (m, 2H, Ph-(CH2)2-CH2), 6.89 – 7.53 (m, 10H, Ph-H + 
N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 31.10, 32.07 (-, 4-F-Ph-CH2-CH2), 42.13 (-, 4-F-
Ph-(CH2)2-CH2), 115.38 (+, 2J = 21.1 Hz, 4-F-Ph-C-3,5), 115.71 (Cquat, C≡N), 121.47 (+, 2 Ph-
C), 126.69 (+, 1 Ph-C), 129.62 (+, 2 Ph-C), 129.73 (+, 3J = 7.9 Hz, 4-F-Ph-C-2,6), 136.36 
(Cquat, 4J = 3.2 Hz, 4-F-Ph-C-1), 151.05 (Cquat, 1 Ph-C), 161.46 (Cquat, 2J = 244.0 Hz, 4-F-Ph-
C-4), 164.04 (Cquat, C=N). IR (cm-1) = 3205 (N-H), 3064, 2944, 2187 (C≡N), 1647 (C=N), 
1448, 1429, 1203. CI-MS (NH3) m/z (%): 298 (100) [M + H]+. Anal. (C17H16FN3O) C, H, N. 
C17H16FN3O (297.33). 
 
1-Cyano-2-phenyl-3-[3-(pyridin-2-yl)propyl]isourea (3.32) 
The title compound was prepared from 3.15 (0.82 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.2 g, 71 %); mp 96 
– 98 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.07 – 2.21 (m, 2H, Pyr-2-CH2-CH2), 3.04 (t, 
2H, 3J = 6.2 Hz, Pyr-2-CH2), 3.54 – 3.64 (m, 2H, Pyr-2-(CH2)2-CH2), 6.95 – 7.88 (m, 8H, Ph-H 
+ Pyr-3,4,5-H), 8.49 (dd, 1H, 3J = 5.9 Hz, 4J = 1.6 Hz, Pyr-6-H), 9.41 (brs, 1H, N-H). 13C-NMR 
(75 MHz, CDCl3): δ [ppm] = 26.94 (-, Pyr-2-CH2-CH2), 35.97 (-, Pyr-2-CH2), 43.57 (-, Pyr-2-
(CH2)2-CH2), 115.89 (Cquat, C≡N), 121.61 (+, Pyr-C-5 + 2 Ph-C), 123.05 (+, Pyr-C-3), 126.41 
(+, 1 Ph-C), 129.50 (+, 2 Ph-C), 136.97 (+, Pyr-C-4), 149.76 (+, Pyr-C-6), 151.29 (Cquat, 1 Ph-
C), 160.12 (Cquat, Pyr-C-2), 163.44 (Cquat, C=N). IR (cm-1) = 3060, 2190 (C≡N), 1607 (C=N), 
1326, 1208. CI-MS (NH3) m/z (%): 281 (100) [M + H]+. Anal. (C16H16N4O) C, H, N. C16H16N4O 
(280.32). 
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1-Cyano-2-phenyl-3-[3-(pyridin-3-yl)propyl]isourea (3.33) 
The title compound was prepared from 3.16 (0.82 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.1 g, 65 %); mp 90 
– 91 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.91 – 2.09 (m, 2H, Pyr-3-CH2-CH2), 2.72 (t, 
2H, 3J = 7.7 Hz, Pyr-3-CH2), 3.38 – 3.53 (m, 2H, Pyr-3-(CH2)2-CH2), 7.00 – 7.58 (m, 8H, Ph-H 
+ Pyr-4,5-H + N-H), 8.42 – 8.50 (m, 2H, Pyr-2,6-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 
30.07, 30.67 (-, Pyr-3-CH2-CH2), 42.06 (-, Pyr-3-(CH2)2-CH2), 115.71 (Cquat, C≡N), 121.46 (+, 
2 Ph-C), 123.50 (+, Pyr-C-5), 126.67 (+, 1 Ph-C), 129.61 (+, 2 Ph-C), 135.81 (+, Pyr-C-4), 
136.17 (Cquat, Pyr-C-3), 147.79 (+, Pyr-C-6), 149.86 (+, Pyr-C-2), 151.06 (Cquat, 1 Ph-C), 
163.99 (Cquat, C=N). IR (cm-1) = 3185 (N-H), 3056, 2937, 2187 (C≡N), 1632 (C=N), 1421, 
1198, 1190. CI-MS (NH3) m/z (%): 281 (100) [M + H]+. Anal. (C16H16N4O) C, H, N. C16H16N4O 
(280.32). 
 
1-Cyano-2-phenyl-3-[3-(pyridin-4-yl)propyl]isourea (3.34) 
The title compound was prepared from 3.17 (0.82 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.34 g, 80 %); mp 
120 – 121 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.86 – 2.11 (m, 2H, Pyr-4-CH2-CH2), 
2.71 (t, 2H, 3J = 7.7 Hz, Pyr-4-CH2), 3.39 – 3.50 (m, 2H, Pyr-4-(CH2)2-CH2), 7.02 – 7.18 (m, 
4H, Ph-H + Pyr-3,5-H), 7.24 – 7.46 (m, 3H, Ph-H), 7.71 (t, 1H, 3J = 5.6 Hz, N-H), 8.49 (dd, 
2H, 3J = 4.4 Hz, 4J = 1.6 Hz, Pyr-2,6-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 29.82, 32.21 (-
, Pyr-4-CH2-CH2), 42.02 (-, Pyr-4-(CH2)2-CH2), 115.76 (Cquat, C≡N), 121.44 (+, 2 Ph-C), 
123.82 (+, Pyr-C-3,5), 126.69 (+, 1 Ph-C), 129.62 (+, 2 Ph-C), 149.88 (+, Pyr-C-2,6), 149.93 
(Cquat, Pyr-C-4), 151.06 (Cquat, Ph-C), 163.99 (Cquat, C=N). IR (cm-1) = 2959, 2823, 2181 
(C≡N), 1600 (C=N), 1452, 1416, 1200. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 281 (100) 
[M + H]+. Anal. (C16H16N4O) C, H, N. C16H16N4O (280.32). 
 
1-Cyano-2-phenyl-3-(3-phenylbutyl)isourea (3.35) 
The title compound was prepared from 3.18 (0.90 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (1.5 g, 82 %); mp 132 
– 134 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.31 (d, 3H, 3J = 6.9 Hz, PhCH3CH), 1.91 – 
2.03 (m, 2H, PhCH3CH-CH2), 2.75 – 2.90 (m, 1H, PhCH3CH), 3.18 – 3.42 (m, 2H, PhCH3CH-
CH2-CH2), 6.83 (t, 1H, 3J = 5.2 Hz, N-H), 6.99 – 7.52 (m, 10H, Ph-H). 13C-NMR (75 MHz, 
CDCl3): δ [ppm] = 22.62 (+, PhCH3CH), 37.49, (-, CH2), 37.56 (+, PhCH3CH), 41.25 (-, CH2), 
115.62 (Cquat, C≡N), 121.46 (+, 2 Ph-C), 126.54 (+, 1 Ph-C), 126.60 (+, 1 Ph-C), 126.87 (+, 2 
Ph-C), 128.76 (+, 2 Ph-C), 129.56 (+, 2 Ph-C), 145.71 (Cquat, 1 Ph-C), 151.05 (Cquat, 1 Ph-C), 
163.91 (Cquat, C=N). IR (cm-1) = 3185 (N-H), 3055, 2955, 2184 (C≡N), 1642 (C=N), 1450, 
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1427, 1201. CI-MS (NH3) m/z (%): 294 (100) [M + H]+. Anal. (C18H19N3O) C, H, N. C18H19N3O 
(293.36). 
 
1-Cyano-2-phenylisourea (3.36)45 
The title compound was prepared from a 7 M solution of ammonia (3.19) in MeOH (0.86 mL, 
6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in DCM (50 mL) according to the general procedure 
yielding a white solid (0.8 g, 83 %); mp 149 – 151 °C. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] 
= 7.13 – 7.20 (m, 2H, Ph-H), 7.24 – 7.32 (m, 1H, Ph-H), 7.37 – 7.46 (m, 2H, Ph-H), 8.58 (brs, 
2H, N-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 114.86 (Cquat, C≡N), 121.60 (+, 2 Ph-C), 
126.09 (+, 1 Ph-C), 129.50 (+, 2 Ph-C), 151.03 (Cquat, 1 Ph-C), 164.53 (Cquat, C=N). IR (cm-1) 
= 3321 (N-H), 3174, 3056, 2200 (C≡N), 1646 (C=N), 1576, 1452, 1203. CI-MS (NH3) m/z 
(%): 179 (100) [M + NH4]+, 162 (71) [M + H]+. Anal. (C8H7N3O) C, H, N. C8H7N3O (161.16). 
 
1-Cyano-3-methyl-2-phenylisourea (3.37)46 
The title compound was prepared from a 8 M solution of methylamine (3.20) in MeOH (0.75 
mL, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in DCM (50 mL) according to the general 
procedure yielding a white solid (0.8 g, 76 %); mp 125 – 126 °C. 1H-NMR (300 MHz, DMSO-
d6) isomers: δ [ppm] = 2.76 (s, 1.4 H, CH3), 2.91 (s, 1.6 H, CH3), 7.14 – 7.54 (m, 5H, Ph-H), 
8.19 (brs, 0.45H, N-H), 8.66 (brs, 0.55H, N-H). 13C-NMR (75 MHz, DMSO-d6) isomers: δ 
[ppm] = 28.69, 29.15 (+, CH3), 114.43, 114.85 (Cquat, C≡N), 120.12, 121.70 (+, 2 Ph-C), 
126.13, 126.26 (+, 1 Ph-C), 129.39, 130.22 (+, 2 Ph-C), 151.14, 151.29 (Cquat, 1 Ph-C), 
160.06, 163.16 (Cquat, C=N). IR (cm-1) = 3189 (N-H), 3015, 2186 (C≡N), 1656 (C=N), 1628, 
1386. CI-MS (NH3) m/z (%): 193 (100) [M + NH4]+, 176 (68) [M + H]+. Anal. (C9H9N3O) C, H, 
N. C9H9N3O (175.19). 
 
1-Cyano-3-ethyl-2-phenylisourea (3.38)47 
The title compound was prepared from a 30 – 40 % solution of ethylamine (3.21) in MeOH 
(0.90 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in DCM (50 mL) according to the general 
procedure yielding a white solid (0.5 g, 45 %); mp 117 – 118 °C. 1H-NMR (300 MHz, CDCl3): 
δ [ppm] = 1.29 (t, 3H, 3J = 7.2 Hz, CH3), 3.41 – 3.55 (m, 2H, CH2), 6.99 (brs, 1H, N-H), 7.09 
(d, 2H, 3J = 7.8 Hz, Ph-H), 7.24 – 7.33 (m, 1H, Ph-H), 7.34 – 7.50 (m, 2H, Ph-H). 13C-NMR 
(75 MHz, CDCl3): δ [ppm] = 14.93 (+, CH3), 37.74, (-, CH2), 115.84 (Cquat, C≡N), 121.50 (+, 2 
Ph-C), 126.60 (+, 1 Ph-C), 129.57 (+, 2 Ph-C), 151.11 (Cquat, 1 Ph-C), 163.97 (Cquat, C=N). IR 
(cm-1) = 3259 (N-H), 2979, 2182 (C≡N), 1626 (C=N), 1419, 1208. CI-MS (NH3) m/z (%): 190 
(100) [M + H]+. Anal. (C10H11N3O) C, H, N. C10H11N3O (189.21).  
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1-Cyano-3-isopropyl-2-phenylisourea (3.39)48 
The title compound was prepared from 3.22 (0.35 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (0.8 g, 68 %); mp 124 
– 126 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.33 (d, 6H, 3J = 6.0 Hz, CH3), 4.04 – 4.22 
(m, 1H, CH), 6.17 (brs, 1H, N-H), 7.09 (d, 2H, 3J = 7.8 Hz, Ph-H), 7.30 (d, 1H, 3J = 7.2 Hz, 
Ph-H), 7.35 – 7.48 (m, 2H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 22.62 (+, CH3), 
45.73, (+, CH), 115.44 (Cquat, C≡N), 121.43 (+, 2 Ph-C), 126.70 (+, 1 Ph-C), 129.60 (+, 2 Ph-
C), 151.05 (Cquat, 1 Ph-C), 163.22 (Cquat, C=N). IR (cm-1) = 3201 (N-H), 3068, 2980, 2189 
(C≡N), 1642 (C=N), 1431, 1200. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 204 (100) [M + 
H]+. Anal. (C11H13N3O) C, H, N. C11H13N3O (203.24). 
 
1-Cyano-3-isobutyl-2-phenylisourea (3.40) 
The title compound was prepared from 3.23 (0.44 g, 6.0 mmol) and 3.6 (1.43 g, 6.0 mmol) in 
DCM (50 mL) according to the general procedure yielding a white solid (0.8 g, 59 %); mp 
103 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.00 (d, 6H, 3J = 6.7 Hz, CH3), 1.86 – 2.03 (m, 
1H, CH), 3.21 – 3.30 (m, 2H, CH2), 6.91 (brs, 1H, N-H), 7.07 (d, 2H, 3J = 7.8 Hz, Ph-H), 7.23 
– 7.33 (m, 1H, Ph-H), 7.34 – 7.46 (m, 2H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 19.92 
(+, CH3), 28.79, (+, CH), 49.90 (-, CH2), 115.68 (Cquat, C≡N), 121.46 (+, 2 Ph-C), 126.58 (+, 1 
Ph-C), 129.56 (+, 2 Ph-C), 151.10 (Cquat, 1 Ph-C), 164.16 (Cquat, C=N). IR (cm-1) = 3194 (N-
H), 3063, 2955, 2190 (C≡N), 1635 (C=N), 1423, 1207. CI-MS (NH3) m/z (%): 218 (100) [M + 
H]+. Anal. (C12H15N3O) C, H, N. C12H15N3O (217.27). 
 
3.4.1.3 Preparation of the cyanoguanidines 3.42-3.48, 3.52-3.58, 3.61-3.77, 3.80 
and 3.81 
General procedure 
Hydrochlorides of 3.41 and 3.51 were converted into the bases by passing a basic ion 
exchanger (Merck, ion exchanger III, mobile phase: MeOH). The isourea (1 eq) and the 
pertinant amine (1.1 eq) were refluxed in MeCN for 12 h. After removal of the solvent in 
vacuo, the crude product was purified by flash chromatography. For analytical purposes a 
small amount of most compounds was converted to the hydrogenoxalate by addition of a 
saturated solution of oxalic acid in Et2O to a solution of the cyanoguanidine in EtOH. 
 
2-Cyano-1-[3-(1H-imidazol-4-yl)propyl]-3-(3-phenylpropyl)guanidine (3.42) 
The title compound was prepared from 3.24 (0.56 g, 2.0 mmol) and 3.41 (0.28 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.45 g, 72 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.80 – 1.95 (m, 4H, 
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Im-4-CH2-CH2 + Ph-CH2-CH2), 2.59 – 2.72 (m, 4H, Im-4-CH2 + Ph-CH2), 3.17 – 3.28 (m, 4H, 
Im-4-(CH2)2-CH2 + Ph-(CH2)2-CH2), 7.04 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.11 – 7.29 (m, 5H, Ph-
H), 8.12 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 23.87 (-, Im-4-
CH2), 29.87 (-, Im-4-CH2-CH2), 32.23 (-, Ph-CH2-CH2), 33.98 (-, Ph-CH2), 41.98 (-, Im-4-
(CH2)2-CH2), 42.42 (-, Ph-(CH2)2-CH2), 117.06 (+, Im-C-5), 120.18 (Cquat, C≡N), 127.03 (+, 
Ph-C-4), 129.45 (+, 2 Ph-C), 129.50 (+, 2 Ph-C), 135.39 (+, Im-C-2), 136.74 (Cquat, Im-C-4), 
142.84 (Cquat, Ph-C-1), 161.26 (Cquat, C=N). IR (cm-1) = 3250 (N-H), 2937 (C-H), 2857 (C-H), 
2157 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 311 (100) [M + H]+. 
HRMS (EI-MS) calcd. for C17H22N6 [M+•] 310.1906; found 310.1903. Anal. (C17H22N6 · 0.25 
H2O) C, H, N. C17H22N6 (310.40). 
 
2-Cyano-1-[3-(1H-imidazol-4-yl)propyl]-3-(2-phenylethyl)guanidine (3.43) 
The title compound was prepared from 3.25 (0.53 g, 2.0 mmol) and 3.41 (0.28 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.37 g, 62 %); mp (hydrogenoxalate) 146 – 149 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.78 – 1.91 (m, 2H, Im-4-CH2-CH2), 2.69 (t, 2H, 3J = 7.6 
Hz, Im-4-CH2), 2.84 (t, 2H, 3J = 7.2 Hz, Ph-CH2), 3.22 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)2-CH2), 
3.44 (t, 2H, 3J = 7.2 Hz, Ph-CH2-CH2), 7.11 – 7.33 (m, 6H, Ph-H, Im-5-H), 8.58 (d, 1H, 4J = 
1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 22.96 (-, Im-4-
CH2), 29.47 (-, Im-4-CH2-CH2), 36.68 (-, Ph-CH2), 41.80 (-, Im-4-(CH2)2-CH2), 44.27 (-, Ph-
CH2-CH2), 116.91 (+, Im-C-5), 120.02 (Cquat, C≡N), 127.58 (+, Ph-C-4), 129.63 (+, 2 Ph-C), 
130.05 (+, 2 Ph-C), 134.93 (+, Im-C-2), 135.43 (Cquat, Im-C-4), 140.12 (Cquat, Ph-C-1), 161.20 
(Cquat, C=N), 167.90 (Cquat, hydrogenoxalate). IR (cm-1) = 3249 (N-H), 2940 (C-H), 2854 (C-
H), 2159 (C≡N), 1576 (C=N). ES-MS (MeOH + NH4OAc) m/z (%): 297 (100) [M + H]+. HRMS 
(EI-MS) calcd. for C16H20N6 [M+•] 296.1749; found 296.1747. Anal. (C16H20N6 · 0.7 C2H2O4 · 
0.5 H2O) C, H, N. C16H20N6 (296.37). 
 
2-Cyano-1-[3-(1H-imidazol-4-yl)propyl]-3-(4-phenylbutyl)guanidine (3.44) 
The title compound was prepared from 3.26 (0.59 g, 2.0 mmol) and 3.41 (0.28 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.51 g, 79 %); mp (hydrogenoxalate) 128 – 130 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.49 – 1.72 (m, 4H, Ph-CH2-CH2-CH2), 1.82 – 1.96 (m, 
2H, Im-4-CH2-CH2), 2.63 (t, 2H, 3J = 7.2 Hz, Im-4-CH2), 2.71 (t, 2H, 3J = 7.5 Hz, Ph-CH2), 
3.17 – 3.30 (m, 4H, Im-4-(CH2)2-CH2 + Ph-(CH2)3-CH2), 7.08 – 7.27 (m, 6H, Ph-H + Im-5-H), 
8.50 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 
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23.09 (-, Im-4-CH2), 29.63 (-, Im-4-CH2-CH2), 29.75, 30.03 (-, Ph-CH2-CH2-CH2), 36.50 (-, 
Ph-CH2), 41.82 (-, Im-4-(CH2)2-CH2), 42.65 (-, Ph-(CH2)3-CH2), 116.91 (+, Im-C-5), 120.19 
(Cquat, C≡N), 126.84 (+, Ph-C-4), 129.38 (+, 2 Ph-C), 129.48 (+, 2 Ph-C), 134.97 (+, Im-C-2), 
135.59 (Cquat, Im-C-4), 143.51 (Cquat, Ph-C-1), 161.23 (Cquat, C=N), 168.22 (Cquat, 
hydrogenoxalate). IR (cm-1) = 3245 (N-H), 2934 (C-H), 2858 (C-H), 2158 (C≡N), 1576 (C=N). 
ES-MS (H2O/MeCN) m/z (%): 325 (100) [M + H]+. HRMS (EI-MS) calcd. for C18H24N6 [M+•] 
324.2062; found 324.2058. Anal. (C18H24N6 · 0.85 C2H2O4) C, H, N. C18H24N6 (324.42). 
 
2-Cyano-1-(3,3-diphenylpropyl)-3-[3-(1H-imidazol-4-yl)propyl]guanidine (3.45) 
The title compound was prepared from 3.27 (0.71 g, 2.0 mmol) and 3.41 (0.28 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 95/3/2 v/v/v) yielding a colorless 
foam-like solid (0.51 g, 66 %); mp (hydrogenoxalate) 156 – 158 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.80 – 1.93 (m, 2H, Im-4-CH2-CH2), 2.28 – 2.39 (m, 2H, 
Ph2CH-CH2), 2.70 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 3.15 (t, 2H, 3J = 7.3 Hz, Ph2CH-CH2-CH2), 
3.21 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)2-CH2), 4.00 (t, 1H, 3J = 7.9 Hz, Ph2CH), 7.31 – 7.11 (m, 
11H, Ph-H + Im-5-H), 8.59 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, 
hydrogenoxalate): δ [ppm] = 22.90 (-, Im-4-CH2), 29.46 (-, Im-4-CH2-CH2), 35.98 (-, 
Ph2CHCH2), 41.73, 41.78 (-, Im-4-(CH2)2-CH2 + Ph2CHCH2-CH2), 50.05 (+, Ph2CH), 116.87 
(+, Im-C-5), 120.12 (Cquat, C≡N), 127.43 (+, 2 Ph-C-4), 128.89 (+, 4 Ph-C), 129.63 (+, 4 Ph-
C), 134.89 (+, Im-C-2), 135.30 (Cquat, Im-C-4), 145.81 (Cquat, 2 Ph-C-1), 161.21 (Cquat, C=N), 
167.51 (Cquat, hydrogenoxalate). IR (cm-1) = 3242 (N-H), 2989 (C-H), 2901 (C-H), 2159 
(C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 387 (100) [M + H]+. HRMS 
(EI-MS) calcd. for C23H26N6 [M+•] 386.2219; found 386.2214. Anal. (C23H26N6 · 0.25 H2O) C, 
H, N. C23H26N6 (386.49). 
 
2-Cyano-1-(3-cyclohexylpropyl)-3-[3-(1H-imidazol-4-yl)propyl]guanidine (3.46) 
The title compound was prepared from 3.28 (0.57 g, 2.0 mmol) and 3.41 (0.28 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 95/3/2 v/v/v) yielding a colorless 
foam-like solid (0.35 g, 55 %); mp (hydrogenoxalate) 144 – 146 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 0.81 – 1.00 (m, 2H, cHex-CH2), 1.10 – 1.35 (m, 6H), 
1.49 – 1.79 (m, 7H), 1.85 – 1.99 (m, 2H, Im-4-CH2-CH2), 2.75 (t, 2H, 3J = 7.5 Hz, Im-4-CH2), 
3.16 (t, 2H, 3J = 7.2 Hz, cHex-(CH2)2-CH2), 3.28 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)2-CH2), 7.25 
(d, 1H, 4J = 1.3 Hz, Im-5-H), 8.58 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, 
hydrogenoxalate): δ [ppm] = 23.03 (-, Im-4-CH2), 27.54 (-, 2 cHex-C), 27.83 (-, CH2), 27.87 (-
, CH2), 29.64 (-, Im-4-CH2-CH2), 34.58 (-, 2 cHex-C), 35.63 (-, CH2), 38.80 (+, cHex-C), 41.81 
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(-, Im-4-(CH2)2-CH2), 43.21 (-, cHex-(CH2)2-CH2), 116.93 (+, Im-C-5), 120.20 (Cquat, C≡N), 
134.97 (+, Im-C-2), 135.47 (Cquat, Im-C-4), 161.23 (Cquat, C=N), 167.72 (Cquat, 
hydrogenoxalate). IR (cm-1) = 3276 (N-H), 2919 (C-H), 2849 (C-H), 2159 (C≡N), 1580 (C=N). 
ES-MS (MeOH + NH4OAc) m/z (%): 317 (100) [M + H]+. HRMS (EI-MS) calcd. for C17H28N6 
[M+•] 316.2375; found 316.2374. Anal. (C17H28N6 · 0.8 C2H2O4) C, H, N. C17H28N6 (316.44). 
 
2-Cyano-1-[3-(1H-imidazol-4-yl)propyl]-3-[2-(phenylthio)ethyl]guanidine (3.47) 
The title compound was prepared from 3.29 (0.60 g, 2.0 mmol) and 3.41 (0.28 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.52 g, 78 %); mp (hydrogenoxalate) 126 – 129 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.83 – 1.96 (m, 2H, Im-4-CH2-CH2), 2.73 (t, 2H, 3J = 7.6 
Hz, Im-4-CH2), 3.11 (t, 2H, 3J = 6.9 Hz, S-CH2-CH2), 3.22 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)2-
CH2), 3.42 (t, 2H, 3J = 6.9 Hz, S-CH2), 7.13 – 7.21 (m, 1H, Ph-4-H), 7.22 – 7.34 (m, 3H, Ph-H 
+ Im-5-H), 7.34 – 7.43 (m, 2H, Ph-H), 8.65 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 22.90 (-, Im-4-CH2), 29.36 (-, Im-4-CH2-CH2), 33.62 (-, 
S-CH2), 41.90 (-, Im-4-(CH2)2-CH2), 42.32 (-, S-CH2-CH2), 116.91 (+, Im-C-5), 119.82 (Cquat, 
C≡N), 127.38 (+, Ph-C-4), 130.20 (+, 2 Ph-C), 130.48 (+, 2 Ph-C), 134.91 (+, Im-C-2), 135.22 
(Cquat, Im-C-4), 136.97 (Cquat, Ph-C-1), 161.18 (Cquat, C=N), 167.52 (Cquat, hydrogenoxalate). 
IR (cm-1) = 3247 (N-H), 2938 (C-H), 2847 (C-H), 2160 (C≡N), 1576 (C=N). ES-MS 
(H2O/MeCN) m/z (%): 329 (100) [M + H]+. HRMS (EI-MS) calcd. for C16H20N6S [M+•] 
328.1470; found 328.1467. Anal. (C16H20N6S · 0.75 C2H2O4 · 0.25 H2O) C, H, N. C16H20N6S 
(328.44). 
 
2-Cyano-1-[3-(1H-imidazol-4-yl)propyl]-3-[2-(1H-indol-3-yl)ethyl]guanidine (3.48) 
The title compound was prepared from 3.30 (0.61 g, 2.0 mmol) and 3.41 (0.28 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.53 g, 79 %); mp (hydrogenoxalate) 160 – 164 °C. 1H-NMR (400 MHz, 
COSY, CD3OD, hydrogenoxalate): δ [ppm] = 1.65 – 1.76 (m, 2H, Im-4-CH2-CH2), 2.58 (t, 2H, 
3J = 7.6 Hz, Im-4-CH2), 3.00 (t, 2H, 3J = 6.9 Hz, indole-3-CH2), 3.13 (t, 2H, 3J = 6.9 Hz, Im-4-
(CH2)2-CH2), 3.50 (t, 2H, 3J = 6.9 Hz, indole-3-CH2-CH2), 6.99 (ddd, 1H, 3J = 7.8 Hz, 3J = 7.0 
Hz, 4J = 1.1 Hz, indole-5-H), 7.05 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.3 Hz, indole-6-H), 
7.10 (s, 1H, indole-2-H), 7.15 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.29 (ddd, 1H, 3J = 8.0 Hz, 4J = 
1.1 Hz, 5J = 0.8 Hz, indole-7-H), 7.56 (ddd, 1H, 3J = 7.8 Hz, 4J = 1.3 Hz, 5J = 0.8 Hz, indole-4-
H), 8.64 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (100 MHz, HMQC, CD3OD, hydrogenoxalate): 
δ [ppm] = 22.63 (-, Im-4-CH2), 26.40 (-, indole-3-CH2), 29.20 (-, Im-4-CH2-CH2), 41.61 (-, Im-
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4-(CH2)2-CH2), 43.71 (-, indole-3-CH2-CH2), 112.37 (+, indole-C-7), 112.70 (Cquat, indole-C-3), 
116.82 (+, Im-C-5), 119.33 (+, indole-C-4), 119.82 (+, indole-C-5), 120.12 (Cquat, C≡N), 
122.47 (+, indole-C-6), 123.98 (+, indole-C-2), 128.75 (Cquat, indole-C-3a), 134.74 (+, Im-C-
2), 135.04 (Cquat, Im-C-4), 138.22 (Cquat, indole-C-7a), 161.29 (Cquat, C=N), 167.11 (Cquat, 
hydrogenoxalate). IR (cm-1) = 3280 (N-H), 2936 (C-H), 2854 (C-H), 2160 (C≡N), 1576 (C=N). 
ES-MS (H2O/MeCN) m/z (%): 336 (100) [M + H]+. HRMS (EI-MS) calcd. for C18H21N7 [M+•] 
335.1858; found 335.1854. Anal. (C18H21N7 · C2H2O4) C, H, N. C18H21N7 (335.41). 
 
2-Cyano-1-[2-(1H-imidazol-4-yl)ethyl]-3-(3-phenylpropyl)guanidine (3.52) 
The title compound was prepared from 3.24 (0.56 g, 2.0 mmol) and 3.51 (0.24 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.44 g, 75 %); mp (hydrogenoxalate) 149 – 151 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.77 – 1.89 (m, 2H, Ph-CH2-CH2), 2.62 (t, 2H, 3J = 7.7 
Hz, Ph-CH2), 2.93 (t, 2H, 3J = 6.9 Hz, Im-4-CH2), 3.19 (t, 2H, 3J = 7.2 Hz, Ph-(CH2)2-CH2), 
3.51 (t, 2H, 3J = 6.9 Hz, Im-4-CH2-CH2), 7.11 – 7.30 (m, 6H, Ph-H + Im-5-H), 8.56 (d, 1H, 4J 
= 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 26.29 (-, Im-4-
CH2), 32.14 (-, Ph-CH2-CH2), 33.93 (-, Ph-CH2), 41.57 (-, Im-4-CH2-CH2), 42.46 (-, Ph-CH2-
CH2-CH2), 117.69 (+, Im-C-5), 119.86 (Cquat, C≡N), 127.06 (+, Ph-C-4), 129.45 (+, 2 Ph-C), 
129.52 (+, 2 Ph-C), 133.20 (Cquat, Im-C-4), 135.15 (+, Im-C-2), 142.78 (Cquat, Ph-C-1), 161.21 
(Cquat, C=N), 167.65 (Cquat, hydrogenoxalate). IR (cm-1) = 3266 (N-H), 2972 (C-H), 2901 (C-
H), 2160 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 297 (100) [M + H]+. 
HRMS (EI-MS) calcd. for C16H19N6 [M – H]+ 295.1671; found 295.1675. Anal. (C16H20N6 · 0.9 
C2H2O4 · 0.25 H2O) C, H, N. C16H20N6 (296.37).  
 
2-Cyano-1-[2-(1H-imidazol-4-yl)ethyl]-3-(2-phenylethyl)guanidine (3.53) 
The title compound was prepared from 3.25 (0.53 g, 2.0 mmol) and 3.51 (0.24 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.40 g, 72 %); mp (hydrogenoxalate) 149 – 151 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 2.78 – 2.92 (m, 4H, Im-4-CH2 + Ph-CH2), 3.38 – 3.50 
(m, 4H, Im-4-CH2-CH2 + Ph-CH2-CH2), 7.14 – 7.32 (m, 6H, Ph-H, Im-5-H), 8.56 (d, 1H, 4J = 
1.2 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 26.26 (-, Im-4-
CH2), 36.59 (-, PhCH2), 41.59 (-, Im-4-CH2-CH2), 44.26 (-, Ph-CH2-CH2), 117.71 (+, Im-C-5), 
119.76 (Cquat, C≡N), 127.61 (+, Ph-C-4), 129.65 (+, 2 Ph-C), 130.03 (+, 2 Ph-C), 133.19 
(Cquat, Im-C-4), 135.21 (+, Im-C-2), 140.03 (Cquat, Ph-C-1), 161.16 (Cquat, C=N), 167.73 (Cquat, 
hydrogenoxalate). IR (cm-1) = 3256 (N-H), 2939 (C-H), 2854 (C-H), 2160 (C≡N), 1576 (C=N). 
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ES-MS (MeOH + NH4OAc) m/z (%): 283 (100) [M + H]+. HRMS (EI-MS) calcd. for C15H18N6 
[M+•] 282.1593; found 282.1588. Anal. (C15H18N6 · 0.8 C2H2O4 · 0.25 H2O) C, H, N. C15H18N6 
(282.34). 
 
2-Cyano-1-[2-(1H-imidazol-4-yl)ethyl]-3-(4-phenylbutyl)guanidine (3.54) 
The title compound was prepared from 3.26 (0.59 g, 2.0 mmol) and 3.51 (0.24 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.46 g, 74 %); mp (hydrogenoxalate) 138 – 140 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.47 – 1.69 (m, 4H, Ph-CH2-CH2-CH2), 2.62 (t, 2H, 3J = 
7.3 Hz, Ph-CH2), 2.93 (t, 2H, 3J = 6.8 Hz, Im-4-CH2), 3.19 (t, 2H, 3J = 6.9 Hz, Ph-(CH2)3-CH2), 
3.51 (t, 2H, 3J = 6.8 Hz, Im-4-CH2-CH2), 7.08 – 7.29 (m, 6H, Ph-H, Im-5-H), 8.57 (d, 1H, 4J = 
1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 26.31 (-, Im-4-
CH2), 29.75, 29.96 (-, Ph-CH2-CH2-CH2), 36.51 (-, Ph-CH2), 41.58 (-, Im-4-CH2-CH2), 42.70 (-
, Ph-(CH2)3-CH2), 117.73 (+, Im-C-5), 119.92 (Cquat, C≡N), 126.90 (+, Ph-C-4), 129.43 (+, 2 
Ph-C), 129.52 (+, 2 Ph-C), 133.16 (Cquat, Im-C-4), 135.15 (+, Im-C-2), 143.51 (Cquat, Ph-C-1), 
161.22 (Cquat, C=N), 167.44 (Cquat, hydrogenoxalate). IR (cm-1) = 3257 (N-H), 2971 (C-H), 
2930 (C-H), 2161 (C≡N), 1576 (C=N). ES-MS (H2O/MeCN) m/z (%): 311 (100) [M + H]+. 
HRMS (EI-MS) calcd. for C17H22N6 [M+•] 310.1906; found 310.1897. Anal. (C17H22N6 · C2H2O4 
· 0.25 H2O) C, H, N. C17H22N6 (310.40). 
 
2-Cyano-1-(3,3-diphenylpropyl)-3-[2-(1H-imidazol-4-yl)ethyl]guanidine (3.55) 
The title compound was prepared from 3.27 (0.71 g, 2.0 mmol) and 3.51 (0.24 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 95/3/2 v/v/v) yielding a colorless 
resin that solidified over Et2O (0.54 g, 72 %); mp 178 – 180 °C. 1H-NMR (300 MHz, CD3OD): 
δ [ppm] = 2.23 – 2.34 (m, 2H, Ph2CH-CH2), 2.76 (t, 2H, 3J = 7.2 Hz, Im-4-CH2), 3.12 (t, 2H, 3J 
= 7.3 Hz, Ph2CH-CH2-CH2), 3.36 (t, 2H, 3J = 7.2 Hz, Im-4-CH2-CH2), 3.97 (t, 1H, 3J = 7.9 Hz, 
Ph2CH), 6.84 (br s, 1H, Im-5-H), 7.10 – 7.31 (m, 10H, Ph-H), 7.55 (d, 1H, 4J = 1.1 Hz, Im-2-
H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 28.07 (-, Im-4-CH2), 36.01 (-, Ph2CH-CH2), 41.68 
(-, Im-4-CH2-CH2), 42.67 (-, Ph2CH-CH2CH2), 50.09 (+, Ph2CH), 120.16 (Cquat, C≡N), 127.41 
(+, 2 Ph-C-4), 128.89 (+, 4 Ph-C), 129.62 (+, 4 Ph-C), 136.28 (+, Im-C-2), 145.84 (Cquat, 2 
Ph-C-1), 161.19 (Cquat, C=N). IR (cm-1) = 3314 (N-H), 2939 (C-H), 2841 (C-H), 2172 (C≡N), 
1584 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 273 (100) [M + H]+. HRMS (EI-MS) 
calcd. for C22H24N6 [M+•] 372.2062; found 372.2056. Anal. (C22H24N6 · 0.25 H2O) C, H, N. 
C22H24N6 (372.47). 
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2-Cyano-1-(3-cyclohexylpropyl)-3-[2-(1H-imidazol-4-yl)ethyl]guanidine (3.56) 
The title compound was prepared from 3.28 (0.57 g, 2.0 mmol) and 3.51 (0.24 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.37 g, 60 %); mp (hydrogenoxalate) 160 – 162 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 0.80 – 0.99 (m, 2H, cHex-CH2), 1.08 – 1.35 (m, 6H, 
cHex), 1.46 – 1.60 (m, 2H, cHex-CH2-CH2), 1.61 – 1.79 (m, 5H, cHex), 2.96 (t, 2H, 3J = 6.8 
Hz, Im-4-CH2), 3.14 (t, 2H, 3J = 7.3 Hz, cHex-(CH2)2-CH2), 3.53 (t, 2H, 3J = 6.8 Hz, Im-4-CH2-
CH2), 7.30 (d, 1H, 4J = 1.4 Hz, Im-5-H), 8.68 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 26.19 (-, Im-4-CH2), 27.53 (-, 2 cHex-C), 27.78 (-, CH2), 
27.82 (-, CH2), 34.57 (-, 2 cHex-C), 35.60 (-, CH2), 38.79 (+, cHex-C), 41.49 (-, Im-4-CH2-
CH2), 43.24 (-, cHex-(CH2)2-CH2), 117.75 (+, Im-C-5), 119.91 (Cquat, C≡N), 132.97 (Cquat, Im-
C-4), 135.09 (+, Im-C-2), 161.20 (Cquat, C=N), 167.13 (Cquat, hydrogenoxalate). IR (cm-1) = 
3277 (N-H), 2921 (C-H), 2848 (C-H), 2158 (C≡N), 1576 (C=N). ES-MS (MeOH + NH4OAc) 
m/z (%): 303 (100) [M + H]+. HRMS (EI-MS) calcd. for C16H26N6 [M+•] 302.2219; found 
302.2218. Anal. (C16H26N6 · C2H2O4) C, H, N. C16H26N6 (302.42). 
 
2-Cyano-1-[2-(1H-imidazol-4-yl)ethyl]-3-[2-(phenylthio)ethyl]guanidine (3.57) 
The title compound was prepared from 3.29 (0.60 g, 2.0 mmol) and 3.51 (0.24 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.51 g, 82 %); mp (hydrogenoxalate) 133 – 135 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 2.94 (t, 2H, 3J = 6.8 Hz, Im-4-CH2), 3.10 (t, 2H, 3J = 6.9 
Hz, S-CH2-CH2), 3.40 (t, 2H, 3J = 6.9 Hz, S-CH2), 3.49 (t, 2H, 3J = 6.8 Hz, Im-4-CH2-CH2), 
7.15 – 7.23 (m, 1H, Ph-4-H), 7.25 – 7.33 (m, 3H, Ph-H + Im-5-H), 7.35 – 7.42 (m, 2H, Ph-H), 
8.71 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 
25.95 (-, Im-4-CH2), 33.61 (-, S-CH2), 41.49 (-, Im-4-CH2-CH2), 42.28 (-, S-CH2-CH2), 117.79 
(+, Im-C-5), 119.50 (Cquat, C≡N), 127.47 (+, Ph-C-4), 130.23 (+, 2 Ph-C), 130.59 (+, 2 Ph-C), 
132.70 (Cquat, Im-C-4), 135.08 (+, Im-C-2), 136.85 (Cquat, Ph-C-1), 161.16 (Cquat, C=N), 
166.73 (Cquat, hydrogenoxalate). IR (cm-1) = 3246 (N-H), 2989 (C-H), 2900 (C-H), 2162 
(C≡N), 1576 (C=N). ES-MS (H2O/MeCN) m/z (%): 315 (100) [M + H]+. HRMS (EI-MS) calcd. 
for C15H18N6S [M+•] 314.1314; found 314.1310. Anal. (C15H18N6S · C2H2O4) C, H, N. 
C15H18N6S (314.41). 
 
2-Cyano-1-[2-(1H-imidazol-4-yl)ethyl]-3-[2-(1H-indol-3-yl)ethyl]guanidine (3.58) 
The title compound was prepared from 3.30 (0.61 g, 2.0 mmol) and 3.51 (0.24 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
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flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless solid 
(0.41 g, 64 %); mp 78 – 82 °C. 1H-NMR (600 MHz, NOESY, CD3OD): δ [ppm] = 2.69 (t, 2H, 
3J = 7.3 Hz, Im-4-CH2), 2.99 (t, 2H, 3J = 7.1 Hz, indole-3-CH2), 3.34 (t, 2H, 3J = 7.3 Hz, Im-4-
CH2-CH2), 3.48 (t, 2H, 3J = 7.1 Hz, indole-3-CH2-CH2), 6.82 (brs, 1H, Im-5-H), 7.03 (ddd, 1H, 
3J = 8.0 Hz, 3J = 7.0 Hz , 4J = 1.0 Hz, indole-5-H), 7.08 – 7.12 (m, 2H, indole-6-H + indole-2-
H), 7.34 (ddd, 1H, 3J = 8.1 Hz, 4J = 1.0 Hz, 5J = 1.0 Hz, indole-7-H), 7.57 (ddd, 1H, 3J = 8.0 
Hz, 4J = 1.2 Hz, 5J = 1.0 Hz, indole-4-H), 7.59 (brs, 1H, Im-2-H). 13C-NMR (150 MHz, HSQC, 
HMBC, CD3OD): δ [ppm] = 26.33 (-, indole-3-CH2), 27.88 (-, Im-4-CH2), 42.58 (-, Im-4-CH2-
CH2), 43.60 (-, indole-3-CH2-CH2), 112.32 (+, indole-C-7), 112.73 (Cquat, indole-C-3), 117.35 
(+, Im-C-5), 119.28 (+, indole-C-4), 119.76 (+, indole-C-5), 120.19 (Cquat, C≡N), 122.45 (+, 
indole-C-6), 123.77 (+, indole-C-2), 128.69 (Cquat, indole-C-3a), 136.21 (+, Im-C-2), 138.22 
(Cquat, indole-C-7a), 161.21 (Cquat, C=N). IR (cm-1) = 3253 (N-H), 2927 (C-H), 2847 (C-H), 
2158 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 322 (100) [M + H]+. 
HRMS (EI-MS) calcd. for C17H19N7 [M+•] 321.1702; found 321.1698. Anal. (C17H22N6 · 0.25 
H2O) C, H, N. C17H19N7 (321.38). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-(3-phenylpropyl)guanidine (3.61) 
The title compound was prepared from 3.24 (0.56 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.47 g, 72 %); mp (hydrogenoxalate) 134 – 137 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.52 – 1.77 (m, 4H, Im-4-CH2-CH2-CH2), 1.78 – 1.92 
(m, 2H, Ph-CH2-CH2), 2.63 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.74 (t, 2H, 3J = 7.3 Hz, Ph-CH2), 
3.15 – 3.27 (m, 4H, Im-4-(CH2)3-CH2 + Ph-(CH2)2-CH2), 7.10 – 7.30 (m, 6H, Im-5-H + Ph-H), 
8.61 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 
25.20 (-, Im-4-CH2), 26.87 (-, Im-4-CH2-CH2), 29.84 (-, Im-4-(CH2)2-CH2), 32.30 (-, Ph-CH2-
CH2), 34.00 (-, PhCH2), 42.17 (-, Im-4-(CH2)3-CH2), 42.43 (-, Ph-(CH2)2-CH2), 116.87 (+, Im-
C-5), 120.29 (Cquat, C≡N), 127.05 (+, Ph-C-4), 129.47 (+, 2 Ph-C), 129.53 (+, 2 Ph-C), 134.80 
(+, Im-C-2), 135.69 (Cquat, Im-C-4), 142.87 (Cquat, Ph-C-1), 161.22 (Cquat, C=N), 167.65 (Cquat, 
hydrogenoxalate). IR (cm-1) = 3250 (N-H), 2937 (C-H), 2857 (C-H), 2158 (C≡N), 1576 (C=N). 
ES-MS (H2O/MeCN) m/z (%): 325 (100) [M + H]+. HRMS (EI-MS) calcd. for C18H24N6 [M+•] 
324.2062; found 324.2055. Anal. (C18H24N6 · 0.9 C2H2O4) C, H, N. C18H24N6 (324.42).  
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-(2-phenylethyl)guanidine (3.62) 
The title compound was prepared from 3.25 (0.53 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
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foam-like solid (0.55 g, 88 %); mp (hydrogenoxalate) 142 – 144 °C. 1H-NMR (400 MHz, 
CD3OD, COSY): δ [ppm] = 1.45 – 1.56 (m, 2H, Im-4-(CH2)2-CH2), 1.56 – 1.67 (m, 2H, Im-4-
CH2-CH2), 2.58 (t, 2H, 3J = 7.3 Hz, Im-4-CH2), 2.82 (t, 2H, 3J = 7.2 Hz, Ph-CH2), 3.14 (t, 2H, 
3J = 7.1 Hz, Im-4-(CH2)3-CH2), 3.42 (t, 2H, 3J = 7.2 Hz, Ph-CH2-CH2), 6.76 (s, 1H, Im-5-H), 
7.15 – 7.30 (m, 5H, Ph-H), 7.53 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (100 MHz, CD3OD, 
HSQC): δ [ppm] = 27.14 (-, Im-4-CH2), 27.66 (-, Im-4-CH2-CH2), 29.86 (-, Im-4-(CH2)2-CH2), 
36.67 (-, PhCH2), 42.47 (-, Im-4-(CH2)3-CH2), 44.15 (-, Ph-CH2-CH2), 117.74 (+, Im-C-5), 
120.19 (Cquat, C≡N), 127.51 (+, Ph-C-4), 129.56 (+, 2 Ph-C), 129.95 (+, 2 Ph-C), 135.73 (+, 
Im-C-2), 137.97 (Cquat, Im-C-4), 140.11 (Cquat, Ph-C-1), 161.13 (Cquat, C=N). IR (cm-1) = 3245 
(N-H), 2935 (C-H), 2857 (C-H), 2158 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 311 (100) [M + H]+. HRMS (EI-MS) calcd. for C17H22N6 [M+•] 310.1906; found 
310.1912. Anal. (C17H22N6 · 0.75 C2H2O4 · 0.5 H2O) C, H, N. C17H22N6 (310.40). 
 
2-Cyano-1-{1-[4-(1H-imidazol-4-yl)butyl]}-3-(4-phenylbutyl)guanidine (3.63) 
The title compound was prepared from 3.26 (0.59 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.45 g, 66 %); mp (hydrogenoxalate) 125 – 128 °C. 1H-NMR (600 MHz, 
CD3OD, NOESY): δ [ppm] = 1.54 – 1.61 (m, 4H, Im-4-(CH2)2-CH2 + Ph-(CH2)2-CH2), 1.62 – 
1.69 (m, 4H, Im-4-CH2-CH2 + Ph-CH2-CH2), 2.61 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 2.63 (t, 2H, 
3J = 7.5 Hz, Ph-CH2), 3.18 – 3.24 (m, 4H, Im-4-(CH2)3-CH2 + Ph-(CH2)3-CH2), 6.77 (s, 1H, Im-
5-H), 7.13 – 7.21 (m, 5H, Ph-H), 7.55 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (150 MHz, 
CD3OD, HSQC): δ [ppm] = 27.23 (-, Im-4-CH2), 27.71 (-, Im-4-CH2-CH2), 29.73, 29.99, 30.05 
(-, Im-4-(CH2)2-CH2 + Ph-CH2-CH2-CH2), 36.49 (-, PhCH2), 42.48, 42.54 (-, Im-4-(CH2)3-CH2, 
Ph-(CH2)3-CH2), 120.39 (Cquat, C≡N), 126.83 (+, Ph-C-4), 129.37 (+, 2 Ph-C), 129.47 (+, 2 
Ph-C), 135.74 (+, Im-C-2), 143.50 (Cquat, Ph-C-1), 161.19 (Cquat, C=N). IR (cm-1) = 3266 (N-
H), 2937 (C-H), 2858 (C-H), 2159 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 339 (100) [M + H]+. HRMS (EI-MS) calcd. for C19H26N6 [M+•] 338.2219; found 338.2224. 
Anal. (C19H26N6 · 0.85 C2H2O4) C, H, N. C19H26N6 (338.45). 
 
2-Cyano-1-(3,3-diphenylpropyl)-3-[4-(1H-imidazol-4-yl)butyl]guanidine (3.64) 
The title compound was prepared from 3.27 (0.71 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
resin that solidified over Et2O (0.46 g, 57 %); mp 80 – 84 °C. 1H-NMR (400 MHz, COSY, 
CD3OD): δ [ppm] = 1.48 – 1.58 (m, 2H, Im-4-(CH2)2-CH2), 1.58 – 1.68 (m, 2H, Im-4-CH2-
CH2), 2.27 – 2.36 (m, 2H, Ph2CH-CH2), 2.59 (t, 2H, 3J = 7.2 Hz, Im-4-CH2), 3.10 – 3.19 (m, 
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4H, Im-4-(CH2)3-CH2 + Ph2CH-CH2-CH2), 3.99 (t, 1H, 3J = 7.8 Hz, Ph2CH), 6.76 (d, 1H, 4J = 
1.1 Hz, Im-5-H), 7.11 – 7.19 (m, 2H, Ph-4-H), 7.23 – 7.30 (m, 8H, Ph-H), 7.52 (d, 1H, 4J = 1.1 
Hz, Im-2-H). 13C-NMR (100 MHz, HMQC, CD3OD): δ [ppm] = 27.21 (-, Im-4-CH2), 27.75 (-, 
Im-4-CH2-CH2), 29.96 (-, Im-4-(CH2)2-CH2), 36.13 (-, Ph2CH-CH2), 41.70, 42.52 (-, Im-4-
(CH2)3-CH2 + Ph2CH-CH2-CH2), 50.12 (+, Ph2CH), 117.82 (+, Im-C-5), 120.39 (Cquat, C≡N), 
127.43 (+, 2 Ph-C-4), 128.91 (+, 4 Ph-C), 129.64 (+, 4 Ph-C), 135.79 (+, Im-C-2), 138.33 
(Cquat, Im-C-4), 145.87 (Cquat, Ph-C-1), 161.21 (Cquat, C=N). IR (cm-1) = 3277 (N-H), 2936 (C-
H), 2858 (C-H), 2159 (C≡N), 1576 (C=N). ES-MS (H2O/MeCN + NH4OAc) m/z (%): 401 (100) 
[M + H]+. HRMS (EI-MS) calcd. for C24H28N6 [M+•] 400.2375; found 400.2372. Anal. (C24H28N6 
· 0.25 H2O) C, H, N. C24H28N6 (400.52). 
 
2-Cyano-1-(3-cyclohexylpropyl)-3-[4-(1H-imidazol-4-yl)butyl]guanidine (3.65) 
The title compound was prepared from 3.28 (0.57 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.49 g, 75 %); mp (hydrogenoxalate) 141 – 143 °C. 1H-NMR (300 MHz, 
CD3OD): δ [ppm] = 0.80 – 0.99 (m, 2H, cHex-CH2), 1.09 – 1.35 (m, 6H), 1.46 – 1.79 (m, 
11H), 2.60 (t, 2H, 3J = 7.1 Hz, Im-4-CH2), 3.15 (t, 2H, 3J = 7.2 Hz, cHex-(CH2)2-CH2), 3.21 (t, 
2H, 3J = 6.8 Hz, Im-4-(CH2)3-CH2), 6.77 (d, 1H, 4J = 1.1 Hz, 1H, Im-5-H), 7.54 (d, 1H, 4J = 1.1 
Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.23 (-, Im-4-CH2), 27.54 (-, 2 cHex-C), 
27.76 (-, Im-4-CH2-CH2), 27.83 (-, CH2), 27.90 (-, CH2), 30.07 (-, Im-4-(CH2)2-CH2), 34.57 (-, 
2 c-Hex-C), 35.61 (-, CH2), 38.79 (+, cHex-C), 42.48 (-, Im-4-(CH2)3-CH2), 43.09 (-, cHex-
(CH2)2-CH2), 117.81 (+, Im-C-5), 120.44 (Cquat, C≡N), 135.77 (+, Im-C-2), 138.00 (Cquat, Im-C-
4), 161.19 (Cquat, C=N). IR (cm-1) = 3265 (N-H), 2922 (C-H), 2848 (C-H), 2158 (C≡N), 1576 
(C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 331 (100) [M + H]+. HRMS (EI-MS) calcd. 
for C18H30N6 [M+•] 330.2532; found 330.2533. Anal. (C18H30N6 · 0.8 C2H2O4 · 0.25 H2O) C, H, 
N. C18H30N6 (330.47). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-[(2-phenylthio)ethyl]guanidine (3.66) 
The title compound was prepared from 3.29 (0.60 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.42 g, 62 %); mp (hydrogenoxalate) 130 – 133 °C. 1H-NMR (300 MHz, 
CD3OD): δ [ppm] = 1.45 – 1.70 (m, 4H, Im-4-CH2-CH2-CH2), 2.58 (t, 2H, 3J = 7.1 Hz, Im-4-
CH2), 3.07 (t, 2H, 3J = 7.0 Hz, S-CH2-CH2), 3.13 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)3-CH2), 3.39 (t, 
2H, 3J = 7.0 Hz, S-CH2), 6.76 (d, 1H, 4J = 1.1 Hz, 1H, Im-5-H), 7.10 – 7.41 (m, 5H, Ph-H), 
7.53 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.17 (-, Im-4-CH2), 
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27.67 (-, Im-4-CH2-CH2), 29.80 (-, Im-4-(CH2)2-CH2), 33.53 (-, S-CH2), 42.27 (-, Im-4-(CH2)3-
CH2), 42.61 (-, S-CH2-CH2), 117.88 (+, Im-C-5), 120.17 (Cquat, C≡N), 127.30 (+, Ph-C-4), 
130.16 (+, 2 Ph-C), 130.35 (+, 2 Ph-C), 135.76 (+, Im-C-2), 136.94 (Cquat, Ph-C-1), 138.10 
(Cquat, Im-C-4), 161.02 (Cquat, C=N). IR (cm-1) = 3267 (N-H), 2989 (C-H), 2901 (C-H), 2159 
(C≡N), 1576 (C=N). ES-MS (MeCN + TFA) m/z (%): 343 (100) [M + H]+. HRMS (EI-MS) 
calcd. for C17H22N6S [M+•] 342.1627; found 342.1625. Anal. (C17H22N6S · 0.75 C2H2O4) C, H, 
N. C17H22N6S (342.46). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-[2-(1H-indol-3-yl)ethyl]guanidine (3.67) 
The title compound was prepared from 3.30 (0.61 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a beige 
foam-like solid (0.58 g, 83 %); mp (hydrogenoxalate) 154 – 156 °C. 1H-NMR (400 MHz, 
COSY, CD3OD): δ [ppm] = 1.33 – 1.44 (m, 2H, Im-4-(CH2)2-CH2), 1.48 – 1.60 (m, 2H, Im-4-
CH2-CH2), 2.52 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 2.97 (t, 2H, 3J = 7.0 Hz, indole-3-CH2), 3.06 (t, 
2H, 3J = 7.2 Hz, Im-4-(CH2)3-CH2), 3.47 (t, 2H, 3J = 7.0 Hz, indole-3-CH2-CH2), 6.73 (d, 1H, 4J 
= 1.4 Hz, Im-5-H), 7.00 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-5-H), 7.05 – 
7.10 (m, 2H, indole-6-H + indole-2-H), 7.32 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.0 Hz, 5J = 0.8 Hz, 
indole-7-H), 7.52 (d, 1H, 4J = 1.2 Hz, Im-2-H), 7.55 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.2 Hz, 5J = 
0.8 Hz, indole-4-H). 13C-NMR (100 MHz, CD3OD, HSQC): δ [ppm] = 26.37 (-, indole-3-CH2), 
27.07 (-, Im-4-CH2), 27.60 (-, Im-4-CH2-CH2), 29.74 (-, Im-4-(CH2)2-CH2), 42.43 (-, Im-4-
(CH2)3-CH2), 43.59 (-, indole-3-CH2-CH2), 112.34 (+, indole-C-7), 112.73 (Cquat, indole-C-3), 
117.85 (+, Im-C-5), 119.26 (+, indole-C-4), 119.79 (+, indole-C-5), 120.41 (Cquat, C≡N), 
122.47 (+, indole-C-6), 123.80 (+, indole-C-2), 128.68 (Cquat, indole-C-3a), 135.69 (+, Im-C-
2), 138.09 (Cquat, Im-C-4), 138.20 (Cquat, indole-C-7a), 161.20 (Cquat, C=N). IR (cm-1) = 3249 
(N-H), 2936 (C-H), 2849 (C-H), 2158 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 350 (100) [M + H]+. HRMS (EI-MS) calcd. for C19H23N7 [M+•] 349.2015; found 
349.2010. Anal. (C19H23N7 · C2H2O4) calcd. C: 57.39, H: 5.73, N: 22.31, found C: 56.50, H: 
6.37, N: 21.57. C19H23N7 (349.43). 
 
2-Cyano-1-[3-(4-fluorophenyl)propyl]-3-[4-(1H-imidazol-4-yl)butyl]guanidine (3.68) 
The title compound was prepared from 3.31 (0.59 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a pale 
yellow foam-like solid (0.55 g, 80 %); mp (hydrogenoxalate) 132 – 134 °C. 1H-NMR (300 
MHz, CD3OD): δ [ppm] = 1.49 – 1.73 (m, 4H, Im-4-CH2-CH2-CH2), 1.76 – 1.90 (m, 2H, Ph-
CH2-CH2), 2.54 – 2.67 (m, 4H, Im-4-CH2 + Ph-CH2), 3.12 – 3.26 (m, 4H, Im-4-(CH2)3-CH2 + 
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Ph-(CH2)2-CH2), 6.77 (d, 1H, 4J = 1.2 Hz, Im-5-H), 6.92 – 7.03 (m, 2H, Ph-H), 7.14 – 7.23 (m, 
2H, Ph-H), 7.53 (d, 1H, 4J = 1.2 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.29 (-, 
Im-4-CH2), 27.76 (-, Im-4-CH2-CH2), 30.01 (-, Im-4-(CH2)2-CH2), 32.36 (-, 4-F-Ph-CH2-CH2), 
33.15 (-, 4-F-PhCH2), 42.30 (-, Im-4-(CH2)3-CH2), 42.53 (-, 4-F-Ph-(CH2)2-CH2), 116.04 (+, 2J 
= 21.3 Hz, 4-F-Ph-C-3,5), 120.34 (Cquat, C≡N), 131.04 (+, 3J = 7.8 Hz, 4-F-Ph-C-2,6), 135.78 
(+, Im-C-2), 138.79 (Cquat, 4J = 3.1 Hz, Ph-C-1), 161.22 (Cquat, C=N), 162.83 (Cquat, 1J = 271.7 
Hz, 4-F-Ph-C-4). IR (cm-1) = 3256 (N-H), 2970 (C-H), 2865 (C-H), 2158 (C≡N), 1576 (C=N), 
1219 (C-F). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 343 (100) [M + H]+. HRMS (EI-MS) 
calcd. for C18H23FN6 [M+•] 342.1968; found 342.1969. Anal. (C18H23FN6 · C2H2O4 · H2O) C, H, 
N. C18H23FN6 (342.41). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-[3-(pyridin-2-yl)propyl]guanidine (3.69) 
The title compound was prepared from 3.32 (0.56 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.59 g, 91 %); mp (hydrogenoxalate) 156 – 158 °C. 1H-NMR (600 MHz, 
CD3OD, COSY): δ [ppm] = 1.54 – 1.61 (m, 2H, Im-4-(CH2)2-CH2), 1.61 – 1.70 (m, 2H, Im-4-
CH2-CH2), 1.90 – 1.97 (m, 2H, Pyr-2-CH2-CH2), 2.60 (t, 2H, 3J = 7.3 Hz, Im-4-CH2), 2.81 (t, 
2H, 3J = 7.5 Hz, Pyr-2-CH2), 3.21 (t, 2H, 3J = 7.1 Hz, Im-4-(CH2)3-CH2), 3.24 (t, 2H, 3J = 7.0 
Hz, Pyr-2-(CH2)2-CH2), 6.76 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.24 (ddd, 1H, 3J = 7.5 Hz, 3J = 5.0 
Hz, 4J = 1.2 Hz, Pyr-5-H), 7.30 (ddd, 1H, 3J = 7.8 Hz, 4J = 1.2 Hz, 5J = 1.0 Hz, Pyr-3-H), 7.53 
(d, 1H, 4J = 1.1 Hz, Im-2-H), 7.74 (ddd, 1H, 3J = 7.8 Hz, 3J = 7.5 Hz, 4J = 1.8 Hz, Pyr-4-H), 
7.74 (ddd, 1H, 3J = 5.0 Hz, 4J = 1.8 Hz, 5J = 1.0 Hz, Pyr-6-H). 13C-NMR (150 MHz, CD3OD, 
HSQC, HMBC): δ [ppm] = 27.14 (-, Im-4-CH2), 27.72 (-, Im-4-CH2-CH2), 29.99 (-, Im-4-
(CH2)2-CH2), 30.48 (-, Pyr-2-CH2), 35.61 (-, Pyr-2-CH2-CH2), 42.20 (-, Pyr-2-(CH2)2-CH2), 
42.52 (-, Im-4-(CH2)3-CH2), 117.87 (+, Im-C-5), 120.24 (Cquat, C≡N), 122.94 (+, Pyr-C-5), 
124.73 (+, Pyr-C-3), 135.73 (+, Im-C-2), 138.20 (Cquat, Im-C-4), 138.83 (+, Pyr-C-4),149.64 
(+, Pyr-C-6), 161.23 (Cquat, C=N), 162.37 (Cquat, Pyr-C-2). IR (cm-1) = 3242 (N-H), 2938 (C-H), 
2857 (C-H), 2159 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 326 (100) 
[M + H]+. HRMS (EI-MS) calcd. for C17H23N7 [M+•] 325.2015; found 325.2009. Anal. (C17H23N7 
· 2 C2H2O4 · H2O) C, H, N. C17H23N7 (325.41). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-[3-(pyridin-3-yl)propyl]guanidine (3.70) 
The title compound was prepared from 3.33 (0.56 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.34 g, 52 %); mp (hydrogenoxalate) 156 – 158 °C. 1H-NMR (400 MHz, 
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CD3OD, COSY): δ [ppm] = 1.52 – 1.61 (m, 2H, Im-4-(CH2)2-CH2), 1.61 – 1.70 (m, 2H, Im-4-
CH2-CH2), 1.82 – 1.93 (m, 2H, Pyr-3-CH2-CH2), 2.60 (t, 2H, 3J = 7.2 Hz, Im-4-CH2), 2.68 (t, 
2H, 3J = 7.8 Hz, Pyr-3-CH2), 3.19 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)2-CH2), 3.24 (t, 2H, 3J = 7.1 
Hz, Pyr-3-CH2-CH2-CH2), 6.76 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.35 (ddd, 1H, 3J = 7.9 Hz, 3J = 
4.9 Hz, 5J = 0.9 Hz, Pyr-5-H), 7.53 (d, 1H, 4J = 1.1 Hz, Im-2-H), 7.70 (ddd, 1H, 3J = 7.9 Hz, 4J 
= 2.3 Hz, 4J = 1.6 Hz, Pyr-4-H), 8.35 (dd, 1H, 3J = 4.9 Hz, 4J = 1.6 Hz, Pyr-6-H), 8.39 (dd, 1H, 
4J = 2.3 Hz, 5J = 0.9 Hz, Pyr-2-H). 13C-NMR (100 MHz, CD3OD, HSQC, HMBC): δ [ppm] = 
27.17 (-, Im-4-CH2), 27.73 (-, Im-4-CH2-CH2), 29.94 (-, Im-4-(CH2)2-CH2), 30.94 (-, Pyr-3-
CH2), 31.81 (-, Pyr-3-CH2-CH2), 42.17 (-, Pyr-3-(CH2)2-CH2), 42.52 (-, Im-4-(CH2)3-CH2), 
117.72 (+, Im-C-5), 120.20 (Cquat, C≡N), 125.22 (+, Pyr-C-5), 135.75 (+, Im-C-2), 138.24 (+, 
Pyr-C-4), 139.31 (Cquat, Pyr-C-3), 147.73 (+, Pyr-C-6), 150.06 (+, Pyr-C-2), 161.22 (Cquat, 
C=N). IR (cm-1) = 3265 (N-H), 2931 (C-H), 2863 (C-H), 2160 (C≡N), 1576 (C=N). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 326 (100) [M + H]+. HRMS (EI-MS) calcd. for C17H23N7 
[M+•] 325.2015; found 325.2014. Anal. (C17H23N7 · 2 C2H2O4 · 1.3 H2O) C, H, N. C17H23N7 
(325.41). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-[3-(pyridin-4-yl)propyl]guanidine (3.71) 
The title compound was prepared from 3.34 (0.56 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.34 g, 52 %); mp (hydrogenoxalate) 155 – 157 °C. 1H-NMR (400 MHz, 
CD3OD, COSY): δ [ppm] = 1.51 – 1.61 (m, 2H, Im-4-(CH2)2-CH2), 1.61 – 1.70 (m, 2H, Im-4-
CH2-CH2), 1.84 – 1.95 (m, 2H, Pyr-4-CH2-CH2), 2.60 (t, 2H, 3J = 7.2 Hz, Im-4-CH2), 2.69 (t, 
2H, 3J = 7.8 Hz, Pyr-4-CH2), 3.19 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)3-CH2), 3.24 (t, 2H, 3J = 7.1 
Hz, Pyr-4-(CH2)2-CH2), 6.77 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.28 (dd, 2H, 3J = 4.5 Hz, 5J = 1.6 
Hz, Pyr-3,5-H), 7.53 (d, 1H, 4J = 1.1 Hz, Im-2-H), 8.39 (dd, 2H, 3J = 4.5 Hz, 5J = 1.6 Hz, Pyr-
2,6-H). 13C-NMR (100 MHz, CD3OD, HSQC, HMBC): δ [ppm] = 27.17 (-, Im-4-CH2), 27.72 (-, 
Im-4-CH2-CH2), 29.94 (-, Im-4-(CH2)2-CH2), 31.02 (-, Pyr-4-CH2-CH2), 33.25 (-, Pyr-4-CH2), 
42.18 (-, Pyr-4-(CH2)2-CH2), 42.51 (-, Im-4-(CH2)3-CH2), 117.58 (+, Im-C-5), 120.18 (Cquat, 
C≡N), 125.62 (+, Pyr-C-3,5), 135.75 (+, Im-C-2), 138.26 (Cquat, Im-C-4), 149.95 (+, Pyr-C-
2,6), 153.69 (Cquat, Pyr-C-4), 161.20 (Cquat, C=N). IR (cm-1) = 3244 (N-H), 2933 (C-H), 2864 
(C-H), 2160 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 326 (100) [M + 
H]+. HRMS (EI-MS) calcd. for C17H23N7 [M+•] 325.2015; found 325.2007. Anal. (C17H23N7 · 2 
C2H2O4 · 2 H2O) C, H, N. C17H23N7 (325.41). 
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2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-(3-phenylbutyl)guanidine (3.72) 
The title compound was prepared from 3.35 (0.59 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.53 g, 78 %); mp (hydrogenoxalate) 135 – 137 °C. 1H-NMR (300 MHz, 
CD3OD): δ [ppm] = 1.25 (d, 3H, 3J = 6.9 Hz, PhCH3CH), 1.54 – 1.60 (m, 2H, Im-4-CH2-CH2-
CH2), 1.78 – 1.90 (m, 2H, PhCH3CH-CH2), 2.59 (t, 2H, 3J = 7.2 Hz, Im-4-CH2), 2.68 – 2.83 
(m, 1H, PhCH3CH), 2.97 – 3.20 (m, 4H, PhCH3CH-CH2-CH2 + Im-4-(CH2)3-CH2), 6.76 (d, 1H, 
4J = 1.1 Hz, 1H, Im-5-H), 7.11 – 7.32 (m, 5H, Ph-H), 7.53 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-
NMR (75 MHz, CD3OD): δ [ppm] = 23.09 (+, CH3), 27.21 (-, Im-4-CH2), 27.74 (-, Im-4-CH2-
CH2), 29.97 (-, Im-4-(CH2)2-CH2), 38.58, (-, PhCH3CH-CH2), 38.93 (+, PhCH3CH), 41.43 (-, 
PhCH3CH-CH2-CH2), 42.48 (-, Im-4-(CH2)3-CH2), 117.69 (+, Im-C-5), 120.39 (Cquat, C≡N), 
127.32 (+, Ph-C-4), 128.05 (+, 2 Ph-C), 129.64 (+, 2 Ph-C), 135.77 (+, Im-C-2), 138.03 (Cquat, 
Im-C-4), 147.85 (Cquat, Ph-C-1), 161.14 (Cquat, C=N). IR (cm-1) = 3250 (N-H), 2930 (C-H), 
2866 (C-H), 2159 (C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 339 (100) 
[M + H]+. HRMS (EI-MS) calcd. for C19H26N6 [M+•] 338.2219; found 338.2210. Anal. (C19H26N6 
· 0.85 C2H2O4) C, H, N. C19H26N6 (338.45). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]guanidine (3.73) 
The title compound was prepared from 3.36 (0.32 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 87.5/10.5/2 v/v/v) yielding a colorless 
foam-like solid (0.35 g, 85 %); mp (hydrogenoxalate) 172 – 174 °C. 1H-NMR (300 MHz, 
CD3OD): δ [ppm] = 1.46 – 1.74 (m, 4H, Im-4-CH2-CH2-CH2), 2.61 (t, 2H, 3J = 7.3 Hz, Im-4-
CH2), 3.17 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)3-CH2), 6.80 (d, 1H, 4J = 1.1 Hz, 1H, Im-5-H), 7.62 
(d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.05 (-, Im-4-CH2), 
27.71 (-, Im-4-CH2-CH2), 29.95 (-, Im-4-(CH2)2-CH2), 42.23 (-, Im-4-(CH2)3-CH2), 117.81 (+, 
Im-C-5), 120.22 (Cquat, C≡N), 135.72 (+, Im-C-2), 137.99 (Cquat, Im-C-4), 161.13 (Cquat, C=N). 
IR (cm-1) = 3312 (N-H), 2940 (C-H), 2858 (C-H), 2164 (C≡N), 1558 (C=N). ES-MS (MeCN + 
TFA) m/z (%): 207 (100) [M + H]+. HRMS (EI-MS) calcd. for C9H14N6 [M+•] 206.1280; found 
206.1281. Anal. (C9H14N6 · C2H2O4 · 0.1 H2O) C, H, N. C9H14N6 (206.25). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-methylguanidine (3.74)8 
The title compound was prepared from 3.37 (0.35 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielding a colorless 
foam-like solid (0.34 g, 77 %); mp (hydrogenoxalate) 143 – 145 °C. 1H-NMR (300 MHz, 
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CD3OD): δ [ppm] = 1.49 – 1.73 (m, 4H, Im-4-CH2-CH2-CH2), 2.60 (t, 2H, 3J = 7.1 Hz, Im-4-
CH2), 2.77 (s, 3H, CH3), 3.20 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)3-CH2), 6.77 (d, 1H, 4J = 1.1 Hz, 
1H, Im-5-H), 7.55 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.18 
(-, Im-4-CH2), 27.75 (-, Im-4-CH2-CH2), 28.73 (+, CH3), 30.07 (-, Im-4-(CH2)2-CH2), 42.50 (-, 
Im-4-(CH2)3-CH2), 117.89 (+, Im-C-5), 120.32 (Cquat, C≡N), 135.77 (+, Im-C-2), 138.21 (Cquat, 
Im-C-4), 161.99 (Cquat, C=N). IR (cm-1) = 3277 (N-H), 2972 (C-H), 2901 (C-H), 2158 (C≡N), 
1577 (C=N). ES-MS (MeCN + TFA) m/z (%): 221 (100) [M + H]+. HRMS (EI-MS) calcd. for 
C10H16N6 [M+•] 220.1436; found 220.1439. Anal. (C10H16N6 · C2H2O4 · 0.4 H2O) C, H, N. 
C10H16N6 (220.27). 
 
2-Cyano-1-ethyl-3-[4-(1H-imidazol-4-yl)butyl]guanidine (3.75) 
The title compound was prepared from 3.38 (0.38 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.39 g, 83 %); mp (hydrogenoxalate) 130 – 133 °C. 1H-NMR (300 MHz, 
CD3OD): δ [ppm] = 1.14 (t, 3H, 3J = 7.2 Hz, CH3), 1.50 – 1.72 (m, 4H, Im-4-CH2-CH2-CH2), 
2.60 (t, 2H, 3J = 7.1 Hz, Im-4-CH2), 3.16 – 3.27 (m, 4H, CH3CH2 + Im-4-(CH2)3-CH2), 6.77 (d, 
1H, 4J = 1.1 Hz, 1H, Im-5-H), 7.55 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): 
δ [ppm] = 15.13 (+, CH3), 27.20 (-, Im-4-CH2), 27.77 (-, Im-4-CH2-CH2), 30.04 (-, Im-4-(CH2)2-
CH2), 37.62 (-, CH2-CH3), 42.51 (-, Im-4-(CH2)3-CH2), 117.95 (+, Im-C-5), 120.48 (Cquat, 
C≡N), 135.79 (+, Im-C-2), 138.15 (Cquat, Im-C-4), 161.10 (Cquat, C=N). IR (cm-1) = 3264 (N-H), 
2934 (C-H), 2858 (C-H), 2155 (C≡N), 1572 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
235 (100) [M + H]+. HRMS (EI-MS) calcd. for C11H18N6 [M+•] 234.1593; found 234.1590. Anal. 
(C11H18N6 · 0.75 C2H2O4) C, H, N. C11H18N6 (234.30). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-isopropylguanidine (3.76) 
The title compound was prepared from 3.39 (0.41 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.39 g, 79 %); mp (hydrogenoxalate) 129 – 131 °C. 1H-NMR (600 MHz, 
CD3OD): δ [ppm] = 1.25 (d, 6H, 3J = 6.5 Hz, CH3), 1.46 – 1.69 (m, 2H, Im-4-(CH2)2-CH2), 
1.62 – 1.69 (m, 2H, Im-4-CH2-CH2), 2.60 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 3.22 (t, 2H, 3J = 7.4 
Hz, Im-4-(CH2)3-CH2), 3.86 (sep, 1H, 3J = 6.5 Hz, CH), 6.77 (d, 1H, 4J = 1.1 Hz, 1H, Im-5-H), 
7.54 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 22.83 (+, CH3), 
27.20 (-, Im-4-CH2), 27.75 (-, Im-4-CH2-CH2), 30.02 (-, Im-4-(CH2)2-CH2), 42.50 (-, Im-4-
(CH2)3-CH2), 45.06 (+, CH), 117.87 (+, Im-C-5), 120.42 (Cquat, C≡N), 135.78 (+, Im-C-2), 
138.15 (Cquat, Im-C-4), 160.37 (Cquat, C=N). IR (cm-1) = 3241 (N-H), 2937 (C-H), 2860 (C-H), 
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2157 (C≡N), 1569 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 249 (100) [M + H]+. 
HRMS (EI-MS) calcd. for C12H20N6 [M+•] 248.1749; found 248.1746. Anal. (C12H20N6 · 0.75 
C2H2O4 · 0.25 H2O) C, H, N. C12H20N6 (248.33). 
 
2-Cyano-1-[4-(1H-imidazol-4-yl)butyl]-3-isobutylguanidine (3.77) 
The title compound was prepared from 3.40 (0.43 g, 2.0 mmol) and 3.60 (0.31 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) yielding a colorless 
foam-like solid (0.28 g, 53 %); mp (hydrogenoxalate) 140 – 143 °C. 1H-NMR (600 MHz, 
CD3OD, COSY): δ [ppm] = 0.90 (d, 6H, 3J = 6.7 Hz, CH3), 1.54 – 1.60 (m, 2H, Im-4-(CH2)2-
CH2), 1.62 – 1.69 (m, 2H, Im-4-CH2-CH2), 1.79 – 1.87 (m, 1H, CH), 2.60 (t, 2H, 3J = 7.3 Hz, 
Im-4-CH2), 2.99 (d, 2H, 3J = 7.2 Hz, (CH3)2CHCH2), 3.21 (t, 2H, 3J = 7.1 Hz, Im-4-(CH2)3-
CH2), 6.76 (d, 1H, 4J = 1.1 Hz, 1H, Im-5-H), 7.54 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (150 
MHz, CD3OD, HSQC): δ [ppm] = 20.83 (+, CH3), 27.15 (-, Im-4-CH2), 27.70 (-, Im-4-CH2-
CH2), 29.55 (+, CH), 30.00 (-, Im-4-(CH2)2-CH2), 42.47 (-, Im-4-(CH2)3-CH2), 50.07 (+, 
(CH3)2CH-CH2)), 117.65 (+, Im-C-5), 120.36 (Cquat, C≡N), 135.72 (+, Im-C-2), 138.10 (Cquat, 
Im-C-4), 161.28 (Cquat, C=N). IR (cm-1) = 3280 (N-H), 2955 (C-H), 2871 (C-H), 2157 (C≡N), 
1576 (C=N). ES-MS (H2O/MeCN) m/z (%): 263 (100) [M + H]+. HRMS (EI-MS) calcd. for 
C13H22N6 [M+•] 262.1906; found 262.1906. Anal. (C13H22N6 · 0.75 C2H2O4 · 0.25 H2O) C, H, N. 
C13H22N6 (262.35). 
 
2-Cyano-1-{2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl}-3-(3-phenylpropyl)-
guanidine (3.80) 
The title compound was prepared from 3.24 (0.56 g, 2.0 mmol) and 3.798 (0.38 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 95/3/2 v/v/v) yielding a pale yellow 
foam-like solid (0.42 g, 61 %); mp (hydrogenoxalate) 148 – 150 °C. 1H-NMR (300 MHz, 
CD3OD, hydrogenoxalate): δ [ppm] = 1.79 – 1.93 (m, 2H, Ph-CH2-CH2), 2.34 (s, 3H, Im-5-
CH3), 2.58 – 2.69 (m, 4H, Ph-CH2 + Im-4-CH2-S-CH2), 3.20 (t, 2H, 3J = 7.1 Hz, Ph-(CH2)2-
CH2), 3.36 (t, 2H, 3J = 7.1 Hz, Im-4-CH2-S-CH2-CH2), 3.84 (s, 2H, Im-4-CH2), 7.10 – 7.30 (m, 
5H, Ph-H), 8.61 (s, 1H, Im-2-H). 13C-NMR (75 MHz, CD3OD, hydrogenoxalate): δ [ppm] = 
9.12 (+, CH3), 24.74 (-, Im-4-CH2), 31.99 (-, Im-4-CH2-S-CH2), 32.16, 33.96 (-, PhCH2-CH2), 
41.95 (-, Im-4-CH2-S-CH2-CH2), 42.48 (-, Ph-(CH2)2-CH2), 119.95 (Cquat, C≡N), 127.08 (+, Ph-
C-4), 127.86, 128.03 (Cquat, Im-C-4,5), 128.03 (+, 2 Ph-C), 129.54 (+, 2 Ph-C), 133.92 (+, Im-
C-2), 142.80 (Cquat, Ph-C-1), 161.14 (Cquat, C=N), 167.00 (Cquat, hydrogenoxalate). IR (cm-1) = 
3253 (N-H), 2989 (C-H), 2901 (C-H), 2161 (C≡N), 1576 (C=N). ES-MS (H2O/MeCN) m/z (%): 
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357 (100) [M + H]+. HRMS (EI-MS) calcd. for C18H24N6S [M+•] 356.1783; found 356.1781. 
Anal. (C18H24N6S · 0.85 C2H2O4 · 0.25 H2O) C, H, N. C18H24N6S (356.49). 
 
2-Cyano-1-(3,3-diphenylpropyl)-3-{2-[(5-methyl-1H-imidazol-4-yl)methylthio]ethyl}-
guanidine (3.81) 
The title compound was prepared from 3.27 (0.71 g, 2.0 mmol) and 3.798 (0.38 g, 2.2 mmol) 
in MeCN (50 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/7 M NH3 in MeOH 98/2 v/v) yielding a pale yellow foam-like 
solid (0.63 g, 73 %); mp (hydrogenoxalate) 144 – 146 °C. 1H-NMR (400 MHz, COSY, 
CD3OD, hydrogenoxalate): δ [ppm] = 2.29 – 2.38 (m, 5H, Ph2CH-CH2 + Im-5-CH3), 2.60 (t, 
2H, 3J = 7.0 Hz, Im-4-CH2-S-CH2), 3.14 (t, 2H, 3J = 7.2 Hz, Ph2CH-CH2-CH2), 3.32 (t, 2H, 3J = 
7.0 Hz, Im-4-CH2-S-CH2-CH2), 3.81 (s, 2H, Im-4-CH2), 4.01 (t, 1H, 3J = 7.9 Hz, Ph2CH), 7.12 
– 7.19 (m, 2H, Ph-4-H), 7.23 – 7.31 (m, 8H, Ph-H), 8.60 (s, 1H, Im-2-H). 13C-NMR (100 MHz, 
HMQC, CD3OD, hydrogenoxalate): δ [ppm] = 9.05 (+, Im-5-CH3), 24.66 (-, Im-4-CH2), 31.94 
(-, Im-4-CH2-S-CH2), 35.84 (-, Ph2CH-CH2), 41.70 (-, Ph2CH-CH2-CH2), 41.94 (-, Im-4-CH2-S-
CH2-CH2), 49.96 (+, Ph2CH), 119.92 (Cquat, C≡N), 127.45 (+, 2 Ph-C-4), 127.76, 128.01 
(Cquat, Im-C-4,5), 128.89 (+, 4 Ph-C), 129.64 (+, 4 Ph-C), 133.87 (+, Im-C-2), 145.74 (Cquat, 2 
Ph-C-1), 161.11 (Cquat, C=N), 166.77 (Cquat, hydrogenoxalate). IR (cm-1) = 3245 (N-H), 2927 
(C-H), 2822 (C-H), 2161 (C≡N), 1576 (C=N). ES-MS (MeOH + NH4OAc) m/z (%): 433 (100) 
[M + H]+. HRMS (EI-MS) calcd. for C24H28N6S [M+•] 432.2096; found 432.2101. Anal. 
(C24H28N6S · C2H2O4 · 0.5 H2O) C, H, N. C24H28N6S (432.58). 
 
3.4.1.4 Preparation of the carbamoylguanidines 3.49, 3.50, 3.59 and 3.78 
General procedure 
The pertinent cyanoguanidine was dissolved in 1 M HCl (25 mL) and left for 14 d at room 
temperature. After removing the solvent in vacuo, the crude product was purified by 
preparative HPLC, followed by flash chromatography under basic conditions to remove 
possible impurities with the corresponding guanidine. 
 
2-Carbamoyl-1-[3-(1H-imidazol-4-yl)propyl]-3-(3-phenylpropyl)guanidine (3.49) 
The title compound was prepared from 3.42 (0.20 g, 0.64 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) followed by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielded a colorless 
semisolid compound (0.20 g, 95 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.79 – 1.94 (m, 
4H, Im-4-CH2-CH2 + Ph-CH2-CH2), 2.57 – 2.72 (m, 4H, Im-4-CH2 + Ph-CH2), 3.12 – 3.27 (m, 
4H, Im-4-(CH2)2-CH2 + Ph-CH2-CH2-CH2), 6.79 (s, 1H, Im-5-H), 7.10 – 7.31 (m, 5H, Ph-H), 
7.55 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 24.83 (-, Im-4-CH2), 
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30.46 (-, Im-4-CH2-CH2) 32.34 (-, Ph-CH2-CH2), 34.05 (-, Ph-CH2), 41.31, 41.38 (-, Im-4-
(CH2)2-CH2 + Ph-CH2-CH2-CH2), 117.87 (+, Im-C-5), 127.02 (+, Ph-C-4), 129.50 (+, 2 Ph-C), 
129.53 (+, 2 Ph-C), 135.93 (+, Im-C-2), 137.62 (Cquat, Im-C-4), 142.90 (Cquat, Ph-C-1), 160.96 
(Cquat, C=N), 169.32 (Cquat, C=O). IR (cm-1) = 3206, 2933, 2864, 1570, 1397, 1369. ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 329 (100) [M + H]+. HRMS (EI-MS) calcd. for C17H24N6O 
[M+•] 328.2012; found 328.2088. C17H24N6O (328.41). 
 
2-Carbamoyl-1-[3-(1H-imidazol-4-yl)propyl]-3-(4-phenylbutyl)guanidine (3.50) 
The title compound was prepared from 3.44 (0.20 g, 0.62 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) followed by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielded a colorless 
semisolid compound (0.17 g, 80 %). 1H-NMR (600 MHz, COSY, CD3OD, trifluoroacetate): δ 
[ppm] = 1.62 – 1.74 (m, 4H, Ph-CH2-CH2-CH2), 1.96 – 2.03 (m, 2H, Im-4-CH2-CH2), 2.66 (t, 
2H, 3J = 7.7 Hz, Ph-CH2), 2.80 (t, 2H, 3J = 7.2 Hz, Im-4-CH2), 3.31 (t, 2H, 3J = 7.0 Hz, Ph-
(CH2)3-CH2), 3.38 (t, 2H, 3J = 6.6 Hz, Im-4-(CH2)2-CH2), 7.12 – 7.27 (m, 5H, Ph-H), 7.33 (brs, 
1H, Im-5-H), 8.79 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (150 MHz, HSQC, HMBC, CD3OD, 
trifluoroacetate): δ [ppm] = 22.56 (-, Im-4-CH2), 28.59 (-, Im-4-CH2-CH2), 29.17, 29.52 (-, Ph-
CH2-CH2-CH2), 36.29 (-, PhCH2), 41.76 (-, Im-4-(CH2)2-CH2), 42.75 (-, Ph-(CH2)3-CH2), 
117.02 (+, Im-C-5), 126.98 (+, Ph-C-4), 129.43 (+, 2 Ph-C), 129.45 (+, 2 Ph-C), 134.35 (Cquat, 
Im-C-4), 134.96 (+, Im-C-2), 143.09 (Cquat, Ph-C-1), 154.55 (Cquat, C=N), 156.86 (Cquat, C=O). 
IR (cm-1) = 3192, 2934, 2858, 1723, 1576, 1594, 1399, 1370. ES-MS (H2O/MeCN) m/z (%): 
343 (100) [M + H]+. HRMS (EI-MS) calcd. for C18H26N6O [M + H]+ 343.2241; found 343.2250. 
C18H26N6O (342.44). 
 
2-Carbamoyl-1-[2-(1H-imidazol-4-yl)ethyl]-3-(3-phenylpropyl)guanidine (3.59) 
The title compound was prepared from 3.52 (0.41 g, 1.38 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 20/80) followed by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 90/8/2 v/v/v) yielded a colorless 
semisolid compound (0.35 g, 81 %). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 
1.89 – 2.04 (m, 2H, Ph-CH2-CH2), 2.70 (t, 2H, 3J = 7.6 Hz, Ph-CH2), 3.07 (t, 2H, 3J = 6.9 Hz, 
Im-4-CH2), 3.24 – 3.37 (m, 2H, overlap with solvent, Ph-CH2-CH2-CH2), 3.65 (t, 2H, 3J = 6.9 
Hz, Im-4-CH2-CH2), 7.14 – 7.32 (m, 5H, Ph-H), 7.43 (d, 1H, 4J = 1.2 Hz, Im-5-H), 8.84 (d, 1H, 
4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 25.27 (-, Im-4-
CH2), 31.20 (-, Ph-CH2-CH2), 33.69 (-, Ph-CH2), 41.37 (-, Im-4-CH2), 42.45 (-, Ph-(CH2)2-
CH2), 118.19 (+, Im-C-5), 127.34 (+, Ph-C-4), 129.47 (+, 2 Ph-C), 129.67 (+, 2 Ph-C), 131.56 
(Cquat, Im-C-4), 135.37 (+, Im-C-2), 142.07 (Cquat, Ph-C-1), 154.71 (Cquat, C=N), 156.86 (Cquat, 
C=O). IR (cm-1) = 3153, 2930, 1662, 1603, 1181, 1128. ES-MS (H2O/MeCN) m/z (%): 315 
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(100) [M + H]+. HRMS (EI-MS) calcd. for C16H22N6O [M+•] 314.1855; found 314.1860. 
C16H22N6O (314.39). 
 
2-Carbamoyl-1-[4-(1H-imidazol-4-yl)butyl]-3-(3-phenylpropyl)guanidine (3.78) 
The title compound was prepared from 3.61 (0.48 g, 1.48 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 10/90, 20 min: 
40/60) followed by flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 92.5/5.5/2 v/v/v) 
yielded a colorless foam-like solid (0.29 g, 57 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 
1.49 – 1.74 (m, 4H, Im-4-CH2-CH2-CH2), 1.78 – 1.93 (m, 2H, Ph-CH2-CH2), 2.55 – 2.70 (m, 
4H, Im-4-CH2 + Ph-CH2), 3.11 – 3.27 (m, 4H, Im-4-(CH2)3-CH2 + Ph-(CH2)2-CH2), 6.76 (d, 
1H, 4J = 1.1 Hz, Im-5-H), 7.10 – 7.29 (m, 5H, Ph-H), 7.53 (d, 1H, 4J = 1.1 Hz, Im-2-H). 13C-
NMR (75 MHz, CD3OD): δ [ppm] = 27.17 (-, Im-4-CH2), 27.88 (-, Im-4-CH2-CH2), 30.14 (-, Im-
4-(CH2)2-CH2), 32.38 (-, Ph-CH2-CH2), 34.06 (-, PhCH2), 41.40, 41.69 (-, Im-4-(CH2)3-CH2 + 
Ph-(CH2)2-CH2), 117.61 (+, Im-C-5), 127.00 (+, Ph-C-4), 129.49 (+, 2 Ph-C), 129.53 (+, 2 Ph-
C), 135.75 (+, Im-C-2), 142.95 (Cquat, Ph-C-1), 160.96 (Cquat, C=N), 169.38 (Cquat, C=O). IR 
(cm-1) = 3200, 2989, 2932, 1569, 1394, 1367. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 343 
(100) [M + H]+. HRMS (LSI-MS) calcd. for C18H27N6O [M + H]+ 343.2241; found 343.2255. 
C18H26N6O (342.43). 
 
3.4.1.5 Preparation of the diamine 3.84 
4,15-Dioxo-8,11-dioxa-5,14-diazaoctadecane-1,18-diyldicarbamic acid dibenzyl ester 
(3.83) 
4-(Benzyloxycarbonylamino)butanoic acid (8.54 g, 36.0 mmol) and CDI (6.42 g, 39.5 mmol) 
were dissolved in THFabs (150 mL). After stirring for 1 h, 3.82 (2.67 g, 18.0 mmol) were added 
and stirred overnight. The precipitated product was filtered and washed with THF (2 x 15 mL) 
yielding a white solid (8.5 g, 80 %); mp 127 – 129 °C. 1H-NMR (400 MHz, DMSO-d6, COSY): 
δ [ppm] = 1.54 – 1.66 (m, 4H, CO-CH2-CH2), 2.06 (t, 4H, 3J = 7.4 Hz, CO-CH2), 2.93 – 3.01 
(m, 4H, CO-(CH2)2-CH2), 3.13 – 3.21 (m, 4H, CONH-CH2), 3.38 (t, 4H, 3J = 5.9 Hz, CONH-
CH2-CH2), 3.48 (s, 4H, O-CH2-CH2-O), 4.99 (s, 4H, Ph-CH2), 7.21 (t, 2H, 3J = 5.5 Hz, N-H), 
7.26 – 7.40 (m, 10H, Ph-H), 7.82 (t, 2H, 3J = 5.5 Hz, N-H). 13C-NMR (100 MHz, DMSO-d6, 
HSQC): δ [ppm] = 25.70 (-, CO-CH2-CH2), 32.68 (-, CO-CH2), 39.98 (-, CONH-CH2), 40.21 (-, 
CO-(CH2)2-CH2), 65.16 (-, Ph-CH2), 69.13 (-, CONH-CH2-CH2), 69.51 (-, O-CH2-CH2-O), 
127.74 (+, 6 Ph-C), 128.35 (+, 4 Ph-C), 137.24 (Cquat, Ph-C-1), 156.07 (Cquat, O-C=O), 171.81 
(Cquat, CH2C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 587 (100) [M + H]+. Anal. 
(C30H42N4O8) C, H, N. C30H42N4O8 (586.68). 
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N,N'-(Ethylenedioxydiethyl)di-4-aminobutanamide (3.84) 
3.83 (7.2 g, 12.3 mmol) was hydrogenated over Pd/C (10 %) (0.72 g, cat.) in MeOH (150 mL) 
at room temperature for 12 h. The catalyst was removed by filtration over Celite and after 
evaporation of the solvent, a colorless semisolid compound was received that was used 
without further purification (3.8 g, 97 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 1.47 – 
1.61 (m, 4H, CO-CH2-CH2), 2.08 (t, 4H, 3J = 7.4 Hz, CO-CH2), 2.42 – 2.53 (m, 4H, CO-
(CH2)2-CH2), 2.84 (brs, 4H, N-H), 3.12 – 3.23 (m, 4H, CONH-CH2), 3.38 (t, 4H, 3J = 5.9 Hz, 
CONH-CH2-CH2), 3.49 (s, 4H, O-CH2-CH2-O), 7.91 (t, 2H, 3J = 5.0 Hz, N-H). 13C-NMR (75 
MHz, DMSO-d6): δ [ppm] = 29.38 (-, CO-CH2-CH2), 32.86 (-, CO-CH2), 38.37 (-, CONH-CH2), 
41.09 (-, CO-(CH2)2-CH2), 69.07 (-, CONH-CH2-CH2), 69.44 (-, O-CH2-CH2-O), 172.25 (Cquat, 
C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 319 (100) [M + H]+. C14H30N4O4 (318.41).  
 
3.4.1.6 Preparation of the bivalent isourea precursors 3.88-3.91 
General procedure 
A solution of the primary amine (1 eq) and diphenyl cyanocarbonimidate (2 eq) in DCM or 
DCM/MeOH was stirred for 1 h at room temperature. After evaporation of the solvent, the 
product was crystallized from Et2O. 
 
1,1'-Dicyano-2,2'-diphenyl-3,3'-[N,N'-(ethylendioxydiethyl)di(aminocarbonylpropyl)]-
diisourea (3.88) 
The title compound was prepared from 3.84 (1.91 g, 6.0 mmol) and 3.6 (2.86 g, 12.0 mmol) 
in DCM/MeOH (60 mL 1/1 v/v) according to the general procedure yielding a white solid (3.5 
g, 96 %); mp 155 – 158 °C. 1H-NMR (600 MHz, DMSO-d6): δ [ppm] = 1.66 – 1.75 (m, 2H, 
CO-CH2-CH2), 1.76 – 1.86 (m, 2H, CO-CH2-CH2), 2.09 (t, 2H, 3J = 7.2 Hz, CO-CH2), 2.16 (t, 
2H, 3J = 7.2 Hz, CO-CH2), 3.14 – 3.22 (m, 6H, CO-(CH2)2-CH2 + CONH-CH2), 3.30 (t, 2H, 3J 
= 6.7 Hz, CONH-CH2), 3.35 – 3.41 (m, 4H, O-CH2-CH2-O), 3.44 – 3.51 (m, 4H, CONH-CH2-
CH2), 7.12 – 7.33 (m, 6H, Ph-H), 7.37 – 7.50 (m, 4H, Ph-H), 7.87 – 7.95 (m, 2H, N-H), 8.62 
(brs, 2H, N-H). 13C-NMR (150 MHz, DMSO-d6): δ [ppm] = 24.25, 25.17 (-, CO-CH2-CH2), 
32.32, 32.35 (-, CO-CH2), 38.51 (-, CONH-CH2), 41.76, 42.10 (-, CO-(CH2)2-CH2), 69.12 (-, 
CONH-CH2-CH2), 69.50 (-, O-CH2-CH2-O), 119.90, 121.72 (Cquat, C≡N), 126.14 (+, Ph-C), 
126.19 (+, Ph-C), 129.46 (+, Ph-C), 130.26 (+, Ph-C), 151.21 (Cquat, Ph-C-1), 151.57 (Cquat, 
Ph-C-1), 159.56 (Cquat, C=N), 162.66 (Cquat, C=N), 171.60 (Cquat, C=O). IR (cm-1) = 3310 (N-
H), 3198 (N-H), 2924, 2857, 2190 (C≡N), 1639 (C=N), 1444, 1420, 1200. ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 607 (100) [M + H]+. Anal. (C30H38N8O6 · 0.5 H2O) C, H, N. 
C30H38N8O6 (606.67). 
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1,1’-Dicyano-2,2’-diphenyl-3,3’-hexamethylendiisourea (3.89) 
The title compound was prepared from 3.85 (0.70 g, 6.0 mmol) and 3.6 (2.86 g, 12.0 mmol) 
in DCM/MeOH (60 mL 1/1 v/v) according to the general procedure yielding a white solid (2.2 
g, 91 %); mp 172 – 173 °C. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 1.21 – 1.73 (m, 8H, 
NH-CH2-(CH2)4-CH2-NH), 3.16 – 3.42 (m, 4H, CH2NH), 7.11 – 7.53 (m, 10H, Ph-H), 8.54 
(brs, 2H, N-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 25.64 (-, NH-(CH2)2-(CH2)2-(CH2)2-
NH), 27.92, 29.00 (-, NH-CH2-CH2-(CH2)2-CH2-CH2-NH), 41.91, 42.21 (-, CH2NH), 114.28, 
114.70 (Cquat, C≡N), 119.68, 121.60 (+, 4 Ph-C), 125.98, 126.12 (+, 2 Ph-C), 129.44, 130.17 
(+, 4 Ph-C), 151.11, 151.61 (Cquat, 2 Ph-C), 159.42, 162.55 (Cquat, C=N). IR (cm-1) = 3186 (N-
H), 2936, 2187 (C≡N), 1635 (C=N), 1441, 1416, 1204. ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 405 (100) [M + H]+. Anal. (C22H24N6O2 · 0.25 H2O) C, H, N. C22H24N6O2 (404.46). 
 
1,1’-Dicyano-2,2’-diphenyl-3,3’-octamethylendiisourea (3.90) 
The title compound was prepared from 3.86 (0.87 g, 6.0 mmol) and 3.6 (2.86 g, 12.0 mmol) 
in DCM (50 mL) according to the general procedure yielding a white solid (2.5 g, 96 %); mp 
150 – 152 °C. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 1.17 – 1.40 (m, 8H, NH-(CH2)2-
(CH2)4-(CH2)2-NH), 1.41 – 1.67 (m, 4H, NH-CH2-CH2-(CH2)4-CH2-CH2-NH), 3.13 – 3.34 (m, 
4H, CH2NH), 7.11 – 7.53 (m, 10H, Ph-H), 8.56 (brs, 2H, N-H). 13C-NMR (75 MHz, DMSO-d6): 
δ [ppm] = 25.64 (-, NH-(CH2)3-(CH2)2-(CH2)3-NH), 27.98, 29.01 (-, NH-CH2-CH2-(CH2)4-CH2-
CH2-NH), 28.42 (-, NH-(CH2)2-CH2-(CH2)2-CH2-(CH2)2-NH), 41.92, 42.23 (-, CH2NH), 114.30, 
114.71 (Cquat, C≡N), 119.69, 121.56 (+, 4 Ph-C), 125.97, 126.11 (+, 2 Ph-C), 129.44, 130.17 
(+, 4 Ph-C), 151.10, 151.59 (Cquat, 2 Ph-C), 159.41, 162.54 (Cquat, C=N). IR (cm-1) = 3177 (N-
H), 3068, 2930, 2193 (C≡N), 1627 (C=N), 1418, 1202. ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 433 (100) [M + H]+. Anal. (C24H28N6O2) C, H, N. C24H28N6O2 (432.52). 
 
1,1’-Dicyano-2,2’-diphenyl-3,3’-decamethylendiisourea (3.91) 
The title compound was prepared from 3.87 (1.03 g, 6.0 mmol) and 3.6 (2.86 g, 12.0 mmol) 
in DCM (50 mL) according to the general procedure yielding a white solid (2.54 g, 92 %); mp 
155 – 157 °C. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 1.15 – 1.40 (m, 12H, NH-(CH2)2-
(CH2)6-(CH2)2-NH), 1.39 – 1.67 (m, 4H, NH-CH2-CH2-(CH2)6-CH2-CH2-NH), 3.13 – 3.42 (m, 
4H, CH2NH), 7.10 – 7.54 (m, 10H, Ph-H), 8.50 (brs, 2H, N-H). 13C-NMR (75 MHz, DMSO-d6): 
δ [ppm] = 25.99 (-, NH-(CH2)4-(CH2)2-(CH2)4-NH), 28.00, 29.00 (-, NH-CH2-CH2-(CH2)6-CH2-
CH2-NH), 28.50, 28.80 (-, NH-(CH2)2-(CH2)2-(CH2)2-(CH2)2-(CH2)2-NH), 41.91, 42.25 (-, 
CH2NH), 114.30, 114.70 (Cquat, C≡N), 119.66, 121.55 (+, 4 Ph-C), 125.94, 126.11 (+, 2 Ph-
C), 129.43, 130.15 (+, 4 Ph-C), 151.10, 151.62 (Cquat, 2 Ph-C), 159.39, 162.53 (Cquat, C=N). 
IR (cm-1) = 3198 (N-H), 2928, 2857, 2183 (C≡N), 1634 (C=N), 1417, 1201. ES-MS 
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(DCM/MeOH + NH4OAc) m/z (%): 461 (100) [M + H]+. Anal. (C26H32N6O2) C, H, N. 
C26H32N6O2 (460.57). 
 
3.4.1.7 Preparation of the bivalent cyanoguanidines 3.92-3.95 
General procedure 
The pertinent isourea (1 eq) and 3.60 (2.2 eq) were refluxed in MeCN for 12 h. After removal 
of the solvent in vacuo, the crude product was purified by flash chromatography. 
 
2,2'-Dicyano-3,3'-bis[4-(1H-imidazol-4-yl)butyl]-1,1'-[N,N'-(ethylendioxydiethyl)di-
(aminocarbonylpropyl)]diguanidine (3.92) 
The title compound was prepared from 3.88 (1.21 g, 2.0 mmol) and 3.60 (0.61 g, 4.4 mmol) 
in MeCN (120 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 85/13/2 v/v/v) yielding a colorless 
foam-like solid (0.63 g, 45 %). 1H-NMR (400 MHz, CD3OD, COSY): δ [ppm] = 1.53 – 1.72 (m, 
8H, Im-4-CH2-CH2-CH2), 1.76 – 1.86 (m, 4H, CO-CH2-CH2), 2.24 (t, 4H, 3J = 7.2 Hz, CO-
CH2), 2.61 (t, 4H, 3J = 7.2 Hz, Im-4-CH2), 3.17 – 3.25 (m, 8H, Im-4-(CH2)3-CH2 + CO-(CH2)2-
CH2), 3.35 (t, 4H, 3J = 5.6 Hz, CONH-CH2), 3.53 (t, 4H, 3J = 5.6 Hz, CONH-CH2-CH2), 3.60 
(s, 4H, O-CH2-CH2-O), 6.79 (d, 2H, 4J = 1.1 Hz, Im-5-H), 7.58 (d, 2H, 4J = 1.1 Hz, Im-2-H). 
13C-NMR (100 MHz, CD3OD, HSQC, HMBC): δ [ppm] = 26.51 (-, CO-CH2-CH2), 27.06 (-, Im-
4-CH2), 27.67 (-, Im-4-CH2-CH2), 29.91 (-, Im-4-(CH2)2-CH2), 33.76 (-, CO-CH2), 40.37 (-, 
CONH-CH2), 42.18 (-, CO-(CH2)2-CH2), 42.52 (-, Im-4-(CH2)3-CH2), 70.60 (-, CONH-CH2-
CH2), 71.32 (-, O-CH2-CH2-O), 117.90 (+, Im-C-5), 120.22 (Cquat, C≡N), 135.72 (+, Im-C-2), 
137.97 (Cquat, Im-C-4), 161.23 (Cquat, C=N), 175.52 (Cquat, C=O). IR (cm-1) = 3279 (N-H), 2927 
(C-H), 2866 (C-H), 2159 (C≡N), 1646 (C=O), 1575 (C=N). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 695 (100) [M - H]-. HRMS (LSI-MS) calcd. for C32H53N14O4 [M + H]+ 697.4369; found 
697.4368. C32H52N14O4 (696.85). 
 
2,2’-Dicyano-3,3’-bis[4-(1H-imidazol-4-yl)butyl]-1,1’-hexamethylendiguanidine (3.93) 
The title compound was prepared from 3.89 (0.81 g, 2.0 mmol) and 3.60 (0.61 g, 4.4 mmol) 
in MeCN (120 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 85/13/2 v/v/v) yielding a colorless 
foam-like solid (0.58 g, 58 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.29 – 1.40 (m, 4H, 
NH-(CH2)2-(CH2)2-(CH2)2-NH), 1.46 – 1.72 (m, 12H, Im-4-CH2-CH2-CH2 + NH-CH2-CH2-
(CH2)2-CH2-CH2-NH), 2.61 (t, 4H, 3J = 7.1 Hz, Im-4-CH2), 3.13 – 3.26 (m, 8H, Im-4-(CH2)3-
CH2 + NH-CH2-(CH2)4-CH2-NH), 6.78 (d, 2H, 4J = 1.1 Hz, Im-5-H), 7.59 (d, 2H, 4J = 1.1 Hz, 
Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.14 (-, Im-4-CH2), 27.53 (-, NH-(CH2)2-
(CH2)2-(CH2)2-NH), 27.74 (-, Im-4-CH2-CH2), 30.04 (-, Im-4-(CH2)2-CH2), 30.48 (-, NH-CH2-
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CH2-(CH2)2-CH2-CH2-NH), 42.52 (-, Im-4-(CH2)3-CH2), 42.72 (-, NH-CH2-(CH2)4-CH2-NH), 
117.89 (+, Im-C-5), 120.48 (Cquat, C≡N), 135.76 (+, Im-C-2), 138.07 (Cquat, Im-C-4), 161.19 
(Cquat, C=N). IR (cm-1) = 3249 (N-H), 2933 (C-H), 2857 (C-H), 2155 (C≡N), 1576 (C=N). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 495 (100) [M + H]+. HRMS (LSI-MS) calcd. for 
C24H39N12 [M + H]+ 495.3415; found 495.3406. C24H38N12 (494.64). 
 
2,2’-Dicyano-3,3’-bis[4-(1H-imidazol-4-yl)butyl]-1,1’-octamethylendiguanidine (3.94) 
The title compound was prepared from 3.90 (0.87 g, 2.0 mmol) and 3.60 (0.61 g, 4.4 mmol) 
in MeCN (120 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 85/13/2 v/v/v) yielding a colorless 
foam-like solid (0.64 g, 62 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.26 – 1.39 (m, 8H, 
NH-(CH2)2-(CH2)4-(CH2)2-NH), 1.45 – 1.73 (m, 12H, Im-4-CH2-CH2-CH2 + NH-CH2-CH2-
(CH2)4-CH2-CH2-NH), 2.60 (t, 4H, 3J = 7.1 Hz, Im-4-CH2), 3.13 – 3.25 (m, 8H, Im-4-(CH2)3-
CH2 + NH-CH2-(CH2)6-CH2-NH), 6.77 (d, 2H, 4J = 1.1 Hz, Im-5-H), 7.55 (d, 2H, 4J = 1.1 Hz, 
Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.20 (-, Im-4-CH2), 27.73, 27.75 (-, Im-4-
CH2-CH2 + NH-(CH2)2-CH2-(CH2)2-CH2-(CH2)2-NH), 30.06 (-, Im-4-(CH2)2-CH2), 30.33, 30.49 
(-, NH-CH2-CH2-CH2-(CH2)2-CH2-CH2-CH2-NH), 42.50 (-, Im-4-(CH2)3-CH2), 42.76 (-, NH-
CH2-(CH2)6-CH2-NH), 117.85 (+, Im-C-5), 120.46 (Cquat, C≡N), 135.77 (+, Im-C-2), 138.16 
(Cquat, Im-C-4), 161.20 (Cquat, C=N). IR (cm-1) = 3263 (N-H), 2971 (C-H), 2901 (C-H), 2155 
(C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 523 (100) [M + H]+. HRMS 
(LSI-MS) calcd. for C26H43N12 [M + H]+ 523.3728; found 523.3725. C26H42N12 (522.69). 
 
2,2’-Dicyano-3,3’-bis[4-(1H-imidazol-4-yl)butyl]-1,1’-decamethylendiguanidine (3.95) 
The title compound was prepared from 3.91 (0.92 g, 2.0 mmol) and 3.60 (0.61 g, 4.4 mmol) 
in MeCN (120 mL) according to the general procedure. The crude product was purified by 
flash chromatography (CHCl3/MeOH/7 M NH3 in MeOH 85/13/2 v/v/v) yielding a colorless 
foam-like solid (0.88 g, 80 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.22 – 1.40 (m, 12H, 
NH-(CH2)2-(CH2)6-(CH2)2-NH), 1.45 – 1.74 (m, 12H, Im-4-CH2-CH2-CH2 + NH-CH2-CH2-
(CH2)6-CH2-CH2-NH), 2.60 (t, 4H, 3J = 7.1 Hz, Im-4-CH2), 3.12 – 3.27 (m, 8H, Im-4-(CH2)3-
CH2 + NH-CH2-(CH2)8-CH2-NH), 6.77 (d, 2H, 4J = 1.1 Hz, Im-5-H), 7.55 (d, 2H, 4J = 1.1 Hz, 
Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.22 (-, Im-4-CH2), 27.76 (-, Im-4-CH2-CH2), 
27.81 (-, NH-(CH2)2-CH2-(CH2)4-CH2-(CH2)2-NH), 30.07 (-, Im-4-(CH2)2-CH2), 30.41, 30.52, 
30.62 (-, NH-CH2-CH2-CH2-(CH2)4-CH2-CH2-CH2-NH), 42.52 (-, Im-4-(CH2)3-CH2), 42.80 (-, 
NH-CH2-(CH2)8-CH2-NH), 117.90 (+, Im-C-5), 120.51 (Cquat, C≡N), 135.78 (+, Im-C-2), 138.16 
(Cquat, Im-C-4), 161.19 (Cquat, C=N). IR (cm-1) = 3263 (N-H), 2972 (C-H), 2856 (C-H), 2156 
(C≡N), 1576 (C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 549 (100) [M - H]-. HRMS 
(LSI-MS) calcd. for C28H47N12 [M + H]+ 551.4041; found 551.4034. C28H46N12 (550.75). 
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3.4.1.8 Preparation of the trityl-protected sulfonylguanidines 3.100 and 3.101 
1-(4-Tosyl)-2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (3.100) 
A mixture of 3.964 (0.41 g, 1.0 mmol) and NaH (60 % dispersion in mineral oil) (0.08 g, 2.0 
mmol) in THFabs (15 mL) was stirred 45 min at 50 °C. After cooling to 0 °C, subsequently 
NEt3 (0.28 mL, 2.0 mmol) and 3.98 (0.19 g, 1.0 mmol) in THFabs (15 mL) were added. Stirring 
was continued overnight at ambient temperature. After removing the solvent in vacuo, the 
crude product was purified by flash chromatography (CHCl3/MeOH/NH3 (aq.) 32 % 80/9/1 
v/v/v) yielding a colorless foam-like solid (0.22 g, 39 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] 
= 1.73 – 1.94 (m, 2H, Im-4-CH2-CH2), 2.36 (s, 3H, CH3), 2.44 – 2.79 (m, 2H, Im-4-CH2), 3.25 
– 3.42 (m, 2H, Im-4-(CH2)2-CH2), 6.72 (s, 1H, Im-5-H), 7.06 – 7.15 (m, 6H, Ph-H), 7.19 (d, 
2H, 3J = 8.0 Hz, Ph-3,5-H), 7.30 – 7.45 (m, 10H, Ph-H + Im-2-H), 7.74 (d, 2H, 3J = 8.0 Hz, 
Ph-2,6-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 564 (100) [M + H]+. C33H33N5O2S 
(563.71). 
 
1-(tert-Butoxycarbonyl)-2-(2-phenylethylsulfonyl)-1-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (3.101) 
To a solution of 3.97 (cf. Chapter 6, 6.30) (0.51 g, 1.0 mmol) and DIEA (0.39 g, 3.0 mmol) in 
DCM (20 mL), 3.99 (0.21 g, 1.0 mmol) dissolved in DCM (10 mL) was added dropwise at 
0 °C. After 1 h, stirring was continued overnight at room temperature and the solvent was 
evaporated. The crude product was purified by flash chromatography (CHCl3/MeOH 97.5/2.5 
v/v) yielding the title compound as colorless oil (0.34 g, 50 %). 1H-NMR (300 MHz, CDCl3) 
isomers: δ [ppm] = 1.47 (s, 3H, C(CH3)3), 1.49 (s, 6H, C(CH3)3), 1.86 – 1.91 (m, 2H, Im-4-
CH2-CH2), 2.51 – 2.63 (m, 2H, Im-4-CH2), 3.04 – 3.17 (m, 2H, Ph-CH2), 3.23 – 3.35 (m, 2H, 
Ph-CH2-CH2), 3.76 – 3.85 (m, 2H, Im-4-(CH2)2-CH2), 6.53 (d, 0.7H, 4J = 1.3 Hz, Im-5-H), 6.55 
(d, 0.3H, 4J = 1.3 Hz, Im-5-H), 7.06 – 7.38 (m, 21H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 678 (100) [M + H]+. C39H43N5O4S (677.85). 
 
3.4.1.9 Preparation of the sulfonylguanidines 3.102 and 3.103 
1-[3-(1H-Imidazol-4-yl)propyl]-2-(4-tosyl)guanidine (3.102) 
A mixture of 3.100 (0.19 g, 0.34 mmol) and TFA (5 mL) in DCM (20 mL) was stirred for 5 h. 
After evaporation of the solvent, the crude product was purified by preparative HPLC 
(MeCN/0.1 % TFA (aq.): 25/75) yielding the title compound as colorless semisolid (0.12 g, 82 
%). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 1.76 – 1.92 (m, 2H, Im-4-CH2-
CH2), 2.38 (s, 3H, CH3), 2.70 (t, 2H, 3J = 7.3 Hz, Im-4-CH2), 3.23 (t, 2H, 3J = 6.7 Hz, Im-4-
(CH2)2-CH2), 7.29 (d, 2H, 3J = 8.3 Hz, Ph-3-H), 7.33 (s, 1H, Im-5-H), 7.72 (d, 2H, 3J = 8.3 Hz, 
Ph-2-H), 8.76 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ 
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[ppm] = 21.46 (+, CH3), 22.35 (-, Im-4-CH2), 29.64 (-, Im-4-CH2-CH2), 40.67 (-, Im-4-(CH2)2-
CH2), 117.02 (+, Im-C-5), 127.21 (+, 2 Ph-C-2), 130.41 (+, 2 Ph-C-3), 134.67 (+, Im-C-2), 
134.85 (Cquat, Im-C-4), 141.99 (Cquat, Ph-C-1), 143.83 (Cquat, Ph-C-4), 158.70 (Cquat, C=N). IR 
(cm-1) = 3159, 2989, 2901, 1663, 1624, 1548, 1166, 1128, 1081. HRMS (EI-MS) calcd. for 
C14H19N5O2S [M+•] 321.1259; found 321.1257. C14H19N5O2S · TFA (435.42). 
 
1-[3-(1H-Imidazol-4-yl)propyl]-2-(2-phenylethylsulfonyl)guanidine (3.103) 
A mixture of 3.101 (0.30 g, 0.44 mmol) and TFA (5 mL) in DCM (20 mL) was stirred for 5 h. 
After evaporation of the solvent, the crude product was purified by preparative HPLC 
(MeCN/0.1 % TFA (aq.): 25/75) yielding the title compound as colorless semisolid (0.14 g, 71 
%). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 1.82 – 1.96 (m, 2H, Im-4-CH2-
CH2), 2.76 (t, 2H, 3J = 7.3 Hz, Im-4-CH2), 3.01 – 3.11 (m, 2H, Ph-CH2), 3.19 (t, 2H, 3J = 6.9 
Hz, Im-4-(CH2)2-CH2), 3.23 – 3.29 (m, 2H, Ph-CH2-CH2), 7.15 – 7.31 (m, 5H, Ph-H), 7.37 (s, 
1H, 4J = 1.3 Hz, Im-5-H), 8.76 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 22.42 (-, Im-4-CH2), 29.48 (-, Im-4-CH2-CH2), 31.42 (-, Ph-CH2), 
40.63 (-, Im-4-(CH2)2-CH2), 56.24 (-, Ph-CH2-CH2), 117.07 (+, Im-C-5), 127.66 (+, Ph-C-4), 
129.44 (+, 2 Ph-C), 129.77 (+, 2 Ph-C), 134.70 (+, Im-C-2), 134.89 (Cquat, Im-C-4), 140.27 
(Cquat, Ph-C-1), 158.95 (Cquat, C=N). IR (cm-1) = 3149, 2972, 2901, 1666, 1625, 1554, 1186, 
1131, 1101. HRMS (EI-MS) calcd. for C15H21N5O2S [M+•] 335.1416; found 335.1421. 
C15H21N5O2S · TFA (449.45). 
 
3.4.1.10 Preparation of 3-(1H-imidazol-4-yl)propan-1-amine 3.41 
2-[3-(1-Trityl-1H-imidazol-4-yl)propyl]isoindoline-1,3-dione (3.105)17 
To a cold solution (0 °C) of 3.1044, 15 (10.00 g, 27.1 mmol) in THFabs (250 mL), phthalimide 
(6.00 g, 40.8 mmol) and triphenylphosphine (10.7 g, 40.8 mmol) were added. Under ice 
cooling DIAD (11.00 g, 54.2 mmol) in THFabs (200 mL) was added dropwise. The mixture was 
allowed to warm to ambient temperature, stirred for 1rh and concentrated in vacuo. The 
precipitated product was filtered, washed twice with cold THF (20 mL) and recrystallized from 
THF/MeCN yielding the title compound as white solid (13.0 g, 96 %); mp 212 °C (ref.17: 217 – 
219 °C). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.93 – 2.09 (m, 2H, Im-4-CH2-CH2), 2.60 (t, 
2H, 3J = 7.7 Hz, Im-4-CH2), 3.73 (t, 2H, 3J = 7.2 Hz, Im-4-(CH2)2-CH2), 6.57 (d, 1H, 4J = 1.3 
Hz, Im-5-H), 7.09 – 7.18 (m, 6H, Ph-H), 7.28 – 7.37 (m, 10H, Ph-H + Im-2-H), 7.64 – 7.72 (m, 
2H, Phth-H), 7.77 – 7.85 (m, 2H, Phth-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 26.03 (-, Im-
4-CH2-CH2), 28.34 (-, Im-4-CH2), 37.70 (-, Im-4-(CH2)2-CH2), 75.11 (Cquat, CPh3), 118.04 (+, 
Im-C-5), 123.15 (+, Phth-C-4, 7), 127.95 (+, 3 Ph-C-4), 128.02 (+, 6 Ph-C), 129.84 (+, 6 Ph-
C), 132.23 (Cquat, Im-C-4), 133.82 (+, Phth-C-5, 6), 138.39 (+, Im-C-2), 140.65 (Cquat, Phth-C-
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3a, 7a), 142.61 (Cquat, 3 Ph-C-1), 168.39 (Cquat, 2 C=O). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 498 (100) [M + H]+. Anal. (C33H27N3O2) C, H, N. C33H27N3O2 (497.59). 
 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine (3.106)49 
A mixture of 3.105 (12.80 g, 25.7 mmol) and hydrazine monohydrate (8.0 mL, 164.6 mmol) in 
n-butanol was refluxed for 1 h. After removal of insoluble material, the filtrate was evaporated 
giving a pale brownish oil that solidified (9.11 g, 96 %); mp 106 – 108 °C. 1H-NMR (300 MHz, 
CDCl3): δ [ppm] = 1.70 – 1.82 (m, 2H, Im-4-CH2-CH2), 2.57 (t, 2H, 3J = 7.5 Hz, Im-4-CH2), 
2.70 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)2-CH2), 6.52 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.08 – 7.18 (m, 
6H, Ph-H), 7.27 – 7.37 (m, 10H, Ph-H + Im-2-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 25.83 
(-, Im-4-CH2), 33.42 (-, Im-4-CH2-CH2), 41.85 (-, Im-4-(CH2)2-CH2), 75.09 (Cquat, CPh3), 
117.79 (+, Im-C-5), 127.97 (+, 3 Ph-C-4), 128.00 (+, 6 Ph-C), 129.81 (+, 6 Ph-C), 138.35 (+, 
Im-C-2), 141.45 (Cquat, Im-C-4), 142.63 (Cquat, 3 Ph-C-1). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 368 (100) [M + H]+. Anal. (C25H25N3 · 0.5 H2O) C, H, N. C25H25N3 (367.49). 
 
3-(1H-Imidazol-4-yl)propan-1-amine (3.41) 
3.106 (8.00 g, 21.8 mmol) was heated under reflux in 1M HCl for 30 min. The cooled mixture 
was filtered and the solvent was removed in vacuo. The obtained residue was recrystallized 
from EtOH yielding a white solid (3.37 g, 78 %); mp (3.41 · 2 HCl) 151 °C (ref.50: 155 – 
157 °C). 1H-NMR (300 MHz, D2O, dihydrochloride): δ [ppm] = 1.89 – 2.03 (m, 2H, Im-4-CH2-
CH2), 2.76 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.96 (t, 2H, 3J = 7.8 Hz, Im-4-(CH2)2-CH2), 7.19 (d, 
1H, 4J = 1.4 Hz, Im-5-H), 8.51 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, D2O, 
dihydrochloride): δ [ppm] = 20.93 (-, Im-4-CH2), 25.62 (-, Im-4-CH2-CH2), 38.49 (-, Im-4-
(CH2)2-CH2), 115.57 (+, Im-C-5), 131.98 (Cquat, Im-C-4), 133.10 (+, Im-C-2). EI-MS (70 eV) 
m/z (%): 125 (11) [M+•], 95 (100) [M – CH2-NH2]+. Anal. (C6H11N3 · 2 HCl) C, H, N. C6H11N3 · 2 
HCl (198.09). 
 
3.4.1.11 Preparation of 4-(1H-imidazol-4-yl)butane-1-amine 3.60 
2-(5-Oxohexyl)isoindoline-1,3-dione (3.108) 
A mixture of 3.107 (25.00 g, 185.7 mmol), finely powdered K2CO3 (38.50 g, 277.8 mmol), 
phthalimide (27.32 g, 185.7 mmol) and catalytical amounts of KI (0.1 g, 0.6 mmol) in DMF 
was stirred for 12 h at 100 °C. The cooled mixture was poured in ice-cold water (1000 mL) 
and extracted with CHCl3 (1 x 600 mL, 2 x 200 mL). The combined organic layers were 
washed with saturated NaHCO3 (400 mL), 2 % HCl (2 x 400 mL), brine (400 mL) and dried 
over Na2SO4. Evaporation to dryness yielded a yellowish oil that crystallized from EtOH/H2O 
as white solid (41.1 g, 91 %); mp 63 °C (ref.51: 57 °C). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 
1.54 – 1.77 (m, 4H, Phth-CH2-CH2-CH2), 2.13 (s, 3H, CH3), 2.49 (t, 2H, 3J = 7.0 Hz, Phth-
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(CH2)3-CH2), 3.69 (t, 2H, 3J = 6.9 Hz, Phth-CH2), 7.67 – 7.75 (m, 2H, Phth-H), 7.79 – 7.87 (m, 
2H, Phth-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 20.82 (-, CH2), 27.97 (-, CH2), 30.00 (+, 
CH3), 37.53 (-, CH2), 42.91 (-, CH2), 123.24 (+, Phth-C-4,7), 132.12 (Cquat, Phth-C-3a, 7a), 
133.95 (+, Phth-C-5,6), 168.43 (Cquat, Phth-C-1,3), 208.38 (Cquat, COCH3). CI-MS (NH3) m/z 
(%): 264 (100) [M + NH4]+. Anal. (C14H15NO3) C, H, N. C14H15NO3 (245.27). 
 
2-(6-Bromo-5-oxohexyl)isoindoline-1,3-dione (3.109)52 
To a solution of 3.108 (93.30 g, 380.4 mmol) and urea (22.85 g, 380.4 mmol) in MeOH (400 
mL), bromine (60.79 g, 380.4 mmol) was rapidly added and stirred for 24 h. The precipitated 
product was filtered, washed with MeOH (20 mL), dried and crystallized from DCM/hexane 
yielding the title compound as a white solid (50.7 g, 41 %); mp 112 – 113 °C. 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.58 – 1.79 (m, 4H, Phth-CH2-CH2-CH2), 2.72 (t, 2H, 3J = 6.9 Hz, 
Phth-(CH2)3-CH2), 3.70 (t, 2H, 3J = 6.8 Hz, Phth-CH2), 3.88 (s, 2H, CH2Br), 7.68 – 7.75 (m, 
2H, Phth-H), 7.80 – 7.88 (m, 2H, Phth-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 20.89 (-, 
CH2), 27.81 (-, CH2), 34.20 (-, CH2), 37.36 (-, CH2), 38.98 (-, CH2), 123.28 (+, Phth-C-4,7), 
132.10 (Cquat, Phth-C-3a, 7a), 133.99 (+, Phth-C-5,6), 168.42 (Cquat, Phth-C-1,3), 201.55 
(Cquat, COCH3). CI-MS (NH3) m/z (%): 343 (13) [M + NH4]+, 341 (13) [M + NH4]+, 263 (100) [M 
– Br + H + NH4]+. Anal. (C14H14BrNO3) C, H, N. C14H14BrNO3 (324.17). 
 
2-(4-(1H-Imidazol-4-yl)butyl)isoindoline-1,3-dione (3.110) 
3.109 (50.00 g, 154.2 mmol) was stirred for 5 h at 160 °C in formamidine (300 mL). After 
removal of the solvent in vacuo, the residue was basified with saturated NaHCO3 (400 mL) 
and extracted with CHCl3 (1 x 600 mL, 2 x 200 mL). The combined organic layers were 
extracted with 5 % HCl (3 x 300 mL), the aqueous solution alkalized with NaHCO3 and 
extracted with CHCl3 (3 x 200 mL). After drying the combined organic layers over Na2SO4, 
the solvent was evaporated yielding a beige solid that was used with further purification (21.5 
g, 52 %); mp 158 – 160 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.54 – 1.82 (m, 4H, Im-4-
CH2-CH2-CH2), 2.67 (t, 2H, 3J = 6.9 Hz, Im-4-CH2), 3.71 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)3-CH2), 
6.78 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.54 (d, 1H, 4J = 0.9 Hz, Im-2-H), 7.67 – 7.88 (m, 4H, Phth-
H). CI-MS (NH3) m/z (%): 270 (100) [M + H]+. C15H15N3O2 (269.30). 
 
4-(1H-Imidazol-4-yl)butan-1-amine (3.60)53  
3.110 (17.00 g, 63.1 mmol) was refluxed overnight in 20 % HCl (350 mL). Insoluble material 
was filtered off and the solvent was evaporated. The remaining dark oil was basified by 
addition of NH3 (aq.) 32 %, evaporated to dryness and purified by flash chromatography 
(DCM/MeOH/NH3 (aq.) 32 % 67/25/8 v/v/v) yielding the title compound as brownish oil (6.7 g, 
76 %). For analytical purposes a small amount was converted to the dihydrobromide and 
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crystallized from EtOAc/EtOH (beige solid); mp (3.60 · 2 HBr) 176 – 177 °C. 1H-NMR (300 
MHz, DMSO-d6, dihydrobromide): δ [ppm] = 1.49 – 1.74 (m, 4H, Im-4-CH2-CH2-CH2), 2.67 (t, 
2H, 3J = 7.1 Hz, Im-4-CH2), 2.73 – 2.89 (m, 2H, Im-4-(CH2)3-CH2), 7.48 (d, 1H, 4J = 1.4 Hz, 
Im-5-H), 7.82 (brs, 3H, NH3+), 9.09 (d, 1H, 4J = 1.4 Hz, Im-2-H), 14.14 (brs, 2H, Im-N-H). 13C-
NMR (75 MHz, DMSO-d6, dihydrobromide): δ [ppm] = 23.05, 24.68, 25.90 (-, Im-4-CH2-CH2-
CH2), 38.22 (-, Im-4-(CH2)3-CH2), 115.54 (+, Im-C-5), 132.73 (Cquat, Im-C-4), 133.62 (+, Im-C-
2). CI-MS (NH3) m/z (%): 140 (100) [M + H]+. Anal. (C7H13N3 · 2 HBr) C, H, N. C7H13N3 
(139.20). 
 
3.4.1.12 Synthesis of the amines 3.11, 3.12 and 3.14-3.18 
(E)-3-(4-Fluorophenyl)acrylonitrile (3.112)  
To a solution of diethyl cyanomethylphosphonate (8.60 g, 48.5 mmol) in THFabs (100 mL), 
NaH (60 % dispersion in mineral oil) (1.94 g, 48.5 mmol) was added in portions. After stirring 
for 1 h at ambient temperature, 3.111 (5.00 g, 40.3 mmol) in THFabs (50 mL) was added 
dropwise and stirred for 5 h. The solvent was evaporated and the crude product purified by 
flash chromatography (PE/EtOAc 95/5 v/v) yielding a beige solid that was recrystallized from 
hexane (colorless needles, 3.9 g, 55 %); mp 66 – 68 °C (ref.54: 64 – 66 °C). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 5.81 (dd, 1H, 3J = 16.6 Hz, 5J = 0.6 Hz, CHCN), 7.05 – 7.16 (m, 2H, 
Ph-H), 7.37 (d, 1H, 3J = 16.6 Hz, PhCH), 7.41 – 7.50 (m, 2H, Ph-H). 13C-NMR (75 MHz, 
CDCl3): δ [ppm] = 96.17 (+, 6J = 2.6 Hz, CHCN), 116.42 (+, 2J = 22.1 Hz, 4-F-Ph-C-3,5), 
118.03 (Cquat, C≡N), 129.43 (+, 3J = 8.7 Hz, 4-F-Ph-C-2,6), 129.86 (Cquat, 4J = 3.4 Hz, 4-F-Ph-
C-1), 149.26 (+, Ph-CH), 164.63 (Cquat, 1J = 253.1 Hz, 4-F-Ph-C-4). EI-MS (70 eV) m/z (%): 
146 (100) [M+•]. Anal. (C9H6FN) C, H, N. C9H6FN (147.15). 
 
3-(4-Fluorophenyl)propanenitrile (3.113) 
To a solution of 3.112 (4.00 g, 26.8 mmol) in MeOH (150 mL), Pd/C (10%) (0.40 g, cat.) was 
added. After stirring for 6 h at room temperature under a hydrogen atmosphere, the catalyst 
was removed by filtration over Celite and the solvent was evaporated. The obtained 
yellowish oil was purified by distillation yielding a colorless oil (3.4 g, 84 %); bp (0.5 mbar) 
80 °C (ref.55 (0.05 mm): 73 – 76 °C). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.60 (t, 2H, 3J = 
7.3 Hz, CH2), 2.93 (t, 2H, 3J = 7.3 Hz, CH2), 6.98 – 7.08 (m, 2H, Ph-H), 7.17 – 7.24 (m, 2H, 
Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 19.61 (+, 6J = 1.3 Hz, CH2CN), 30.83 (+, Ph-
CH2), 115.79 (+, 2J = 22.1 Hz, 4-F-Ph-C-3,5), 118.98 (Cquat, C≡N), 129.91 (+, 3J = 8.1 Hz, 4-
F-Ph-C-2,6), 133.76 (Cquat, 4J = 3.3 Hz, 4-F-Ph-C-1), 162.06 (Cquat, 1J = 245.6 Hz, 4-F-Ph-C-
4). EI-MS (70 eV) m/z (%): 149 (17) [M+•], 109 (100) [M – CH2CN]+. Anal. (C9H8FN · 0.1 H2O) 
C, H, N. C9H8FN (149.16). 
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3-(4-Fluorophenyl)propan-1-amine (3.14)56 
To a solution of 3.113 (3.30 g, 22.1 mmol) in anhydrous Et2O (150 mL), LiAlH4 (1.68 g, 44.2 
mmol) was added in portions. After refluxing for 2 h, the mixture was cooled externally with 
ice and 1.7 mL H2O, 1.7 mL NaOH 15 % and 5.1 mL H2O were consecutively added. The 
insoluble material was removed by filtration, washed with Et2O (2 x 50 mL) and the solvent of 
the combined organic layers was evaporated. The remaining oil was purified by distillation 
yielding a colorless oil (2.2 g, 65 %); bp (0.5 mbar) 50 – 54 °C. For analytical purposes a 
small amount was converted to the hydrochloride (addition of 5 – 6 M HCl in 2-propanol to a 
solution of 3.14 in EtOH) and recrystallized from TBME/EtOH (white solid); mp (3.14 · 2 HCl) 
142 – 144 °C (ref.24: 151 °C). 1H-NMR (300 MHz, DMSO-d6, hydrochloride): δ [ppm] = 1.78 – 
1.92 (m, 2H, CH2CH2NH3+), 2.64 (t, 2H, 3J = 7.7 Hz, CH2), 2.74 (t, 2H, 3J = 7.5 Hz, CH2), 7.07 
– 7.17 (m, 2H, Ph-H), 7.21 – 7.31 (m, 2H, Ph-H), 8.13 (brs, 3H, N-H). 13C-NMR (75 MHz, 
DMSO-d6, hydrochloride): δ [ppm] = 28.72 (-, Ph-CH2-CH2), 30.87 (-, Ph-CH2), 38.06 (-, 
CH2NH3+), 114.99 (+, 2J = 21.0 Hz, 4-F-Ph-C-3,5), 129.95 (+, 3J = 7.9 Hz, 4-F-Ph-C-2,6), 
136.94 (Cquat, 4J = 3.1 Hz, 4-F-Ph-C-1), 160.63 (Cquat, 1J = 241.3 Hz, 4-F-Ph-C-4). EI-MS (70 
eV) m/z (%): 153 (10) [M+•], 44 (100). Anal. (C9H12FN · HCl) C, H, N. C9H12FN (153.20). 
 
3-Phenylbut-2-enenitrile (3.115) 
To a solution of diethyl cyanomethylphosphonate (14.2 g, 80 mmol) in THFabs (100 mL), NaH 
(60 % dispersion in mineral oil) (3.2 g, 40 mmol) was added in portions. After stirring for 1 h 
at ambient temperature, 3.114 (8.0 g, 67 mmol) in THFabs (50 mL) was added dropwise and 
stirred for 5 h. The solvent was evaporated and the obtained oil was purified by distillation 
yielding a colorless oil (7.6 g, 79 %); bp (0.5 mbar) 78 – 80 °C (ref.24 bp0.05 120 °C). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 2.48 (d, 3H, 4J = 1.1 Hz, CH3), 5.62 (q, 1H, 4J = 1.1 Hz, CHCN), 
7.37 – 7.50 (m, 5H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 20.27 (+, CH3), 95.59 (+, 
CHCN), 117.69 (Cquat, C≡N), 125.90 (+, 2 Ph-C), 128.88 (+, 2 Ph-C), 130.31 (+, Ph-C), 
138.26 (Cquat, Ph-C), 159.83 (Cquat, CCH3). EI-MS (70 eV) m/z (%): 143 (100) [M+•]. C10H9N 
(143.19). 
 
3-Phenylbut-2-en-1-amine (3.116) 
To a solution of 3.115 (3.8 g, 26.5 mmol) in anhydrous Et2O (50 mL), LiAlH4 (0.52 g, 13.3 
mmol) was added in portions. After refluxing for 2 h, the mixture was cooled externally with 
ice and 0.6 mL H2O, 0.6 mL NaOH 15 % and 2.4 mL H2O were consecutively added. The 
insoluble material was removed by filtration, washed with Et2O (2 x 20 mL) and the solvent of 
the combined organic layers was evaporated. The remaining oil was purified by distillation 
(bp (0.5 mbar) 75 – 77 °C) yielding a colorless oil which was converted to the hydrochloride 
(addition of 5 – 6 M HCl in 2-propanol to a solution of 3.116 in EtOH) and recrystallized from 
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EtOH/Et2O yielding a white solid (2.4 g, 46 %); mp (3.116 · HCl) 216 – 217 °C (ref.24: 
214 °C). 1H-NMR (300 MHz, DMSO-d6, hydrochloride): δ [ppm] = 2.06 (d, 3H, 4J = 1.2 Hz, 
CH3), 3.62 (d, 2H, 3J = 7.0 Hz, CH2), 5.81 – 5.90 (m, 1H, CH), 7.26 – 7.46 (m, 5H, Ph-H), 
8.30 (brs, 3H, N-H). 13C-NMR (75 MHz, DMSO-d6, hydrochloride): δ [ppm] = 15.86 (+, CH3), 
36.95 (-, CH2), 119.86 (-, CH), 125.47 (+, 2 Ph-C), 127.59 (+, 1 Ph-C), 128.37 (+, 2 Ph-C), 
139.46 (Cquat, C=CH), 141.73 (Cquat, Ph-C-1). CI-MS (NH3) m/z (%): 148 (100) [M + H]+. Anal. 
(C10H13N · HCl) C, H, N. C10H13N · HCl (183.68). 
 
3-Phenylbutan-1-amine (3.18)24 
To a solution of 3.116 · HCl (2.30 g, 12.5 mmol) in EtOH (100 mL), Pd/C (10%) (0.23 g, cat.) 
was added. After stirring for 6 h at room temperature under a hydrogen atmosphere, the 
catalyst was removed by filtration over Celite and the solvent was evaporated. The residue 
was dissolved in H2O (20 mL) and dried by lyophilization yielding a white solid (2.2 g, 95 %); 
mp (3.18 · HCl) 128 – 129 °C. 1H-NMR (300 MHz, DMSO-d6, hydrochloride): δ [ppm] = 1.21 
(d, 3H, 3J = 6.9 Hz, CH3), 1.77 – 1.90 (m, 2H, PhCH3CH-CH2), 2.44 – 2.74 (m, 2H, CH2-
NH3+), 2.74 – 2.89 (m, 1H, PhCH3CH), 7.16 – 7.37 (m, 5H, Ph-H), 8.02 (brs, 3H, N-H). 13C-
NMR (75 MHz, DMSO-d6, hydrochloride): δ [ppm] = 21.93 (+, CH3), 34.98 (-, PhCH3CH-CH2), 
36.30 (+, PhCH3CH), 37.23 (-, CH2NH3+), 126.17 (-, Ph-C-4), 126.70 (-, 2 Ph-C), 128.40 (-, 2 
Ph-C), 145.74 (Cquat, Ph-C-1). CI-MS (NH3) m/z (%): 150 (100) [M + H]+. Anal. (C10H15N · 
HCl) C, H, N. C10H15N · HCl (185.69). 
 
General procedure for the synthesis the 2-[3-(pyridyl)propyl]isoindoline-1,3-diones 
(3.120-3.122) 
To a cold solution (0 °C) of the pertinent 3-pyridylpropan-1-ol (5.0 g, 36.4 mmol) in THFabs 
(100 mL), phthalimide (5.9 g, 40.1 mmol) and triphenylphosphine (10.52 g, 40.1 mmol) were 
added. Under external cooling with ice, DIAD (8.11 g, 40.1 mmol) in THFabs (50 mL) was 
added dropwise. The mixture was allowed to warm and stirred overnight at ambient 
temperature. After concentration in vacuo, the crude product was subjected to flash 
chromatography. For analytical purposes a small amount of the purified product was 
converted into the picrate by addition of a saturated solution of picric acid in EtOH and 
recrystallized from EtOH/H2O. 
 
2-[3-(Pyridin-2-yl)propyl]isoindoline-1,3-dione (3.120)23  
The title compound was prepared from 3.117 according to the general procedure and purified 
by flash chromatography (PE/EtOAc 70/30 v/v) yielding a brownish oil (7.3 g, 75 %); mp 
(3.120 · C6H3N3O7) 139 – 140 °C. 1H-NMR (300 MHz, DMSO-d6, dipicrate): δ [ppm] = 2.00 – 
2.13 (m, 2H, Pyr-2-CH2-CH2), 3.04 (t, 2H, 3J = 8.0 Hz, Pyr-2-CH2), 3.67 (t, 2H, 3J = 6.5 Hz, 
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Pyr-2-(CH2)2-CH2), 7.81 – 7.92 (m, 5H, Pyr-5-H + Phth-H), 7.98 (d, 1H, 3J = 8.0 Hz, Pyr-3-H), 
8.44 – 8.52 (m, 1H, Pyr-4-H), 8.58 (s, 2H, picrate-H), 8.79 (dd, 1H, 3J = 5.8 Hz, 4J = 1.7 Hz, 
Pyr-6-H). 13C-NMR (75 MHz, DMSO-d6, dipicrate): δ [ppm] = 27.39 (-, Pyr-2-CH2-CH2), 30.49 
(-, Pyr-2-CH2), 36.64 (-, Pyr-2-(CH2)2-CH2), 122.95 (-, Phth-C-4,7), 124.08 (Cquat, picrate-C-4), 
124.47 (+, Pyr-C-5), 125.10 (+, picrate-C-3,5), 126.56 (+, Pyr-C-3), 131.58 (Cquat, Phth-C-
3a,7a), 134.34 (+, Phth-C-5,6), 141.75 (Cquat, picrate-C-2,6), 141.85 (+, Pyr-C-6), 145.73 (+, 
Pyr-C-4), 156.28 (Cquat, Pyr-C-2), 160.69 (Cquat, picrate-C-1), 167.91 (Cquat, C=O). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 267 (100) [M + H]+. Anal. (C16H14N2O2 · C6H3N3O7) C, H, 
N. C16H14N2O2 (266.29). 
 
2-[3-(Pyridin-3-yl)propyl]isoindoline-1,3-dione (3.121)23  
The title compound was prepared from 3.118 according to the general procedure and purified 
by flash chromatography (PE/EtOAc 60/40 v/v) yielding a pale yellow solid (5.4 g, 56 %); mp 
(3.121 · C6H3N3O7) 145 – 146 °C. 1H-NMR (300 MHz, DMSO-d6, dipicrate): δ [ppm] = 1.91 – 
2.06 (m, 2H, Pyr-3-CH2-CH2), 2.85 (t, 2H, 3J = 7.9 Hz, Pyr-3-CH2), 3.64 (t, 2H, 3J = 6.7 Hz, 
Pyr-3-(CH2)2-CH2), 7.80 – 7.91 (m, 4H, Phth-H), 7.99 (dd, 1H, 3J = 8.0 Hz, 3J = 5.7 Hz, Pyr-5-
H), 8.52 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.9 Hz, 4J = 1.4 Hz, Pyr-4-H), 8.58 (s, 2H, picrate-H), 8.77 
(dd, 1H, 3J = 5.7 Hz, 4J = 1.4 Hz, Pyr-6-H), 8.84 (d, 1H, 4J = 1.9 Hz, Pyr-2-H). 13C-NMR (75 
MHz, DMSO-d6, dipicrate): δ [ppm] = 28.76 (-, Pyr-3-CH2-CH2), 28.99 (-, Pyr-3-CH2), 36.72 (-
, Pyr-3-(CH2)2-CH2), 122.92 (-, Phth-C-4,7), 124.06 (Cquat, picrate-C-4), 125.10 (+, picrate-C-
3,5), 126.54 (+, Pyr-C-5), 131.60 (Cquat, Phth-C-3a,7a), 134.29 (+, Phth-C-5,6), 139.99 (+, 
Pyr-C-6), 141.03 (Cquat, Pyr-C-3), 141.71 (+, Pyr-C-2), 141.76 (Cquat, picrate-C-2,6), 145.60 
(+, Pyr-C-4), 160.70 (Cquat, picrate-C-1), 167.94 (Cquat, C=O). ES-MS (H2O/MeCN) m/z (%): 
267 (100) [M + H]+. Anal. (C16H14N2O2 · C6H3N3O7) C, H, N. C16H14N2O2 (266.29). 
 
2-[3-(Pyridin-4-yl)propyl]isoindoline-1,3-dione (3.122)23  
The title compound was prepared from 3.119 according to the general procedure and purified 
by flash chromatography (PE/EtOAc 60/40 v/v) yielding a beige solid (7.4 g, 90 %); mp 
(3.122 · C6H3N3O7) 180 – 182 °C. 1H-NMR (300 MHz, DMSO-d6, picrate): δ [ppm] = 1.95 – 
2.07 (m, 2H, Pyr-4-CH2-CH2), 2.95 (t, 2H, 3J = 7.8 Hz, Pyr-4-CH2), 3.64 (t, 2H, 3J = 6.7 Hz, 
Pyr-4-(CH2)2-CH2), 7.80 – 7.90 (m, 4H, Phth-H), 7.98 (dd, 2H, 3J = 6.7 Hz, 4J = 1.5 Hz, Pyr-
3,5-H), 8.57 (s, 2H, picrate-H), 8.81 (dd, 2H, 3J = 6.7 Hz, 4J = 1.5 Hz, Pyr-2,6-H). 13C-NMR 
(75 MHz, DMSO-d6, picrate): δ [ppm] = 27.99 (-, Pyr-4-CH2-CH2), 32.33 (-, Pyr-4-CH2), 36.77 
(-, Pyr-4-(CH2)2-CH2), 122.90 (-, Phth-C-4,7), 124.07 (Cquat, picrate-C-4), 125.11 (+, picrate-
C-3,5), 126.79 (+, Pyr-C-3,5), 131.59 (Cquat, Phth-C-3a,7a), 134.26 (+, Phth-C-5,6), 141.36 
(+, Pyr-C-2,6), 141.74 (Cquat, picrate-C-2,6), 160.70 (Cquat, picrate-C-1), 162.35 (Cquat, Pyr-C-
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4), 167.94 (Cquat, 2 C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 267 (100) [M + H]+. Anal. 
(C16H14N2O2 · C6H3N3O7) C, H, N. C16H14N2O2 (266.29). 
 
General procedure for the preparation of the 3-pyridylpropan-1-amines (3.15-3.17) 
A mixture of the pertinent 2-(3-pyridylpropyl)isoindoline-1,3-dione (1 eq) and hydrazine 
monohydrate (6 eq) in EtOH was stirred overnight at room temperature. After removal of 
insoluble material and concentration in vacuo, the crude product was subjected to flash 
chromatography. For analytical purposes a small amount of the purified product was 
converted into the dipicrate by addition of a saturated solution of picric acid in EtOH and 
recrystallized from EtOH/H2O. 
 
3-(Pyridin-2-yl)propan-1-amine (3.15)23  
The title compound was prepared from 3.120 (7.00 g, 26.3 mmol) and hydrazine 
monohydrate (7.7 mL, 157.8 mmol) in EtOH (200 mL) according to the general procedure 
and purified by flash chromatography (CHCl3/MeOH/NH3 (aq.) 32 % 80/18/2 v/v/v) yielding a 
brownish oil (3.6 g, 85 %); mp (3.15 · 2 C6H3N3O7) 188 – 190 °C. 1H-NMR (300 MHz, DMSO-
d6, dipicrate): δ [ppm] = 1.91 – 2.04 (m, 2H, Pyr-2-CH2-CH2), 2.79 – 2.93 (m, 2H, Pyr-2-
(CH2)2-CH2), 3.03 (t, 2H, 3J = 7.7 Hz, Pyr-2-CH2), 7.72 (brs, 3H, NH3+), 7.82 – 7.93 (m, 2H, 
Pyr-3,5-H), 8.40 – 8.49 (m, 1H, Pyr-4-H), 8.59 (s, 2H, picrate-H), 8.82 (dd, 1H, 3J = 5.7 Hz, 4J 
= 1.7 Hz, Pyr-6-H). 13C-NMR (75 MHz, DMSO-d6, dipicrate): δ [ppm] = 26.21 (-, Pyr-2-CH2-
CH2), 30.28 (-, Pyr-2-CH2), 38.03 (-, Pyr-2-(CH2)2-CH2), 124.17 (Cquat, picrate-C-4), 124.37 (+, 
Pyr-C-5), 125.12 (+, picrate-C-3,5), 126.14 (+, Pyr-C-3), 141.75 (Cquat, picrate-C-2,6), 142.85 
(+, Pyr-C-6), 144.97 (+, Pyr-C-4), 156.07 (Cquat, Pyr-C-2), 160.71 (Cquat, picrate-C-1). ES-MS 
(MeCN + TFA) m/z (%): 137 (100) [M + H]+. Anal. (C8H12N2 · 2 C6H3N3O7) C, H, N. C8H12N2 
(136.19). 
 
3-(Pyridin-3-yl)propan-1-amine (3.16)23  
The title compound was prepared from 3.121 (5.20 g, 19.5 mmol) and hydrazine 
monohydrate (5.7 mL, 117.0 mmol) in EtOH (150 mL) according to the general procedure 
and purified by flash chromatography (CHCl3/MeOH/NH3 (aq.) 32 % 80/18/2 v/v/v) yielding a 
pale yellow oil (2.6 g, 88 %); mp (3.16 · 2 C6H3N3O7) 218 °C (dec.). 1H-NMR (300 MHz, 
DMSO-d6, dipicrate): δ [ppm] = 1.83 – 1.97 (m, 2H, Pyr-3-CH2-CH2), 2.76 – 2.90 (m, 4H, Pyr-
3-CH2-CH2-CH2), 7.69 (brs, 3H, N-H), 7.99 (dd, 1H, 3J = 8.1 Hz, 3J = 6.0 Hz, Pyr-5-H), 8.42 
(ddd, 1H, 3J = 8.1 Hz, 4J = 2.0 Hz, 4J = 1.4 Hz, Pyr-4-H), 8.59 (s, 2H, picrate-H), 8.78 – 8.82 
(m, 2H, Pyr-6-H + Pyr-2-H). 13C-NMR (75 MHz, DMSO-d6, dipicrate): δ [ppm] = 27.70 (-, Pyr-
3-CH2-CH2), 28.39 (-, Pyr-3-CH2), 38.01 (-, Pyr-3-(CH2)2-CH2), 124.15 (Cquat, picrate-C-4), 
125.12 (+, picrate-C-3,5), 126.56 (+, Pyr-C-5), 140.16 (Cquat, Pyr-C-3), 140.69 (+, Pyr-C-6), 
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141.75 (Cquat, picrate-C-2,6), 142.10 (+, Pyr-C-2), 144.98 (+, Pyr-C-4), 160.72 (Cquat, picrate-
C-1). ES-MS (H2O/MeOH + NH4OAc) m/z (%): 137 (100) [M + H]+. Anal. (C8H12N2 · 2 
C6H3N3O7) C, H, N. C8H12N2 (136.19). 
 
3-(Pyridin-4-yl)propan-1-amine (3.17)23  
The title compound was prepared from 3.122 (7.20 g, 27.0 mmol) and hydrazine 
monohydrate (7.9 mL, 162.0 mmol) in EtOH (250 mL) according to the general procedure 
and purified by flash chromatography (CHCl3/MeOH/NH3 (aq.) 32% 80/18/2 v/v/v) yielding a 
colorless oil (2.9 g, 79 %); mp (3.17 · 2 C6H3N3O7) 210 – 211 °C (dec.). 1H-NMR (300 MHz, 
DMSO-d6, dipicrate): δ [ppm] = 1.86 – 1.99 (m, 2H, Pyr-4-CH2-CH2), 2.77 – 2.90 (m, 2H, Pyr-
4-CH2-CH2-CH2), 2.94 (t, 2H, 3J = 7.8 Hz, Pyr-4-CH2), 7.71 (brs, 3H, N-H), 7.92 (dd, 2H, 3J = 
6.7 Hz, 4J = 1.4 Hz, Pyr-3,5-H), 8.59 (s, 2H, picrate-H), 8.84 (d, 2H, 3J = 6.7 Hz, 4J = 1.4 Hz, 
Pyr-2,6-H). 13C-NMR (75 MHz, DMSO-d6, dipicrate): δ [ppm] = 26.92 (-, Pyr-4-CH2-CH2), 
31.62 (-, Pyr-4-CH2), 38.11 (-, Pyr-4-(CH2)2-CH2), 124.17 (Cquat, picrate-C-4), 125.13 (+, 
picrate-C-3,5), 126.62 (+, Pyr-C-3,5), 141.74 (Cquat, picrate-C-2,6), 141.90 (+, Pyr-C-2,6), 
160.72 (Cquat, picrate-C-1), 161.17 (Cquat, Pyr-C-4). ES-MS (H2O/MeOH + NH4OAc) m/z (%): 
137 (100) [M + H]+. Anal. (C8H12N2 · 2 C6H3N3O7) C, H, N. C8H12N2 (136.19). 
 
2-(Phenylthio)ethanamine (3.12) 
A solution of 3.123 (2.2 g, 20 mmol), bromoethylamine · HBr (4.1 g, 20 mmol) and KtBuO 
(4.5 g, 40 mmol) in anhydrous MeOH (160 mL) was stirred for 48 h at room temperature 
under a nitrogen atmosphere. The solvent was removed in vacuo, 1 M NaOH (30 mL) was 
added to the residue and extracted with Et2O (3 x 80 mL). After evaporation of the combined 
organic layers, 1 M HCl (50 mL) was added, the solvent was removed under reduced 
pressure and H2O (20 mL) was added. The solvent was removed by lyophilization giving a 
white solid (3.4 g, 89 %); mp (3.12 · HCl) 116 – 117 °C (ref.57: 100 – 102 °C). 1H-NMR (300 
MHz, DMSO-d6, hydrochloride): δ [ppm] = 2.85 – 3.00 (m, 2H, CH2-NH3+), 3.28 – 3.29 (m, 
2H, S-CH2), 7.21 – 7.29 (m, 1H, Ph-4-H), 7.31 – 7.48 (m, 4H, Ph-H), 8.32 (brs, 3H, NH3+). 
13C-NMR (75 MHz, DMSO-d6, hydrochloride): δ [ppm] = 29.00 (-, S-CH2), 37.97 (-, CH2-
NH3+), 126.27 (+, Ph-C-4), 128.50 (+, 2 Ph-C), 129.21 (+, 2 Ph-C), 134.21 (Cquat, Ph-C-1). CI-
MS (NH3) m/z (%): 154 (100) [M + H]+. Anal. (C8H11NS · HCl) C, H, N. C8H11NS · HCl 
(189.71). 
 
3-Cyclohexylpropan-1-amine hydrochloride (3.11)24 
To a solution of 3.7 · HCl (2.58 g, 15.0 mmol) in EtOH (50 mL), Rh/C (5 %) (0.45 g, cat.) was 
added. After hydrogenation for 24 h at room temperature at 75 bar, the catalyst was removed 
by filtration over Celite and the solvent was concentrated in vacuo. The title compound was 
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crystallized by addition of Et2O yielding a white solid (2.5 g, 94 %); mp (3.11 · HCl) 217 – 
219 °C. 1H-NMR (300 MHz, DMSO-d6, hydrochloride): δ [ppm] = 0.73 – 0.96 (m, 2H, CH2), 
1.05 – 1.30 (m, 6H), 1.48 – 1.74 (m, 7H), 2.63 – 2.78 (m, 2H, CH2-NH3+), 8.07 (brs, 3H, 
NH3+). 13C-NMR (75 MHz, DMSO-d6, hydrochloride): δ [ppm] = 24.21 (-, CH2), 25.63 (-, 2 
CH2), 26.01 (-, CH2), 32.53 (-, 2 CH2), 33.35 (-, CH2), 36.46 (+, CH), 38.83 (-, CH2-NH3+). CI-
MS (NH3) m/z (%): 142 (100) [M + H]+. Anal. (C9H19N · HCl · 0.25 H2O) C, H, N. C9H19N · HCl 
(177.71). 
 
3.4.1.13 Preparation of 2-phenylethanesulfonic acid (3.125) and 2-phenyl-
ethanesulfonyl chloride (3.99) 
2-Phenylethanesulfonic acid (3.125)25 
To a cold solution (0 °C) of 3.124 (4.5 g, 32.5 mmol) in DCM (140 mL), a 32 % solution of 
peracetic acid in acetic acid (w/w) (20.5 mL, 97.5 mmol) was added dropwise. The solution 
was allowed to warm to ambient temperature and stirred for additional 2 h. The solvent was 
removed under reduced pressure yielding a dark red oil that was used without further 
purification. (6.0 g, 99 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 3.05 – 3.16 (m, 2H, Ph-
CH2), 3.27 – 3.38 (m, 2H, CH2SO3H), 7.12 – 7.36 (m, 5H, Ph-H). 13C-NMR (75 MHz, CDCl3): 
δ [ppm] = 29.92 (-, Ph-CH2), 52.99 (-, CH2SO3H), 126.99 (-, Ph-C-4), 128.42 (-, 2 Ph-C), 
128.85 (-, 2 Ph-C), 137.53 (Cquat, Ph-C-1). EI-MS (70 eV) m/z (%): 186 (4) [M+•], 104 (100) [M 
– H2SO3]+•. C8H10O3S (186.23). 
 
2-Phenylethanesulfonyl chloride (3.99)25 
To a solution of 3.125 (1.86 g, 10.0 mmol) in DCM (135 mL), thionylchloride (14.2 mL, 200 
mmol) was added at 0 °C. After addition of DMF (1.5 mL), the mixture was warmed to 35 °C 
and stirred for 16 h. The solvent was removed in vacuo and the crude product was subjected 
to flash chromatography (PE/EtOAc 90/10 v/v) yielding a colorless oil (1.3 g, 63 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 3.29 – 3.39 (m, 2H, Ph-CH2), 3.86 – 3.95 (m, 2H, CH2SO3Cl), 
7.21 – 7.41 (m, 5H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 30.48 (-, Ph-CH2), 66.22 (-, 
CH2SO3Cl), 127.68 (-, Ph-C-4), 128.54 (-, 2 Ph-C), 129.21 (-, 2 Ph-C), 135.61 (Cquat, Ph-C-1). 
EI-MS (70 eV) m/z (%): 204 (9) [M+•], 104 (100) [M – HSO2Cl]+•. C8H9ClO2S (204.67). 
 
3.4.2 Pharmacological methods 
3.4.2.1 Materials 
Histamine dihydrochloride was purchased from Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany). Thioperamide maleate and iodophenpropit dihydrobromide were from Tocris 
Bioscience (Ellisville, USA). The H4R antagonist JNJ 7777120 was a gift from Dr. R. 
Chapter 3 106 
Thurmond (Department of Immunology, Johnson & Johnson Pharmaceutical R&D, San 
Diego, CA). [3H]mepyramine, [3H]tiotidine, [3H]N-α-methylhistamine and [3H]histamine were 
from PerkinElmer Life Sciences (Boston, MA). [γ-32P]GTP was synthesized according to a 
previously described method.58 [32P]Pi (8,500 – 9,100 Ci/mmol orthophosphoric acid) was 
from PerkinElmer Life Sciences (Boston, MA). All unlabeled nucleotides, glycerol-3-
phosphate dehydrogenase, triose phosphate isomerase, glyceraldehyde-3-phosphate 
dehydrogenase and lactate dehydrogenase were from Roche (Mannheim, Germany). 3-
Phosphoglycerate kinase and L-α-glycerol phosphate were from Sigma. GF/C filters were 
from Whatman (Maidstone, UK). 
 
3.4.2.2 Steady-state GTPase activity assay 
GTPase activity assays were performed as previously described for the H1R27, H2R26, H3R 
and H4R4. H1R assays: Sf9 insect cell membranes coexpressing the hH1R and RGS4 were 
employed, H2R assays: Sf9 insect cell membranes expressing the hH2R-GsαS fusion protein 
were employed, H3R assays: Sf9 insect cell membranes coexpressing the hH3R, mammalian 
Giα2, Gβ1γ2 and RGS4 were employed, H4R assays: Sf9 insect cell membranes coexpressing 
the hH4R-RGS19 fusion protein, mammalian Giα2 and Gβ1γ2 were employed. The respective 
membranes were thawed, sedimented by a 10 min centrifugation at 4 °C and 13,000g. 
Membranes were resuspended in 10 mM Tris/HCl, pH 7.4. Each assay tube contained Sf9 
membranes expressing the respective HR subtype (10 – 20 µg protein/tube), MgCl2 (H1/2R 
assays: 1.0 mM, H3/4R assays: 5.0 mM), 100 µM EDTA, 100 µM ATP, 100 nM GTP, 100 µM 
adenylyl imidophosphate, 5 mM creatine phosphate, 40 µg creatine kinase and 0.2 % (w/v) 
bovine serum albumin in 50 mM Tris/HCl, pH 7.4 and the investigated ligands at various 
concentrations. All H4R assays additionally contained 100 mM NaCl. For the determination of 
KB values (antagonist mode of the GTPase activity assay) histamine was added to the 
reaction mixtures (final concentrations: H1R: 200 nM; H2R: 1 µM; H3/4R: 100 nM).  
Reaction mixtures (80 µL) were conducted for 2 min at 25 °C. After the addition of 20 µl of 
[γ-32P]GTP (0.1 µCi/tube), reaction mixtures were incubated for 20 min at 25 °C. Reactions 
were terminated by the addition of 900 µL slurry consisting of 5% (w/v) activated charcoal 
and 50 mM NaH2PO4, pH 2.0. Charcoal absorbs nucleotides but not Pi. Charcoal-quenched 
reaction mixtures were centrifuged for 7 min at room temperature at 13000g. 600 µL of the 
supernatant were removed and 32Pi was determined by liquid scintillation counting. 
Spontaneous [γ-32P]GTP degradation was determined in tubes containing all components 
described above, plus a high concentration of unlabeled GTP (1 mM) that due to competition 
with [γ-32P]GTP prevents [γ-32P]GTP hydrolysis by enzymatic activities present in Sf9 
membranes. Spontaneous [γ-32P]GTP degradation was <1 % of the total amount of 
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radioactivity added. The experimental conditions chosen ensured that not more than 10 % of 
the total amount of [γ-32P]GTP added was converted to 32Pi. 
 
3.4.2.3 Radioligand binding assays26, 27 
For the binding experiments the Sf9 insect cell membranes described in 3.4.2.3 were 
employed. The respective membranes were thawed and sedimented by a 10 min 
centrifugation at 4 °C and 13,000g. Membranes were resuspended in binding buffer (12.5 
mM MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 7.4). Each tube (total volume 500 µL) 
contained 50 µg (hH1R, hH3R), 120 µg (hH4R) or 250 µg (hH2R) of membrane protein. 
Competition binding experiments were performed in the presence of 5 nM [3H]mepyramine 
(hH1R), 10 nM [3H]tiotidine (hH2R), 3 nM [3H]N-α-methylhistamine (hH3R) or 10 nM 
[3H]histamine (hH4R) and increasing concentrations of unlabeled ligands. Incubations were 
conducted for 60 min at 25 °C and shaking at 250 rpm. Bound radioligand was separated 
from free radioligand by filtration through 0.3 % polyethyleneimine-pretreated GF/C filters, 
followed by three washes with 2 mL of cold binding buffer (4 °C) using a Brandel Harvester. 
Filter-bound radioactivity was determined after an equilibration phase of at least 12 h by 
liquid scintillation counting. 
 
3.4.2.4 Histamine H1R assay on guinea pig ileum4 
Guinea pigs of either sex (250 – 500 g) were stunned by a blow on the neck and 
exsanguinated. The ileum was rapidly removed, rinsed and cut into segments of 1.5 – 2.0 cm 
length. The tissues were mounted isotonically (preload of 5 mN) in a jacketed 20-mL organ 
bath that was filled with Tyrode's solution of the following composition [mM]: NaCl 137, KCl 
2.7, CaCl2
 
1.8, MgCl2
 
1.0, NaH2PO4
 
0.4, NaHCO3
 
11.9, and glucose 5.0. The solution 
additionally contained atropine to block cholinergic M receptors at a concentration not 
affecting H1
 
receptors (0.05 µM). The solution was aerated with 95% O2 – 5% CO2
 
and 
warmed to a constant temperature of 37 °C. During an equilibration period of 80 min, the 
tissues were stimulated three times with histamine (1 µM, then 10 µM) followed by washout. 
Up to four cumulative concentration-response curves were determined on each tissue: a first 
to histamine (0.01 – 30 μM), and the 2nd – 4th to histamine in the presence of increasing 
concentrations of antagonist (incubation time 10 – 15 min). pEC50 differences were not 
corrected since four successive curves for histamine were super imposable under these 
conditions (n > 10). 
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3.4.2.5 Histamine H2R assay on the isolated spontaneously beating guinea pig 
right atrium4  
Hearts were rapidly removed from guinea pigs used for studies on the ileum (see above). 
The right atrium was quickly dissected and set up isometrically in Krebs-Henseleit solution 
under a diastolic resting force of 5 mN in a jacketed 20 mL organ bath of 32.5 °C as 
previously described.59
 
The bath fluid (composition [mM]: NaCl 118.1, KCl 4.7, CaCl2
 
1.8, 
MgSO4
 
1.64, KH2PO4
 
1.2, NaHCO3
 
25.0, glucose 5.0, sodium pyruvate 2.0) was gassed with 
95% O2 – 5% CO2
 
and additionally contained (RS)-propranolol (0.3 μM) and mepyramine (1 
μM). Experiments were started after 30 min of continuous washing and an additional 
equilibration period of 15 min. Antagonists: Two successive concentration-frequency curves 
to histamine (0.1 – 30 μM) were established, the first in the absence and the second in the 
presence of the compound under study (incubation time 30 min). Agonists: Two successive 
concentration-frequency curves were established, the first to histamine (0.1 – 30 μM) and the 
second for the agonist under study. Furthermore, the sensitivity to 30 μM cimetidine was 
routinely checked at the end of each H2R
 
agonist concentration-effect curve established in 
the absence of an H2R antagonist, and a significant reduction of frequency was always 
observed after 15 – 30 min.  
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Chapter 4 
 
NG-Acylated imidazolylalkylguanidines: 
synthesis and structure-activity relationships 
at the histamine receptor subtypes 
 
4.1 Introduction 
The development of less basic H2R agonists relative 
to established guanidine-type compounds like 
impromidine (4.1)1, 2 or arpromidine (4.2)3, 4 (Figure 
4.1) resulted in NG-acylated imidazolylpropyl-
guanidines5-7, a new class of potent H2R agonists 
(Figure 4.1). The acylguanidine moiety was found to 
be a useful bioisosteric replacement of the strongly 
basic guanidine group to obtain potent H2R agonists 
with more favorable pharmacokinetic properties.7 
However, various of these acylguanidine-type H2R 
agonists even exhibited higher activities at the hH3R 
and hH4R relative to the hH2R (Figure 4.1 and Table 
4.1). Mostly, the efficacies of these compounds were 
high at the hH2R and hH4R but rather low at the 
hH3R. 
The unexpected pharmacological activities of these 
compounds at HR subtypes other than H2R 
prompted us to modify the structures of the 
evaluated NG-acylated imidazolylpropylguanidines 
with the aim to elaborate the potential of generating 
selective acylguanidine-type HR ligands and to investigate structure-activity and structure-
selectivity relationships. 
 
 
Figure 4.1. Structures of the guanidine-
type H2R agonists impromidine and 
arpromidine and NG-acylated imidazolyl-
propylguanidines with activity at the 
H2R, H3R and H4R. 
Chapter 4 114 
In this medicinal chemistry project we focused on the imidazolylpropylguanidine part and left 
the acyl residues unaffected (Figure 4.2). The three-membered carbon chain separating the 
imidazole ring from the acylguanidine or guanidine group has been shown to be optimal for 
H2R agonistic activity.1, 7 To elucidate the optimal distance of the linker for H3R and H4R 
activity, the higher and lower homologs were investigated. Since a central methyl branch in 
the alkyl chain was not well tolerated with respect to H2R activity,8 we examined this 
modification as a possibility to increase selectivity for other HR subtypes. The same 
consideration was the rationale for the preparation of NG-methylated guanidine analogs.3 As 
5-methylhistamine has proven to be a selective H4R agonist (cf. Chapter 3),9 substitution of 
the imidazole ring with a methyl group in position 5 was regarded as an opportunity for 
shifting selectivity toward the H4R. 
This chapter presents the synthesis of NG-acylated imidazolylalkylguanidines structurally 
modified according to Figure 4.2 and the functional pharmacological activities of these 
compounds at the different HR subtypes. The structure-activity and structure-selectivity 
relationships at the HR subtypes will be discussed. 
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Figure 4.2. Overview about the structural modifications of NG-acylated imidazolylpropylguanidines 
described in this chapter. 
 
4.2 Chemistry 
The imidazolylalkylamines 4.13, 4.14, 4.23 and 4.25, and imidazolylalkylalcohols 4.19 and 
4.20 that are precursors for the synthesis of the corresponding guanidines were prepared 
according to Scheme 4.1. To reduce polarity and facilitate separation of the intermediates, 
the imidazole ring was initially trityl-protected in each case. The imidazolylethylamines 4.13 
and 4.14 were prepared by analogy with a synthetic pathway described for the synthesis of 
5-methylhistamine by Davey and colleagues.10 Reaction of the aldehydes 4.7 and 4.8 with 
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nitromethane in the presence of ammonia acetate in a Henry reaction11 formed the 
nitroalkenes 4.9 and 4.10. Reduction in two steps via the aldoximes 4.11 and 4.12 provided 
the imidazolylethylamines 4.13 and 4.14. The imidazolylpropanols 4.19 and 4.20 were 
obtained via Horner-Wadsworth-Emmons reaction12 of the aldehydes 4.7 and 4.8 with triethyl 
phosphonoacetate followed by hydrogenation of the C=C double bond and reduction of the 
ester functionality with LiAlH4. 3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol was treated with 
thionyl chloride to yield the chloride 4.21.13 Elongation of the carbon chain by Kolbe nitrile 
synthesis14 and reduction of the nitrile 4.22 with LiAlH4 gave the amine 4.23. The N-
methylated imidazolylpropylamine 4.25 was prepared in two steps by aminolysis of methyl 3-
(1-trityl-1H-imidazol-4-yl)propanoate followed by reduction of the amide 4.24. 
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Scheme 4.1. Synthesis of the imidazolylalkylamines 4.13, 4.14, 4.23 and 4.25, and imidazolylalkyl-
alcohols 4.19 and 4.20. Reagents and conditions: (i) TrCl (1.1 eq), NEt3 (1.8 eq), MeCN, 20 h, rt; (ii) 
NH4OAc (1.1 eq), MeNO2 (excess), 5 h, 50 °C; (iii) Pd/C (10 %) (cat.), NaH2PO2 · H2O (11 eq), THF, 1 
h, rt; (iv) LiAlH4 (3 eq), THF, 3 h, 0 °C  rt; (v) triethyl phosphonoacetate (1.5 eq), NaH (60 % 
dispersion in mineral oil) (1.5 eq), THF, overnight, reflux; (vi) Pd/C (10 %) (cat.), EtOH, 3 h, rt; (vii) 
LiAlH4 (2 eq), THF/Et2O, 2 h, reflux; (viii) SOCl2 (2 eq), THF, 3 h, 0 °C  rt; (ix) KCN (2 eq), KI (cat.), 
DMSO, 24 h, 80 °C; (x) LiAlH4 (2 eq), THF/Et2O, 3h, reflux; (xi) MeNH2 (50 eq), MeOH, overnight, rt; 
(xii) LiAlH4 (2 eq), THF/Et2O, 3h, reflux. 
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The preparation of the guanidinylation reagents 4.27-4.29 is depicted in Scheme 4.2. 
Successive reactions of guanidine with Boc-anhydride15 and benzyl chloroformate produced 
4.277. Acylation of guanidine with benzyl chloroformate under basic conditions gave the di-
Cbz-protected guanidine 4.28. Compound 4.29 was obtained by further reaction with triflic 
anhydride.16, 17 4.2718 and 4.28 are versatile reagents for the guanidinylation of alcohols 
applying Mitsunobu conditions,16, 19 whereas 4.29 is useful for the conversion of amines to 
guanidines. 
 
 
 
Scheme 4.2. Synthesis of the guanidinylation reagents 4.27-4.29. Reagents and conditions: (i) NaOH 
(2 eq), Boc2O (0.8 eq), 1,4-dioxane/H2O, overnight, 0 °C  rt. (ii) benzyl succinimidyl carbonate (1 
eq), DMF, overnight, rt; (iii) benzyl chloroformate (3 eq), NaOH (5 eq), H2O/DCM, 20 h, 0 °C; (iv) Tf2O 
(1 eq), NaH (60 % dispersion in mineral oil) (2 eq), chlorobenzene, overnight, - 45 °C  rt.  
 
The imidazolylalkylamines 4.13, 4.14, 4.23 and 4.25 were treated with the guanidinylation 
reagent 4.29 to yield the corresponding di-Cbz protected guanidines 4.30-4.33 (Scheme 
4.3).17 Removing the Cbz protection groups by catalytic hydrogenation gave the guanidines 
4.34-4.37. The imidazolylalkylalcohols 4.19 and 4.20 were converted to the diurethane-
protected guanidines 4.38 and 4.40 under Mitsunobu conditions.7, 16, 19 Cleavage of the Cbz-
groups by hydrogenolysis afforded the guanidine 4.39 and the Boc-protected guanidine 4.41, 
respectively. As in the Mitsunobu reaction alkylation of 4.27 can occur at the nitrogen bearing 
the Boc- or the Cbz-group, regioisomers of 4.40 and 4.41 were obtained. 
 
 
Scheme 4.3. Synthesis of the imidazolylalkylguanidines 4.34-4.37, 4.39 and 4.41. Reagents and 
conditions: (i) NEt3 (1 eq), DCM, overnight, rt; (ii) H2, Pd/C (10 %) (cat.), MeOH, 3 h, rt; (iii) PPh3 (1.5 
eq), DIAD (1.5 eq), THF, overnight, 0 °C  rt; (iv) H2, Pd/C (10 %) (cat.), MeOH, 3 h, rt. 
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NG-acylated imidazolylalkylguanidines 4.42-4.52 and 4.57-4.62 were obtained by NG-
acylation of the free guanidine group of 4.34-4.37 and 4.39 with the carboxylic acids 4.42a-
d.7, 20, 21 4.53-4.56 were synthesized by coupling the carboxylic acids 4.42a-d to NG-Boc-
protected guanidine 4.41 (cf. Chapter 6). Cleavage of the protective groups was performed 
with trifluoroacetic acid giving the NG-acylated imidazolylalkylguanidines 4.63-4.83 (Scheme 
4.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4.4. Synthesis of the NG-acylated imidazolylalkylguanidines 4.63-4.83 and the corresponding 
protected intermediates 4.42-4.62. Reagents and conditions: (i) for 4.42-4.52 and 4.57-4.62: CDI (1.2 
eq), NaH (60 % dispersion in mineral oil) (2 eq), THF, 5 h, rt. (ii) for 4.53-4.56: EDC · HCl (1.2 eq), 
DMAP (1.1 eq), DCM, 24 h, 0 °C  rt. (iii) TFA (20 %), DCM, 5 h, rt. a or R3 = Boc and R4 = H (mixture 
of isomers). 
No. R1 R2 R3 R4 R5 R6 n 
4.42a - - - - Ph Me - 
4.42b - - - - 2-thienyl Me - 
4.42c - - - - Ph Ph - 
4.42d - - - - 2-thiazolyl Ph - 
4.42, 4.63 H H H H Ph Me 0 
4.43, 4.64 H H H H 2-thienyl Me 0 
4.44, 4.65 H H H H Ph Ph 0 
4.45, 4.66 H H H H Ph Me 2 
4.46, 4.67 H H H H 2-thienyl Me 2 
4.47, 4.68 H H H H Ph Ph 2 
4.48, 4.69 H H H H 2-thiazolyl Ph 2 
4.49, 4.70 H Me H H Ph Me 1 
4.50, 4.71 H Me H H 2-thienyl Me 1 
4.51, 4.72 H Me H H Ph Ph 1 
4.52, 4.73 H Me H H 2-thiazolyl Ph 1 
4.53, 4.74 Me H Ha Boca Ph Me 1 
4.54, 4.75 Me H Ha Boca 2-thienyl Me 1 
4.55, 4.76 Me H Ha Boca Ph Ph 1 
4.56, 4.77 Me H Ha Boca 2-thiazolyl Ph 1 
4.57, 4.78 Me H H H Ph Me 0 
4.58, 4.79 Me H H H 2-thienyl Me 0 
4.59, 4.807 Me H H H Ph Ph 0 
4.60, 4.81 Me H H H 2-thiazolyl Ph 0 
4.61, 4.82 H H Me H Ph Me 1 
4.62, 4.83 H H Me H Ph Ph 1 
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4.3 Pharmacological results and discussion 
The potencies and efficacies of the synthesized compounds were evaluated on the four 
human HR subtypes in steady-state GTPase assays determining the enzymatic hydrolysis of 
radioactively labeled [γ-32P]GTP after G-protein activation via the respective HR subtype 
(Table 4.1). These pharmacological studies were performed using membrane preparations of 
Sf9 insect cells expressing the hH1R plus RGS4, the hH2R-GsαS fusion protein, the hH3R plus 
Giα2 plus Gβ1γ2 plus RGS4 or the hH4R-RGS19 fusion protein plus Giα2 plus Gβ1γ2.7, 22, 23 
In addition, selected compounds were evaluated for H1R and H2R activity at the guinea pig 
(gp) ileum and guinea pig right atrium, respectively (Table 4.2). 
 
4.3.1 Potencies and efficacies of the prepared compounds at the hH1R, hH2R, 
hH3R and hH4R in the steady-state GTPase assay 
Modification of the chain connecting the imidazole ring with the acylguanidine moiety in 4.63-
4.73 considerably changed the pharmacological activities of the compounds at the HR 
subtypes relative to the reference compounds 4.3-4.6, containing a three-membered carbon 
chain. Shortening the chain length in 4.63 and 4.64 substantially increased potency at the 
hH1R and yielded partial agonists. In particular 4.63, with an efficacy of 0.5, confirmed the 
potential of some NG-acylated imidazolylalkylguanidines to activate the hH1R and to provide 
possible lead structures for the development of hH1R agonists, as previously described by 
Xie et al. for the acylguanidine UR-AK57.6 The decrease in efficacy of the diarylpropanoyl 
analog 4.65 at the hH2R relative to 4.5 has already been reported (Emax = 0.69  Emax = 
0.17).7 In contrast, 4.63 and 4.64, containing smaller 3-arylbutanoyl residues, retained higher 
efficacies at this HR subtype (Emax ≈ 0.50). Potencies of the NG-acylated imidazolylethyl-
guanidines 4.63-4.65 at the hH2R moderately decreased. Obviously, reducing chain length is 
better tolerated in terms of efficacy at the hH2R for less bulky substituents, but is generally 
unfavorable with respect to both potency and efficacy. At the hH3R, the activities of 4.63 and 
4.64 were not substantially different from those of the reference compounds 4.3 and 4.4. 
However, the diphenylpropanoyl analog 4.65 had drastically increased efficacy (Emax = 0.04 
 Emax = 0.66) at this HR subtype. Apparently, the combination of an ethylene spacer 
between the imidazole ring and acylguanidine group and a bulky acyl substituent opens the 
route to acylguanidine-type compounds displaying highest efficacy at the hH3R. At the hH4R, 
4.63-4.65 were moderate inverse agonists (KB = 150 – 240 nM, Emax = -0.07 – -0.30). 
The substantial influence of the chain length on the pharmacological activities at the HRs is 
also visible for 4.66-4.69, containing a four-membered carbon chain. Contrary to the 
acylguanidines with an ethylene linker (4.63-4.65), 4.66-4.69 were devoid of hH2R agonistic 
activity and showed neutral antagonist properties. The potencies of 4.66 and 4.67 carrying 
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3-arylbutanoyl residues were lowered, whereas potencies of the diarylpropanoyl analogs 
4.68 and 4.69 were not affected relative to the reference compounds 4.3-4.6. At the hH3R, 
increasing chain length diminished efficacy and produced – with exception of 4.67 – inverse 
agonists. For the potencies a similar trend as that at the hH2R was observed. Regarding the 
hH4R, for 4.66-4.69 agonistic activity was shifted toward inverse agonism and potencies were 
5 to 20 times lower compared to 4.3-4.6. 
Taken together, these findings evidence the distance between the imidazole ring and the 
acylguanidine group to largely affect HR activity. As already observed for the guanidine-type 
H2R agonists,1 a three-membered carbon chain proved to be favored for acylguanidine-type 
H2R agonists, underlining the bioisosteric quality of the guanidine and the acylguanidine 
group.7 Likewise, at the hH3R, potencies in general peaked with a trimethylene spacer which 
also was required for agonistic activity of the compounds at the hH4R. By contrast, a two-
membered carbon chain was optimal for hH1R activity. 
The compounds chain-branched β to the imidazole ring (4.70-4.73) exhibited a certain 
decrease in potency at the hH2R and low efficacies (Emax = 0.10 – 0.31). At the hH3R, the 
3-arylbutanoyl analogs 4.70 and 4.71 displayed 5- to 10-fold reduced potencies relative to 
the reference compounds 4.3 and 4.4 and were neutral antagonists. Contrary, the 
pharmacological properties of the diarylpropanoyl analogs 4.72 and 4.73 were just slightly 
affected. Regarding the hH4R, β-methylation of the propyl chain was deleterious for agonistic 
efficacy and substantially lowered potencies. Obviously, the carbon chain of the NG-acylated 
imidazolylpropylguanidines is sensitive toward substitution with respect to hH2R and hH4R 
activation. Steric factors may prevent the stabilization of an active receptor conformation with 
compounds 4.70-4.73. 
Besides methyl-branching of the spacer, a methyl substitution was introduced in position 5 of 
the imidazole ring (4.74-4.77). Potencies of 4.74-4.77 at the hH2R slightly increased, 
whereas efficacies were remarkably lower compared to those of the reference compounds 
4.3-4.6. The activities of 4.74-4.77 at the hH3R strongly depended on the acyl residue. 4.76 
and 4.77, containing bulky diarylpropanoyl moieties, displayed substantially reduced 
potencies and low efficacies (Emax = 0.03 – 0.16). In contrast, for the 3-arylbutanoyl analogs 
4.74 and 4.75 potencies decreased just slightly relative to the reference compounds 4.3 and 
4.4, but an essential increase in efficacy was observed (Emax ≈ 0.85). Apparently, depending 
on the acyl residue, methyl substitution of the imidazole ring in position 5 provides highly 
potent hH3R ligands with high efficacies. Unexpectedly, at the hH4R this modification was not 
well tolerated since the compounds showed reduced potencies and drastically decreased 
efficacies relative to 4.3-4.6. These results are in contrast to the pharmacological profile of 5-
methylhistamine which binds > 500 times less potent to the hH3R relative to histamine and 
was found to be a potent and selective full hH4R agonist.9 Obviously, identical structural 
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modifications at the imidazole ring of the NG-acylated imidazolylpropylguanidines and 
histamine do not shift the pharmacological properties at the HRs toward the same direction. 
Therefore, different binding modes for the imidazole ring of the acylguanidine-type 
compounds and histamine can be expected both at the hH3R and hH4R. 
Contrary to the selective hH4R agonist 5-methylhistamine,9 the evaluated acylguanidine 
analogs 4.78-4.81 exhibited no agonistic activity at the hH2R and hH4R. Moreover, in general 
the potencies at these HR subtypes were notedly decreased relative to the higher homologs 
4.74-4.77, again confirming a three-membered carbon chain to be more favorable for high 
potency and efficacy at the hH2R and hH4R. Interestingly, similar to 4.74-4.77, the 
compounds bearing 3-arylbutanoyl residues (4.78 and 4.79) behaved as rather potent partial 
hH3R agonists with up to 40-fold selectivity over all other HR subtypes, whereas 4.80 and 
4.81, carrying more bulky acyl groups, exerted considerably reduced activities devoid of 
agonistic efficacy. 
Methylation of the guanidine-NH bearing the imidazolylpropyl portion in 4.82 and 4.83 
resulted in dramatically reduced activities and a loss of agonistic efficacy at all HR subtypes. 
Obviously, this guanidine-NH group is crucial for the interaction with amino acid residues of 
the HRs, for example by forming a hydrogen bond. This experimental finding confirms results 
from an H2R homology model, suggesting the acylguanidine group of NG-acylated 
imidazolylpropylguanidines to form charge-assisted hydrogen bonds with the conserved Asp-
98 in transmembrane domain 3 (TM3).7, 24 As in the case of the hH2R, the basic amino group 
of histamine is assumed to interact with the corresponding conserved Asp (Asp-94) in TM3 at 
the hH4R.25 Since the hH4R agonistic efficacy is lost as well upon N-methylation of the 
guanidine moiety in 4.82 and 4.83, a comparable interaction between the receptor protein 
and the acylguanidine group of NG-acylated imidazolylpropylguanidines can be expected at 
both the hH4R and the hH2R.  
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4.3.2 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 
The investigated NG-acylated imidazolylalkylguanidines (Table 4.2) behaved as weak 
antagonists with pA2 values in the range of 5 – 6 at the guinea pig ileum.  
At the gpH2R, all investigated compounds suffered a decrease in potency relative to the 
compounds 4.3-4.6 but usually partial agonistic activity retained. Increasing the chain length 
between the imidazole ring and the acylguanidine group by one methylene group (4.66) 
substantially lowered potency and efficacy at the gpH2R relative to 4.3. This observation is in 
agreement with data for the higher homolog of impromidine (4.1) that likewise proved to be 
significantly less potent and efficacious at the gpH2R.1 In contrast, at the human isoform the 
agonistic efficacy of 4.66 determined in GTPase assays was completely abolished.  
Methylation of the carbon chain in β-position position to the imidazole ring in 4.70 decreased 
potency at the gpH2R compared to compound 4.3, whereas efficacy was just moderately 
reduced. This corresponds to the behavior of the impromidine-like counterpart that also 
showed a diminished potency and efficacy at the gpH2R when a methyl group was 
introduced.8 At the hH2R, the decrease in efficacy of compound 4.70 was considerably more 
pronounced. 
A methyl group in position 5 of the imidazole ring resulted in compounds 4.74-4.77, 
displaying comparably high efficacies relative to 4.3-4.6 at the gpH2R. However, the 
potencies were about 5-fold lower. This is contrary to the human isoform, where efficacy 
substantially decreased, whereas potency even slightly increased. Obviously, an active 
conformation of the gpH2R can be well stabilized regardless of the presence of a methyl 
group at the imidazole ring, whereas at the human receptor the 5-methyl group is deleterious 
for agonistic efficacy. 
Compared to the reference compounds 4.3-4.6, potencies of the 5-methylhistamine analogs 
4.78-4.81 dropped by almost two orders of magnitude at the gpH2R and also efficacies 
decreased, in particular for 4.80 and 4.81, bearing a bulky diarylpropanoyl residue. In 
contrast, at the hH2R, 4.78-4.81 exhibited no agonistic efficacy. 
Methylation of the guanidine-NH adjacent to the imidazolylpropyl group (4.82) yielded a 
virtually inactive compound at the guinea pig right atrium. As observed at the hH2R, the 
unsubstituted guanidine-NH is crucial for receptor binding. In the arpromidine (4.2) series, 
methylation of the opposite guanidine-NH, bearing the diarylpropyl residue, caused a drastic 
reduction of potency at the gpH2R but the compound still displayed nearly full agonistic 
efficacy (Emax = 0.8).3 Obviously, the guanidine-NH attached to the imidazolylpropyl group 
seems to be more critical for the interaction with the gpH2R, in particular, with respect to 
receptor activation. 
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The evaluated compounds turned out to be more potent at the hH2R than at the gpH2R. This 
may appear exceptional as guanidine- and acylguanidine-type H2R agonists have usually 
been more potent at the gpH2R.5, 6, 28 However, it has to be considered that the guinea pig 
right atrium and the GTPase activity assay are different pharmacological analysis systems, in 
particular with regard to the receptor system (H2R-GsαS fusion protein versus native non-
fused receptor), read-out or different access to the receptors in membrane preparations and 
isolated organs. Actually, potencies of acylguanidine-type H2R agonists determined at the 
guinea pig right atrium were lower than potencies determined in the GTPase assay on the 
gpH2R-GsαS fusion protein.29 This observation may explain the lower potencies of the 
evaluated compounds at the gpH2R (guinea pig right atrium) relative to the hH2R (GTPase 
assay). 
 
Table 4.2. Pharmacological activities of selected compounds at the guinea pig ileum (gpH1R) and the 
guinea pig right atrium (gpH2R). 
a number of experiments, b pEC50 was calculated from the mean shift ∆pEC50 of the agonist curve 
relative to the histamine reference curve by equation: pEC50 = 6.00 + 0.13 + ∆pEC50. Summand 0.13 
represents the mean desensitization observed for control organs when two successive curves for 
histamine were performed (0.13 ± 0.02, n = 16). The SEM given for pEC50 is the SEM calculated for ∆pEC50, c efficacy, maximal response (%), relative to the maximal increase in heart rate induced by the 
reference compound histamine; n.d.: not determined. 
gpH1R  gpH2R 
Compound 
pA2 na  pEC50b /(pA2)/[pD2’] Emaxc na 
histamine - -  6.00 ± 0.10 1.00 ± 0.02 > 50 
4.3 (UR-AK24)7  5.87 ± 0.14 2  7.80 ± 0.07 0.99 ± 0.02 4 
4.47 n.d.   7.42 ± 0.10 0.99 ± 0.02 3 
4.5 (UR-PG80)7  6.13 ± 0.05 10  7.55 ± 0.09 0.85 ± 0.03 5 
4.67 5.33 ± 0.05 18  7.42 ± 0.03 1.00 ± 0.01 3 
4.66 5.66 ± 0.04 18  5.92 ± 0.11 0.47 ± 0.01 2 
4.70 5.88 ± 0.12 18  6.11 ± 0.16 0.80 ± 0.04 3 
4.74 5.50 ± 0.02 12  7.11 ± 0.08 0.98 ± 0.03 3 
4.75 5.77 ± 0.03 12  6.68 ± 0.11 0.94 ± 0.03 2 
4.76 5.65 ± 0.05 8  6.75 ± 0.23 0.73 ± 0.04 4 
4.77 5.45 ± 0.04 12  6.80 ± 0.02 1.03 ± 0.09 2 
4.78 5.51 ± 0.04 6  5.71 ± 0.04 0.78 ± 0.02 2 
4.79 5.49 ± 0.03 12  5.69 ± 0.11 0.72 ± 0.05 2 
4.80 5.30 ± 0.03 12  5.71 ± 0.01 0.44 ± 0.01 2 
4.81 4.88 ± 0.08 8  5.40 ± 0.13 0.43 ± 0.05 2 
4.82 < 4.5 18  (< 4.3) [4.08 ± 0.05] < 0.10 3 
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4.3.3 Summary and conclusion 
Regarding the hH1R, potencies and agonistic efficacies could be increased by shortening the 
chain length separating the imidazole ring from the acylguanidine group (4.63-4.64). All other 
modifications produced just poorly active compounds. 
A three-membered carbon chain separating the imidazole ring from the acylguanidine group 
proved to be crucial for high hH2R agonistic potency. Higher (4.66-4.69) and lower homologs 
(4.63-4.65) as well as methyl-branched analogs (4.70-4.73) were unfavorable with respect to 
both potency and efficacy, confirming findings from guanidine-type H2R agonists.1, 8 
Methylation of the imidazole ring in position 5 (4.74-4.77) slightly increased potency, but 
considerably reduced efficacy at the hH2R. Taken together, in this series of compounds all 
performed modifications significantly reduced efficacy at the hH2R confirming an 
imidazolylpropylguanidine group to be essential for potent acylguanidine-type hH2R agonists. 
Concerning gpH2R agonism, the structural modifications reduced potencies relative to 4.3-
4.6. However, the imidazolylpropylguanidine portion was less sensitive toward modifications 
concerning agonistic activity at this species isoform than at the human counterpart. This 
offers the opportunity to obtain compounds with species-dependent efficacies. Such 
compounds may be of interest as tools to study differences in the activation of both H2R 
species isoforms. 
Many of the structural modifications affected H2R activity in a similar way as previously 
observed in the class of guanidine-type H2R agonists.1, 3, 8 This further confirms the 
acylguanidine group to be an appropriate bioisostere with reduced basicity for the guanidine 
moiety.7 
Most striking concerning the hH3R was the ability to essentially increase efficacy of 
acylguanidine-type compounds by modifying the imidazolylpropylguanidine portion. In 
particular, introduction of a methyl group to the imidazole ring in position 5 opened access to 
compounds showing – in contrast to the reference compounds – both highest potency and 
efficacy at this HR subtype (4.74, 4.75, 4.78 and 4.79). These findings disclose the possibility 
to develop selective acylguanidine-type hH3R agonists. In contrast to standard H3R agonists 
such as (R)-α-methylhistamine, which features insufficient peroral absorption and poor brain 
penetration30, NG-acylated imidazolylpropylguanidines have been shown to be orally 
bioavailable and to penetrate the blood-brain barrier in mice.7 Therefore, such acylguanidine-
type H3R agonists may become useful pharmacological probes for further studying the role of 
the H3R in the CNS. In addition, H3R agonists have been discussed as possible drugs for the 
treatment of insomnia31, pain32, myocardial ischaemic arrhythmias33 and neurogenic 
inflammation34, 35. 
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Concerning the hH4R, the imidazolylpropylguanidine group was extremely sensitive toward 
structural variations. All compounds showed lower potencies compared to the reference 
compounds and negligible agonistic efficacies. 
In summary, potencies, efficacies and HR subtype selectivities of the NG-acylated 
imidazolylpropylguanidines 4.3-4.6 could be broadly altered by modifying the 
imidazolylpropylguanidine portion. The ability of NG-acylated imidazolylalkylguanidines to 
provide ligands for all four HR subtypes further confirms this moiety to serve as a “privileged 
structure”.7 Therefore, this structural motif is a promising building block for the development 
of potent and selective HR ligands as pharmacological tools, including compounds with 
combined activities at certain HR subtypes.  
 
4.4 Experimental section 
4.4.1 Chemistry 
4.4.1.1 General conditions 
Commercial reagents and chemicals were purchased from Acros Organics (Geel, Belgium), 
IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany), Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Munich, 
Germany), TCI Europe (Zwijndrecht, Belgium) and used without further purification. 
Deuterated solvents for NMR spectroscopy were from Deutero GmbH (Kastellaun, 
Germany). All solvents were of analytical grade or distilled prior to use. If moisture-free 
conditions were required, reactions were performed in dried glassware under inert 
atmosphere (argon or nitrogen). Anhydrous DMF was purchased from Sigma-Aldrich Chemie 
GmbH. 3-(1-Trityl-1H-imidazol-4-yl)propan-1-ol was a gift from Prof. Dr. Sigurd Elz, 
Department of Pharmaceutical/Medicinal Chemistry I, University of Regensburg. Flash 
chromatography was performed on silica gel (Merck silica gel 60, 40 - 63 µM). Reactions 
were monitored by TLC on aluminum plates coated with silica gel (Merck silica gel 60 F254, 
thickness 0.2 mm). The compounds were detected by UV light (254 nm), a 0.3 % solution of 
ninhydrine in n-butanol (amines) or a 1.0 % solution of Fast Blue B salt (Sigma-Aldrich 
Chemie GmbH) in EtOH/H2O = 30/70 (v/v). All melting points are uncorrected and were 
measured on a Büchi 530 apparatus (Büchi GmbH, Essen, Germany).  
Nuclear Magnetic Resonance spectra (1H-NMR and 13C-NMR) were recorded with Bruker 
Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz) or Bruker Avance 600 (1H: 600.1 MHz; 13C: 
150.9 MHz) NMR spectrometers (Bruker BioSpin GmbH, Rheinstetten, Germany). Chemical 
shifts are given in δ (ppm) relative to external standards. Abbreviations for the multiplicities of 
the signals: s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), m (multiplet), brs (for 
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broad singlet) and combinations thereof. The multiplicity of carbon atoms (13C-NMR) was 
determined by DEPT 135 (distortionless enhancement by polarization transfer): “+” primary 
and tertiary carbon atom (positive DEPT 135 signal), “-“ secondary carbon atom (negative 
DEPT 135 signal), “quat” quaternary carbon atom. In certain cases 2D-NMR techniques 
(COSY, HMQC, HSQC, HMBC, NOESY) were used to assign 1H and 13C chemical shifts. 
Infrared spectra (IR) were measured on a Bruker Tensor 27 spectrometer equipped with an 
ATR (attenuated total reflexion) unit from Harrick Scientific Products Inc. (Ossining/NY, US). 
Mass spectra (MS) were recorded on a Finnigan MAT 95 (EI-MS 70 eV, HR-MS), Finnigan 
SSQ 710A (CI-MS (NH3)) and on a Finnigan ThermoQuest TSQ 7000 (ES-MS) 
spectrometer. The peak-intensity in % relative to the strongest signal is indicated in 
parenthesis. Elemental analysis (C, H, N, Heraeus Elementar Vario EL III) were performed 
by the Analytical Department of the University Regensburg and are within ± 0.4 % unless 
otherwise noted. 
Preparative HPLC was performed with a pump model K-1800 (Knauer, Berlin, Germany), the 
column was Eurosphere-100 (250 x 32 mm) (Knauer), which was attached to a UV-detector 
model K-2000 (Knauer). UV detection of the compounds was done at 210 nm. The 
temperature was 25 °C and the flow rate 37 ml/min. The mobile phase was 0.1 % TFA in 
millipore water and MeCN. Analytical HPLC was performed on a system from Thermo 
Separation Products (TSP) equipped with a SN 400 controller, P4000 pump, an AS3000 
autosampler and a Spectra Focus UV/VIS detector. Stationary phase was a Eurosphere-100 
C-18 (250 x 4.0 mm, 5 μm) column (Knauer) thermostated at 30 °C. The flow rate was 0.8 
ml/min and the dead time (t0) was 3.32 min. As mobile phase gradients of MeCN/0.05 % TFA 
(aq.) were used and the absorbance was detected at 210 nm. Compound purities were 
calculated as the percentage peak area of the analyzed compound by UV detection at 210 
nm. HPLC conditions, retention times (tR), capacity factors (k’ = (tR – t0)/t0) and purities of the 
synthesized compounds are listed in the appendix (Chapter 9). 
 
4.4.1.2 Preparation of the 2-(1-trityl-1H-imidazol-4-yl)ethanamines 4.13 and 4.14 
1-Trityl-1H-imidazole-4-carbaldehyde36 (4.7) 
To a solution of 1H-imidazole-4-carbaldehyde (5.0 g, 52.0 mmol) and trityl chloride (16.0 g, 
57.2 mmol) in MeCN (165 mL), NEt3 (13.0 mL, 93.6 mmol) was added dropwise. After 20 h, 
hexane (17 mL) and H2O (170 mL) were added and the mixture was stirred for 30 min. The 
precipitated product was filtered and washed with H2O (2 x 20 mL). Recrystallization from 
EtOAc/hexane yielded a beige solid (15.1 g, 86 %); mp 192 – 194 °C (ref.36: 193 – 196 °C). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.06 – 7.16 (m, 6H, Ph-H), 7.31 – 7.41 (m, 9H, Ph-H), 
7.53 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.61 (d, 1H, 4J = 1.3 Hz, Im-2-H), 9.88 (s, 1H, COH). 13C-
NMR (75 MHz, CDCl3): δ [ppm] = 76.39 (Cquat, CPh3), 126.80 (+, Im-C-5), 128.42 (+, 6 Ph-C), 
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128.57 (+, 3 Ph-C-4), 129.69 (+, 6 Ph-C), 140.65 (+, Im-C-2), 140.90 (Cquat, Im-C-2), 141.56 
(Cquat, 3 Ph-C-1), 186.61 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 677 (4) [2M 
+ H]+, 243 (100) [CPh3+]. Anal. (C23H18N2O) C, H, N. C23H18N2O (338.40).  
 
5-Methyl-1-trityl-1H-imidazole-4-carbaldehyde (4.8)37 
To a solution of 5-methyl-1-trityl-1H-imidazole-4-carbaldehyde (5.3 g, 48.1 mmol) and trityl 
chloride (14.7 g, 52.9 mmol) in MeCN (160 mL), NEt3 (12.1 mL, 86.6 mmol) was added 
dropwise. After 20 h, hexane (16 mL) and H2O (160 mL) were added and the mixture was 
stirred for 30 min. The precipitated product was filtered and washed with H2O (2 x 20 mL). 
Recrystallization from EtOAc/hexane yielded a beige solid (15.3 g, 90 %); mp 162 – 165 °C. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.55 (s, 3H, CH3), 7.12 – 7.21 (m, 6H, Ph-H), 7.30 – 
7.39 (m, 10H, Ph-H + Im-2-H), 9.11 (s, 1H, COH). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 
15.77 (+, CH3), 76.19 (Cquat, CPh3), 128.43 (+, 6 Ph-C), 128.47 (+, 3 Ph-C-4), 128.58 (Cquat, 
Im-C-4), 129.59 (+, 6 Ph-C), 141.53 (+, Im-C-2), 141.58 (Cquat, 3 Ph-C-1), 151.68 (Cquat, Im-
C-5), 181.17 (Cquat, C=O). CI-MS (NH3) m/z (%): 353 (9) [M + H]+, 243 (100) [CPh3+]. Anal. 
(C24H20N2O) C, H, N. C24H20N2O (352.43). 
 
 
(E)-4-(2-Nitrovinyl)-1-trityl-1H-imidazole (4.9)38 
A mixture of 4.7 (6.8 g, 20.1 mmol) and NH4OAc (1.7 g, 22.1 mmol) in an excess of 
nitromethane (55 mL) was stirred at 50 °C for 5 h (light protection!). After removing the 
solvent in vacuo, the remaining residue was triturated with H2O (60 mL), filtered and washed 
with Et2O (2 x 20 mL) yielding a yellow solid (6.4 g, 84 %); mp 218 – 220 °C. 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 7.07 – 7.17 (m, 6H, Ph-H), 7.23 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.32 – 
7.41 (m, 9H, Ph-H), 7.52 (d, 1H, 4J = 1.3 Hz, Im-2-H), 7.76 (d, 1H, 3J = 13.1 Hz, vinyl-CH), 
7.83 (d, 1H, 3J = 13.1 Hz, vinyl-CH). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 76.22 (Cquat, 
CPh3), 127.38 (+, Im-C-5), 128.40 (+, 6 Ph-C), 128.56 (+, 3 Ph-C), 129.65 (+, 6 Ph-C), 
130.88 (+, vinyl-C), 133.01 (Cquat, Im-C-4), 135.81 (+, vinyl-C), 141.29 (+, Im-C-2), 141.64 
(Cquat, 3 Ph-C-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 382 (3) [M + H]+, 243 (100) 
[CPh3+]. Anal. (C24H19N3O2) C, H, N. C24H19N3O2 (381.43). 
 
(E)-5-Methyl-4-(2-nitrovinyl)-1-trityl-1H-imidazole (4.10) 
A mixture of 4.8 (8.5 g, 24.2 mmol) and NH4OAc (2.1 g, 26.6 mmol) in an excess of 
nitromethane (65 mL) was stirred at 50 °C for 5 h (light protection!). After removing the 
solvent in vacuo, the remaining residue was taken up in DCM (100 mL) and extracted with 
water (2 x 30 mL). The organic layer was evaporated and the crude product was crystallized 
from MeOH/Et2O yielding a yellow solid (7.9 g, 82 %); mp 176 – 178 °C. 1H-NMR (300 MHz, 
CDCl3): δ [ppm] = 1.62 (s, 3H, CH3), 7.09 – 7.18 (m, 6H, Ph-H), 7.33 – 7.41 (m, 9H, Ph-H), 
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7.46 (s, 1H, Im-2H), 7.83 (d, 1H, 3J = 13.0 Hz, vinyl-CH), 7.88 (d, 1H, 3J = 13.0 Hz, vinyl-CH). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 12.21 (+, CH3), 75.88 (Cquat, CPh3), 128.38 (+, 6 Ph-C), 
128.40 (+, 3 Ph-C-4), 129.91 (+, 6 Ph-C), 130.13 (+, vinyl-C), 132.84 (Cquat, Im-C-4), 134.99 
(+, vinyl-C), 137.15 (Cquat, Im-C-5), 140.40 (+, Im-C-2), 140.94 (Cquat, 3 Ph-C-1). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 396 (100) [M + H]+. Anal. (C25H21N3O2) C, H, N. 
C25H21N3O2 (395.45). 
 
2-(1-Trityl-1H-imidazol-4-yl)acetaldehyde oxime (4.11) 
To a solution of 4.9 (6.3 g, 16.6 mmol) and Pd/C (10 %) (0.40 g, cat.) in THF (100 mL), a 
solution of NaH2PO2 · H2O (19.2 g, 181 mmol) in H2O (50 mL) was added dropwise. After 
addition was complete, the mixture was stirred for 1 h. The catalyst was removed by filtration 
over Celite and EtOAc (50 mL) was added to the filtrate. The filtrate was washed with a 
saturated K2CO3 solution (100 mL), dried over MgSO4 and concentrated in vacuo. 
Crystallization from MeCN gave a beige solid (3.5 g, 57 %); mp 182 – 184 °C (dec.). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 3.46 (d, 2H, 3J = 5.0 Hz, CH2), 6.75 (d, 1H, 4J = 1.3 Hz, Im-
5-H), 6.81 (t, 1H, 3J = 5.0 Hz, CHNOH), 7.05 – 7.15 (m, 6H, Ph-H), 7.30 (d, 1H, 4J = 1.3 Hz, 
Im-2-H), 7.31 – 7.47 (m, 9H, Ph-H), 10.90 (s, 1H, OH). 13C-NMR (75 MHz, DMSO-d6): δ 
[ppm] = 24.40 (-, Im-4-CH2), 74.45 (Cquat, CPh3), 118.15 (+, Im-C-5), 127.89 (+, 3 Ph-C-4), 
128.12 (+, 6 Ph-C), 129.13 (+, 6 Ph-C), 136.53 (Cquat, Im-C-4), 137.90 (+, Im-C-2), 142.21 
(Cquat, 3 Ph-C-1), 148.04 (+, CHNOH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 368 (56) [M 
+ H]+, 243 (100) [CPh3+]. Anal. (C24H21N3O · 0.25 H2O) C, H, N. C24H21N3O (367.44). 
 
2-(5-Methyl-1-trityl-1H-imidazol-4-yl)acetaldehyde oxime (4.12) 
To a solution of 4.10 (6.3 g, 15.9 mmol) and Pd/C (10 %) (0.38 g, cat.) in THF (100 mL), a 
solution of NaH2PO2 · H2O (18.3 g, 173 mmol) in H2O (50 mL) was added dropwise. After 
addition was complete, the mixture was stirred for 1 h. The catalyst was removed by filtration 
over Celite and EtOAc (50 mL) was added to the filtrate. The filtrate was washed with a 
saturated K2CO3 solution (100 mL), dried over MgSO4 and concentrated in vacuo. After 
addition of MeCN, the product precipitated and was recrystallized from MeCN/EtOAc yielding 
a beige solid (4.1 g, 68 %); mp 188 – 189 °C (dec.). 1H-NMR (300 MHz, CDCl3) isomers: δ 
[ppm] = 1.39 (s, 3H, CH3), 3.42 (d, 0.6H, 3J = 6.2 Hz, CH2), 3.63 (d, 1.4 H, 3J = 5.1 Hz, CH2), 
6.91 (t, 0.7H, 3J = 5.1 Hz, CHNOH), 7.09 – 7.18 (m, 6H, Ph-H), 7.28 – 7.36 (m, 10H, Ph-H + 
Im-2-H), 7.50 (t, 0.3H, 3J = 6.2 Hz, CHNOH), 10.44 (brs, 1H, OH). 13C-NMR (75 MHz, CDCl3) 
dominating isomer: δ [ppm] = 11.62 (+, CH3), 23.68 (-, Im-4-CH2), 75.06 (Cquat, CPh3), 126.13 
(Cquat, Im-C), 127.93 (+, 3 Ph-C-4), 128.05 (+, 6 Ph-C), 130.09 (+, 6 Ph-C), 135.36 (Cquat, Im-
C), 137.15 (+, Im-C-2), 141.77 (Cquat, 3 Ph-C-1), 149.88 (+, CHNOH). ES-MS (DCM/MeOH + 
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NH4OAc) m/z (%): 382 (100) [M + H]+. Anal. (C25H23N3O · 0.75 H2O) C, H, N. C25H23N3O 
(381.47). 
 
2-(1-Trityl-1H-imidazol-4-yl)ethanamine (4.13)39 
To a mixture of LiAlH4 (0.99 g, 26.1 mmol) in THFabs (60 mL), 4.11 (3.2 g, 8.7 mmol) was 
added in portions at 0 °C. The mixture was allowed to warm to room temperature. After 
stirring for 3 h, the mixture was cooled externally with ice and 2.6 mL H2O, 2.6 mL NaOH 15 
% and 10.4 mL H2O were consecutively added. The insoluble material was removed by 
filtration and washed with THF (2 x 20 mL). The combined organic layers were washed with 
a saturated solution of K2CO3, dried over Na2SO4 and evaporation of the solvent yielded a 
brownish foam-like solid that was used without further purification. (2.8 g, 91 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 2.66 (t, 2H, 3J = 6.6 Hz, Im-4-CH2), 2.96 (t, 2H, 3J = 6.6 Hz, 
CH2-NH2), 6.59 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.07 – 7.18 (m, 6H, Ph-H), 7.24 – 7.39 (m, 10H, 
Ph-H + Im-2-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 32.61 (-, Im-4-CH2), 41.94 (-, CH2-
NH2), 75.15 (Cquat, CPh3), 118.62 (+, Im-C-5), 128.02 (+, 3 Ph-C-4), 128.04 (+, 6 Ph-C), 
129.79 (+, 6 Ph-C), 138.70 (+, Im-C-2), 139.50 (Cquat, Im-C-4), 142.58 (Cquat, 3 Ph-C-1). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 354 (26) [M + H]+, 243 (100) [CPh3+]. C24H23N3 
(353.46). 
 
2-(5-Methyl-1-trityl-1H-imidazol-4-yl)ethanamine (4.14) 
To a mixture of LiAlH4 (0.87 g, 22.8 mmol) in THFabs (50 mL), 4.12 (2.9 g, 7.6 mmol) was 
added in portions at 0 °C. The mixture was allowed to warm to room temperature. After 
stirring for 3 h, the mixture was cooled externally with ice and 2.3 mL H2O, 2.3 mL NaOH 15 
% and 9.2 mL H2O were consecutively added. The insoluble material was removed by 
filtration and washed with THF (2 x 15 mL). The combined organic layers were washed with 
a saturated solution of K2CO3, dried over Na2SO4 and evaporation of the solvent yielded a 
pale yellow foam-like solid that was used without further purification. (2.2 g, 76 %). 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 1.32 (s, 3H, CH3), 2.49 (t, 2H, overlap with solvent, 3J = 7.0 
Hz, Im-4-CH2), 2.79 (t, 2H, 3J = 7.0 Hz, CH2-NH2), 7.04 – 7.13 (m, 6H, Ph-H), 7.33 – 7.46 (m, 
10H, Ph-H + Im-2-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 11.27 (+, CH3), 29.57 (-, Im-
4-CH2), 41.20 (-, CH2-NH2), 74.02 (Cquat, CPh3), 124.83 (Cquat, Im-C-5), 127.81 (+, 3 Ph-C-4), 
128.07 (+, 6 Ph-C), 129.44 (+, 6 Ph-C), 136.31 (+, Im-C-2), 137.67 (Cquat, Im-C-4), 141.54 
(Cquat, 3 Ph-C-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 368 (100) [M + H]+. C25H25N3 
(367.49). 
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4.4.1.3 Preparation of the 3-(1-trityl-1H-imidazol-4-yl)propan-1-ols 4.19 and 4.20 
(E)-Ethyl 3-(5-methyl-1-trityl-1H-imidazol-4-yl)acrylate (4.15)40 
To a solution of triethyl phosphonoacetate (14.6 g, 13.0 mL, 65.1 mmol) in THFabs (250 mL), 
NaH (60 % dispersion in mineral oil) (2.60 g, 65.1 mmol) was added in portions. After stirring 
for 1 h at ambient temperature, a solution of 4.8 (15.3 g, 43.4 mmol) in THFabs (150 mL) was 
added dropwise. When addition was complete, the mixture was refluxed overnight. The 
solvent was evaporated and the crude product was dissolved in EtOAc (200 mL) and washed 
with water (3 x 60 mL). The organic layer was dried over Na2SO4, evaporated and the crude 
product purified by flash chromatography (PE/EtOAc 80/20 v/v). Recrystallization from 
EtOAc/hexane yielded the E-isomer as white solid (13.2 g, 72 %); mp 175 – 176 °C. 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 1.29 (t, 3H, 3J = 7.1 Hz, CH2CH3), 1.57 (s, 3H, Im-5-CH3), 4.22 
(q, 2H, 3J = 7.1 Hz, CH2CH3), 6.58 (d, 1H, 3J = 15.4 Hz, CHCO), 7.09 – 7.19 (m, 6H, Ph-H), 
7.28 – 7.41 (m, 10H, Ph-H + Im-2-H), 7.56 (d, 1H, 3J = 15.4 Hz, Im-4-CH). 13C-NMR (75 
MHz, CDCl3): δ [ppm] = 11.99 (+, Im-5-CH3), 14.44 (+, CH2CH3), 60.12 (-, CH2CH3), 75.40 
(Cquat, CPh3), 115.36 (+, CHCO), 128.15 (+, 3 Ph-C-4), 128.21 (+, 6 Ph-C), 129.99 (+, 6 Ph-
C), 132.90 (Cquat, Im-C), 135.11 (+, Im-4-CH), 136.40 (Cquat, Im-C), 139.43 (+, Im-C-2), 
141.38 (Cquat, 3 Ph-C-1), 167.95 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 423 
(100) [M + H]+. Anal. (C28H26N2O2) C, H, N. C28H26N2O2 (422.52). 
 
(E)-Ethyl 2-methyl-3-(1-trityl-1H-imidazol-4-yl)acrylate (4.16)  
To a solution of triethyl phosphonoacetate (9.0 g, 8.1 mL, 37.8 mmol) in THFabs (150 mL), 
NaH (60 % dispersion in mineral oil) (1.51 g, 37.8 mmol) was added in portions. After stirring 
for 1 h at ambient temperature, a solution of 4.7 (8.54 g, 25.2 mmol) in THFabs (75 mL) was 
added dropwise. When addition was complete, the mixture was refluxed overnight. The 
solvent was evaporated and the crude product was taken up in EtOAc (150 mL) and washed 
with water (3 x 50 mL). The organic layer was dried over Na2SO4, evaporated and the crude 
product purified by flash chromatography (PE/EtOAc 70/30 v/v). Recrystallization from 
EtOAc/hexane yielded the E-isomer as white solid (7.9 g, 74 %); mp 158 – 159 °C. 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 1.30 (t, 3H, 3J = 7.1 Hz, CH2CH3), 2.20 (d, 3H, 4J = 1.8 Hz, 
CH=CCH3), 4.21 (q, 2H, 3J = 7.1 Hz, CH2CH3), 7.02 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.11 – 7.19 
(m, 6H, Ph-H), 7.30 – 7.39 (m, 9H, Ph-H), 7.51 – 7.53 (m, 2H, Im-2-H + CH=C). 13C-NMR (75 
MHz, CDCl3): δ [ppm] = 14.14 (+, CH3), 14.40 (+, CH3), 60.61 (-, CH2CH3), 75.71 (Cquat, 
CPh3), 124.61 (+, Im-C-5), 125.47 (Cquat, CH=C), 128.22 (+, 6 Ph-C), 128.29 (+, 3 Ph-C-4), 
129.75 (+, 6-Ph-C), 130.47 (+, CH=CCH3), 138.03 (Cquat, Im-C-4), 139.51 (+, Im-C-2), 142.07 
(Cquat, 3 Ph-C-4), 169.00 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 423 (56) [M 
+ H]+, 243 (100) [CPh3+]. Anal. (C28H26N2O2) C, H, N. C28H26N2O2 (422.52). 
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Ethyl 3-(5-methyl-1-trityl-1H-imidazol-4-yl)propanoate (4.17) 
To a solution of 4.15 (6.7 g, 15.9 mmol) in EtOH (150 mL), Pd/C (10 %) (0.67 g, cat.) was 
added. After stirring for 3 h at room temperature (TLC control) under a hydrogen 
atmosphere, the catalyst was removed by filtration over Celite and the solvent was 
evaporated. The crude product was purified by flash chromatography (PE/EtOAc 60/40 v/v) 
yielding a colorless oil that solidified in vacuo (white solid, 6.4 g, 94 %); mp 94 – 95 °C. 1H-
NMR (300 MHz, CDCl3): δ [ppm] = 1.24 (t, 3H, 3J = 7.1 Hz, CH2CH3), 1.39 (s, 3H, Im-5-CH3), 
2.68 (t, 2H, 3J = 7.4 Hz, CH2), 2.79 (t, 2H, 3J = 7.4 Hz, CH2), 4.11 (q, 2H, 3J = 7.1 Hz, 
CH2CH3), 7.08 – 7.17 (m, 6H, Ph-H), 7.22 (s, 1H, Im-2-H), 7.28 – 7.37 (m, 9H, Ph-H). 13C-
NMR (75 MHz, CDCl3): δ [ppm] = 11.63 (+, Im-5-CH3), 14.31 (+, CH2CH3), 22.73 (-, Im-4-
CH2), 34.25 (-, Im-4-CH2-CH2), 60.22 (-, CH2CH3), 74.78 (Cquat, CPh3), 125.22 (Cquat, Im-C), 
127.81 (+, 3 Ph-C-4), 127.95 (+, 6 Ph-C), 130.11 (+, 6 Ph-C), 137.42 (+, Im-C-2), 138.54 
(Cquat, Im-C), 142.04 (Cquat, 3 Ph-C-1), 173.45 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 425 (100) [M + H]+. Anal. (C28H28N2O2) C, H, N. C28H28N2O2 (424.53). 
 
Ethyl 2-methyl-3-(1-trityl-1H-imidazol-4-yl)propanoate (4.18) 
To a solution of 4.16 (7.5 g, 17.8 mmol) in a mixture of EtOH (200 mL) and THF (50 mL), 
Pd/C (10 %) (0.75 g, cat.) was added. After stirring for 3 h at room temperature (TLC control) 
under a hydrogen atmosphere, the catalyst was removed by filtration over Celite and the 
solvent was evaporated. The crude product was purified by flash chromatography (PE/EtOAc 
60/40 v/v) yielding a white solid. (7.0 g, 93 %); mp 138 °C. 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 1.15 (d, 3H, 3J = 6.9 Hz, Im-4-CH2-CH-CH3), 1.16 (t, 3H, 3J = 7.1 Hz, CH2CH3), 2.61 
(dd, 1H, 2J = 13.8 Hz, 3J = 6.5 Hz, Im-4-CH2), 2.76 – 2.89 (m, 1H, Im-4-CH2-CH), 2.93 (dd, 
1H, 2J = 13.8 Hz, 3J = 7.2 Hz, Im-4-CH2), 3.97 – 4.10 (m, 2H, CH2CH3), 6.53 (d, 1H, 4J = 1.4 
Hz, Im-5-H), 7.08 – 7.17 (m, 6H, Ph-H), 7.28 – 7.37 (m, 10H, Ph-H + Im-2-H). 13C-NMR (75 
MHz, CDCl3): δ [ppm] = 14.27 (+, CH2CH3), 16.98 (+, Im-4-CH2-CH-CH3), 32.44 (-, Im-4-CH2-
CH), 39.95 (+, Im-4-CH2-CH), 60.16 (-, CH2CH3), 75.12 (Cquat, CPh3), 118.86 (+, Im-C-5), 
128.01 (+, 9 Ph-C), 129.80 (+, 6 Ph-C), 138.36 (+, Im-C-2), 139.12 (Cquat, Im-C-4), 142.54 
(Cquat, 3 Ph-C-4), 176.37 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 425 (55) [M 
+ H]+, 243 (100) [CPh3+]. Anal. (C28H26N2O2) C, H, N. C28H28N2O2 (424.53). 
 
3-(5-Methyl-1-trityl-1H-imidazol-4-yl)propan-1-ol (4.19)41 
To a solution of 4.17 (5.2 g, 12.2 mmol) in a mixture of THFabs (100 mL) and anhydrous Et2O 
(30 mL), LiAlH4 (0.93 g, 24.4 mmol) was added in portions at 0 °C. After stirring for 15 min, 
the mixture was allowed to warm to room temperature and refluxed for 2 h. The mixture was 
cooled externally with ice and 1.0 mL H2O, 1.0 mL NaOH 15 % and 4.0 mL H2O were 
consecutively added. Insoluble material was removed by filtration and washed with THF (2 x 
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30 mL). After removing the solvent in vacuo, the crude product was subjected to flash 
chromatography (CHCl3/MeOH 95:5 v/v) and recrystallized from MeCN yielding a white solid 
(3.0 g, 64 %); mp 157 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.38 (s, 3H, Im-5-CH3), 1.81 
– 1.92 (m, 2H, Im-4-CH2-CH2), 2.65 (t, 2H, 3J = 6.5 Hz, Im-4-CH2), 3.71 (t, 2H, 3J = 5.6 Hz, 
Im-4-(CH2)2-CH2), 4.97 (brs, 1H, OH), 7.07 – 7.17 (m, 6H, Ph-H), 7.28 (s, 1H, Im-2-H), 7.29 – 
7.36 (m, 9H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 11.64 (+, Im-5-CH3), 24.51 (-, Im-
4-CH2), 31.68 (-, Im-4-CH2-CH2), 62.55 (-, Im-4-(CH2)2-CH2), 75.19 (Cquat, CPh3), 125.25 
(Cquat, Im-C), 128.02 (+, 3 Ph-C-4), 128.11 (+, 6 Ph-C), 130.04 (+, 6 Ph-C), 136.55 (+, Im-C-
2), 138.78 (Cquat, Im-C), 141.62 (Cquat, 3 Ph-C-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
383 (100) [M + H]+. Anal. (C26H26N2O) C, H, N. C26H26N2O (382.50). 
 
2-Methyl-3-(1-trityl-1H-imidazol-4-yl)propan-1-ol (4.20) 
To a solution of 4.18 (6.5 g, 15.3 mmol) in a mixture of THFabs (80 mL) and anhydrous Et2O 
(40 mL), LiAlH4 (1.16 g, 30.6 mmol) was added in portions at 0 °C. After stirring for 15 min, 
the mixture was allowed to warm to room temperature and refluxed for 2 h. The mixture was 
cooled externally with ice and 1.2 mL H2O, 1.2 mL NaOH 15 % and 4.8 mL H2O were 
consecutively added. Insoluble material was removed by filtration and washed with THF (2 x 
30 mL). After removing the solvent in vacuo, the crude product was subjected to flash 
chromatography (CHCl3/MeOH 95:5 v/v) yielding a white solid (3.5 g, 60 %); mp 132 – 133 
°C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.87 (d, 3H, 3J = 6.9 Hz, CH3), 1.93 – 2.07 (m, 1H, 
Im-4-CH2-CH), 2.52 (dd, 1H, 2J = 14.6 Hz, 3J = 7.0 Hz, Im-4-CH2), 2.64 (dd, 1H, 2J = 14.6 Hz, 
3J = 5.0 Hz, Im-4-CH2), 3.44 (dd, 1H, 2J = 11.2 Hz, 3J = 7.1 Hz, Im-4-CH2-CH-CH2), 3.59 (dd, 
1H, 2J = 11.2 Hz, 3J = 4.4 Hz, Im-4-CH2-CH-CH2), 4.56 (brs, 1H, OH), 6.54 (d, 1H, 4J = 1.3 
Hz, Im-5-H), 7.08 – 7.19 (m, 6H, Ph-H), 7.28 – 7.41 (m, 10H, Ph-H + Im-2-H). 13C-NMR (75 
MHz, CDCl3): δ [ppm] = 17.15 (+, CH3), 33.04 (-, Im-4-CH2), 35.72 (+, Im-4-CH2-CH), 67.98 (-
, Im-4-CH2-CH-CH2), 75.21 (Cquat, CPh3), 118.90 (+, Im-C-5), 128.06 (+, 9 Ph-C), 129.79 (+, 
6 Ph-C), 138.19 (+, Im-C-2), 139.53 (Cquat, Im-C-4), 142.46 (Cquat, 3 Ph-C-4). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 383 (75) [M + H]+, 243 (100) [CPh3+]. Anal. (C26H26N2O) C, 
H, N. C26H26N2O (382.50). 
 
4.4.1.4 Preparation of 4-(1-trityl-1H-imidazol-4-yl)butan-1-amine 4.23 
4-(3-Chloropropyl)-1-trityl-1H-imidazole (4.21) 
To a solution of 3-(1-trityl-1H-imidazol-4-yl)propan-1-ol7, 42 (20.0 g, 54.3 mmol) in THFabs (300 
mL), thionylchloride (7.9 mL, 12.9 g, 108.6 mmol) was added dropwise at 0 °C. After stirring 
for 1 h at 0 °C and 2 h at ambient temperature, the solvent was concentrated in vacuo. The 
product was crystallized by addition of Et2O (100 mL) yielding a white solid. (22.3 g, 97 %). 
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To obtain the free base a 1 M solution of NaOH was added to the hydrochloride and 
extracted with DCM. The organic layer was dried over Na2SO4 followed by evaporation of the 
solvent; mp (4.21 · HCl) 143 °C (ref.42: 147°C). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.05 – 
2.16 (m, 2H, Im-4-CH2-CH2), 2.69 (t, 2H, 3J = 7.3 Hz, Im-4-CH2), 3.54 (t, 2H, 3J = 6.5 Hz, Im-
4-(CH2)2-CH2), 6.57 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.09 – 7.18 (m, 6H, Ph-H), 7.28 – 7.35 (m, 
9H, Ph-H), 7.36 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 25.55 (-, 
Im-4-CH2), 32.11 (-, Im-4-CH2-CH2), 44.60 (-, Im-4-(CH2)2-CH2), 75.17 (Cquat, CPh3), 118.35 
(+, Im-C-5), 128.02 (+, 3 Ph-C-4), 128.04 (+, 6 Ph-C), 129.78 (+, 6 Ph-C), 138.60 (+, Im-C-2), 
140.07 (Cquat, Im-C-4), 142.57 (Cquat, 3 Ph-C-1). ES-MS (MeOH + NH4OAc) m/z (%): 387 (74) 
[M + H]+, 243 (100) [CPh3+]. Anal. (C25H23ClN2 · HCl) C, H, N. C25H23ClN2 (386.92). 
 
4-(1-Trityl-1H-imidazol-4-yl)butanenitrile (4.22) 
To a mixture of KCN (3.36 g, 51.6 mmol) and KI (0.2 g, cat.) in anhydrous DMSO (200 mL) at 
80 °C, a solution of 4.21 (10.0 g, 25.8 mmol) in anhydrous DMSO (50 mL) was added 
dropwise. When the addition was complete, the mixture was stirred for 24 h at 80 °C. After 
cooling to room temperature, the mixture was poured in water/NH3 (800 mL, pH = 8 – 9) and 
extracted with DCM (3 x 250 mL). The organic phase was washed with water (3 x 250 mL), 
dried over Na2SO4 and evaporated. The crude product was purified by flash chromatography 
(DCM/MeOH/NH3 (aq.) 32 % 95.5/2.5/2 v/v/v) yielding a brownish solid (6.5 g, 67 %); mp 100 
– 102 °C (ref.43: yellow oil). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.97 – 2.09 (m, 2H, Im-4-
CH2-CH2), 2.35 (t, 2H, 3J = 7.1 Hz, Im-4-CH2), 2.71 (t, 2H, 3J = 7.2 Hz, Im-4-(CH2)2-CH2), 
6.62 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.08 – 7.18 (m, 6H, Ph-H), 7.29 – 7.39 (m, 9H, Ph-H), 7.47 
(d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 16.45 (-, Im-4-(CH2)2-
CH2), 24.97 (-, Im-4-CH2-CH2), 26.59 (-, Im-4-CH2), 75.71 (Cquat, CPh3), 118.85 (+, Im-C-5), 
119.64 (Cquat, C≡N), 128.21 (+, 3 Ph-C-4), 128.27 (+, 6 Ph-C), 129.70 (+, 6 Ph-C), 138.34 (+, 
Im-C-2), 138.43 (Cquat, Im-C-4), 142.06 (Cquat, 3 Ph-C-1). IR (cm-1) = 3059, 2936, 2245 (C≡N), 
1735, 1492, 1445. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 378 (78) [M + H]+, 243 (100) 
[CPh3+]. Anal. (C26H23N3) C, H, N. C26H23N3 (377.48). 
 
4-(1-Trityl-1H-imidazol-4-yl)butan-1-amine (4.23)44 
To a solution of 4.22 (6.0 g, 15.9 mmol) in a mixture of THFabs (75 mL) and anhydrous Et2O 
(75 mL), LiAlH4 (1.21 g, 31.8 mmol) was added in portions at 0 °C. After stirring for 15 min, 
the mixture was allowed to warm to room temperature and refluxed for 3 h. The mixture was 
cooled externally with ice and 1.2 mL H2O, 1.2 mL NaOH 15 % and 4.8 mL H2O were 
consecutively added. Insoluble material was removed by filtration and washed with THF (2 x 
30 mL). The organic layer was washed with a saturated solution of NaHCO3, water and brine 
and dried over Na2SO4. After removing the solvent in vacuo, a pale yellow oil was obtained 
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that was used without further purification (5.2 g, 86 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 
1.40 – 1.76 (m, 2H, Im-4-CH2-CH2-CH2), 2.54 (t, 2H, 3J = 7.5 Hz, Im-4-CH2), 2.68 (t, 2H, 3J = 
7.0 Hz, Im-4-(CH2)2-CH2), 6.52 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.09 – 7.18 (m, 6H, Ph-H), 7.25 
– 7.37 (m, 10H, Ph-H + Im-2-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 26.66 (-, CH2), 28.36 
(-, CH2), 33.63 (-,CH2), 42.09 (-, Im-4-(CH2)2-CH2), 75.08 (Cquat, CPh3), 117.72 (+, Im-C-5), 
127.95 (+, 3 Ph-C-4), 127.99 (+, 6 Ph-C), 129.82 (+, 6 Ph-C), 138.31 (+, Im-C-2), 141.88 
(Cquat, Im-C-4), 142.67 (Cquat, 3 Ph-C-1). ES-MS (MeOH + NH4OAc) m/z (%): 382 (100) [M + 
H]+. C26H27N3 (381.51). 
 
4.4.1.5 Preparation of N-methyl-3-(1-trityl-1H-imidazol-4-yl)propan-1-amine 4.25 
N-Methyl-3-(1-trityl-1H-imidazol-4-yl)propanamide (4.24) 
To a solution of methyl 3-(1-trityl-1H-imidazol-4-yl)propanoate7, 42 (8.0 g, 20.2 mmol) in 
MeOH (250 mL), a 8 M solution of methylamine in EtOH (126 mL, 1.01 mol) was added and 
stirred overnight. After removing the solvent in vacuo, the crude product was purified by flash 
chromatography (CHCl3/MeOH 95/5 v/v) and recrystallized from MeCN/EtOAc yielding a 
white solid (6.5 g, 81 %); mp 181 – 182 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.54 (t, 2H, 
3J = 7.0 Hz, Im-4-CH2-CH2), 2.74 (d, 3H, 3J = 4.8 Hz, CH3), 2.84 (t, 2H, 3J = 7.0 Hz, Im-4-
CH2), 6.51 (brs, 1H, N-H), 6.58 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.07 – 7.16 (m, 6H, Ph-H), 7.27 
– 7.39 (m, 10H, Ph-H + Im-2-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 24.39 (-, Im-4-CH2), 
26.39 (-, CH3), 36.58 (-, Im-4-CH2-CH2), 75.23 (Cquat, CPh3), 118.43 (+, Im-C-5), 128.07 (+, 9 
Ph-C), 129.77 (+, 6 Ph-C), 138.33 (+, Im-C-2), 140.24 (Cquat, Im-4-C), 142.43 (Cquat, Ph-C), 
173.59 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 396 (100) [M + H]+. Anal. 
(C26H25N3O) C, H, N. C26H25N3O (395.50). 
 
N-Methyl-3-(1-trityl-1H-imidazol-4-yl)propan-1-amine (4.25)45 
To a solution of 4.24 (6.0 g, 15.2 mmol) in THFabs (100 mL) and anhydrous Et2O (75 mL), 
LiAlH4 (1.15 g, 30.3 mmol) was added in portions at 0 °C. After stirring for 15 min, the mixture 
was allowed to warm to room temperature and refluxed for 3 h. The mixture was cooled 
externally with ice and 1.2 mL H2O, 1.2 mL NaOH 15 % and 4.8 mL H2O were consecutively 
added. Insoluble material was removed by filtration and washed with THF (2 x 30 mL). The 
organic layer was washed with a saturated solution of NaHCO3, water and brine and dried 
over Na2SO4. After removing the solvent in vacuo, a light yellow oil was obtained that was 
used without further purification (5.1 g, 88 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.74 – 
1.90 (m, 2H, Im-4-CH2-CH2), 2.40 (s, 3H, CH3), 2.53 – 2.62 (m, 4H, Im-4-CH2-CH2-CH2), 6.52 
(d, 1H, 4J = 1.1 Hz, Im-5-H), 7.08 – 7.37 (m, 16H, Ph-H + Im-2-H). 13C-NMR (75 MHz, 
CDCl3): δ [ppm] = 26.24, 29.51 (-, Im-4-CH2-CH2), 36.53 (+, CH3), 51.67 (-, Im-4-(CH2)2-CH2), 
75.08 (Cquat, CPh3), 117.88 (+, Im-C-5), 127.97 (+, 3 Ph-C), 128.01 (+, 6 Ph-C), 129.82 (+, 6 
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Ph-C), 138.30 (+, Im-C-2), 141.51 (Cquat, Im-C-4), 142.61 (Cquat, 3 Ph-C-1). ES-MS 
(DCM/MeOH + TFA) m/z (%): 382 (100) [M + H]+. C26H27N3 (381.51). 
 
4.4.1.6 Preparation of the guanidinylation reagents 4.26-4.29 
N1-(tert-Butoxycarbonyl)guanidine (4.26)15 
To a solution of guanidine · HCl (7.5 g, 78.9 mmol) in 4 M NaOH (40 mL, 160 mmol), a 
solution of di-tert-butyl dicarbonate (13.71 g, 62.8 mmol) in 1,4-dioxane (80 mL) was added 
dropwise at 0 °C. After the addition was complete, the mixture was stirred overnight at room 
temperature. The solvent was removed under reduced pressure and the crude product was 
suspended in H2O (20 mL), stirred for 15 min and filtered off. This procedure was repeated 
with Et2O (20 mL) yielding a white solid. (6.6 g, 66 %); mp > 280 °C. 1H-NMR (300 MHz, 
DMSO-d6): δ [ppm] = 1.34 (s, 9H, CH3), 6.83 (brs, 4H, N-H). 13C-NMR (75 MHz, DMSO-d6): δ 
[ppm] = 28.17 (+, CH3), 75.41 (Cquat, C(CH3)3), 162.29, 163.19 (Cquat, C=O + C=N). CI-MS 
(NH3) m/z (%): 160 (100) [M + H]+. Anal. (C6H13N3O2) C, H, N. C6H13N3O2 (159.19). 
 
N1-(Benzyloxycarbonyl)-N2-(tert-butoxycarbonyl)guanidine (4.27)18 
To a solution of 4.26 (4.5 g, 28.3 mmol) in anhydrous DMF (70 mL), benzyl succinimidyl 
carbonate (7.1 g, 28.3 mmol) was added in portions. After stirring overnight, crushed ice (20 
g) was added and sonicated for 10 min. The precipitate was filtered off, washed with MeOH 
(10 mL) and recrystallized from MeOH yielding a white solid (7.0 g, 84 %); mp 124 °C. 1H-
NMR (300 MHz, DMSO-d6): δ [ppm] = 1.43 (s, 9H, CH3), 5.06 (s, 2H, CH2), 7.27 – 7.42 (m, 
5H, Ph-H), 8.52 (brs, 1H, N-H), 8.71 (brs, 1H, N-H), 10.61 (brs, 1H, N-H). 13C-NMR (75 MHz, 
DMSO-d6): δ [ppm] = 27.65 (+, CH3), 65.73 (-, CH2), 80.95 (Cquat, C(CH3)3), 127.53 (+, 2 Ph-
C), 127.67 (+, Ph-C-4), 128.28 (+, 2 Ph-C), 136.87 (Cquat, Ph-C-1), 155.37, 158.82, 161.26 
(Cquat, 2 C=O + C=N). CI-MS (NH3) m/z (%): 294 (100) [M + H]+. Anal. (C14H19N3O4) C, H, N. 
C14H19N3O4 (293.32). 
 
N1,N2-Bis(benzyloxycarbonyl)guanidine (4.28)  
To a solution of guanidine · HCl (8.4 g, 87.9 mmol) and NaOH (17.6 g, 439.5 mmol) in H2O 
(90 mL), DCM (175 mL) was added and benzyl chloroformate (37.6 mL, 45.0 g, 263.7 mmol) 
was added dropwise at 0 °C. After stirring for 20 h at 0 °C, DCM (200 mL) was added to the 
mixture and the layers were separated. The aqueous layer was extracted with DCM (200 mL) 
and the combined organic layers were washed with H2O and dried over MgSO4. After 
removing the solvent in vacuo, the crude product was recrystallized from MeOH giving 
colorless crystals. (21.3 g, 74 %); mp 145 – 146 °C. (ref.16: 149 – 150°C). 1H-NMR (300 MHz, 
DMSO-d6): δ [ppm] = 5.11 (s, 4H, CH2), 7.27 – 7.45 (m, 10H, Ph-H), 8.69 (brs, 2H, N-H), 
10.89 (brs, 1H, N-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 66.15 (-, 2 CH2), 127.66 (+, 4 
Structure-activity relationships of NG-acylated imidazolylalkylguanidines 137
Ph-C), 127.86 (+, 2 Ph-C-4), 128.32 (+, 4 Ph-C), 136.32 (Cquat, 2 Ph-C-1), 158.78 (Cquat, 
C=O). ES-MS (MeCN/H2O + TFA) m/z (%): 328 (100) [M + H]+. Anal. (C17H17N3O4) C, H, N. 
C17H17N3O4 (327.33). 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-trifluoromethanesulfonylguanidine (4.29)16 
To a solution of 4.28 (13.5 g, 41.2 mmol) in anhydrous chlorobenzene (350 mL), NaH (60 % 
dispersion in mineral oil) (3.30 g, 82.4 mmol) was added in portions at 0 °C (argon 
atmosphere). After stirring for 1 h at 0 °C, the mixture was cooled to –45 °C and 
trifluoromethanesulfonic anhydride (6.9 mL, 11.62 g, 41.2 mmol) was added. The mixture 
was allowed to warm to ambient temperature and stirred overnight. After evaporation of the 
solvent, EtOAc (300 mL) and a 2 M solution of KHSO4 (75 mL) were added to the residue. 
The organic layer was washed with H2O and brine, dried over MgSO4 and removed in vacuo. 
Purification was performed by flash chromatography (PE/EtOAc 80/20 v/v) yielding a 
colorless semisolid compound (16.2 g, 86 %). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 7.33 
– 7.46 (m, 10H, Ph-H), 11.56 (brs, 2H, N-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 67.78 
(-, 2 CH2), 128.22 (+, 4 Ph-C), 128.40 (+, 2 Ph-C), 128.42 (+, 4 Ph-C), 134.93 (Cquat, 2 Ph-C-
1), 151.37, 152.12 (Cquat, C=O, C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 460 (100) [M 
+ H]+. C18H16F3N3O6S (459.40). 
 
4.4.1.7 Preparation of the diurethane-protected 1-trityl-1H-imidazol-4-ylalkyl-
guanidines 4.30-4.33 
General procedure 
To a solution of the pertinent amine (1 eq) and 4.29 (0.9 eq) in DCM, NEt3 (1 eq) was added. 
After stirring overnight at room temperature, the organic layer was washed with saturated 
NaHCO3 solution, water and brine and dried over Na2SO4. The solvent was removed in 
vacuo and the crude product was purified by flash chromatography. 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-[2-(1-trityl-1H-imidazol-4-yl)ethyl]guanidine (4.30)7 
The title compound was prepared from 4.13 (6.8 g, 19.2 mmol), 4.29 (7.95 g, 17.3 mmol) and 
NEt3 (2.7 mL, 1.94 g, 19.2 mmol) in DCM (100 mL) according to the general procedure. 
Purification by flash chromatography (PE/EtOAc 60/40 v/v) yielded a pale yellow foam-like 
solid (5.6 g, 49 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.79 (t, 2H, 3J = 6.6 Hz, Im-4-CH2), 
3.69 – 3.79 (m, 2H, Im-4-CH2-CH2), 5.11 (s, 2H, Ph-CH2), 5.15 (s, 2H, Ph-CH2), 6.62 (d, 1H, 
4J = 1.2 Hz, Im-5-H), 7.09 – 7.18 (m, 6H, Ph-H), 7.23 – 7.43 (m, 20H, Ph-H + Im-2-H), 8.63 
(t, 1H, 3J = 5.0 Hz, N-H), 11.73 (brs, 1H, N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 27.76 (-, 
Im-4-CH2), 40.82 (-, Im-4-CH2-CH2), 67.15 (-, Ph-CH2), 68.01 (-, Ph-CH2), 75.26 (Cquat, CPh3), 
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118.80 (+, Im-C-5), 127.90 (+, 1 Ph-C), 128.04 (+, 3 Ph-C), 128.07 (+, 6 Ph-C), 128.20 (+, 2 
Ph-C), 128.42 (+, 4 Ph-C), 128.72 (+, 2 Ph-C), 128.78 (+, 1 Ph-C), 129.84 (+, 6 Ph-C), 
134.71 (Cquat, 1 Ph-C-1), 136.87 (Cquat, 1 Ph-C-1), 138.04 (Cquat, Im-C-4), 138.91 (+, Im-C-2), 
142.47 (Cquat, 3 Ph-C-1), 153.59 (Cquat, C=O), 155.91 (Cquat, C=O), 163.75 (Cquat, C=N). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 664 (100) [M + H]+. C41H37N5O4 (663.76). 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-[2-(5-methyl-1-trityl-1H-imidazol-4-yl)ethyl]guanidine 
(4.31) 
The title compound was prepared from 4.14 (4.0 g, 10.9 mmol), 4.29 (4.5 g, 9.8 mmol) and 
NEt3 (1.5 mL, 1.10 g, 10.9 mmol) in DCM (60 mL) according to the general procedure. 
Purification by flash chromatography (PE/EtOAc 60/40 v/v) yielded a pale yellow foam-like 
solid (5.6 g, 84 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.38 (s, 3H, CH3), 2.87 (t, 2H, 3J = 
6.2 Hz, Im-4-CH2), 3.77 – 3.87 (m, 2H, Im-4-CH2-CH2), 5.09 (s, 2H, Ph-CH2), 5.19 (s, 2H, Ph-
CH2), 7.05 – 7.17 (m, 6H, Ph-H), 7.24 – 7.43 (m, 20H, Ph-H + Im-2-H), 8.62 (t, 1H, 3J = 5.0 
Hz, N-H), 11.72 (brs, 1H, N-H). 13C-NMR (150 MHz, CDCl3): δ [ppm] = 11.50 (+, CH3), 25.41 
(-, Im-4-CH2), 40.66 (-, Im-4-CH2-CH2), 67.11 (-, Ph-CH2), 68.11 (-, Ph-CH2), 76.15 (Cquat, 
CPh3), 127.85 (+, 2 Ph-C), 128.01 (+, 4 Ph-C), 128.35 (+, 6 Ph-C), 128.46 (+, 3 Ph-C), 
128.71 (+, 3 Ph-C), 128.78 (+, 1 Ph-C), 129.83 (Cquat, Im-C), 129.94 (+, 6 Ph-C), 134.64 
(Cquat, 1 Ph-C-1), 136.24 (+, Im-C-2), 136.82 (Cquat, 1 Ph-C-1), 140.80 (Cquat, 3 Ph-C-1), 
141.47 (Cquat, Im-C), 153.53 (Cquat, C=O), 156.00 (Cquat, C=N), 163.69 (Cquat, C=O). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 678 (100) [M + H]+. C42H39N5O4 (677.79). 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-[4-(1-trityl-1H-imidazol-4-yl)butyl]guanidine (4.32) 
The title compound was prepared from 4.23 (4.5 g, 11.8 mmol), 4.29 (4.9 g, 10.6 mmol) and 
NEt3 (1.6 mL, 1.19 g, 11.8 mmol) in DCM (60 mL) according to the general procedure. 
Purification by flash chromatography (DCM/MeOH 99/1 v/v) yielded a pale yellow foam-like 
solid (3.8 g, 52 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.51 – 1.74 (m, 4H, Im-4-CH2-CH2-
CH2), 2.56 (t, 2H, 3J = 7.1 Hz, Im-4-CH2), 3.35 – 3.37 (m, 2H, Im-4-(CH2)3-CH2), 5.11 (s, 2H, 
Ph-CH2), 5.16 (s, 2H, Ph-CH2), 6.52 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.09 – 7.18 (m, 6H, Ph-H), 
7.27 – 7.43 (m, 20H, Ph-H + Im-2-H), 8.29 (t, 1H, 3J = 5.0 Hz, N-H), 11.74 (brs, 1H, N-H). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 26.58, 27.98, 28.55 (-, Im-4-CH2-CH2-CH2), 41.08 (-, 
Im-4-(CH2)3-CH2), 67.14 (-, Ph-CH2), 68.12 (-, Ph-CH2), 75.13 (Cquat, CPh3), 117.96 (+, Im-C-
5), 127.87 (+, 1 Ph-C), 127.98 (+, 3 Ph-C), 128.02 (+, 6 Ph-C), 128.13 (+, 2 Ph-C), 128.40 (+, 
2 Ph-C), 128.47 (+, 2 Ph-C), 128.72 (+, 2 Ph-C), 128.78 (+, 1 Ph-C), 129.81 (+, 6 Ph-C), 
134.71 (Cquat, 1 Ph-C-1), 136.90 (Cquat, 1 Ph-C-1), 138.39 (+, Im-C-2), 141.25 (Cquat, Im-C-4), 
142.61 (Cquat, 3 Ph-C-1), 153.88, 155.93, 163.76 (Cquat, 2 C=O + C=N). ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 692 (100) [M + H]+. C43H41N5O4 (691.82). 
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N1,N2-Bis(benzyloxycarbonyl)-N3-methyl-N3-[3-(1-trityl-1H-imidazol-4-yl)propyl]-
guanidine (4.33) 
The title compound was prepared from 4.25 (4.0 g, 10.5 mmol), 4.29 (4.4 g, 9.5 mmol) and 
NEt3 (1.5 mL, 1.06 g, 10.5 mmol) in DCM (60 mL) according to the general procedure. 
Purification by flash chromatography (DCM/MeOH 99/1 v/v) yielded a pale yellow foam-like 
solid (4.5 g, 62 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.77 – 1.98 (m, 2H, Im-4-CH2-
CH2), 2.50 (t, 2H, 3J = 6.5 Hz, Im-4-CH2), 2.99 (s, 3H, CH3), 3.57 (t, 2H, 3J = 6.8 Hz, Im-4-
(CH2)2-CH2), 5.08 (brs, 4H, PhCH2), 6.53 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.03 – 7.48 (m, 26H, 
Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 692 (100) [M + H]+. C43H41N5O4 
(691.82). 
 
4.4.1.8 Preparation of the diurethane-protected 3-(1-trityl-1H-imidazol-4-yl)-
propylguanidines 4.38 and 4.40 
General procedure 
To a solution of the pertinent alcohol 4.19 or 4.20 (1 eq), the diurethane-protected guanidine 
4.27 or 4.28 (1.75 eq) and PPh3 (1.5 eq) in THFabs, DIAD (1.5 eq) in THFabs was added 
dropwise at 0 °C. After the addition was complete, the solution was allowed to warm to room 
temperature and stirred overnight. The solvent was removed in vacuo and the crude product 
purified by flash chromatography. 
 
N1,N2-Bis(benzyloxycarbonyl)-N1-[3-(1-trityl-1H-imidazol-4-yl)-2-
methylpropyl]guanidine (4.38) 
The title compound was prepared from a solution of 4.20 (4.0 g, 10.5 mmol), 4.28 (6.02 g, 
18.4 mmol), PPh3 (4.14 g, 15.8 mmol) in THFabs (100 mL) and a solution of DIAD (3.1 mL, 
3.19 g, 15.8 mmol) in THFabs (25 mL) according to the general procedure. Purification by 
flash chromatography (PE/EtOAc 80/20 v/v) yielded a colorless foam-like solid. (6.1 g, 84 %). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.81 (d, 3H, 3J = 6.3 Hz, CH3), 2.27 – 2.42 (m, 2H, Im-
4-CH2), 2.50 – 2.65 (m, 1H, Im-4-CH2-CH), 3.92 – 4.04 (d, 2H, 3J = 6.3 Hz, Im-4-CH2-CH-
CH2), 5.10 (s, 2H, Ph-CH2), 5.18 (s, 2H, Ph-CH2), 6.50 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.06 – 
7.16 (m, 6H, Ph-H), 7.20 – 7.39 (m, 20H, Ph-H + Im-2-H), 9.26 (brs, 1H, N-H), 9.44 (brs, 1H, 
N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 17.34 (+, CH3), 33.04 (+, Im-4-CH2-CH), 33.40 (-, 
Im-4-CH2), 49.89 (-, Im-4-CH2-CH-CH2), 66.97 (-, Ph-CH2), 68.84 (-, Ph-CH2), 75.07 (Cquat, 
CPh3), 118.75 (+, Im-C-5), 127.69 (+, 1 Ph-C), 127.78 (+, 2 Ph-C), 127.99 (+, 3 Ph-C), 
128.01 (+, 6 Ph-C), 128.37 (+, 4 Ph-C), 128.66 (+, 1 Ph-C), 128.71 (+, 2 Ph-C), 129.82 (+, 6 
Ph-C), 134.80 (Cquat, Ph-C), 137.18 (Cquat, Ph-C), 138.31 (+, Im-C-2), 139.80 (Cquat, Im-C-4), 
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142.62 (Cquat, 3 Ph-C-1), 156.24 (Cquat, C=N), 161.20 (Cquat, C=O), 163.90 (Cquat, C=O). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 692 (100) [M + H]+. C43H41N5O4 (691.82). 
 
N1-(Benzyloxycarbonyl)-N2-(tert-butoxycarbonyl)-N1-[3-(5-methyl-1-trityl-1H-imidazol-4-
yl)propyl]guanidine and N1-(Benzyloxycarbonyl)-N2-(tert-butoxycarbonyl)-N3-[3-(5-
methyl-1-trityl-1H-imidazol-4-yl)propyl]guanidine (4.40) 
The title compound (mixture of isomers) was prepared from a solution of 4.19 (4.6 g, 12.0 
mmol), 4.27 (6.16 g, 21.0 mmol), PPh3 (4.72 g, 18.0 mmol) in THFabs (100 mL) and a solution 
of DIAD (3.6 mL, 3.64 g, 18.0 mmol) in THFabs (25 mL) according to the general procedure. 
Purification by flash chromatography (PE/EtOAc 80/20 v/v) yielded a colorless foam-like 
solid. (6.3 g, 80 %). 1H-NMR (300 MHz, CDCl3) isomers: δ [ppm] = 1.31 (s, 0.8H, Im-5-CH3), 
1.35 (s, 2.2H, Im-5-CH3), 1.45 (s, 2.4H, C(CH3)3), 1.50 (s, 6.6H, C(CH3)3), 1.86 – 2.00 (m, 
2H, Im-4-CH2-CH2), 2.42 – 2.53 (m, 2H, Im-4-CH2), 3.90 – 4.01 (m, 2H, Im-4-(CH2)2-CH2), 
5.11 (s, 1.5H, PhCH2), 5.20 (s, 0.5H, PhCH2), 7.06 – 7.39 (m, 21H, Ph-H + Im-2-H), 9.38 
(brs, 1H, N-H), 9.42 (brs, 1H, N-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 658 (100) [M + 
H]+. C39H41N5O4 (643.77). 
 
4.4.1.9 Preparation of the trityl-protected imidazolylalkylguanidines 4.34-4.37, 
4.39 and 4.41 
General procedure 
A mixture of the pertinent diurethane-protected guanidine and catalytical amounts of Pd/C 
(10 %) in MeOH was stirred under a hydrogen atmosphere at room temperature for 
approximately 3 h (TLC control). After the Cbz-groups were quantitatively cleaved, the 
catalyst was removed by filtration over Celite and the solvent was evaporated. 
 
N-(2-(1-Trityl-1H-imidazol-4-yl)ethyl)guanidine (4.34)7 
The title compound was prepared from 4.30 (5.5 g, 8.3 mmol) and Pd/C (10 %) (0.55 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a colorless foam-like solid 
(3.1 g, 94 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 2.77 (t, 2H, 3J = 7.1 Hz, Im-4-CH2), 
3.40 (t, 2H, 3J = 7.1 Hz, Im-4-CH2-CH2), 6.80 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.10 – 7.18 (m, 
6H, Ph-H), 7.34 – 7.40 (m, 9H, Ph-H), 7.43 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, 
CD3OD): δ [ppm] = 28.71 (-, Im-4-CH2), 42.34 (-, Im-4-CH2-CH2), 76.99 (Cquat, CPh3), 120.86 
(+, Im-C-5), 129.35 (+, 6 Ph-C), 129.45 (+, 3 Ph-C), 130.92 (+, 6 Ph-C), 138.51 (Cquat, Im-C-
4), 139.78 (+, Im-C-2), 143.69 (Cquat, 3 Ph-C-1), 158.86 (Cquat, C=N). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 396 (100) [M + H]+. HRMS (EI-MS) calcd. for C25H25N5 [M+•] 395.2110; 
found 395.2109. C25H25N5 (395.50). 
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N-[2-(5-Methyl-1-trityl-1H-imidazol-4-yl)ethyl]guanidine (4.35) 
The title compound was prepared from 4.31 (5.4 g, 8.0 mmol) and Pd/C (10 %) (0.54 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a colorless foam-like solid 
(3.1 g, 95 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.43 (s, 3H, CH3), 2.72 (t, 2H, 3J = 7.0 
Hz, Im-4-CH2), 3.42 (t, 2H, 3J = 7.0 Hz, Im-4-CH2-CH2), 7.10 – 7.19 (m, 6H, Ph-H), 7.25 (s, 
1H, Im-2-H), 7.34 – 7.43 (m, 9H, Ph-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 11.99 (+, 
CH3), 29.58 (-, Im-4-CH2), 42.22 (-, Im-4-CH2-CH2), 76.64 (Cquat, CPh3), 128.47 (Cquat, Im-C), 
129.37 (+, 9 Ph-C), 131.22 (+, 6 Ph-C), 137.01 (Cquat, Im-C), 138.60 (+, Im-C-2), 143.01 
(Cquat, 3 Ph-C-1), 158.65 (Cquat, C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 410 (100) [M 
+ H]+. HRMS (EI-MS) calcd. for C26H27N5 [M+•] 409.2267; found 409.2270. C26H27N5 (409.53). 
 
N-[4-(1-Trityl-1H-imidazol-4-yl)butyl]guanidine (4.36) 
The title compound was prepared from 4.32 (3.7 g, 5.3 mmol) and Pd/C (10 %) (0.37 g, cat.) 
in MeOH (100 mL) according to the general procedure yielding a colorless foam-like solid 
(2.2 g, 98 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.47 – 1.74 (m, 4H, Im-4-CH2-CH2-
CH2), 2.55 (t, 2H, 3J = 7.1 Hz, Im-4-CH2), 3.15 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)3-CH2), 6.66 (d, 
1H, 4J = 1.3 Hz, Im-5-H), 7.09 – 7.19 (m, 6H, Ph-H), 7.33 – 7.42 (m, 10H, Ph-H + Im-2-H). 
13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.54, 28.31, 29.43 (+, Im-4-CH2-CH2-CH2), 42.26 (-, 
Im-4-(CH2)3-CH2), 76.83 (Cquat, CPh3), 119.75 (+, Im-C-5), 129.30 (+, 6 Ph-C), 129.40 (+, 3 
Ph-C), 130.90 (+, 6 Ph-C), 139.38 (+, Im-C-2), 142.06 (Cquat, Im-C-4), 143.80 (Cquat, 3 Ph-C-
1), 158.88 (Cquat, C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 424 (97) [M + H]+, 243 
(100) [CPh3+]. HRMS (EI-MS) calcd. for C27H29N5 [M+•] 423.2423; found 423.2417. C27H29N5 
(423.55). 
 
N-Methyl-N-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (4.37) 
The title compound was prepared from 4.33 (4.4 g, 6.4 mmol) and Pd/C (10 %) (0.44 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a colorless foam-like solid 
(2.6 g, 96 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.82 – 1.97 (m, 2H, Im-4-CH2-CH2), 
2.54 (t, 2H, 3J = 7.3 Hz, Im-4-CH2), 2.98 (s, 3H, CH3), 3.38 (t, 2H, 3J = 7.5 Hz, Im-4-(CH2)2-
CH2), 6.71 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.07 – 7.19 (m, 6H, Ph-H), 7.27 – 7.43 (m, 10H, Ph-
H + Im-2-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 25.19 (-, Im-4-CH2-CH2), 27.81 (-, Im-4-
CH2), 36.28 (+, CH3), 50.99 (-, Im-4-CH2), 76.89 (Cquat, CPh3), 119.83 (+, Im-C-5), 129.35 (+, 
6 Ph-C), 129.42 (+, 3 Ph-C), 130.91 (+, 6 Ph-C), 138.48 (+, Im-C-2), 141.32 (Cquat, Im-C-4), 
143.76 (Cquat, 3 Ph-C-1), 158.68 (Cquat, C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 424 
(100) [M + H]+. HRMS (EI-MS) calcd. for C27H29N5 [M+•] 423.2423; found 423.2424. C27H29N5 
(423.55). 
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N-[2-Methyl-3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (4.39) 
The title compound was prepared from 4.38 (6.0 g, 8.7 mmol) and Pd/C (10 %) (0.60 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a colorless foam-like solid 
(3.5 g, 95 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 0.90 (d, 3H, 3J = 6.7 Hz, CH3), 1.96 – 
2.11 (m, 1H, CH), 2.39 (dd, 1H, 2J = 14.5 Hz, 3J = 7.0 Hz, Im-4-CH2), 2.58 (dd, 1H, 2J = 14.5 
Hz, 3J = 6.1 Hz, Im-4-CH2), 3.00 (dd, 1H, 2J = 13.5 Hz, 3J = 6.9 Hz, Im-4-CH2-CH-CH2), 3.14 
(dd, 1H, 2J = 13.5 Hz, 3J = 6.3 Hz, Im-4-CH2-CH-CH2), 6.69 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.10 
– 7.19 (m, 6H, Ph-H), 7.33 – 7.40 (m, 9H, Ph-H), 7.41 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR 
(75 MHz, CD3OD): δ [ppm] = 17.61 (+, CH3), 32.84 (-, Im-4-CH2), 34.73 (+, Im-4-CH2-CH), 
47.88 (-, Im-4-CH2-CH-CH2), 76.86 (Cquat, CPh3), 120.91 (+, Im-C-5), 129.33 (+, 6 Ph-C), 
129.42 (+, 3 Ph-C), 130.88 (+, 6 Ph-C), 139.47 (+, Im-C-2), 140.00 (Cquat, Im-C-4), 143.76 
(Cquat, 3 Ph-C-4), 159.20 (Cquat, C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 424 (100) [M 
+ H]+. HRMS (EI-MS) calcd. for C27H29N5 [M+•] 423.2423; found 423.2415. C27H29N5 (423.55). 
 
N1-(tert-Butoxycarbonyl)-N1-[3-(5-methyl-1-trityl-1H-imidazol-4-yl)propyl]guanidine and 
N1-(tert-Butoxycarbonyl)-N2-[3-(5-methyl-1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(4.41) 
The title compound (mixture of isomers) was prepared from 4.40 (6.2 g, 9.4 mmol) and Pd/C 
(10 %) (0.62 g, cat.) in MeOH (150 mL) according to the general procedure yielding a 
colorless foam-like solid (4.7 g, 98 %). 1H-NMR (300 MHz, CDCl3) isomers: δ [ppm] = 1.35 
(s, 0.8H, Im-5-CH3), 1.36 (s, 2.2H, Im-5-CH3), 1.47 (s, 2.4H, CH3), 1.48 (s, 6.6H, CH3), 1.81 – 
2.05 (m, 2H, Im-4-CH2-CH2), 2.38 (t, 0.5H, 3J = 6.8 Hz, Im-4-CH2), 2.49 (t, 1.5H, 3J = 7.0 Hz, 
Im-4-CH2), 3.34 (t, 0.5H, 3J = 6.7 Hz, Im-4-(CH2)2-CH2), 3.66 – 3.82 (m, 1.5H, Im-4-(CH2)2-
CH2), 7.09 – 7.41 (m, 16H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 510 
(100) [M + H]+. HRMS (EI-MS) calcd. for C31H35N5O2 [M+•] 523.2947; found 523.2960. 
C31H35N5O2 (509.64). 
 
4.4.1.10 Preparation of the trityl-protected NG-acylated imidazolylalkyl-
guanidines 4.42-4.52 and 4.57-4.62 
General procedure 
A solution of the pertinent carboxylic acid (1 eq) and CDI (1.2 eq) in THFabs (15 mL) was 
stirred for 1 h under argon atmosphere at room temperature. In a separate flask NaH (60 % 
dispersion in mineral oil) (2 eq) was added to a solution of the pertinent guanidine (1 eq) in 
THFabs (15 mL) under argon atmosphere, stirred for 45 min at 30 – 35 °C and allowed to cool 
to ambient temperature. Both mixtures were united and stirred for 5 h under argon 
atmosphere. EtOAc (50 mL) was added and the organic phase was washed with H2O (3 x 20 
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mL) and dried over Na2SO4. After evaporation of the solvent, the crude product was purified 
by flash chromatography. 
 
N1-(3-Phenylbutanoyl)-N2-[2-(1-trityl-1H-imidazol-4-yl)ethyl]guanidine (4.42) 
The title compound was prepared from 4.42a (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.34 (396 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (230 mg, 42 %). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.28 (d, 3H, 3J = 6.9 Hz, PhCH3CH), 2.56 (dd, 1H, 2J = 14.6 Hz, 3J = 
8.4 Hz, PhCH3CH-CH2), 2.64 – 2.87 (m, 3H, Im-4-CH2 + PhCH3CH-CH2), 3.28 – 3.39 (m, 1H, 
PhCH3CH), 3.56 (t, 2H, 3J = 6.1 Hz, Im-4-CH2-CH2), 6.62 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.06 – 
7.39 (m, 21H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 542 (100) [M + H]+. 
C35H35N5O (541.69). 
 
N1-[3-(Thiophen-2-yl)butanoyl]-N2-[2-(1-trityl-1H-imidazol-4-yl)ethyl]guanidine (4.43)  
The title compound was prepared from 4.42b7 (170 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.34 (396 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow oil (250 mg, 46 %). 1H-NMR (300 MHz, CDCl3): 
δ [ppm] = 1.39 (d, 3H, 3J = 6.9 Hz, ThioCH3CH), 2.49 (dd, 1H, 2J = 15.0 Hz, 3J = 8.5 Hz, 
ThioCH3CH-CH2), 2.67 (dd, 1H, 2J = 15.0 Hz, 3J = 6.3 Hz, ThioCH3CH-CH2), 2.82 (t, 2H, 3J = 
6.1 Hz, Im-4-CH2), 3.55 – 3.70 (m, 3H, Im-4-CH2-CH2 + ThioCH3CH), 6.63 (d, 1H, 4J = 1.2 
Hz, Im-5-H), 6.83 – 6.93 (m, 2H, Thio-3,4-H), 7.04 – 7.15 (m, 6H, Ph-H), 7.28 – 7.41 (m, 
11H, Ph-H + Thio-5-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 548 (100) [M + 
H]+. C33H33N5OS (547.71). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[2-(1-trityl-1H-imidazol-4-yl)ethyl]guanidine (4.44)7  
The title compound was prepared from 4.42c (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.34 (396 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless oil (360 mg, 60 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 2.75 (t, 2H, 3J = 5.8 Hz, Im-4-CH2), 3.02 (d, 2H, 3J = 7.8 Hz, Ph2CH-CH2), 3.53 (t, 
2H, 3J = 6.6 Hz, Im-4-CH2-CH2), 4.60 (t, 1H, 3J = 7.8 Hz, Ph2CH), 6.58 (d, 1H, 4J = 1.2 Hz, 
Im-5-H), 7.03 – 7.40 (m, 26H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 604 
(100) [M + H]+. C40H37N5O (603.75). 
 
 
Chapter 4 144 
N1-(3-Phenylbutanoyl)-N1-[4-(1-trityl-1H-Imidazol-4-yl)butyl]guanidine (4.45) 
The title compound was prepared from 4.42a (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.36 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (340 mg, 60 %). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.28 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.57 – 1.76 (m, 4H, Im-4-CH2-
CH2-CH2), 2.52 – 2.66 (m, 3H, Im-4-CH2 + PhCH3CH-CH2), 2.73 (dd, 1H, 2J = 15.0 Hz, 3J = 
6.8 Hz, PhCH3CH-CH2), 3.21 – 3.40 (m, 3H, Im-4-(CH2)3-CH2 + PhCH3CH), 6.55 (d, 1H, 4J = 
1.3 Hz, Im-5-H), 7.06 – 7.40 (m, 21H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 570 (100) [M + H]+. C37H39N5O (569.74). 
 
N1-[3-(Thiophen-2-yl)butanoyl]-N2-[4-(1-trityl-1H-imidazol-4-yl)butyl]guanidine (4.46) 
The title compound was prepared from 4.42b7 (170 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.36 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (280 mg, 49 %). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.36 (d, 3H, 3J = 6.9 Hz, ThioCH3CH), 1.63 – 1.72 (m, 4H, Im-4-CH2-
CH2-CH2), 2.50 (dd, 1H, 2J = 14.8 Hz, 3J = 8.6 Hz, ThioCH3CH-CH2), 2.57 (t, 2H, 3J = 6.5 Hz, 
Im-4-CH2), 2.70 (dd, 1H, 2J = 14.8 Hz, 3J = 6.1 Hz, ThioCH3CH-CH2), 3.23 (t, 2H, 3J = 7.6 Hz, 
Im-4-(CH2)3-CH2), 3.57 – 3.71 (m, 1H, ThioCH3CH), 6.55 (d, 1H, 4J = 1.3 Hz, Im-5-H), 6.84 
(ddd, 1H, 3J = 3.5 Hz, 4J = 1.2 Hz, 4J = 1.0 Hz, Thio-3-H), 6.89 (dd, 1H, 3J = 5.1 Hz, 3J = 3.5 
Hz, Thio-4-H), 7.08 (dd, 1H, 3J = 5.1 Hz, 4J = 1.2 Hz, Thio-5-H), 7.09 – 7.16 (m, 6H, Ph-H), 
7.29 – 7.37 (m, 10H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 576 (100) [M 
+ H]+. C35H37N5OS (575.77). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[4-(1-trityl-1H-imidazol-4-yl)butyl]guanidine (4.47) 
The title compound was prepared from 4.42c (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.36 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow foam-like solid (230 mg, 36 %). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.54 – 1.69 (m, 4H, Im-4-CH2-CH2-CH2), 2.54 (t, 2H, 3J = 6.2 Hz, Im-
4-CH2), 3.08 (d, 2H, 3J = 7.9 Hz, Ph2CHCH2), 3.20 (t, 2H, 3J = 7.9 Hz, Im-4-(CH2)3-CH2), 4.62 
(t, 1H, 3J = 7.9 Hz, Ph2CH), 6.54 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.05 – 7.39 (m, 26H, Ph-H + 
Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 632 (100) [M + H]+. C42H41N5O (631.81). 
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N1-[3-Phenyl-3-(thiazol-2-yl)propanoyl]-N2-[4-(1-trityl-1H-Imidazol-4-yl)butyl]guanidine 
(4.48) 
The title compound was prepared from 4.42d7 (233 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.36 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a brownish oil (220 mg, 34 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 1.58 – 1.67 (m, 4H, Im-4-CH2-CH2-CH2), 2.55 (t, 2H, 3J = 6.3 Hz, Im-4-CH2), 3.04 
(dd, 1H, 2J = 15.9 Hz, 3J = 7.0 Hz, PhThiazCH-CH2), 3.19 (t, 2H, 3J = 7.3 Hz, Im-4-(CH2)3-
CH2), 3.38 (dd, 1H, 2J = 15.9 Hz, 3J = 8.1 Hz, PhThiazCH-CH2), 4.96 – 5.04 (m, 1H, 
PhThiazCH), 6.53 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.07 – 7.41 (m, 22H, Ph-H + Thiaz-5-H + Im-
2-H), 7.66 (d, 1H, 3J = 3.3 Hz, Thiaz-4-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 639 
(100) [M + H]+. C39H38N6OS (638.82). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)-2-methylpropyl]guanidine (4.49) 
The title compound was prepared from 4.42a (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.39 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless oil (270 mg, 47 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 0.84 – 0.99 (m, 3H, Im-4-CH2-CH-CH3), 1.27 – 1.37 (m, 3H, PhCH3CH), 1.99 – 2.15 
(m, 1H, Im-4-CH2-CH), 2.27 – 2.91 (m, 4H, Im-4-CH2 + PhCH3CH-CH2), 3.09 – 3.26 (m, 1H, 
Im-4-CH2-CH-CH2), 3.29 – 3.43 (m, 1H, PhCH3CH), 3.42 – 3.57 (m, 1H, Im-4-CH2-CH-CH2), 
6.52 – 6.61 (m, 1H, Im-5-H), 7.06 – 7.41 (m, 21H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 570 (100) [M + H]+. C37H39N5O (569.74). 
 
N1-[3-(Thiophen-2-yl)butanoyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)-2-methylpropyl]-
guanidine (4.50) 
The title compound was prepared from 4.42b7 (170 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.39 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless oil (320 mg, 56 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 0.87 – 0.99 (m, 3H, Im-4-CH2-CH-CH3), 1.37 – 1.44 (m, 3H, ThioCH3CH), 2.01 – 
2.18 (m, 1H, Im-4-CH2-CH), 2.28 – 2.98 (m, 4H, Im-4-CH2 + ThioCH3CH-CH2), 3.10 – 3.28 
(m, 1H, Im-4-CH2-CH-CH2), 3.42 – 3.58 (m, 1H, Im-4-CH2-CH-CH2), 3.59 – 3.74 (m, 1H, 
ThioCH3CH), 6.52 (m, 1H, Im-5-H), 6.84 – 6.94 (m, 2H, Thio-3,4-H), 7.05 – 7.12 (m, 7H, Ph-
H + Thio-5-H), 7.30 – 7.40 (m, 10H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 576 (67) [M + H]+, 482 (100). C35H37N5OS (575.77). 
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N1-(3,3-Diphenylpropanoyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)-2-methylpropyl]guanidine 
(4.51) 
The title compound was prepared from 4.42c (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.39 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless oil (230 mg, 40 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 0.79 – 1.00 (m, 3H, CH3), 1.94 – 2.16 (m, 1H, Im-4-CH2-CH), 2.22 – 2.69 (m, 2H, Im-
4-CH2), 2.99 – 3.26 (m, 3H, Im-4-CH2-CH-CH2 + Ph2CH-CH2), 3.34 – 3.61 (m, 1H, Im-4-CH2-
CH-CH2), 4.53 – 4.70 (m, 1H, Ph2CH), 6.49 – 6.61 (m, 1H, Im-5-H), 7.05 – 7.41 (m, 26H, Ph-
H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 632 (100) [M + H]+. C42H41N5O 
(631.81).  
 
N1-[3-Phenyl-3-(thiazol-2-yl)propanoyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)-2-methylpropyl]-
guanidine (4.52) 
The title compound was prepared from 4.42d7 (233 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.39 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a brownish foam-like solid (230 mg, 36 %). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 0.84 – 1.02 (m, 3H, Im-4-CH2-CH-CH3), 1.95 – 2.17 (m, 1H, Im-4-
CH2-CH), 2.27 – 2.71 (m, 2H, Im-4-CH2), 2.99 – 3.13 (m, 1H, PhThiazCH-CH2), 3.13 – 3.26 
(m, 1H, Im-4-CH2-CH-CH2), 3.34 – 3.47 (m, 1H, PhThiazCH-CH2), 3.47 – 3.61 (m, 1H, Im-4-
CH2-CH-CH2), 4.98 – 5.07 (m, 1H, PhThiazCH), 6.52 – 6.60 (m, 1H, Im-5-H), 7.27 – 7.38 (m, 
22H, Ph-H, Im-2-H, Thiaz-5-H), 7.67 (d, 1H, 3J = 3.3 Hz, Thiaz-4-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 639 (75) [M + H]+, 482 (100). C39H38N6OS (638.82). 
 
N1-(3-Phenylbutanoyl)-N2-[2-(5-methyl-1-trityl-1H-imidazol-4-yl)ethyl]guanidine (4.57) 
The title compound was prepared from 4.42a (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.35 (410 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (390 mg, 70 %). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.30 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.33 (s, 3H, Im-5-CH3), 2.68 – 
2.81 (m, 3H, Im-4-CH2 + PhCH3CH-CH2), 2.87 (dd, 1H, 2J = 15.6 Hz, 3J = 7.6 Hz, PhCH3CH-
CH2), 3.32 – 3.45 (m, 1H, PhCH3CH), 3.69 (t, 2H, 3J = 5.7 Hz, Im-4-CH2-CH2), 7.03 – 7.39 
(m, 20H, Ph-H), 7.72 (s, 1H, Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 556 (100) [M 
+ H]+. C36H37N5O (555.71). 
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N1-[2-(5-Methyl-1-trityl-1H-imidazol-4-yl)ethyl]-N2-[3-(thiophen-2-yl)butanoyl]guanidine 
(4.58) 
The title compound was prepared from 4.42b7 (170 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.35 (410 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow oil (210 mg, 37 %). 1H-NMR (300 MHz, CDCl3): 
δ [ppm] = 1.35 (s, 3H, Im-5-CH3), 1.39 (d, 3H, 3J = 6.9 Hz, ThioCH3CH), 2.73 – 2.84 (m, 3H, 
ThioCH3CH-CH2 + Im-4-CH2), 2.92 (dd, 1H, 2J = 15.6 Hz, 3J = 7.4 Hz, ThioCH3CH-CH2), 3.52 
– 3.72 (m, 3H, Im-4-CH2-CH2 + ThioCH3CH), 6.82 – 6.94 (m, 2H, Thio-H), 7.04 – 7.18 (m, 
7H, Ph-H + Thio-H), 7.26 – 7.41 (m, 10H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 562 (100) [M + H]+. C34H35N5OS (561.74). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[2-(5-methyl-1-trityl-1H-imidazol-4-yl)ethyl]guanidine 
(4.59) 
The title compound was prepared from 4.42c (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.35 (410 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (400 mg, 65 %).1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.32 (s, 3H, Im-5-CH3), 2.73 (t, 2H, 3J = 5.4 Hz, Im-4-CH2), 3.25 (d, 
2H, 3J = 7.9 Hz, Ph2CH-CH2), 3.66 (t, 2H, 3J = 5.4 Hz, Im-4-CH2-CH2), 4.67 (t, 1H, 3J = 7.9 
Hz, Ph2CH), 7.05 – 7.41 (m, 26H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
618 (100) [M + H]+. C41H39N5O (617.78) 
 
N1-[2-(5-Methyl-1-trityl-1H-imidazol-4-yl)ethyl]-N2-[3-phenyl-3-(thiazol-2-yl)propanoyl]-
guanidine (4.60) 
The title compound was prepared from 4.42d7 (233 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.35 (410 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a brownish oil (290 mg, 46 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 1.31 (s, 3H, Im-5-CH3), 2.66 (t, 2H, 3J = 6.0 Hz, Im-4-CH2), 3.06 (dd, 1H, 2J = 16.0 
Hz, 3J = 7.0 Hz, PhThiazCH-CH2), 3.41 (dd, 1H, 2J = 16.0 Hz, 3J = 8.0 Hz, PhThiazCH-CH2), 
3.52 (t, 2H, 3J = 6.0 Hz, Im-4-CH2-CH2), 4.97 – 5.05 (m, 1H, PhThiazCH), 7.16 – 7.41 (m, 
22H, Ph-H + Im-2-H + Thiaz-5-H), 7.66 (d, 1H, 3J = 3.3 Hz, Thiaz-4-H). ES-MS (DCM/MeOH 
+ NH4OAc) m/z (%): 625 (100) [M + H]+. C38H36N6OS (624.80).  
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N1-Methyl-N2-(3-phenylbutanoyl)-N1-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (4.61) 
The title compound was prepared from 4.42a (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.37 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless oil (380 mg, 67 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 1.28 (d, 3H, 3J = 6.9 Hz, PhCH3CH), 1.84 – 2.01 (m, 2H, Im-4-CH2-CH2), 2.45 – 2.59 
(m, 3H, Im-4-CH2 + PhCH3CH-CH2), 2.66 (dd, 1H, 2J = 14.6 Hz, 3J = 6.4 Hz, PhCH3CH-CH2), 
3.03 (brs, 3H, NCH3), 3.30 – 3.49 (m, 3H, Im-4-(CH2)2-CH2 + PhCH3CH), 6.54 (d, 1H, 4J = 
1.2 Hz, Im-5-H), 7.07 – 7.39 (m, 21H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 570 (100) [M + H]+. C37H39N5O (569.74). 
 
N1-(3,3-Diphenylpropanoyl)-N2-methyl-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(4.62) 
The title compound was prepared from 4.42c (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 4.37 (424 mg, 1.0 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH/NH3 
(aq.) 32 % 95/3/2 v/v/v) yielded a colorless oil (410 mg, 65 %). 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 1.78 – 2.00 (m, 2H, Im-4-CH2-CH2), 2.49 (t, 2H, 3J = 6.3 Hz, Im-4-CH2), 2.97 (brs, 
3H, NCH3), 3.06 (d, 2H, 3J = 7.8 Hz, Ph2CHCH2), 3.33 – 3.47 (m, 2H, Im-4-(CH2)2-CH2), 4.69 
(t, 1H, 3J = 7.8 Hz, Ph2CH), 6.53 (d, 1H, 4J = 1.1 Hz, Im-5-H), 7.04 – 7.41 (m, 26H, Ph-H + 
Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 632 (100) [M + H]+. C42H41N5O (631.81). 
 
4.4.1.11 Preparation of the Boc/trityl-protected NG-acylated imidazolylpropyl-
guanidines 4.53-4.56 
General procedure 
To a solution of the pertinent carboxylic acid (1 eq) and of Boc-protected guanidine 4.41 (1 
eq) in DCM (20 mL), EDC · HCl (1.2 eq) and DMAP (1.1 eq) were added at 0 °C. After 
stirring for 4 h at 0 °C, the solution was allowed to warm to ambient temperature and stirred 
for additional 20 h. DCM (20 mL) was added and the organic phase was washed with water 
and brine and dried over Na2SO4. The solvent was evaporated and the crude product purified 
by flash chromatography. 
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N1-(tert-Butoxycarbonyl)-N1-[3-(5-methyl-1-trityl-1H-imidazol-4-yl)propyl]-N2-(3-phenyl-
butanoyl)guanidine and N1-(tert-Butoxycarbonyl)-N2-[3-(5-methyl-1-trityl-1H-imidazol-4-
yl)propyl]-N3-(3-phenylbutanoyl)guanidine (4.53) 
The title compound (mixture of isomers) was prepared from 4.42a (164 mg, 1.0 mmol), 4.41 
(524 mg, 1.0 mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH 
97.5/2.5 v/v) yielded a colorless oil (450 mg, 67 %). 1H-NMR (300 MHz, CDCl3) isomers: δ 
[ppm] = 1.22 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.37 (s, 3H, Im-5-CH3), 1.49 (s, 7H, C(CH3)3), 
1.50 (s, 2H, C(CH3)3), 1.86 – 1.99 (m, 2H, Im-4-CH2-CH2), 2.45 – 2.66 (m, 4H, Im-4-CH2 + 
PhCH3CH-CH2), 3.25 – 3.37 (m, 1H, PhCH3CH), 3.88 – 3.99 (m, 2H, Im-4-(CH2)2-CH2), 7.08 
– 7.36 (m, 21H, Ph-H + Im-2-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 670 (100) [M + 
H]+. C42H47N5O3 (669.85). 
 
N1-(tert-Butoxycarbonyl)-N1-[3-(5-methyl-1-trityl-1H-imidazol-4-yl)propyl]-N2-[3-
(thiophen-2-yl)butanoyl]guanidine and N1-(tert-Butoxycarbonyl)-N2-[3-(5-methyl-1-trityl-
1H-imidazol-4-yl)propyl]-N3-[3-(thiophen-2-yl)butanoyl]guanidine (4.54) 
The title compound (mixture of isomers) was prepared from 4.42b7 (170 mg, 1.0 mmol) (164 
mg, 1.0 mmol), 4.41 (524 mg, 1.0 mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 
mg, 1.1 mmol) according to the general procedure. Purification by flash chromatography 
(CHCl3/MeOH 97.5/2.5 v/v) yielded a colorless oil (490 mg, 72 %). 1H-NMR (300 MHz, 
CDCl3) isomers: δ [ppm] = 1.30 (d, 3H, 3J = 6.9 Hz, ThioCH3CH), 1.37 (s, 3H, Im-5-CH3), 
1.50 (s, 9H, C(CH3)3), 1.86 – 2.00 (m, 2H, Im-4-CH2-CH2), 2.44 – 2.72 (m, 4H, Im-4-CH2 + 
ThioCH3CH-CH2), 3.36 – 3.49 (m, 1H, ThioCH3CH), 3.89 – 4.00 (m, 2H, Im-4-(CH2)2-CH2), 
6.75 – 6.93 (m, 2H, Thio-3,4-H), 7.01 – 7.39 (m, 17H, Ph-H + Im-2-H + Thio-5-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 676 (100) [M + H]+. C40H45N5O3S (675.88). 
 
N1-(tert-Butoxycarbonyl)-N2-(3,3-diphenylpropanoyl)-N1-[3-(5-methyl-1-trityl-1H-imida-
zol-4-yl)propyl]guanidine and N1-(tert-Butoxycarbonyl)-N2-(3,3-diphenylpropanoyl)-N3-
[3-(5-methyl-1-trityl-1H-imidazol-4-yl)propyl]guanidine (4.55) 
The title compound (mixture of isomers) was prepared from 4.42c (226 mg, 1.0 mmol), 4.41 
(524 mg, 1.0 mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH 
97.5/2.5 v/v) yielded a colorless oil (390 mg, 53 %). 1H-NMR (300 MHz, CDCl3) isomers: δ 
[ppm] = 1.39 (s, 3H, Im-5-CH3), 1.48 (s, 6H, C(CH3)3), 1.48 (s, 3H, C(CH3)3), 1.87 – 2.01 (m, 
2H, Im-4-CH2-CH2), 2.43 – 2.57 (m, 2H, Im-4-CH2), 3.07 (d, 1.3H, 3J = 7.9 Hz, Ph2CH-CH2), 
3.12 (d, 0.7H, 3J = 8.1 Hz, Ph2CH-CH2), 3.86 – 3.97 (m, 2H, Im-4-(CH2)2-CH2), 4.56 (t, 1H, 3J 
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= 7.8 Hz, Ph2CH), 4.61 (t, 1H, 3J = 7.8 Hz, Ph2CH), 7.04 – 7.44 (m, 26H, Ph-H + Im-2-H). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 732 (100) [M + H]+. C47H49N5O3 (731.92). 
 
N1-(tert-Butoxycarbonyl)-N1-[3-(5-methyl-1-trityl-1H-imidazol-4-yl)propyl]-N2-[3-phenyl-
3-(thiazol-2-yl)propanoyl]guanidine and N1-(tert-Butoxycarbonyl)-N2-[3-(5-methyl-1-
trityl-1H-imidazol-4-yl)propyl]-N3-[3-phenyl-3-(thiazol-2-yl)propanoyl]guanidine (4.56) 
The title compound (mixture of isomers) was prepared from 4.42d7 (233 mg, 1.0 mmol), 4.41 
(524 mg, 1.0 mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH 
97.5/2.5 v/v) yielded a brownish oil (410 mg, 55 %). 1H-NMR (300 MHz, CDCl3) isomers: δ 
[ppm] = 1.38 (s, 3H, Im-5-CH3), 1.48 (s, 7.5H, C(CH3)3), 1.48 (s, 1.5H, C(CH3)3) 1.84 – 1.97 
(m, 2H, Im-4-CH2-CH2), 2.44 – 2.56 (m, 2H, Im-4-CH2), 3.05 – 3.16 (m, 1H, PhThiazCH-
CH2), 3.38 – 3.49 (m, 1H, PhThiazCH-CH2), 3.86 – 3.95 (m, 2H, Im-4-(CH2)2-CH2), 4.97 – 
5.05 (m, 1H, PhThiazCH), 7.09 – 7.37 (m, 22H, Ph-H + Im-2-H + Thiaz-5-H), 7.63 (d, 0.85H, 
3J = 3.3 Hz, Thiaz-4-H), 7.67 (d, 0.15H, 3J = 3.3 Hz, Thiaz-4-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 739 (100) [M + H]+. C44H46N6O3S (738.94). 
 
4.4.1.12 Preparation of the NG-acylated imidazolylpropylguanidines 4.63-4.83 
General procedure 
The pertinent Boc/trityl-protected NG-acylated imidazolylpropylguanidine was stirred for 5 h in 
a mixture of TFA (5.0 mL) and DCM (20 mL). After removing the solvent in vacuo, the crude 
product was purified by preparative HPLC. All compounds were dried by lyophilization and 
obtained as trifluoroacetates. 
 
N1-[2-(1H-Imidazol-4-yl)ethyl]-N2-(3-phenylbutanoyl)guanidine (4.63) 
The title compound was prepared from 4.42 (220 mg, 0.41 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 22.5/72.5) yielded a 
colorless semisolid compound (80 mg, 37 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.19 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 2.59 (dd, 1H, 2J = 14.8 Hz, 3J = 9.2 Hz, 
PhCH3CH-CH2), 2.69 (dd, 1H, 2J = 14.8 Hz, 3J = 6.3 Hz, PhCH3CH-CH2), 2.93 (t, 2H, 3J = 6.6 
Hz, Im-4-CH2), 3.03 – 3.21 (m, 1H, PhCH3CH), 3.47 (t, 2H, 3J = 6.6 Hz, Im-4-CH2-CH2), 7.10 
– 7.32 (m, 6H, Ph-H + Im-5-H), 8.50 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, D2O, 
trifluoroacetate): δ [ppm] = 21.18 (+, PhCH3CH), 22.80 (-, Im-4-CH2), 36.61 (+, PhCH3CH), 
39.85 (-, Im-4-CH2-CH2), 45.06 (-, PhCH3CH-CH2), 116.63 (+, Im-C-5), 126.88 (+, 2 Ph-C), 
126.99 (+, Ph-C-4), 128.89 (+, 2 Ph-C), 129.38 (Cquat, Im-C-4), 133.56 (+, Im-C-2), 144.84 
(Cquat, Ph-C-1), 152.97 (Cquat, C=N), 176.02 (Cquat, C=O). IR (cm-1) = 3144, 3034, 2847, 1662, 
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1630, 1177, 1131. HRMS (EI-MS) calcd. for C16H21N5O [M+•] 299.1746; found 299.1744. 
C16H21N5O · 2 TFA (527.42). 
 
N1-[2-(1H-Imidazol-4-yl)ethyl]-N2-[3-(thiophen-2-yl)butanoyl]guanidine (4.64) 
The title compound was prepared from 4.43 (240 mg, 0.44 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a 
colorless semisolid compound (62 mg, 27 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.26 (d, 3H, 3J = 7.0 Hz, ThioCH3CH), 2.60 (dd, 1H, 2J = 15.0 Hz, 3J = 9.0 Hz, 
ThioCH3CH-CH2), 2.72 (dd, 1H, 2J = 15.0 Hz, 3J = 6.2 Hz, ThioCH3CH-CH2), 2.95 (t, 2H, 3J = 
6.6 Hz, Im-4-CH2), 3.40 – 3.56 (m, 3H, Im-4-CH2-CH2 + ThioCH3CH), 6.81 (ddd, 1H, 3J = 3.5 
Hz, 4J = 1.2 Hz, 4J = 0.7 Hz, Thio-3-H), 6.88 (dd, 1H, 3J = 5.0 Hz, 3J = 3.5 Hz, Thio-4-H), 7.14 
– 7.20 (m, 2H, Thio-5-H + Im-5-H), 8.51 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, 
D2O, trifluoroacetate): δ [ppm] = 22.12 (+, ThioCHCH3), 22.82 (-, Im-4-CH2), 31.95 (+, 
ThioCH3CH), 39.92 (-, Im-4-CH2-CH2), 46.06 (-, ThioCH3CH-CH2), 116.69 (+, Im-C-5), 
123.67, 123.90 (+, Thio-C-3,4), 127.15 (+, Thio-C-5), 129.40 (Cquat, Im-C-4), 133.61 (+, Im-C-
2), 148.70 (Cquat, Thio-C-2), 153.02 (Cquat, C=N), 175.52 (Cquat, C=O). IR (cm-1) = 3139, 3023, 
2852, 1662, 1626, 1182, 1126. HRMS (EI-MS) calcd. for C14H19N5OS [M+•] 305.1310; found 
305.1312. C14H19N5OS · 2 TFA (533.44). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[2-(1H-imidazol-4-yl)ethyl]guanidine (4.65) 
The title compound was prepared from 4.44 (350 mg, 0.58 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 35/65) yielded a white 
solid (80 mg, 23 %); mp 69 – 72 °C. 1H-NMR (300 MHz, D2O, trifluoroacetate): δ [ppm] = 
2.90 (t, 2H, 3J = 6.6 Hz, Im-4-CH2), 3.16 (d, 2H, 3J = 8.2 Hz, Ph2CH-CH2), 3.45 (t, 2H, 3J = 
6.6 Hz, Im-4-CH2-CH2), 4.42 (t, 1H, 3J = 8.2 Hz, Ph2CH), 7.10 (d, 1H, 4J = 1.3 Hz, Im-5-H), 
7.13 – 7.31 (m, 10H, Ph-H), 8.47 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, D2O, 
trifluoroacetate): δ [ppm] = 22.78 (-, Im-4-CH2), 39.88 (-, Im-4-CH2-CH2), 42.25 (-, Ph2CH-
CH2), 46.52 (+, Ph2CH), 116.59 (+, Im-C-5), 127.16 (+, 2 Ph-C-4), 127.40 (+, 4 Ph-C), 129.04 
(+, 4 Ph-C), 129.35 (Cquat, Im-C-4), 133.53 (+, Im-C-2), 142.82 (Cquat, 2 Ph-C-1), 152.93 
(Cquat, C=N), 175.22 (Cquat, C=O). IR (cm-1) = 3141, 2989, 2900, 1667, 1594, 1190, 1131. 
HRMS (EI-MS) calcd. for C21H23N5O [M+•] 361.1903; found 310.1905. C21H23N5O · 2 TFA 
(589.49). 
 
N1-[4-(1H-Imidazol-4-yl)butyl]-N2-(3-phenylbutanoyl)guanidine (4.66) 
The title compound was prepared from 4.45 (330 mg, 0.58 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
colorless semisolid compound (160 mg, 50 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
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[ppm] = 1.22 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.47 – 1.65 (m, 4H, Im-4-CH2-CH2-CH2), 2.57 – 
2.67 (m, 3H, Im-4-CH2 + PhCH3CH-CH2), 2.73 (dd, 1H, 2J = 14.7 Hz, 3J = 6.3 Hz, PhCH3CH-
CH2), 3.11 – 3.26 (m, 3H, Im-4-(CH2)3-CH2 + PhCH3CH), 7.10 (d, 1H, 4J = 1.4 Hz, Im-5-H), 
7.13 – 7.32 (m, 5H, Ph-H), 8.25 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, D2O, 
trifluoroacetate): δ [ppm] = 21.19 (+, PhCH3CH), 23.33, 24.81, 26.46 (-, Im-4-CH2-CH2-CH2), 
36.71 (+, PhCH3CH), 40.94 (-, Im-4-(CH2)3-CH2), 45.17 (-, PhCH3CH-CH2), 115.27 (+, Im-C-
5), 126.93 (+, 2 Ph-C), 127.02 (+, Ph-C-4), 128.94 (+, 2 Ph-C), 132.78 (+, Im-C-2), 133.42 
(Cquat, Im-C-4), 144.92 (Cquat, Ph-C-1), 152.72 (Cquat, C=N), 176.06 (Cquat, C=O). IR (cm-1) = 
3140, 2969, 2868, 1662, 1627, 1178, 1130. HRMS (EI-MS) calcd. for C18H25N5O [M+•] 
327.2059; found 327.2059. C18H25N5O · 2 TFA (555.47). 
 
N1-[4-(1H-Imidazol-4-yl)butyl]-N2-[3-(thiophen-2-yl)butanoyl]guanidine (4.67) 
The title compound was prepared from 4.46 (270 mg, 0.47 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
colorless semisolid compound (150 mg, 57 %). Prep. HPLC (MeCN/0.1 % TFA (aq.): 
27.5/72.5). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ [ppm] = 1.27 (d, 3H, 3J = 7.0 Hz, 
ThioCH3CH), 1.46 – 1.64 (m, 4H, Im-4-CH2-CH2-CH2), 2.55 – 2.67 (m, 3H, Im-4-CH2 + 
ThioCH3CH-CH2), 2.72 (dd, 1H, 2J = 14.9 Hz, 3J = 6.2 Hz, ThioCH3CH-CH2), 3.18 (t, 2H, 3J = 
6.2 Hz, Im-4-(CH2)3-CH2), 3.42 – 3.56 (m, 1H, ThioCH3CH), 6.82 (ddd, 1H, 3J = 3.5 Hz, 4J = 
1.3 Hz, 4J = 0.6 Hz, Thio-3-H), 6.85 (dd, 1H, 3J = 5.0 Hz, 3J = 3.5 Hz, Thio-4-H), 7.10 (d, 1H, 
4J = 1.4 Hz, Im-5-H), 7.15 (dd, 1H, 3J = 5.0 Hz, 4J = 1.3 Hz, Thio-5-H), 8.43 (d, 1H, 4J = 1.4 
Hz, Im-2-H). 13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 22.13 (+, ThioCH3CH), 
23.30, 24.81, 26.43 (-, Im-4-CH2-CH2-CH2), 32.00 (+, ThioCH3CH), 40.94 (-, Im-4-(CH2)3-
CH2), 46.08 (-, ThioCH3CH-CH2), 115.24 (+, Im-C-5), 123.67, 123.88 (+, Thio-C-3,4), 127.13 
(+, Thio-C-5), 132.73 (+, Im-C-2), 133.38 (Cquat, Im-C-4), 148.73 (Cquat, Thio-C-2), 152.70 
(Cquat, C=N), 175.50 (Cquat, C=O). IR (cm-1) = 3133, 2989, 2900, 1662, 1627, 1178, 1129. 
HRMS (EI-MS) calcd. for C16H23N5OS [M+•] 333.1623; found 333.1618. C16H23N5OS · 2 TFA 
(561.50). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[4-(1H-imidazol-4-yl)butyl]guanidine (4.68) 
The title compound was prepared from 4.47 (220 mg, 0.35 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 35/65) yielded a white 
solid (96 mg, 44 %); mp 78 – 82 °C. 1H-NMR (300 MHz, D2O, trifluoroacetate): δ [ppm] = 
1.48 – 1.64 (m, 4H, Im-4-CH2-CH2-CH2), 2.64 (t, 2H, 3J = 6.8 Hz, Im-4-CH2), 3.15 – 3.26 (m, 
4H, Im-4-(CH2)3-CH2 + Ph2CHCH2), 4.50 (t, 1H, 3J = 6.8 Hz, Ph2CH), 7.10 (d, 1H, 4J = 1.4 Hz, 
Im-5-H), 7.15 – 7.34 (m, 10H, Ph-H), 8.47 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, 
D2O, trifluoroacetate): δ [ppm] = 23.34, 24.81, 26.44 (-, Im-4-CH2-CH2-CH2), 41.01 (-, Im-4-
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(CH2)3-CH2), 42.38 (-, Ph2CH-CH2), 46.66 (+, Ph2CH), 115.28 (+, Im-C-5), 127.22 (+, 2 Ph-C-
4), 127.57 (+, 4 Ph-C), 129.11 (+, 4 Ph-C), 132.79 (+, Im-C-2), 133.42 (Cquat, Im-C-4), 142.95 
(Cquat, Ph-C-1), 152.71 (Cquat, C=N), 175.30 (Cquat, C=O). IR (cm-1) = 3027, 2866, 1665, 1601, 
1181, 1128. HRMS (EI-MS) calcd. for C23H27N5O [M+•] 389.2216; found 389.2220. C23H27N5O 
· 2 TFA (617.54). 
 
N1-[4-(1H-Imidazol-4-yl)butyl]-N2-[3-phenyl-3-(thiazol-2-yl)propanoyl]guanidine (4.69) 
The title compound was prepared from 4.48 (210 mg, 0.33 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a pale 
yellow semisolid compound (170 mg, 70 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.41 – 1.62 (m, 4H, Im-4-CH2-CH2-CH2), 2.59 (t, 2H, 3J = 6.8 Hz, Im-4-CH2), 3.15 (t, 
2H, 3J = 6.3 Hz, Im-4-(CH2)3-CH2), 3.31 (dd, 1H, 2J = 16.6 Hz, 3J = 8.1 Hz, PhThiazCH-CH2), 
3.46 (dd, 1H, 2J = 16.6 Hz, 3J = 7.3 Hz, PhThiazCH-CH2), 5.04 (dd, 1H, 3J = 8.1 Hz, 3J = 7.3 
Hz, PhThiazCH), 7.04 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.21 – 7.35 (m, 5H, Ph-H), 7.65 (d, 1H, 3J 
= 3.7 Hz, Thiaz-5-H), 7.79 (d, 1H, 3J = 3.7 Hz, Thiaz-4-H), 8.41 (d, 1H, 4J = 1.4 Hz, Im-2-H). 
13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 23.26, 24.77, 26.37 (-, Im-4-CH2-CH2-
CH2), 41.00 (-, Im-4-(CH2)3-CH2), 41.50 (-, PhThiazCHCH2), 42.95 (+, PhThiazCH), 115.19 
(+, Im-C-5), 122.41 (+, Thiaz-C-5), 127.85 (+, 2 Ph-C), 127.85 (+, Ph-C-4), 128.73 (+, 2 Ph-
C), 132.69 (+, Im-C-2), 133.32 (Cquat, Im-C-4), 137.14 (+, Thiaz-C-4), 138.11 (Cquat, Ph-C-1), 
152.51 (Cquat, C=N), 172.92, 175.30 (Cquat, Thiaz-C-2 + C=O). IR (cm-1) = 3133, 2989, 2901, 
1663, 1627, 1131. HRMS (EI-MS) calcd. for C20H24N6OS [M+•] 396.1735; found 396.1732. 
C20H24N6OS · 3 TFA (738.58). 
 
N1-[3-(1H-Imidazol-4-yl)-2-methylpropyl]-N2-(3-phenylbutanoyl)guanidine (4.70) 
The title compound was prepared from 4.49 (250 mg, 0.44 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 30/70) yielded a 
colorless semisolid compound (106 mg, 43 %). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): 
δ [ppm] = 0.98 (d, 3H, 3J = 6.7 Hz, Im-4-CH2-CH-CH3), 1.32 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 
2.09 – 2.26 (m, 1H, Im-4-CH2-CH), 2.59 (dd, 1H, 2J = 15.0 Hz, 3J = 8.7 Hz, Im-4-CH2), 2.74 
(dd, 1H, 2J = 15.2 Hz, 3J = 7.4 Hz, PhCH3CH-CH2), 2.81 (dd, 1H, 2J = 15.2 Hz, 3J = 7.7 Hz, 
PhCH3CH-CH2), 2.86 (ddd, 1H, 2J = 15.0 Hz, 3J = 8.7 Hz, 4J = 1.7 Hz, Im-4-CH2), 3.14 – 3.39 
(m, 3H, Im-4-CH2-CH-CH2 + PhCH3CH), 7.11 – 7.32 (m, 5H, Ph-H), 7.37 (d, 1H, 4J = 1.3 Hz, 
Im-5-H), 8.79 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 17.23 (+, Im-4-CH2-CHCH3), 22.32 (+, PhCH3CH), 29.83 (-, Im-4-CH2), 33.76 (+, Im-
4-CH2-CH), 37.75 (+, PhCH3CH), 46.17 (-, PhCH3CH-CH2), 47.57 (-, Im-4-CH2-CH-CH2), 
117.97 (+, Im-C-5), 127.72 (+, Ph-C-4), 127.97 (+, 2 Ph-C), 129.68 (+, 2 Ph-C), 133.13 (Cquat, 
Im-C-4), 134.99 (+, Im-C-2), 146.42 (Cquat, Ph-C-1), 155.45 (Cquat, C=N), 176.23 (Cquat, C=O). 
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IR (cm-1) = 3139, 2972, 2901, 1663, 1627, 1174, 1136. HRMS (LSI-MS) calcd. for C18H26N5O 
[M + H]+ 328.2132; found 328.2137. C18H26N5O · 2 TFA (555.47). 
 
N1-[3-(1H-Imidazol-4-yl)-2-methylpropyl]-N2-[3-(thiophen-2-yl)butanoyl]guanidine (4.71) 
The title compound was prepared from 4.50 (250 mg, 0.43 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
colorless semisolid compound (90 mg, 37 %). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 0.99 (d, 3H, 3J = 6.7 Hz, Im-4-CH2-CH-CH3), 1.40 (d, 3H, 3J = 7.0 Hz, ThioCH3CH), 
2.09 – 2.30 (m, 1H, Im-4-CH2-CH), 2.61 (dd, 1H, 2J = 15.0 Hz, 3J = 8.7 Hz, Im-4-CH2), 2.77 
(dd, 1H, 2J = 15.4 Hz, 3J = 7.2 Hz, ThioCH3CH-CH2), 2.84 (dd, 1H, 2J = 15.4 Hz, 3J = 7.5 Hz, 
ThioCH3CH-CH2), 2.88 (dd, 1H, 2J = 15.0 Hz, 3J = 5.3 Hz, Im-4-CH2), 3.17 – 3.31 (m, 2H, Im-
4-CH2-CH-CH2), 3.57 – 3.71 (m, 1H, ThioCH3CH), 6.87 – 6.93 (m, 2H, Thio-3,4-H), 7.19 (dd, 
1H, 3J = 4.1 Hz, 4J = 2.2 Hz, Thio-5-H), 7.37 (s, 1H, Im-5-H), 8.79 (d, 1H, 4J = 1.3 Hz, Im-2-
H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 17.25 (+, Im-4-CH2-CH-CH3), 
23.22 (+, ThioCH3CH), 29.85 (-, Im-4-CH2), 33.00 (+, ThioCH3CH), 33.78 (+, Im-4-CH2-CH), 
47.09 (-, ThioCH-CH2), 47.63 (-, Im-4-CH2-CH-CH2), 117.98 (+, Im-C-5), 124.24, 124.48 (+, 
Thio-C-3,4), 127.77 (+, Thio-C-5), 133.13 (Cquat, Im-C-4), 134.99 (+, Im-C-2), 149.96 (Cquat, 
Thio-C-2), 155.46 (Cquat, C=N), 175.73 (Cquat, C=O). IR (cm-1) = 3133, 2970, 2901, 1662, 
1627, 1184, 1127. HRMS (EI-MS) calcd. for C16H24N5OS [M + H]+ 334.1696; found 334.1692. 
C16H23N5OS · 2 TFA (561.50). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1H-imidazol-4-yl)-2-methylpropyl]guanidine (4.72) 
The title compound was prepared from 4.51 (210 mg, 0.33 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 35/65) yielded a white 
solid (100 mg, 49 %); mp 54 – 57 °C. 1H-NMR (600 MHz, D2O, trifluoroacetate, COSY): δ 
[ppm] = 0.81 (d, 3H, 3J = 6.7 Hz, Im-4-CH2-CH-CH3), 2.00 – 2.11 (m, 1H, Im-4-CH2-CH), 2.48 
(dd, 1H, 2J = 15.2 Hz, 3J = 8.4 Hz, Im-4-CH2), 2.63 (dd, 1H, 2J = 15.2 Hz, 3J = 5.8 Hz, Im-4-
CH2), 3.07 (dd, 1H, 2J = 13.9 Hz, 3J = 6.8 Hz, Im-4-CH2-CH-CH2), 3.11 (dd, 1H, 2J = 13.9 Hz, 
3J = 7.0 Hz, Im-4-CH2-CH-CH2), 3.20 (d, 2H, 3J = 8.2 Hz, Ph2CH-CH2), 4.47 (t, 1H, 3J = 8.2 
Hz, Ph2CH), 7.10 (s, 1H, Im-5-H), 7.15 – 7.30 (m, 10H, Ph-H), 8.36 (s, 1H, Im-2-H). 13C-NMR 
(150 MHz, D2O, trifluoroacetate, HSQC, HMBC): δ [ppm] = 16.02 (+, Im-4-CH2-CH-CH3), 
28.25 (-, Im-4-CH2), 31.86 (+, Im-4-CH2-CH), 42.29 (-, Ph2CH-CH2), 46.31 (-, Im-4-CH2-CH-
CH2), 46.56 (+, Ph2CH), 116.26 (+, Im-C-5), 127.18 (+, 2 Ph-C-4), 127.50 (+, 4 Ph-C), 129.06 
(+, 4 Ph-C), 131.13 (Cquat, Im-C-4), 133.02 (+, Im-C-2), 142.86 (Cquat, 2 Ph-C-1), 152.90 
(Cquat, C=N), 175.29 (Cquat, C=O). IR (cm-1) = 3182, 3033, 2858, 1663, 1629, 1188, 1130. 
HRMS (LSI-MS) calcd. for C23H28N5O [M + H]+ 390.2288; found 390.2285. C23H27N5O · 2 TFA 
(617.54). 
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N1-[3-(1H-Imidazol-4-yl)-2-methylpropyl]-N2-[3-phenyl-3-(thiazol-2-yl)propanoyl]-
guanidine (4.73) 
The title compound was prepared from 4.52 (220 mg, 0.34 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 35/65) yielded a pale 
yellow semisolid (79 mg, 31 %). 1H-NMR (600 MHz, CD3OD, trifluoroacetate): δ [ppm] = 1.00 
(d, 3H, 3J = 6.7 Hz, Im-4-CH2-CH-CH3), 2.16 – 2.25 (m, 1H, Im-4-CH2-CH), 2.62 (dd, 1H, 2J = 
15.1 Hz, 3J = 8.8 Hz, Im-4-CH2), 2.89 (ddd, 1H, 2J = 15.1 Hz, 3J = 5.4 Hz, 4J = 2.8 Hz, Im-4-
CH2), 3.19 – 3.30 (m, 3H, Im-4-CH2-CH-CH2 + PhThiazCH-CH2), 3.61 (dd, 1H, 2J = 16.4 Hz, 
3J = 8.4 Hz, PhThiazCH-CH2), 4.99 (dd, 1H, 3J = 8.4 Hz, 3J = 6.7 Hz, PhThiazCH), 7.27 – 
7.38 (m, 5H, Ph-H), 7.39 (s, 1H, Im-5-H), 7.48 (d, 1H, 3J = 3.3 Hz, Thiaz-5-H), 7.71 (d, 1H, 3J 
= 3.3 Hz, Thiaz-4-H), 8.81 (d, 1H, 4J = 1.0 Hz, Im-2-H). 13C-NMR (150 MHz, CD3OD, 
trifluoroacetate, HSQC): δ [ppm] = 17.18 (+, Im-4-CH2-CH-CH3), 29.80 (-, Im-4-CH2), 33.74 
(+, Im-4-CH2-CH), 43.55 (-, PhThiazCHCH2), 45.94 (+, PhThiazCH), 47.58 (-, Im-4-CH2-CH-
CH2), 117.94 (+, Im-C-5), 121.20 (+, Thiaz-C-5), 128.91 (+ , Ph-C-4), 129.05 (+, 2 Ph-C), 
130.09 (+, 2 Ph-C), 133.09 (Cquat, Im-C-4), 134.98 (+, Im-C-2), 142.31 (Cquat, Ph-C-1), 142.83 
(+, Thiaz-C-4), 155.32 (Cquat, C=N), 174.29, 174.93 (Cquat, C=O + Thiaz-C-2). IR (cm-1) = 
3131, 3030, 2853, 1663, 1627, 1170, 1130. HRMS (EI-MS) calcd. for C20H24N6OS [M+•] 
396.1732; found 396.1731. C20H24N6OS · 3 TFA (738.58). 
 
N1-[3-(5-Methyl-1H-imidazol-4-yl)propyl]-N2-(3-phenylbutanoyl)guanidine (4.74) 
The title compound was prepared from 4.53 (340 mg, 0.43 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 30/70) yielded a 
colorless semisolid compound (147 mg, 62 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.20 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.76 – 1.88 (m, 2H, Im-4-CH2-CH2), 2.09 (s, 3H, 
Im-5-CH3), 2.58 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 2.62 (dd, 1H, 2J = 15.0 Hz, 3J = 9.2 Hz, 
PhCH3CH-CH2), 2.62 (dd, 1H, 2J = 15.0 Hz, 3J = 6.4 Hz, PhCH3CH-CH2), 3.09 – 3.26 (m, 3H, 
Im-4-(CH2)2-CH2 + PhCH3CH), 7.12 – 7.33 (m, 5H, Ph-H), 8.25 (s, 1H, Im-2-H). 13C-NMR (75 
MHz, CD3OD, trifluoroacetate): δ [ppm] = 8.78 (+, Im-5-CH3), 21.55 (-, Im-4-CH2), 22.37 (+, 
PhCH3CH), 28.22 (-, Im-4-CH2-CH2), 37.69 (+, PhCH3CH), 41.65 (-, Im-4-(CH2)2-CH2), 46.10 
(-, PhCH3CH-CH2), 126.85 (Cquat, Im-C-5), 127.73 (+, Ph-C-4), 127.97 (+, 2 Ph-C), 129.03 
(Cquat, Im-C-4), 129.68 (+, 2 Ph-C), 133.32 (+, Im-C-2), 146.45 (Cquat, Ph-C-1), 155.26 (Cquat, 
C=N), 176.09 (Cquat, C=O). IR (cm-1) = 3027, 2901, 1663, 1603, 1178, 1127. HRMS (EI-MS) 
calcd. for C18H25N5O [M+•] 327.2059; found 327.2052. C18H25N5O · 2 TFA (555.47). 
 
N1-[3-(5-Methyl-1H-imidazol-4-yl)propyl]-N2-[3-(thiophen-2-yl)butanoyl]guanidine (4.75) 
The title compound was prepared from 4.54 (470 mg, 0.70 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
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colorless semisolid compound (220 mg, 56 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.29 (d, 3H, 3J = 7.0 Hz, ThioCH3CH), 1.79 – 1.94 (m, 2H, Im-4-CH2-CH2), 2.12 (s, 
3H, Im-5-CH3), 2.62 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 2.65 (dd, 1H, 2J = 15.0 Hz, 3J = 9.0 Hz, 
ThioCH3CH-CH2), 2.75 (dd, 1H, 2J = 15.0 Hz, 3J = 6.2 Hz, ThioCH3CH-CH2), 3.20 (t, 2H, 3J = 
6.7 Hz, Im-4-(CH2)2-CH2), 3.45 – 3.60 (m, 1H, ThioCH3CH), 6.86 (ddd, 1H, 3J = 3.5 Hz, 4J = 
1.3 Hz, 4J = 0.7 Hz, Thio-3-H), 6.90 (dd, 1H, 3J = 5.0 Hz, 3J = 3.5 Hz, Thio-4-H), 7.20 (dd, 1H, 
3J = 5.0 Hz, 4J = 1.3 Hz, Thio-5-H), 8.28 (s, 1H, Im-2-H). 13C-NMR (75 MHz, D2O, 
trifluoroacetate): δ [ppm] = 7.94 (+, Im-5-CH3), 20.01 (-, Im-4-CH2), 22.25 (+, ThioCHCH3), 
26.26 (-, Im-4-CH2-CH2), 31.93 (+, ThioCH3CH), 40.44 (-, Im-4-(CH2)2-CH2), 45.98 (-, 
ThioCH3CH-CH2), 123.69, 123.93 (+, Thio-C-3,4), 125.44 (Cquat, Im-C-5), 127.04 (+, Thio-C-
5), 127.20 (Cquat, Im-C-4), 131.37 (+, Im-C-2), 148.80 (Cquat, Thio-C-2), 152.83 (Cquat, C=N), 
175.50 (Cquat, C=O). IR (cm-1) = 3036, 2876, 1662, 1177, 1128. HRMS (EI-MS) calcd. for 
C16H23N5OS [M+•] 333.1623; found 333.1621. C16H23N5OS · 2 TFA (561.50). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(5-methyl-1H-imidazol-4-yl)propyl]guanidine (4.76) 
The title compound was prepared from 4.55 (260 mg, 0.36 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 35/65) yielded a white 
solid (120 mg, 54 %); mp 54 – 57 °C. 1H-NMR (300 MHz, D2O, trifluoroacetate): δ [ppm] = 
1.74 – 1.89 (m, 2H, Im-4-CH2-CH2), 2.06 (s, 3H, Im-5-CH3), 2.57 (t, 2H, 3J = 7.4 Hz, Im-4-
CH2), 3.12 – 3.25 (m, 4H, Im-4-(CH2)2-CH2 + Ph2CH-CH2), 4.47 (t, 1H, 3J = 8.2 Hz, Ph2CH), 
7.12 – 7.32 (m, 10H, Ph-H), 8.18 (s, 1H, Im-2-H). 13C-NMR (75 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 8.78 (+, Im-5-CH3), 21.52 (-, Im-4-CH2), 28.16 (-, Im-4-CH2-CH2), 
41.65 (-, Im-4-(CH2)2-CH2), 43.80 (-, Ph2CH-CH2), 48.06 (+, Ph2CH), 126.85 (Cquat, Im-C-5), 
127.83 (+, 2 Ph-C-4), 128.83 (+, 4 Ph-C), 128.99 (Cquat, Im-C-4), 129.73 (+, 4 Ph-C), 133.31 
(+, Im-C-2), 144.53 (Cquat, 2 Ph-C-1), 155.17 (Cquat, C=N), 175.53 (Cquat, C=O). IR (cm-1) = 
3031, 2909, 1664, 1599, 1180, 1129. HRMS (EI-MS) calcd. for C23H27N5O [M+•] 389.2216; 
found 389.2216. C23H27N5O · 2 TFA (617.54). 
 
N1-[3-(5-Methyl-1H-imidazol-4-yl)propyl]-N2-[3-phenyl-3-(thiazol-2-yl)propanoyl]-
guanidine (4.77) 
The title compound was prepared from 4.56 (390 mg, 0.53 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
white solid (150 mg, 38 %); mp 58 – 61. 1H-NMR (600 MHz, D2O, trifluoroacetate, COSY): δ 
[ppm] = 1.78 – 1.88 (m, 2H, Im-4-CH2-CH2), 2.08 (s, 3H, Im-5-CH3), 2.59 (t, 2H, 3J = 7.3 Hz, 
Im-4-CH2), 3.18 (t, 2H, 3J = 6.5 Hz, Im-4-(CH2)2-CH2), 3.23 (dd, 1H, 2J = 16.3 Hz, 3J = 8.0 Hz, 
PhThiazCH-CH2), 3.41 (dd, 1H, 2J = 16.3 Hz, 3J = 7.7 Hz, PhThiazCH-CH2), 4.90 (dd, 1H, 3J 
= 8.0 Hz, 3J = 7.7 Hz, PhThiazCH), 7.20 – 7.35 (m, 5H, Ph-H), 7.40 (d, 1H, 3J = 3.3 Hz, 
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Thiaz-5-H), 7.61 (d, 1H, 3J = 3.3 Hz, Thiaz-4-H), 8.25 (s, 1H, Im-2-H). 13C-NMR (150 MHz, 
D2O, trifluoroacetate, HSQC, HMBC): δ [ppm] = 7.90 (+, Im-5-CH3), 19.95 (-, Im-4-CH2), 
26.20 (-, Im-4-CH2-CH2), 40.40 (-, Im-4-(CH2)2-CH2), 42.06 (-, PhThiazCH-CH2), 44.17 (+, 
PhThiazCH), 120.61 (+, Thiaz-C-5), 125.41 (Cquat, Im-C-5), 127.04 (Cquat, Im-C-4), 127.75 (+, 
2 Ph-C), 128.09 (+, Ph-C-4), 129.28 (+, 2 Ph-C), 131.37 (+, Im-C-2), 140.29 (Cquat, Ph-C-1), 
141.64 (+, Thiaz-C-4), 152.99 (Cquat, C=N), 173.17 (Cquat, Thiaz-C-2), 174.24 (Cquat, C=O). IR 
(cm-1) = 2989, 2901, 1668, 1652, 1179, 1129. HRMS (LSI-MS) calcd. for C20H25N6OS [M + 
H]+ 397.1805; found 397.1803. C20H24N6OS · 3 TFA (738.58). 
 
N1-[2-(5-Methyl-1H-imidazol-4-yl)ethyl]-N2-(3-phenylbutanoyl)guanidine (4.78) 
The title compound was prepared from 4.57 (360 mg, 0.65 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a white 
solid (150 mg, 43 %). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 1.30 (d, 3H, 3J 
= 7.0 Hz, PhCH3CH), 2.23 (s, 3H, Im-5-CH3), 2.73 (dd, 1H, 2J = 15.3 Hz, 3J = 7.4 Hz, 
PhCH3CH-CH2), 2.79 (dd, 1H, 2J = 15.3 Hz, 3J = 7.8 Hz, PhCH3CH-CH2), 2.98 (t, 2H, 3J = 6.6 
Hz, Im-4-CH2), 3.22 – 3.36 (m, 1H, PhCH3CH), 3.56 (t, 2H, 3J = 6.6 Hz, Im-4-CH2-CH2), 7.14 
– 7.32 (m, 5H, Ph-H), 8.72 (s, 1H, Im-2-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 8.82 (+, Im-5-CH3), 22.43 (+, PhCH3CH), 23.45 (-, Im-4-CH2), 37.67 (+, PhCH3CH), 
41.23 (-, Im-4-CH2-CH2), 46.03 (-, PhCH3CH-CH2), 126.32 (Cquat, Im-C-5), 127.75 (+, Ph-C-
4), 127.97 (+, 2 Ph-C), 128.32 (Cquat, Im-C-4), 129.69 (+, 2 Ph-C), 133.80 (+, Im-C-2), 146.40 
(Cquat, Ph-C-1), 155.30 (Cquat, C=N), 176.11 (Cquat, C=O). IR (cm-1) = 3036, 2876, 1670, 1602, 
1179, 1128. HRMS (EI-MS) calcd. for C17H23N5O [M+•] 313.1903; found 310.1899. C17H23N5O 
· 2 TFA (541.44). 
 
N1-[2-(5-Methyl-1H-imidazol-4-yl)ethyl]-N2-[3-(thiophen-2-yl)butanoyl]guanidine (4.79) 
The title compound was prepared from 4.58 (200 mg, 0.36 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a 
colorless semisolid compound (51 mg, 26 %). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 1.38 (d, 3H, 3J = 7.0 Hz, ThioCH3CH), 2.26 (s, 3H, Im-5-CH3), 2.76 (dd, 1H, 2J = 15.6 
Hz, 3J = 7.1 Hz, ThioCH3CH-CH2), 2.82 (dd, 1H, 2J = 15.6 Hz, 3J = 7.6 Hz, ThioCH3CH-CH2), 
3.00 (t, 2H, 3J = 6.6 Hz, Im-4-CH2), 3.58 (t, 2H, 3J = 6.6 Hz, Im-4-CH2-CH2), 3.55 – 3.70 (m, 
1H, ThioCH3CH), 6.89 (ddd, 1H, 3J = 3.5 Hz, 4J = 1.4 Hz, 4J = 0.7 Hz, Thio-3-H), 6.91 (dd, 
1H, 3J = 4.9 Hz, 3J = 3.5 Hz, Thio-4-H), 7.20 (dd, 1H, 3J = 4.9 Hz, 4J = 1.4 Hz, Thio-5-H), 8.73 
(s, 1H, Im-2-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 8.85 (+, Im-5-CH3), 
23.27 (+, ThioCHCH3), 23.47 (-, Im-4-CH2), 32.93 (+, ThioCH3CH), 41.31 (-, Im-4-CH2-CH2), 
46.99 (-, ThioCH3CH-CH2), 124.27, 124.48 (+, Thio-C-3,4), 126.34 (Cquat, Im-C-5), 127.79 (+, 
Thio-C-5), 128.34 (Cquat, Im-C-4), 133.83 (+, Im-C-2), 149.93 (Cquat, Thio-C-2), 155.28 (Cquat, 
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C=N), 175.59 (Cquat, C=O). IR (cm-1) = 3035, 2905, 1663, 1180, 1128. HRMS (EI-MS) calcd. 
for C15H21N5OS [M+•] 319.1467; found 319.1465. C15H21N5OS · 2 TFA (547.47). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[2-(5-methyl-1H-imidazol-4-yl)ethyl]guanidine (4.80) 
The title compound was prepared from 4.59 (360 mg, 0.58 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 35/65) yielded a white 
solid (182 mg, 52 %); mp 58 – 61 °C. 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 
2.18 (s, 3H, Im-5-CH3), 2.96 (t, 2H, 3J = 6.5 Hz, Im-4-CH2), 3.25 (d, 2H, 3J = 8.0 Hz, Ph2CH-
CH2), 3.54 (t, 2H, 3J = 6.5 Hz, Im-4-CH2-CH2), 4.58 (t, 1H, 3J = 8.0 Hz, Ph2CH), 7.13 – 7.31 
(m, 10H, Ph-H), 8.71 (s, 1H, Im-2-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 
8.80 (+, Im-5-CH3), 23.43 (-, Im-4-CH2), 41.24 (-, Im-4-CH2-CH2), 43.78 (-, Ph2CH-CH2), 
48.04 (+, Ph2CH), 126.30 (Cquat, Im-C-5), 127.84 (+, 2 Ph-C-4), 128.34 (Cquat, Im-C-4) 128.82 
(+, 4 Ph-C), 129.73 (+, 4 Ph-C), 133.79 (+, Im-C-2), 144.49 (Cquat, 2 Ph-C-1), 155.24 (Cquat, 
C=N), 175.57 (Cquat, C=O). IR (cm-1) = 3151, 2901, 1665, 1599, 1183, 1129. HRMS (EI-MS) 
calcd. for C22H25N5O [M+•] 375.2059; found 375.2051. C22H25N5O · 2 TFA (603.51). 
 
N1-[2-(5-Methyl-1H-imidazol-4-yl)ethyl]-N2-[3-phenyl-3-(thiazol-2-yl)propanoyl]guanidine 
(4.81) 
The title compound was prepared from 4.60 (270 mg, 0.43 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a 
colorless semisolid compound (33 mg, 11 %). 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 2.23 (s, 3H, Im-5-CH3), 2.99 (t, 2H, 3J = 6.6 Hz, Im-4-CH2), 3.21 (dd, 1H, 2J = 16.4 
Hz, 3J = 6.6 Hz, PhThiazCH-CH2), 3.51 – 3.63 (m, 3H, Im-4-CH2-CH2 + PhThiazCH-CH2), 
4.95 (dd, 1H, 3J = 8.5 Hz, 3J = 6.6 Hz, PhThiazCH), 7.24 – 7.37 (m, 5H, Ph-H), 7.47 (d, 1H, 
3J = 3.4 Hz, Thiaz-5-H), 7.69 (d, 1H, 3J = 3.4 Hz, Thiaz-4-H), 8.72 (s, 1H, Im-2-H). 13C-NMR 
(75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 8.83 (+, Im-5-CH3), 23.46 (-, Im-4-CH2), 41.35 
(-, Im-4-CH2-CH2), 43.51 (-, PhThiazCH-CH2), 45.92 (+, PhThiazCH), 121.24 (+, Thiaz-C-5), 
126.32 (Cquat, Im-C-5), 128.36 (Cquat, Im-C-4), 128.93 (+, Ph-C-4), 129.08 (+, 2 Ph-C), 130.13 
(+, 2 Ph-C), 133.81 (+, Im-C-2), 142.33 (Cquat, Ph-C-1), 142.87 (+, Thiaz-C-4), 155.23 (Cquat, 
C=N), 174.29, 174.89 (Cquat, Thiaz-C-2 + C=O). IR (cm-1) = 3155, 2989, 2901, 1663, 1178, 
1127. HRMS (EI-MS) calcd. for C19H22N6OS [M+•] 382.1576; found 382.1582. C19H22N6OS · 3 
TFA (724.55). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N1-methyl-N2-(3-phenylbutanoyl)guanidine (4.82) 
The title compound was prepared from 4.61 (370 mg, 0.65 mmol) according to the general 
procedure. Purification by preparative HPLC (0.1 % TFA (aq.): 0 min: 15/85, 20 min: 35/65) 
yielded a colorless semisolid compound (189 mg, 52 %). 1H-NMR (600 MHz, D2O, 
Structure-activity relationships of NG-acylated imidazolylalkylguanidines 159
trifluoroacetate, COSY, 358 K): δ [ppm] = 1.89 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 2.45 – 2.53 
(m, 2H, Im-4-CH2-CH2), 3.20 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 3.42 (d, 1H, 3J = 7.8 Hz, 
PhCH3CH-CH2), 3.55 (s, 3H, NCH3), 3.83 – 3.90 (m, 1H, PhCH3CH), 3.91 – 4.00 (m, 2H, Im-
4-(CH2)2-CH2), 7.78 (s, 1H, Im-5-H), 7.79 – 7.96 (m, 5H, Ph-H), 9.15 (s, 1H, Im-2-H). 13C-
NMR (150 MHz, D2O, trifluoroacetate, HSQC, HMBC, 358 K): δ [ppm] = 21.51 (-, Im-4-CH2), 
22.03 (+, PhCH3CH), 25.40 (-, Im-4-CH2-CH2), 37.20 (+, NCH3), 37.26 (+, PhCH3CH), 45.35 
(-, PhCH3CH-CH2), 50.95 (-, Im-4-(CH2)2-CH2), 116.21 (+, Im-C-5), 127.57 (+, 2 Ph-C), 
127.62 (+, Ph-C-4), 129.58 (+, 2 Ph-C), 133.06 (Cquat, Im-C-4), 134.00 (+, Im-C-2), 145.92 
(Cquat, Ph-C-1), 153.46 (Cquat, C=N), 175.54 (Cquat, C=O). IR (cm-1) = 3128, 2989, 2901, 1659, 
1620, 1176, 1129. HRMS (EI-MS) calcd. for C18H25N5O [M+•] 327.2059; found 327.2064. 
C18H25N5O · 2 TFA (555.47). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1H-imidazol-4-yl)propyl]-N2-methylguanidine (4.83) 
The title compound was prepared from 4.62 (400 mg, 0.63 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 20/80, 20 min: 
45/65) yielded a white solid (202 mg, 52 %); mp 52 – 56 °C. 1H-NMR (600 MHz, D2O, 
trifluoroacetate, 358 K): δ [ppm] = 2.42 – 2.50 (m, 2H, Im-4-CH2-CH2), 3.15 (t, 2H, 3J = 7.5 
Hz, Im-4-CH2), 3.55 (s, 3H, NCH3), 3.93 (d, 2H, 3J = 8.0 Hz, Ph2CHCH2), 3.95 (t, 2H, 3J = 7.2 
Hz, Im-4-(CH2)2-CH2), 5.15 (t, 1H, 3J = 8.0 Hz, Ph2CH), 7.76 (s, 1H, Im-5-H), 7.80 – 7.96 (m, 
10H, Ph-H), 9.15 (s, 1H, Im-2-H). 13C-NMR (150 MHz, D2O, trifluoroacetate, HSQC, HMBC, 
358 K): δ [ppm] = 21.50 (-, Im-4-CH2), 25.37 (-, Im-4-CH2-CH2), 37.24 (+, NCH3), 42.89 (-, 
Ph2CH-CH2), 47.53 (-, Ph2CH), 51.10 (-, Im-4-(CH2)2-CH2), 116.1 7 (-, Im-C-5), 127.78 (+, 4 
Ph-C), 128.27 (+, 2 Ph-C-4), 129.68 (+, 4 Ph-C), 133.04 (Cquat, Im-C-4), 133.98 (+, Im-C-2), 
143.74 (Cquat, Ph-C-1), 153.45 (Cquat, C=N), 174.77 (Cquat, C=O). IR (cm-1) = 3136, 3028, 
2868, 1659, 1620, 1177, 1126. HRMS (EI-MS) calcd. for C23H27N5O [M+•] 389.2216; found 
389.2218. C23H27N5O · 2 TFA (617.54). 
 
4.4.2 Pharmacological methods 
4.4.2.1 Materials 
Histamine dihydrochloride was purchased from Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany). Thioperamide maleate was from Tocris Bioscience (Ellisville, USA). [γ-32P]GTP 
was synthesized according to a previously described method.46 [32P]Pi (8,500 – 9,100 
Ci/mmol orthophosphoric acid) was from PerkinElmer Life Sciences (Boston, MA). All 
unlabeled nucleotides, glycerol-3-phosphate dehydrogenase, triose phosphate isomerase, 
glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase were from Roche 
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(Mannheim, Germany). 3-Phosphoglycerate kinase and L-α-glycerol phosphate was from 
Sigma. 
 
4.4.2.2 Steady-state GTPase activity assay 
See section 3.4.2.2. 
 
4.4.2.3 Histamine H1R assay on guinea pig ileum7 
See section 3.4.2.4. 
 
4.4.2.4 Histamine H2R assay on the isolated spontaneously beating guinea pig 
right atrium7  
See section 3.4.2.5. 
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Chapter 5 
 
Synthesis and structure-activity relationships 
of NG-acylated arylpropylguanidines at the 
histamine receptor subtypes 
 
5.1 Introduction 
Guanidine-type compounds like arpromidine and analogs represent highly potent H2R 
agonists.1, 2 However, the strong basic guanidine group that is crucial for receptor activation 
also provides unfavorable pharmacokinetic properties of the compounds, for instance, very 
low absorption after oral administration and lack of penetration across the blood brain 
barrier.3 These drawbacks could be resolved by replacing the guanidine group (pKa ≈ 13) 
with a considerably less basic acylguanidine moiety (pKa ≈ 8, Figure 5.1: 5.1-5.4).3-6 
However, these NG-acylated imidazolylpropylguanidines developed as H2R agonists lacked 
selectivity toward the hH3R and hH4R (Table 5.1). This drawback could be overcome in a 
recent study by replacing the imidazole ring with other heterocycles. Since the histamine 
analog and H2R agonist amthamine (5.5) had been shown to be inactive at the H3R,7 
substitution of the imidazole ring in the acylguanidine-type H2R agonists with an 
aminothiazole heterocycle was elucidated as possibility to increase H2R selectivity. Indeed, 
introduction of 2-aminothiazole or 2-amino-4-methylthiazole rings revealed selective 
acylguanidine-type H2R agonists devoid of agonistic activity at other HRs (5.6 and 5.7).3 As 
this bioisosteric replacement of the 1H-imidazol-4-yl ring was successful to increase 
selectivity for an HR subtype, in the present study additional heterocycles were introduced 
with the aim to identify further bioisosteres for the 1H-imidazol-4-yl ring and thereby improve 
HR subtype selectivity of NG-acylated imidazolylpropylguanidines. Moreover, structure-
activity relationships of NG-acylated hetarylpropylguanidines were analyzed. 
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Figure 5.1. Structures of NG-acylated imidazolylpropylguanidines, which are active at the H2R, H3R 
and H4R (5.1-5.4), the H2R agonist amthamine (5.5) and related potent and selective acylguanidine-
type H2R agonists (5.6 and 5.7). 
 
The attention was turned to heterocycles that had already been employed in the 
development of HR ligands, especially for the preparation of hetaryl analogs of histamine 
(Figure 5.2).8, 9 Several of these histamine analogs proved to be just poorly active at the H1R 
and the H2R and therefore, the bioisosteric approach was also tried with respect to shift the 
selectivity of some NG-acylated arylpropylguanidines toward the H3R or the H4R. 
 
 
 
Figure 5.2. Imidazole replacement in acylguanidine-type non-selective H2R agonists. Overview about 
the introduced aromatic rings. 
 
5.2 Chemistry 
The amines and alcohols required for the preparation of the arylpropylguanidines 5.46-5.54 
were synthesized as depicted in Scheme 5.1. Reduction of 5.8 with LiAlH4 followed by 
aminomethylation in a Mannich reaction10 gave the furan analog 5.10. The 
imidazolylpropanol 5.12 was prepared by deprotonation of the methyl group in 5.11 with 
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n-BuLi in THF and treatment with oxirane as electrophile.11 Introduction of a three-membered 
carbon chain to the pyrazole core was performed by C-C coupling of the trityl-protected 
iodopyrazole 5.13 with propargyl alcohol under Sonogashira conditions12 using Pd(PPh3)2Cl2 
and CuI as catalyst. Hydrogenation of the triple bond over Pd/C (10 %) provided the 
pyrazolylpropanol 5.16. The triazolylpropanol 5.22 was obtained in five steps starting from 
1H-1,2,4-triazole (5.17). After trityl-protection of 5.17,13, 14 5.18 was treated with n-BuLi and 
DMF in THF to afford the aldehyde 5.19.15 Elongation of the side chain by two carbon atoms 
was carried out via Horner-Wadsworth-Emmons reaction employing triethyl phosphono-
acetate.16 Subsequent hydrogenation of the C=C double bond and reduction of the ethyl 
ester yielded 5.22. Conversion of the pyridylpropanols 5.23-5.25 to the corresponding 
phthalimides 5.26-5.28 under Mitsunobu conditions17 followed by hydrazinolysis gave the 
pyridylpropylamines 5.29-5.31.18 
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Scheme 5.1. Synthesis of the arylpropyl alcohols 5.10, 5.12, 5.16 and 5.22, and the 
pyridylpropylamines 5.29-5.31. Reagents and conditions: (i) LiAlH4 (2 eq), Et2O, overnight, 0 °C  rt; 
(ii) NH(CH3)2 · HCl (1.6 eq), (CH2O)n (1.6 eq), EtOH, overnight, reflux; (iii) oxirane (5 eq), n-BuLi (1.1 
eq), THF, overnight, - 78 °C  rt; (iv) TrCl (1 eq), NEt3 (1.2 eq), DCM, 12 h, 0 °C  rt; (v) 
Pd(PPh3)2Cl2 (0.03 eq), CuI (0.05 eq), DIPA (4.5 eq), propargyl alcohol (1.1 eq), DMF, 48 h, - 15 °C  
rt; (vi) H2, Pd/C (10 %) (cat.), MeOH, overnight, rt; (vii) TrCl (1 eq), NEt3 (1 eq), DCM, overnight, rt; 
(viii) TMEDA (1 eq), n-BuLi (1.1 eq), DMF (0.9 eq), THF, 12 h, -78 °C; (ix) triethyl phosphonoacetate 
(1.2 eq), NaH (60 % dispersion in mineral oil) (1.2 eq), THF, overnight, rt; (x) H2, Pd/C (10 %) (cat.), 
EtOH/THF, overnight, rt; (xi) LiAlH4 (2 eq), THF, 2 h, 0 °C  reflux; (xii) phthalimide (1.1 eq), PPh3 
(1.1 eq), DIAD (1.1 eq), THF, overnight, 0 °C  rt. (xiii) N2H4 · H2O (6 eq), EtOH, overnight, rt. 
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The arylpropylguanidines 5.46-5.54 were synthesized starting from the corresponding 
arylpropyl alcohols 5.10, 5.12, 5.16 and 5.22 or arylpropylamines 5.29-5.33 (Scheme 5.2). 
Conversion of the alcohol functionality to the di-Cbz-protected guanidines 5.37-5.40 was 
accomplished under Mitsunobu conditions17 according to Feichtinger and colleagues.19 
Treatment of the arylpropylamines 5.29-5.33 with the triflyl-di-Cbz-protected guanidine 5.3619 
provided the di-Cbz protected arylpropylguanidines 5.41-5.45. Finally, the arylpropyl-
guanidines 5.46-5.54 were obtained by hydrogenolytic cleavage of the Cbz groups. 
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Scheme 5.2. Synthesis of the arylpropylguanidines 5.46-5.54. Reagents and conditions: (i) benzyl 
chloroformate (3 eq), NaOH (5 eq), H2O/DCM, 20 h, 0 °C; (ii) Tf2O (1 eq), NaH (60 % dispersion in 
mineral oil) (2 eq), chlorobenzene, overnight, - 45 °C  rt; (iii) PPh3 (1.5 eq), DIAD (1.5 eq), THF, 
overnight, 0 °C  rt; (iv) NEt3 (1 eq), DCM, overnight, rt; (v) H2, Pd/C (10 %) (cat.), MeOH, 3 h, rt. 
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The designated NG-acylated arylpropylguanidines were prepared following the synthetic 
pathway outlined in Scheme 5.3. Coupling of the CDI-activated carboxylic acids20, 21 5.55-
5.58 to the arylpropylguanidines 5.46-5.54 gave the acylguanidines 5.59-5.80.3 Heterocycles 
bearing a trityl group were deprotected under acidic conditions yielding 5.81-5.88. 
 
 
Scheme 5.3. Synthesis of the NG-acylated arylpropylguanidines 5.59-5.72 and 5.81-5.88, and the 
trityl-protected intermediates 5.73-5.80. Reagents and conditions: (i) CDI (1.2 eq), NaH (60 % 
dispersion in mineral oil) (2 eq), THF, 5 h, rt. (ii) TFA (20 %), DCM, 5 h, rt. 
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5.3 Pharmacological results and discussion 
The potencies and efficacies of the synthesized compounds were evaluated for all HR 
subtypes in steady-state GTPase assays determining the enzymatic hydrolysis of 
radioactively labeled [γ-32P]GTP after G-protein activation via the respective HR subtype 
(Table 5.1). These pharmacological studies were performed using membrane preparations of 
Sf9 insect cells expressing the hH1R plus RGS4, the hH2R-GsαS fusion protein, the hH3R plus 
Giα2 plus Gβ1γ2 plus RGS4 or the hH4R-RGS19 fusion protein plus Giα2 plus Gβ1γ2.3, 22, 23 
Selected compounds were additionally investigated for H1R and H2R activity at the guinea 
pig (gp) ileum and guinea pig right atrium, respectively (Table 5.2).  
 
5.3.1 Potencies and efficacies of the prepared compounds at the hH1R, hH2R, 
hH3R and hH4R in the steady-state GTPase assay 
First it was verified that – with respect to pharmacological activity at the HR subtypes – the 
imidazole ring of the NG-acylated imidazolylpropylguanidines can not just be substituted by 
an arbitrary aromatic ring. Therefore, the imidazole ring was replaced with a phenyl ring (5.59 
and 5.60). As expected, potencies at the hH2/3/4Rs dramatically decreased and agonistic 
activity was lost. However, at the hH2R, the potencies of the compounds (KB = 1,300 nM) 
were comparable to that of the H2R antagonists cimetidine or ranitidine.24 
Replacing the imidazole ring in UR-AK24 with a 2-pyridyl ring resulted in a hH2R partial 
agonist (5.61) with a potency comparable to that of the endogenous ligand histamine (EC50 = 
840 nM, Emax = 0.30). At the hH1R, this compound also behaved as weak partial agonist. 
These findings are in agreement with data for the 2-pyridyl analog of histamine, betahistine, 
which has been found to exert weak agonism at the hH1R and hH2R.23, 24 The bulky 
diphenylpropanoyl residue in 5.62 was not tolerated in terms of agonistic potency. At the 
hH3R and hH4R, 5.61 and 5.62 were almost inactive. The 3- and 4-pyridyl-analogs 5.63-5.66 
displayed moderate antagonistic activity at the hH2R and negligible activities at the other HR 
subtypes. 
Replacement of the imidazole ring with the 5-[(dimethylamino)methyl]furan-2-yl group from 
the H2R antagonist ranitidine afforded rather potent hH2R antagonists (5.67-5.70). All 
prepared compounds turned out to be superior to ranitidine (KB = 840 nM)24 at the hH2R, 
highest potency was observed for the diphenylpropanoyl analog 5.68 (KB = 94 nM). 5.67-5.70 
were weak inverse agonists at the hH3R and almost inactive at the hH1R and hH4R. 
Next to new heterocycles also isomers of the 1H-imidazol-4-yl ring were investigated. The 
1H-imidazol-1-yl isomer 5.71 turned out to be essentially equiefficacious (Emax = 0.77) at the 
hH4R relative to the reference compound UR-AK24 (Emax = 0.84), but potency suffered a 
65-fold decrease (EC50 = 15 nM  EC50 = 1,000 nM). At all other HRs, 5.71 bound very 
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weakly (KB > 10 µM). However, these findings show that in contrast to other HR subtypes an 
accessible NH-group in the imidazole ring obviously is not required to stabilize an active 
hH4R conformation, but is crucial for high potency at this HR subtype. As visible with the 
diphenylpropanoyl analog 5.72, that is almost inactive at the hH4R, the ability to activate the 
hH4R strongly depends on the constitution of the acyl residue. 
For the 1H-imidazol-2-yl isomers 5.81-5.84 similar pharmacological activities at the hH4R 
were observed as for the 1H-imidazol-1-yl isomers 5.71 and 5.72. Both 3-arylbutanoyl 
analogs (5.81 and 5.82) exhibited moderate partial agonistic potency, however the efficacies 
were substantially lower (5.81: Emax = 0.35, 5.82: Emax = 0.50) relative to 5.1 and 5.2. Like for 
the isomer 5.72, a diarylpropanoyl residue in 5.83 and 5.84 abolished agonism at the hH4R. 
At the other HR subtypes, 5.81-5.84 were very weak antagonists or inverse agonists.  
Both imidazole isomers demonstrate that the hH4R with respect to agonistic activity better 
tolerates modifications in the arrangement of the nitrogen atoms in the imidazole ring than 
other HR subtypes. 
Replacing the imidazole ring in UR-AK24 with a 1H-pyrazol-4-yl ring (5.85) resulted in a 
moderate decrease in potency and efficacy at the hH2R (EC50 = 240 nM, Emax = 0.44). 
Interestingly, this compound was virtually inactive at all other HRs. Therefore, replacing the 
imidazole ring with a pyrazole ring turned out to be a promising approach for shifting 
selectivity toward the hH2R. However, contrary to the reference compound UR-PG80, the 
bulky diphenylpropanoyl residue in 5.86 was deleterious for agonistic activity at the hH2R. 
Compared to the pyrazole 5.85, the 1H-1,2,4-triazol-3-yl analog 5.87 was more efficacious, 
but exerted a moderately reduced potency (EC50 = 740 nM, Emax = 0.66). In contrast to the 
pyrazole 5.86, the triazole analog 5.88 exhibited partial agonistic activity at the hH2R and 
showed a slightly increased potency relative to 5.87 (EC50 = 410 nM, Emax = 0.42). This 
observation suggests the triazole and the pyrazole containing acylguanidines to feature 
different binding modes at the hH2R. Obviously, triazole compounds offer more chemical 
space for the modification of the acyl residue than the pyrazole analogs which may be 
favorable with respect to the further development of potent hH2R agonists. Like the pyrazole 
analogs 5.85 and 5.86, the triazoles 5.87 and 5.88 were almost inactive at the other HRs.  
Next to the distinct position of the nitrogen atoms in the five membered ring, the main 
difference between the imidazole ring (pKa ≈ 7)6 and the pyrazole (pKa ≈ 3)6 and triazole 
(pKa ≈ 3)6 cycles is the drastically decreased basicity. Obviously, for hH2R activity the 
presence of an heterocycle that is protonable under physiological conditions is not required. 
This constitutes an opportunity to increase H2R selectivity. 
Chapter 5 172 
  
Structure-activity relationships of NG-acylated arylpropylguanidines 173
 
Chapter 5 174 
5.3.2 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 
At the guinea-pig ileum the investigated NG-acylated arylpropylguanidines (Table 5.2) usually 
acted as moderate H1R antagonists. 
Like at the hH2R, introduction of a phenyl (5.60), 3-pyridyl (5.63), 4-pyridyl (5.65), 5-
[(dimethylamino)methyl]furan-2-yl (5.67), 1H-imidazol-1-yl (5.71) and 1H-imidazol-2-yl ring 
(5.81) resulted in a loss of agonistic efficacy at the gpH2R relative to the reference 
compounds 5.1-5.4 and yielded weakly active gpH2R antagonists. Remarkably, the H2R 
antagonistic activity of compound 5.67 was comparable to that of cimetidine at the guinea pig 
right atrium.27 
Substitution of the 1H-imidazol-4-yl ring with a 2-pyridyl ring (5.61) produced a partial gpH2R 
agonist with increased potency relative to histamine, but, as at the hH2R, rather low efficacy 
(Emax = 0.26). This corresponds to the histamine analogs 2-(2-pyridyl)ethanamine and 
betahistine that likewise display weak partial agonistic activity at the guinea pig right atrium.8 
Replacing the 1H-imidazol-4-yl ring with a 1H-pyrazol-4-yl ring (5.85 and 5.86) resulted in 
compounds retaining partial agonistic activity at the gpH2R. However, relative to UR-AK24 
and UR-PG80, potency decreased by about one order of magnitude and efficacy was 
reduced. With respect to efficacy the introduction of a 1H-1,2,4-triazol-3-yl ring in 5.87 and 
5.88 was considerably more favorable. These compounds turned out to be equiefficacious to 
their 1H-imidazol-4-yl analogs UR-AK24 and UR-PG80, whereas potency moderately 
decreased by a factor of about 6. These findings show the 1H-1,2,4-triazol-3-yl ring to be a 
possible bioisostere for the 1H-imidazol-4-yl ring with respect to gpH2R activity. At the hH2R, 
both potency and efficacy of 5.87 and 5.88 were reduced relative to UR-AK24 and UR-PG80, 
demonstrating the gpH2R to better tolerate the substitution of the imidazole with a triazole 
ring. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Structure-activity relationships of NG-acylated arylpropylguanidines 175
Table 5.2. Pharmacological activities of selected compounds at the guinea pig ileum (gpH1R) and the 
guinea pig right atrium (gpH2R). 
a number of experiments, b pEC50 was calculated from the mean shift ∆pEC50 of the agonist curve 
relative to the histamine reference curve by equation: pEC50 = 6.00 + 0.13 + ∆pEC50. Summand 0.13 
represents the mean desensitization observed for control organs when two successive curves for 
histamine were performed (0.13 ± 0.02, n = 16). The SEM given for pEC50 is the SEM calculated for ∆pEC50, c pD’2 values given in brackets for compounds producing a significant, concentration-
dependent reduction of the maximal response of histamine; d efficacy, maximal response (%), relative 
to the maximal increase in heart rate induced by the reference compound histamine, e Emax (histamine) 
at 10 µM 5.67: 0.68 ± 0.01; f Emax (histamine) at 30 µM 5.71: 0.69 ± 0.03; g Emax (histamine) at 30 µM 
5.81: 0.54 ± 0.09; h pA2 of cimetidine (10 µM, n = 2): 6.32 ± 0.06; n.d.: not determined. 
 
5.3.3 Summary and conclusion 
For most investigated acylguanidines replacement of the 1H-imidazol-4-yl ring with other 
heterocycles or isomers resulted in considerably reduced potency and efficacy at the hH2R, 
hH3R and hH4R. This underlines the substantial contribution of an appropriate arrangement 
of the nitrogen atoms in the heterocycle for binding to the H2R, H3R and H4R and for 
stabilizing an active conformation of the H2R and H4R. Only very restricted modifications of 
gpH1R gpH2R 
compound 
pA2 na pEC50b/(pA2)/[pD’2]c Emaxd na 
Histamine - -  6.00 ± 0.10 1.00 ± 0.02 > 50 
5.1 (UR-AK24)3  5.87 ± 0.14 4  7.80 ± 0.07 0.99 ± 0.02 4 
5.3 (UR-PG80)3  6.13 ± 0.05 10  7.55 ± 0.09 0.85 ± 0.03 5 
5.60 n.d.   (< 4.5) [< 4.5] - 2 
5.61 n.d.   6.71 ± 0.04 0.26 ± 0.03 3 
5.63 n.d.   (< 4.5) [4.22 ± 0.04] - 2 
5.65 n.d.   (4.72 ± 0.34) [4.54 ± 0.03] - 2 
5.67 5.52 ± 0.06 18  (6.28 ± 0.13) 0e 2 
5.71 5.95 ± 0.05 18  (< 4.5) [4.16 ± 0.05] 0
f 2 
5.81 5.63 ± 0.04 18  (4.90 ± 0.16) [4.44 ± 0.15] < 10
g 2 
5.85 5.42 ± 0.10 15  6.33 ± 0.07 0.54 ± 0.03 3 
5.86 5.59 ± 0.09 17  6.44 ± 0.11 0.41 ± 0.05 3 
5.87 5.83 ± 0.07 16  7.00 ± 0.07h 1.00 ± 0.02 3 
5.88 5.79 ± 0.04 16  6.69 ± 0.02 0.83 ± 0.06 3 
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this structural moiety of the acylguanidine-type compounds were tolerated with respect to HR 
activity. 
The phenyl- (5.59 and 5.60), 3-pyridyl- (5.63 and 5.64), 4-pyridyl- (5.65 and 5.66) or 
substituted furan (5.67-5.70) analogs were virtually inactive at all HR subtypes. Replacement 
of the 1H-imidazol-4-yl ring with the 1H-imidazol-1-yl (5.71 and 5.72) and 1H-imidazol-2-yl 
(5.81-5.84) isomers afforded compounds (5.71, 5.82 and 5.83) exhibiting partial agonistic 
activity only at the hH4R. Most striking was 5.71 that displayed a comparably high efficacy as 
the reference compound UR-AK24 at this HR subtype. However, for all compounds 
potencies were substantially reduced. As these acylguanidines were poorly active at the 
other HR subtypes and the hH4R activity largely depended on the type of acyl residue, further 
modifications in this area appear promising with respect to the development of more potent 
and selective hH4R agonists. 
Introduction of a 2-pyridyl (5.61 and 5.62), a 1H-pyrazol-4-yl (5.85 and 5.86) or a 1H-1,2,4-
triazol-3-yl (5.87 and 5.88) ring provided compounds exhibiting partial to full agonistic activity 
at the hH2R and gpH2R. Except to the 2-pyridyl analogs, these compounds had negligible 
activities at the other hHR subtypes. In particular, the triazole ring was identified as a 
promising bioisostere for the imidazole ring with respect to H2R activity. At the gpH2R, the 
NG-acylated triazolylpropylguanidines (5.87 and 5.88) were equiefficacious to UR-AK24 and 
UR-PG80. In contrast to UR-AK24 and UR-PG80, 5.87 and 5.88 proved to be virtually 
inactive at all other hHR subtypes, demonstrating the 1H-1,2,4-triazol-3-yl ring to be a 
versatile heterocycle toward H2R selectivity. However, the reported bioisosteric replacement 
of the imidazole ring with a 2-aminothiazole or a 2-amino-4-methylthiazole ring (Figure 5.1) 
yielded selective H2R agonists with higher potencies relative to the triazole analogs at the 
H2R.28 Nevertheless, NG-acylated triazolylpropylguanidines may be of interest as a 
replacement of the corresponding aminothiazoles since the latter raised suspicion to have 
toxic effects in cellular assays. Additionally, thiazoles have been reported to form toxic 
metabolites after oxidative cleavage of the ring.29-31 In contrast, the triazole ring is considered 
as relatively stable to oxidation by oxygenases32 and therefore may be a promising 
alternative bioisostere for the imidazole ring to obtain selective acylguanidine-type H2R 
agonists. 
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5.4 Experimental section 
5.4.1 Chemistry 
5.4.1.1 General conditions 
Commercial reagents and chemicals were purchased from Acros Organics (Geel, Belgium), 
IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany), Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Munich, 
Germany), TCI Europe (Zwijndrecht, Belgium) and used without further purification. 2-Methyl-
1-trityl-1H-imidazole was a gift from Dr. Birgit Striegl, Department of Pharmaceutical/ 
Medicinal Chemistry I, University of Regensburg. Deuterated solvents for NMR spectroscopy 
were from Deutero GmbH (Kastellaun, Germany). All solvents were of analytical grade or 
distilled prior to use. If moisture-free conditions were required, reactions were performed in 
dried glassware under inert atmosphere (argon or nitrogen). Anhydrous DMF was purchased 
from Sigma-Aldrich Chemie GmbH. Flash chromatography was performed on silica gel 
(Merck silica gel 60, 40 - 63 µM). Reactions were monitored by TLC on aluminum plates 
coated with silica gel (Merck silica gel 60 F254, thickness 0.2 mm). The compounds were 
detected by UV light (254 nm) or a 0.3 % solution of ninhydrine in n-butanol (amines). All 
melting points are uncorrected and were measured on a Büchi 530 apparatus (Büchi GmbH, 
Essen, Germany). 
Nuclear Magnetic Resonance spectra (1H-NMR and 13C-NMR) were recorded with Bruker 
Avance 300, Bruker Avance 400 or Bruker Avance 600 NMR spectrometers (Bruker BioSpin 
GmbH, Rheinstetten, Germany). Chemical shifts are given in δ (ppm) relative to external 
standards. Abbreviations for the multiplicities of the signals: s (singlet), d (doublet), t (triplet), 
q (quartet), quin (quintet), m (multiplet), brs (for broad singlet) and combinations thereof. The 
multiplicity of carbon atoms (13C-NMR) was determined by DEPT 135 (distortionless 
enhancement by polarization transfer): “+” primary and tertiary carbon atom (positive DEPT 
135 signal), “-“ secondary carbon atom (negative DEPT 135 signal), “quat” quaternary 
carbon atom. In certain cases 2D-NMR techniques (COSY, HMQC, HSQC, HMBC, NOESY) 
were used to assign 1H and 13C chemical shifts. Infrared spectra (IR) were measured on a 
Bruker Tensor 27 spectrometer equipped with an ATR (attenuated total reflexion) unit from 
Harrick Scientific Products Inc. (Ossining/NY, US). Mass spectra (MS) were recorded on a 
Finnigan MAT 95 (EI-MS 70 eV, HR-MS), Finnigan SSQ 710A (CI-MS (NH3)) and on a 
Finnigan ThermoQuest TSQ 7000 (ES-MS) spectrometer. The peak-intensity in % relative to 
the strongest signal is indicated in parenthesis. Elemental analysis (C, H, N, Heraeus 
Elementar Vario EL III) were performed by the Analytical Department of the University 
Regensburg and are within ± 0.4 % unless otherwise noted. 
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Preparative HPLC was performed with a pump model K-1800 (Knauer, Berlin, Germany), the 
column was Eurosphere-100 (250 x 32 mm) (Knauer), which was attached to a UV-detector 
model K-2000 (Knauer). UV detection of the compounds was done at 210 nm. The 
temperature was 25 °C and the flow rate 37 ml/min. The mobile phase was 0.1 % TFA in 
millipore water and MeCN. Analytical HPLC was performed on a system from Thermo 
Separation Products (TSP) equipped with a SN 400 controller, P4000 pump, an AS3000 
autosampler and a Spectra Focus UV/VIS detector. Stationary phase was a Eurosphere-100 
C-18 (250 x 4.0 mm, 5 μm) column (Knauer) thermostated at 30 °C. The flow rate was 
0.8 ml/min and the dead time (t0) was 3.32 min. As mobile phase gradients of MeCN/0.05 % 
TFA (aq.) were used and the absorbance was detected at 210 nm. Compound purities were 
calculated as the percentage peak area of the analyzed compound by UV detection at 
210 nm. HPLC conditions, retention times (tR), capacity factors (k’ = (tR – t0)/t0) and purities of 
the synthesized compounds are listed in the appendix (Chapter 9). 
 
5.4.1.2 Preparation of the arylpropylalcohols 5.10, 5.12, 5.16 and 5.22, and 
arylpropylamines 5.29-5.31 
3-(Furan-2-yl)propan-1-ol (5.9)33 
To a solution of 5.8 (10.0 g, 59.4 mmol) in Et2O (200 mL), LiAlH4 (4.51 g, 118.8 mmol) was 
added in portions at 0 °C. After addition was complete, the mixture was allowed to warm to 
ambient temperature and stirred overnight. The mixture was cooled externally with ice and 
subsequently 4.5 mL H2O, 4.5 mL NaOH 15 % and 18 mL H2O were added. Insoluble 
material was removed by filtration and washed with Et2O (2 x 50 mL). The combined organic 
layers were washed with H2O and brine and dried over Na2SO4. Evaporation of the solvent 
provided a colorless oil that was used without further purification (6.1 g, 81 %). 1H-NMR (300 
MHz, CDCl3): δ [ppm] = 1.85 – 1.96 (m, 2H, Fur-2-CH2-CH2), 2.73 (t, 2H, 3J = 7.4 Hz, Fur-2-
CH2), 3.68 (t, 2H, 3J = 6.4 Hz, Fur-2-(CH2)2-CH2), 6.01 (m, 1H, Fur-3-H), 6.28 (dd, 1H, 3J = 
3.1 Hz, 3J = 1.9 Hz, Fur-4-H), 6.28 (dd, 1H, 3J = 1.9 Hz, 4J = 0.8 Hz, Fur-5-H). 13C-NMR (75 
MHz, CDCl3): δ [ppm] = 24.34 (-, Fur-2-CH2-CH2), 31.03 (-, Fur-2-CH2), 62.09 (-, Fur-2-
(CH2)2-CH2), 105.07 (+, Fur-C-3), 110.17 (+, Fur-C-4), 140.99 (+, Fur-C-5), 155.59 (Cquat, 
Fur-C-2). CI-MS (NH3) m/z (%): 127 (100) [M + H]+. C7H10O2 (126.15). 
 
3-{5-[(Dimethylamino)methyl]furan-2-yl}propan-1-ol (5.10)10 
A solution of 5.9 (5.51 g, 43.7 mmol), dimethylamine · HCl (5.55 g, 68.1 mmol) and 
paraformaldehyde (2.05 g, 68.1 mmol) in EtOH (100 mL) was refluxed overnight. After 
removing the solvent under reduced pressure, an aqueous solution of NaOH (1 M, 100 mL) 
was added and the aqueous layer was extracted with Et2O (3 x 80 mL). The combined 
organic layers were dried over Na2SO4 and the solvent removed in vacuo yielding a colorless 
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oil (6.8 g, 85 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.82 – 1.94 (m, 2H, Fur-2-CH2-CH2), 
2.23 (s, 6H, CH3), 2.70 (t, 2H, 3J = 7.4 Hz, Fur-2-CH2), 3.39 (s, 2H, Fur-5-CH2), 3.64 (t, 2H, 3J 
= 6.4 Hz, Fur-2-(CH2)2-CH2), 5.91 (d, 1H, 3J = 3.0 Hz, Fur-3-H), 6.06 (d, 1H, 3J = 3.0 Hz, Fur-
4-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 24.47 (-, Fur-2-CH2-CH2), 31.14 (-, Fur-2-CH2), 
44.92 (+, 2 CH3), 55.92 (-, Fur-5-CH2), 61.91 (-, Fur-2-(CH2)2-CH2), 105.45 (+, Fur-C-3), 
109.20 (+, Fur-C-4), 150.99 (Cquat, Fur-C-5), 155.59 (Cquat, Fur-C-2). CI-MS (NH3) m/z (%): 
184 (100) [M + H]+. C10H17NO2 (183.25). 
 
3-(1-Trityl-1H-imidazol-2-yl)propan-1-ol (5.12)11 
5.1111 (8.0 g, 23.4 mmol) was dissolved in THFabs (240 mL) under an argon atmosphere and 
cooled to – 78 °C. n-BuLi 1.6 M in hexane (15.6 mL, 25.0 mmol) was added dropwise 
(internal temperature < – 65 °C) and stirred for 1 h at – 78 °C. Oxirane (ca. 5.9 mL, 5.15 g, 
117 mmol) was condensed into THFabs (5 mL) at – 78 °C and added to the mixture. The 
reaction mixture was allowed to slowly warm to ambient temperature and stirred overnight. 
After addition of NH4Cl (1 M, 150 mL), the product was extracted with EtOAc (4 x 70 mL) and 
the combined organic layers dried over Na2SO4. The solvent was removed in vacuo and 
purification by flash chromatography (DCM/MeOH 97.5/2.5 v/v) yielded a white solid (4.5 g, 
52 %); mp 154 – 155 °C (ref.11: 157.5 – 157.9 °C). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 
1.31 – 1.42 (m, 2H, Im-2-CH2-CH2), 2.09 (t, 2H, 3J = 6.3 Hz, Im-2-CH2), 3.50 (t, 2H, 3J = 5.3 
Hz, Im-2-(CH2)2-CH2), 6.68 (d, 1H, 3J = 1.5 Hz, Im-4-H), 6.91 (d, 1H, 3J = 1.5 Hz, Im-5-H), 
7.08 – 7.17 (m, 6H, Ph-H), 7.29 – 7.38 (m, 9H, Ph-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 
29.18, 29.49 (-, Im-2-CH2-CH2), 62.87 (-, Im-2-(CH2)2-CH2), 75.01 (Cquat, CPh3), 121.34 (+, 
Im-C-5), 124.73 (+, Im-C-4), 127.95 (+, 3 Ph-C-4), 128.11 (+, 6 Ph-C), 129.89 (+, 6 Ph-C), 
142.46 (Cquat, 3 Ph-C-1), 150.45 (Cquat, Im-C-2). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
369 (44) [M + H]+, 243 (100) [CPh3+]. Anal. (C25H24N2O) C, H, N. C25H24N2O (368.47)  
 
4-Iodo-1-trityl-1H-pyrazole (5.14)34 
To a solution of 5.13 (5.0 g, 25.8 mmol) and tritylchloride (7.19 g, 25.8 mmol) in DCM (100 
mL), NEt3 (4.3 mL, 3.13 g, 31.0 mmol) was added dropwise at 0 °C. After addition was 
complete, the mixture was allowed to warm to ambient temperature and stirred for 12 h. The 
organic layer was washed with H2O (2 x 30 mL) and dried over Na2SO4. After concentration 
in vacuo, the product was crystallized from DCM/hexane and washed with hexane yielding a 
white solid (7.3 g, 65 %); mp 189 °C. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 6.99 – 7.07 
(m, 6H, Ph-H), 7.32 – 7.41 (m, 9H, Ph-H), 7.44 (d, 1H, 4J = 0.5 Hz, Pyraz-3-H), 7.74 (d, 1H, 
4J = 0.5 Hz, Pyraz-5-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 57.42 (Cquat, Pyraz-C-4), 
78.53 (Cquat, CPh3), 127.81 (+, 9 Ph-C), 129.49 (+, 6 Ph-C), 135.99 (+, Pyraz-C-5), 142.36 
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(Cquat, 3 Ph-C-1), 144.23 (+, Pyraz-C-3). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 437 (1) [M 
+ H]+, 243 (100) [CPh3+]. Anal. (C22H17IN2) C, H, N. C22H17IN2 (436.29). 
 
3-(1-Trityl-1H-pyrazol-4-yl)prop-2-yn-1-ol (5.15) 
To a solution of 5.14 (10.6 g, 24.3 mmol), Pd(PPh3)2Cl2 (0.51 g, 0.7 mmol), CuI (0.23 g, 1.2 
mmol) and diisopropylamine (15.5 mL, 11.1 g, 109.4 mmol) in degassed DMF, a solution of 
propargylalcohol (1.5 g, 26.7 mmol) in THF (10 mL) was added at –15 °C. After addition was 
complete, the mixture was stirred for 48 h at room temperature. The solvent was removed in 
vacuo, the residue dissolved in 200 mL EtOAc and washed with water (2 x 80 mL). After 
drying over MgSO4, the solvent was evaporated and the crude product purified by flash 
chromatography (PE/EtOAc 80/20 v/v) yielding a beige solid (7.2 g, 81 %); mp 194 – 196 °C. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.68 (brs, 1H, OH), 4.40 (s, 2H, CH2), 7.09 – 7.17 (m, 
6H, Ph-H), 7.27 – 7.36 (m, 9H, Ph-H), 7.52 (d, 1H, 4J = 0.5 Hz, Pyraz-H), 7.74 (d, 1H, 4J = 
0.5 Hz, Pyraz-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 51.70 (-, CH2), 77.45 (Cquat, CPh3), 
79.18 (Cquat, Pyraz-4-C≡C), 88.31 (Cquat, Pyraz-4-C≡C), 101.26 (Cquat, Pyraz-C-4), 127.88 (+, 
6 Ph-C), 127.98 (+, 3 Ph-C), 130.12 (+, 6 Ph-C), 135.61 (+, Pyraz-C-5), 142.22 (+, Pyraz-C-
3), 142.64 (Cquat, 3 Ph-C-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 729 (12) [2M + H]+, 
243 (100) [CPh3+]. Anal. (C25H20N2O · 0.25 H2O) C, H, N. C25H20N2O (364.44). 
 
3-(1-Trityl-1H-pyrazol-4-yl)propan-1-ol (5.16) 
5.15 (7.1 g, 19.5 mmol) was dissolved in MeOH (200 mL) and hydrogenated over Pd/C (10 
%) (0.71 g) at room temperature overnight. After removing the catalyst by filtration over 
Celite, the solvent was evaporated and the crude product recrystallized from MeCN yielding 
a beige solid (6.8 g, 95 %); mp 94 – 97 °C (ref.35: 129 – 131 °C (Et2O)). 1H-NMR (300 MHz, 
DMSO-d6): δ [ppm] = 1.55 – 1.68 (m, 2H, Pyraz-4-CH2-CH2), 2.42 (t, 2H, 3J = 7.6 Hz, Pyraz-
4-CH2), 3.37 (t, 2H, 3J = 6.4 Hz, Pyraz-4-(CH2)2-CH2), 4.39 (brs, 1H, OH), 6.98 – 7.42 (m, 
16H, Ph-H + Pyraz-H), 7.47 (s, 1H, Pyraz-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 19.84 
(-, Pyraz-4-CH2), 33.64 (-, Pyraz-4-CH2-CH2), 59.83 (-, Pyraz-4-(CH2)2-CH2), 77.51 (Cquat, 
CPh3), 119.74 (Cquat, Pyraz-C-4), 127.52 (+, 3 Ph-C-4), 127.62 (+, 6 Ph-C), 129.54 (+, 6 Ph-
C), 130.17 (+, Pyraz-C-5), 138.98 (+, Pyraz-C-3), 143.12 (Cquat, 3 Ph-C-1). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 369 (30) [M + H]+, 243 (100) [CPh3+]. Anal. (C25H24N2O) C, 
H, N. C25H24N2O (368.47). 
 
1-Trityl-1H-1,2,4-triazole (5.18)  
To a solution of 5.17 (6.91 g, 100 mmol) and tritylchloride (27.9 g, 100 mmol) in DCM (100 
mL), NEt3 (13.8 mL, 10.1 g, 100 mmol) was added dropwise. After addition was complete, 
the mixture was stirred overnight. The organic layer was washed with a saturated solution of 
Structure-activity relationships of NG-acylated arylpropylguanidines 181
NaCl (3 x 30 mL) and dried over Na2SO4. After concentration in vacuo, the residue was 
recrystallized from MeCN yielding a white solid (27.2 g, 87 %); mp 208 °C (ref.15: 213 - 214 
°C). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 7.09 – 7.19 (m, 6H, Ph-H), 7.29 – 7.39 (m, 9H, 
Ph-H), 8.03 (s, 1H, Triaz-H), 8.08 (s, 1H, Triaz-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 
78.14 (Cquat, CPh3), 128.09 (+, 6 Ph-C), 128.31 (+, 3 Ph-C), 130.00 (+, 6 Ph-C), 141.92 (Cquat, 
3 Ph-C-1), 145.75 (+, Triaz-C-5), 151.91 (+, Triaz-C-3). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 623 (22) [2M + H]+, 243 (100) [CPh3+]. Anal. (C21H17N3) C, H, N. C21H17N3 (311.38). 
 
1-Trityl-1H-1,2,4-triazole-5-carbaldehyde (5.19)15  
5.18 (10.0 g, 32.1 mmol) and TMEDA (4.8 mL, 3.73 g, 32.1 mmol) were dissolved in THFabs 
(200 mL) under an argon atmosphere and cooled to – 78 °C. n-BuLi 1.6 M in hexane (22.1 
mL, 35.3 mmol) was added dropwise (internal temperature < – 65 °C) and stirred for 1 h at –
 78 °C. Anhydrous DMF (22.6 mL, 21.42 g, 29.3 mmol) was added dropwise to the mixture. 
After addition was complete, the mixture was stirred for 12 h at – 78 °C. The reaction mixture 
was allowed to warm to – 30 °C and poured in 200 mL of ice cold H2O. Extraction with EtOAc 
(3 x 150 mL), drying over Na2SO4 and evaporation of the volatiles gave the crude product. 
Purification by flash chromatography (PE/EtOAc 70/30 v/v) followed by recrystallization from 
EtOAc/hexane yielded a white solid (8.8 g, 25.8 mmol); mp 150 – 152 °C (ref.14: 156 °C). 1H-
NMR (300 MHz, CDCl3): δ [ppm] = 7.05 – 7.17 (m, 6H, Ph-H), 7.29 – 7.40 (m, 9H, Ph-H), 
8.10 (s, 1H, Triaz-3-H), 9.15 (s, 1H, COH). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 80.29 (Cquat, 
CPh3), 128.12 (+, 6 Ph-C), 128.52 (+, 3 Ph-C), 129.83 (+, 6 Ph-C), 141.65 (Cquat, 3 Ph-C-1), 
150.02 (+, Triaz-C-3), 151.67 (Cquat, Triaz-C-5), 177.98 (Cquat, C=O). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 372 (2) [M + MeOH + H]+, 243 (100) [CPh3+]. Anal. (C22H17N3O) C, H, N. 
C22H17N3O (339.39). 
 
Ethyl 3-(1-trityl-1H-1,2,4-triazol-5-yl)acrylate (5.20) 
To a solution of triethyl phosphonoacetate (6.67 g, 5.90 mL, 29.8 mmol) in THFabs (150 mL) 
NaH (60 % dispersion in mineral oil) (1.19 g, 29.8 mmol) was added in portions. After stirring 
for 1 h at ambient temperature, a solution of 5.19 (8.43 g, 24.8 mmol) in THFabs (75 mL) was 
added dropwise. When addition was complete, the mixture was stirred overnight at room 
temperature. The solvent was evaporated and the crude product was taken up in EtOAc 
(150 mL) and washed with water (3 x 50 mL). The organic layer was dried over Na2SO4, 
evaporated and the crude product purified by flash chromatography (PE/EtOAc 60/40 v/v) 
giving the E- and Z-isomer. Recrystallization from EtOAc/hexane yielded the E-isomer and 
the Z-isomer as white solid (E: 6.4 g, Z: 1.8 g, 67 %); mp (E) 184 – 186 °C, mp (Z) 145 – 
146 °C. 1H-NMR (300 MHz, CDCl3) (E)-isomer: δ [ppm] = 1.17 (t, 3H, 3J = 7.1 Hz, CH3), 4.06 
(q, 2H, 3J = 7.1 Hz, CH2), 6.59 (dd, 1H, 3J = 15.4 Hz, 5J = 0.6 Hz, Triaz-5-CH), 6.69 (d, 1H, 3J 
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= 15.4 Hz, CHCO), 7.06 – 7.17 (m, 6H, Ph-H), 7.28 – 7.38 (m, 9H, Ph-H), 7.97 (d, 1H, 5J = 
0.6 Hz, Triaz-3-H). 13C-NMR (75 MHz, CDCl3) (E)-isomer: δ [ppm] = 14.12 (+, CH3), 60.65 (-, 
CH2), 79.02 (Cquat, CPh3), 124.59 (+, vinyl-C), 128.01 (+, 6 Ph-C), 128.23 (+, 3 Ph-C), 129.32 
(+, vinyl-C), 129.97 (+, 6 Ph-C), 141.89 (Cquat, 3 Ph-C-1), 149.59 (+, Triaz-C-3), 152.39 (Cquat, 
Triaz-C-5), 165.47 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 410 (1) [M + H]+, 
243 (100) [CPh3+]. Anal. E-isomer (C26H23N3O2) C, H, N. C26H23N3O2 (409.48). 
1H-NMR (300 MHz, CDCl3) (Z)-isomer: δ [ppm] = 1.24 (t, 3H, 3J = 7.2 Hz, CH3), 4.19 (q, 2H, 
3J = 7.2 Hz, CH2), 5.56 (d, 1H, 3J = 12.0 Hz, Triaz-5-CH), 5.68 (d, 1H, 3J = 12.0 Hz, CHCO), 
7.10 – 7.20 (m, 6H, Ph-H), 7.26 – 7.38 (m, 9H, Ph-H), 7.96 (s, 1H, Triaz-3-H). 13C-NMR (75 
MHz, CDCl3) (Z)-isomer: δ [ppm] = 14.02 (+, CH3), 60.84 (-, CH2), 78.66 (Cquat, CPh3), 125.09 
(+, vinyl-C), 125.45 (+, vinyl-C), 127.85 (+, 6 Ph-C), 128.16 (+, 3 Ph-C), 130.29 (+, 6 Ph-C), 
141.72 (Cquat, 3 Ph-C-1), 149.29 (+, Triaz-C-3), 151.66 (Cquat, Triaz-C-5), 165.52 (Cquat, C=O). 
ES-MS (DCM/MeOH + NH4OAc) Z-isomer m/z (%): 410 (100) [M + H]+. Anal. Z-isomer 
(C26H23N3O2) C, H, N. C26H23N3O2 (409.48). 
 
Ethyl 3-(1-trityl-1H-1,2,4-triazol-5-yl)propanoate (5.21)36 
5.20 (8.0 g, 19.5 mmol) was dissolved in a mixture of EtOH (120 mL) / THF (30 mL) and 
hydrogenated over Pd/C (10 %) (0.80 g) at room temperature overnight. After removing the 
catalyst by filtration over Celite, the solvent was evaporated and the crude product 
recrystallized from hexane/EtOAc yielding a white solid (6.3 g, 79 %); mp 140 – 141 °C. 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.19 (t, 3H, 3J = 7.1 Hz, CH3), 2.17 – 2.25 (m, 2H, 
CH2), 2.28 – 2.35 (m, 2H, CH2), 4.06 (q, 2H, 3J = 7.1 Hz, CH2CH3), 7.09 – 7.18 (m, 6H, Ph-
H), 7.28 – 7.39 (m, 9H, Ph-H), 7.87 (s, 1H, Triaz-3-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 
14.20 (+, CH3), 24.38 (-, CH2), 31.09 (-, CH2), 60.47 (-, CH2CH3), 77.89 (Cquat, CPh3), 127.90 
(+, 6 Ph-C), 127.93 (+, 3 Ph-C), 130.04 (+, 6 Ph-C), 141.78 (Cquat, 3 Ph-C-1), 148.63 (+, 
Triaz-C-3), 156.60 (Cquat, Triaz-C-5), 172.18 (Cquat, C=O). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 412 (100) [M + H]+. Anal. (C26H25N3O2) C, H, N. C26H25N3O2 (411.50). 
 
3-(1-Trityl-1H-1,2,4-triazol-5-yl)propan-1-ol (5.22)36 
To a solution of 5.21 (6.0 g, 14.6 mmol) in THFabs, LiAlH4 (1.11 g, 29.2 mmol) was added in 
portions at 0 °C. After addition was complete, the mixture was allowed to warm to room 
temperature and refluxed for 2 h. Subsequently, under external ice cooling, H2O (1.1 mL), 
NaOH 15 % (1.1 mL) and H2O (4.4 mL) were added, insoluble material filtered off and 
washed with THF (2 x 50 mL). The combined organic layers were dried over Na2SO4 and the 
solvent evaporated in vacuo. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 
v/v) followed by recrystallization from hexane/EtOAc yielded a white solid (4.1 g, 76 %). 1H-
NMR (300 MHz, CDCl3): δ [ppm] = 1.34 – 1.47 (m, 2H, Triaz-5-CH2-CH2), 2.18 (t, 2H, 3J = 
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6.7 Hz, Triaz-5-CH2), 3.39 – 3.51 (m, 2H, Triaz-5-(CH2)2-CH2), 3.75 (brs, 1H, O-H), 7.06 – 
7.17 (m, 6H, Ph-H), 7.28 – 7.38 (m, 9H, Ph-H), 7.88 (s, 1H, Triaz-3-H). 13C-NMR (75 MHz, 
CDCl3): δ [ppm] = 27.27, 29.07 (-, Triaz-5-CH2-CH2), 62.30 (-, Triaz-5-(CH2)2-CH2), 77.93 
(Cquat, CPh3), 127.91 (+, 6 Ph-C), 127.94 (+, 3 Ph-C), 129.89 (+, 6 Ph-C), 141.92 (Cquat, 3 Ph-
C-1), 148.13 (+, Triaz-C-3), 157.82 (Cquat, Triaz-C-5). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 370 (100) [M + H]+. Anal. (C24H23N3O) C, H, N. C24H23N3O (369.46). 
 
Preparation of the 2-[3-(pyridyl)propyl]isoindoline-1,3-diones 5.26-5.28 
For the preparation of 5.26-5.28 see section 3.4.1.12 (compounds 3.120-3.122). 
 
Preparation of the 3-pyridylpropan-1-amines 5.29-5.31 
For the preparation of 5.29-5.31 see section 3.4.1.12 (compounds 3.15-3.17). 
 
5.4.1.3 Preparation of the guanidinylation reagents 5.35 and 5.36 
For the preparation of 5.35 and 5.36 see section 4.4.1.6 (compounds 4.28 and 4.29). 
 
5.4.1.4 Preparation of the di-Cbz-protected arylpropylguanidines 5.37-5.40 
General procedure 
To a solution of the pertinent alcohol (1 eq), the di-Cbz-protected guanidine 5.35 (1.5 eq) and 
PPh3 (1.5 eq) in THFabs, DIAD (1.5 eq) in THFabs was added dropwise at 0 °C. After the 
addition was complete, the solution was allowed to warm to room temperature and stirred 
overnight. The solvent was removed in vacuo and the crude product purified by flash 
chromatography. 
 
N1,N2-Bis(benzyloxycarbonyl)-N1-(3-{5-[(dimethylamino)methyl]furan-2-
yl}propyl)guanidine (5.37) 
The title compound was prepared from a solution of 5.10 (2.18 g, 11.9 mmol), 5.35 (5.84 g, 
17.9 mmol), PPh3 (4.68 g, 17.9 mmol) in THFabs (100 mL) and a solution of DIAD (3.5 mL, 
3.61 g, 17.9 mmol) in THFabs (30 mL) according to the general procedure. Purification by 
flash chromatography (DCM/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow oil. 
(4.1 g, 70 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.88 – 2.02 (m, 2H, Fur-2-CH2-CH2), 
2.22 (s, 6H, CH3), 2.61 (t, 2H, 3J = 7.5 Hz, Fur-2-CH2), 3.35 (s, 2H, Fur-5-CH2), 4.06 (t, 2H, 3J 
= 7.5 Hz, Fur-2-(CH2)2-CH2), 5.15 (s, 2H, Ph-CH2), 5.23 (s, 2H, Ph-CH2), 5.93 (d, 1H, 3J = 3.0 
Hz, Fur-3-H), 6.00 (d, 1H, 3J = 3.0 Hz, Fur-4-H), 9.25 (brs, 1H, N-H), 9.44 (brs, 1H, N-H). 13C-
NMR (75 MHz, CDCl3): δ [ppm] = 25.38 (-, CH2), 26.86 (-, CH2), 44.47 (-, Fur-2-(CH2)2-CH2), 
44.97 (+, 2 CH3), 55.96 (-, Fur-5-CH2), 67.06 (-, Ph-CH2), 68.89 (-, Ph-CH2), 105.35 (+, Fur-
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C-3), 109.12 (+, Fur-C-4), 127.82 (+, 1 Ph-C), 127.95 (+, 2 Ph-C), 128.30 (+, 2 Ph-C), 128.41 
(+, 2 Ph-C), 128.80 (+, 3 Ph-C), 134.75 (Cquat, 1 Ph-C-1), 137.06 (Cquat, 1 Ph-C-1), 150.58 
(Cquat, Fur-C-5), 154.90 (Cquat, Fur-C-2), 155.96, 160.62, 163.97 (Cquat, 2 C=O + C=N). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 493 (100) [M + H]+. C27H32N4O5 (492.57). 
 
N1,N2-Bis(benzyloxycarbonyl)-N1-[3-(1-trityl-1H-imidazol-2-yl)propyl]guanidine (5.38) 
The title compound was prepared from a solution of 5.12 (3.9 g, 10.6 mmol), 5.35 (5.20 g, 
15.9 mmol), PPh3 (4.17 g, 15.9 mmol) in THFabs (100 mL) and a solution of DIAD (3.1 mL, 
3.22 g, 15.9 mmol) in THFabs (30 mL) according to the general procedure. Purification by 
flash chromatography (PE/EtOAc 60/40 v/v) yielded a colorless foam-like solid. (5.6 g, 78 %). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.59 – 1.74 (m, 2H, Im-2-CH2-CH2), 1.93 (t, 2H, 3J = 
8.2 Hz, Im-2-CH2), 3.75 (t, 2H, 3J = 6.8 Hz, Im-2-(CH2)2-CH2), 5.07 (s, 2H, Ph-CH2), 5.08 (s, 
2H, Ph-CH2), 6.66 (d, 1H, 3J = 1.5 Hz, Im-4-H), 6.94 (d, 1H, 3J = 1.5 Hz, Im-5-H), 7.03 – 7.09 
(m, 6H, Ph-H), 7.20 – 7.42 (m, 19H, Ph-H), 9.08 (brs, 1H, N-H), 9.36 (brs, 1H, N-H). 13C-
NMR (75 MHz, CDCl3): δ [ppm] = 26.95, 27.83 (-, Im-2-CH2-CH2), 44.10 (-, Im-2-(CH2)2-CH2), 
67.10 (+, Ph-CH2), 68.59 (+, Ph-CH2), 74.70 (Cquat, CPh3), 121.18 (+, Im-C-5), 125.49 (+, Im-
C-4), 127.78 (+, 3 Ph-C), 127.83 (+, 1 Ph-C), 128.00 (+, 6 Ph-C), 128.07 (+, 2 Ph-C), 128.10 
(+, 2 Ph-C), 128.40 (+, 2 Ph-C), 128.63 (+, 1 Ph-C), 128.73 (+, 2 Ph-C), 129.74 (+, 6 Ph-C), 
134.81 (Cquat, Ph-C-1), 137.09 (Cquat, Ph-C-1), 142.53 (Cquat, 3 Ph-C-1), 149.74 (Cquat, Im-C-
2), 155.80, 160.49, 163.75 (Cquat, 2 C=O + C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
678 (100) [M + H]+. C42H39N5O4 (677.79). 
 
N1,N2-Bis(benzyloxycarbonyl)-N1-[3-(1-trityl-1H-pyrazol-4-yl)propyl]guanidine (5.39) 
The title compound was prepared from a solution of 5.16 (4.4 g, 11.9 mmol), 5.35 (5.86 g, 
17.9 mmol), PPh3 (4.69 g, 17.9 mmol) in THFabs (100 mL) and a solution of DIAD (3.5 mL, 
3.62 g, 17.9 mmol) in THFabs (30 mL) according to the general procedure. Purification by 
flash chromatography (PE/EtOAc 80/20 v/v) followed by crystallization from DCM/hexane 
yielded a white solid. (6.1 g, 76 %); mp 144 – 145 °C. 1H-NMR (300 MHz, CDCl3): δ [ppm] = 
1.73 – 1.89 (m, 2H, Pyraz-4-CH2-CH2), 2.40 (t, 2H, 3J = 7.9 Hz, Pyraz-4-CH2), 4.02 (t, 2H, 3J 
= 7.4 Hz, Pyraz-4-(CH2)2-CH2), 5.13 (s, 2H, Ph-CH2), 5.19 (s, 2H, Ph-CH2), 7.09 – 7.18 (m, 
7H, Ph-H + Pyraz-3-H), 7.24 – 7.42 (m, 19H, Ph-H), 7.44 (s, 1H, Pyraz-5-H), 9.26 (brs, 1H, 
N-H), 9.44 (brs, 1H, N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 21.66 (-, Pyraz-4-CH2), 
29.87 (-, Pyraz-4-CH2-CH2), 44.65 (-, Pyraz-4-(CH2)2-CH2), 67.06 (+, Ph-CH2), 68.82 (+, Ph-
CH2), 78.37 (Cquat, CPh3), 119.39 (Cquat, Pyraz-C-4), 127.64 (+, 3 Ph-C), 127.70 (+, 6 Ph-C), 
127.85 (+, 1 Ph-C), 127.96 (+, 2 Ph-C), 128.30 (+, 2 Ph-C), 128.44 (+, 2 Ph-C), 128.82 (+, 2 
Ph-C), 128.85 (+, 1 Ph-C), 130.17 (+, 6 Ph-C), 130.36 (+, Pyraz-C-5), 134.72 (Cquat, 1 Ph-C-
1), 137.05 (Cquat, 1 Ph-C-1), 139.10 (+, Pyraz-C-3), 143.48 (Cquat, 3 Ph-C-1), 155.96, 160.67, 
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163.98 (Cquat, 2 C=O + C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 678 (100) [M + H]+. 
Anal. (C42H39N5O4) C, H, N. C42H39N5O4 (677.79). 
 
N1,N2-Bis(benzyloxycarbonyl)-N1-[3-(1-trityl-1H-1,2,4-triazol-5-yl)propyl]guanidine (5.40) 
The title compound was prepared from a solution of 5.22 (3.86 g, 10.4 mmol), 5.35 (5.14 g, 
15.7 mmol), PPh3 (4.12 g, 15.7 mmol) in THFabs (100 mL) and a solution of DIAD (3.1 mL, 
3.17 g, 15.7 mmol) in THFabs (50 mL) according to the general procedure. Purification by 
flash chromatography (PE/EtOAc 80/20 v/v) followed by recrystallization from EtOAc/hexane 
yielded a white solid. (6.2 g, 87 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.59 – 1.71 (m, 
2H, Triaz-5-CH2-CH2), 2.02 (t, 2H, 3J = 8.1 Hz, Triaz-5-CH2), 3.77 (t, 2H, 3J = 6.9 Hz, Triaz-5-
(CH2)2-CH2), 5.09 (s, 2H, Ph-CH2), 5.10 (s, 2H, Ph-CH2), 7.01 – 7.10 (m, 6H, Ph-H), 7.19 – 
7.42 (m, 19H, Ph-H), 7.86 (s, 1H, Triaz-5-H), 9.11 (brs, 1H, N-H), 9.37 (brs, 1H, N-H). 13C-
NMR (75 MHz, CDCl3): δ [ppm] = 26.37, 26.56 (-,Triaz-5-CH2-CH2), 43.83 (-, Triaz-5-(CH2)2-
CH2), 67.10 (+, Ph-CH2), 68.77 (+, Ph-CH2), 77.66 (Cquat, CPh3), 127.81 (+, 3 Ph-C), 127.83 
(+, 6 Ph-C), 127.93 (+, 1 Ph-C), 128.11 (+, 2 Ph-C), 128.20 (+, 2 Ph-C), 128.45 (+, 2 Ph-C), 
128.79 (+, 3 Ph-C), 129.75 (+, 6 Ph-C), 134.66 (Cquat, 1 Ph-C-1), 136.97 (Cquat, 1 Ph-C-1), 
141.94 (Cquat, 3 Ph-C-1), 148.71 (+, Triaz-C-3), 155.73, 160.43, 163.76 (Cquat, 2 C=O + C=N). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 679 (100) [M + H]+. Anal. (C41H38N6O4) C, H, N. 
C41H38N6O4 (678.78). 
 
5.4.1.5 Preparation of the di-Cbz-protected arylpropylguanidines 5.41-5.45 
General procedure 
To a solution of the pertinent amine (1 eq) and 5.36 (0.9 eq) in DCM NEt3 (1 eq) was added. 
After stirring overnight at room temperature, the organic layer was washed with saturated 
NaHCO3 solution, water and brine and dried over Na2SO4. The solvent was removed in 
vacuo and the crude product was purified by flash chromatography. 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-(3-phenylpropyl)guanidine (5.41) 
The title compound was prepared from 5.32 (0.78 g, 5.8 mmol), 5.36 (2.39 g, 5.2 mmol) and 
NEt3 (0.8 mL, 0.59 g, 5.8 mmol) in DCM (50 mL) according to the general procedure. 
Purification by flash chromatography (PE/EtOAc 80/20 v/v) yielded a colorless oil (1.8 g, 70 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.86 – 1.99 (m, 1H, Ph-CH2-CH2), 2.68 (t, 2H, 3J = 
7.7 Hz, Ph-CH2), 3.42 – 3.52 (m, 2H, Ph-(CH2)2-CH2), 5.14 (s, 2H, Ph-CH2-O), 5.19 (s, 2H, 
Ph-CH2-O), 7.14 – 7.45 (m, 15H, Ph-H), 8.36 (t, 1H, 3J = 4.8 Hz, N-H), 11.76 (s, 1H, N-H). 
13C-NMR (75 MHz, CDCl3): δ [ppm] = 30.56 (-, Ph-CH2-CH2), 33.03 (-, Ph-CH2), 40.57 (-, Ph-
CH2-CH2-CH2), 67.21 (-, Ph-CH2-O), 68.19 (-, Ph-CH2-O), 126.08 (+, 1 Ph-C), 127.92 (+, 1 
Ph-C), 128.16 (+, 2 Ph-C), 128.38 (+, 2 Ph-C), 128.42 (+, 2 Ph-C), 128.48 (+, 2 Ph-C), 
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128.50 (+, 2 Ph-C), 128.73 (+, 2 Ph-C), 128.81 (+, 1 Ph-C), 134.69 (Cquat, 1 Ph-C), 136.88 
(Cquat, 1 Ph-C), 141.07 (Cquat, 1 Ph-C), 153.94 (Cquat, C=O), 156.05 (Cquat, C=N), 163.78 (Cquat, 
C=O). CI-MS (NH3) m/z (%): 446 (99) [M + H]+, 312 (100) [M – Ph-CH2-OCO + H]+. 
C26H27N3O4 (445.51). 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-[3-(pyridin-2-yl)propyl]guanidine (5.42) 
The title compound was prepared from 5.29 (1.71 g, 12.6 mmol), 5.36 (5.19 g, 11.3 mmol) 
and NEt3 (1.7 mL, 1.27 g, 12.6 mmol) in DCM (100 mL) according to the general procedure. 
Purification by flash chromatography (PE/EtOAc 80/20 v/v) yielded a pale yellow oil (4.3 g, 
84 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.99 – 2.11 (m, 2H, Pyr-2-CH2-CH2), 2.85 (t, 
2H, 3J = 7.6 Hz, Pyr-2-CH2), 3.45 – 3.54 (m, 2H, Pyr-2-(CH2)2-CH2), 5.12 (s, 2H, PhCH2), 
5.17 (s, 2H, PhCH2), 7.08 (ddd, 1H, 3J = 7.5 Hz, 3J = 4.9 Hz, 4J = 1.2 Hz, Pyr-5-H), 7.15 (ddd, 
1H, 3J = 7.8 Hz, 4J = 1.2 Hz, 5J = 0.9 Hz, Pyr-3-H), 7.56 (ddd, 1H, 3J = 7.8 Hz, 3J = 7.5 Hz, 4J 
= 1.8 Hz, Pyr-4-H), 8.44 (t, 1H, 3J = 5.0 Hz, N-H), 8.51 (ddd, 1H, 3J = 4.9 Hz, 4J = 1.8 Hz, 5J = 
0.9 Hz, Pyr-6-H), 11.72 (brs, 1H, N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 28.67 (-, Pyr-2-
CH2-CH2), 35.34 (-, Pyr-2-CH2), 40.63 (-, Pyr-2-(CH2)2-CH2), 67.17 (-, PhCH2), 68.16 (-, 
PhCH2), 121.26 (+, Pyr-C-5), 122.93 (+, Pyr-C-3), 127.93 (+, 1 Ph-C), 128.18 (+, 2 Ph-C), 
128.43 (+, 2 Ph-C), 128.52 (+, 2 Ph-C), 128.73 (+, 2 Ph-C), 128.81 (+, 1 Ph-C), 134.70 (Cquat, 
1 Ph-C-1), 136.46 (+, Pyr-C-4), 136.86 (Cquat, 1 Ph-C-1), 149.41 (+, Pyr-C-6), 153.82, 156.03, 
163.76 (Cquat, 2 C=O + C=N), (Cquat, C=O), 160.77, (Cquat, Pyr-C-2). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 447 (100) [M + H]+. C25H26N4O4 (446.50). 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-[3-(pyridin-3-yl)propyl]guanidine (5.43) 
The title compound was prepared from 5.30 (1.93 g, 14.2 mmol), 5.36 (5.86 g, 12.8 mmol) 
and NEt3 (2.0 mL, 1.44 g, 14.2 mmol) in DCM (100 mL) according to the general procedure. 
Purification by flash chromatography (PE/EtOAc 60/40 v/v) yielded a colorless oil (4.4 g, 76 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.86 – 1.99 (m, 2H, Pyr-3-CH2-CH2), 2.67 (t, 2H, 3J 
= 7.8 Hz, Pyr-3-CH2), 3.43 – 3.54 (m, 2H, Pyr-3-(CH2)2-CH2), 5.13 (s, 2H, PhCH2), 5.18 (s, 
2H, PhCH2), 7.19 (dd, 1H, 3J = 7.8 Hz, 3J = 4.8 Hz, 5J = 0.6 Hz, Pyr-5-H), 7.27 – 7.43 (m, 
10H, Ph-H), 7.51 (ddd, 1H, 3J = 7.8 Hz, 4J = 2.1 Hz, 4J = 1.8 Hz, Pyr-4-H), 8.38 (t, 1H, 3J = 
5.1 Hz, N-H), 8.42 – 8.49 (m, 2H, Pyr-2,6-H), 11.75 (brs, 1H, N-H). 13C-NMR (75 MHz, 
CDCl3): δ [ppm] = 30.19, 30.32 (-, Pyr-3-CH2-CH2), 40.38 (-, Pyr-3-(CH2)2-CH2), 67.23 (-, 
PhCH2), 68.26 (-, PhCH2), 123.40 (+, Pyr-C-5), 127.98 (+, 1 Ph-C), 128.19 (+, 2 Ph-C), 
128.45 (+, 2 Ph-C), 128.51 (+, 2 Ph-C), 128.74 (+, 2 Ph-C), 128.86 (+, 1 Ph-C), 134.60 (Cquat, 
1 Ph-C-1), 135.78 (+, Pyr-C-4), 136.34 (Cquat, Pyr-C-3), 136.78 (Cquat, 1 Ph-C-1), 147.72 (+, 
Pyr-C-6), 149.91 (+, Pyr-C-2), 153.95, 156.10, 163.73 (Cquat, 2 C=O + C=N). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 447 (100) [M + H]+. C25H26N4O4 (446.50). 
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N1,N2-Bis(benzyloxycarbonyl)-N3-[4-(pyridin-4-yl)propyl]guanidine (5.44) 
The title compound was prepared from 5.31 (1.43 g, 10.5 mmol), 5.36 (4.34 g, 9.5 mmol) and 
NEt3 (1.5 mL, 1.06 g, 10.5 mmol) in DCM (100 mL) according to the general procedure. 
Purification by flash chromatography (PE/EtOAc 40/60 v/v) yielded a colorless oil (3.7 g, 88 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.85 – 2.01 (m, 2H, Pyr-4-CH2-CH2), 2.66 (t, 2H, 3J 
= 7.7 Hz, Pyr-4-CH2), 3.40 – 3.54 (m, 2H, Pyr-4-(CH2)2-CH2), 5.13 (s, 2H, PhCH2), 5.18 (s, 
2H, PhCH2), 7.12 (dd, 2H, 3J = 4.4 Hz, 4J = 1.6 Hz, Pyr-3,5-H), 7.28 – 7.43 (m, 10H, Ph-H), 
8.37 (t, 1H, 3J = 5.0 Hz, N-H), 7.12 (dd, 2H, 3J = 4.4 Hz, 4J = 1.6 Hz, Pyr-2,6-H), 11.74 (brs, 
1H, N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 29.49, 32.32 (-, Pyr-4-CH2-CH2), 40.35 (-, 
Pyr-4-(CH2)2-CH2), 67.25 (-, PhCH2), 68.29 (-, PhCH2), 123.81 (+, Pyr-C-3,5), 128.01 (+, 1 
Ph-C), 128.20 (+, 2 Ph-C), 128.46 (+, 2 Ph-C), 128.51 (+, 2 Ph-C), 128.75 (+, 2 Ph-C), 
128.87 (+, 1 Ph-C), 134.58 (Cquat, 1 Ph-C-1), 136.74 (Cquat, 1 Ph-C-1), 149.91 (+, Pyr-C-2,6), 
150.00 (Cquat, Pyr-C-4), 153.96, 156.10, 163.73 (Cquat, 2 C=O + C=N). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 447 (100) [M + H]+. C25H26N4O4 (446.50). 
 
N1,N2-Bis(benzyloxycarbonyl)-N3-[3-(1H-imidazol-1-yl)propyl]guanidine (5.45) 
The title compound was prepared from 5.33 (2.09 g, 16.7 mmol), 5.36 (6.90 g, 15.0 mmol) 
and NEt3 (2.3 mL, 1.69 g, 16.7 mmol) in DCM (100 mL) according to the general procedure. 
Purification by flash chromatography (DCM/MeOH 97.5/2.5 v/v) yielded a pale yellow oil (5.4 
g, 83 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 2.00 – 2.14 (m, 2H, Im-1-CH2-CH2), 3.39 – 
3.49 (m, 2H, Im-1-(CH2)2-CH2), 4.00 (t, 2H, 3J = 7.0 Hz, Im-1-CH2), 5.13 (s, 2H, Ph-CH2), 
5.18 (s, 2H, Ph-CH2), 6.94 – 6.96 (m, 1H, Im-4-H), 7.04 – 7.06 (m, 1H, Im-5-H), 7.27 – 7.43 
(m, 10H, Ph-H), 7.50 – 7.52 (m, 1H, Im-2-H), 8.38 (t, 1H, 3J = 5.6 Hz, N-H), 11.72 (brs, 1H, 
N-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 30.73 (-, Im-1-CH2-CH2), 37.93 (-, Im-1-(CH2)2-
CH2), 44.43 (-, Im-1-CH2), 67.29 (-, Ph-CH2), 68.41 (-, Ph-CH2), 118.81 (+, Im-C-5), 128.05 
(+, 1 Ph-C), 128.15 (+, 2 Ph-C), 128.49 (+, 2 Ph-C), 128.55 (+, 2 Ph-C), 128.77 (+, 2 Ph-C), 
128.92 (+, 1 Ph-C), 129.67 (+, Im-C-4), 134.50 (Cquat, 1 Ph-C-1), 136.64 (Cquat, 1 Ph-C-1), 
137.11 (+, Im-C-2), 153.94, 156.30, 163.65 (Cquat, 2 C=O + C=N). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 436 (100) [M + H]+. C23H25N5O4 (435.48). 
 
5.4.1.6 Preparation of the arylpropylguanidines 5.46-5.54 
General procedure 
A mixture of the pertinent di-Cbz-protected guanidine and catalytical amounts of Pd/C (10 %) 
in MeOH was stirred under an hydrogen atmosphere at room temperature for approximately 
3 h (TLC control). After the Cbz-groups were quantitatively cleaved, the catalyst was 
removed by filtration over Celite and the solvent was evaporated. For analytical purposes a 
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small amount of some compounds (5.37, 5.41, 5.43-5.45) was converted into the picrate by 
addition of a saturated solution of picric acid in EtOH and recrystallization from EtOH/H2O. 
 
N-(3-{5-[(Dimethylamino)methyl]furan-2-yl}propyl)guanidine (5.46) 
The title compound was prepared from 5.37 (3.0 g, 6.1 mmol) and Pd/C (10 %) (0.30 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a colorless oil (1.3 g, 95 %); 
mp (5.46 · 2 C6H3N3O7) 185 – 187 °C (dec.). 1H-NMR (300 MHz, DMSO-d6, dipicrate): δ 
[ppm] = 1.72 – 1.86 (m, 2H, Fur-2-CH2-CH2), 2.65 (t, 2H, 3J = 7.7 Hz, Fur-2-CH2), 2.73 (s, 
6H, CH3), 3.09 – 3.22 (m, 2H, Fur-2-(CH2)2-CH2), 4.31 (s, 2H, Fur-5-CH2), 6.23 (d, 1H, 3J = 
3.2 Hz, Fur-3-H), 6.60 (d, 1H, 3J = 3.2 Hz, Fur-4-H), 7.02 (brs, 4H, N-H), 7.48 (t, 1H, 3J = 5.6 
Hz, N-H), 8.60 (s, 4H, picrate-H), 9.73 (brs, 1H, N-H). 13C-NMR (75 MHz, DMSO-d6, 
dipicrate): δ [ppm] = 24.46 (-, CH2), 26.72 (-, CH2), 40.01 (-, Fur-2-(CH2)2-CH2), 41.52 (+, 2 
CH3), 51.80 (-, Fur-5-CH2), 106.77 (+, Fur-C-3), 114.94 (+, Fur-C-4), 124.14 (Cquat, picrate-C-
4), 125.14 (+, picrate-C-3,5), 141.75 (Cquat, picrate-C-2,6), 142.69 (Cquat, Fur-C-5), 156.55 
(Cquat, C=N), 156.81 (Cquat, Fur-C-2) 160.73 (Cquat, picrate-C-1). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 225 (100) [M + H]+. Anal. (C11H20N4O · 2 C6H3N3O7) C, H, N. C11H20N4O 
(224.30). 
 
N-[3-(1-Trityl-1H-imidazol-2-yl)propyl]guanidine (5.47) 
The title compound was prepared from 5.38 (5.57 g, 8.2 mmol) and Pd/C (10 %) (0.56 g, 
cat.) in MeOH (150 mL) according to the general procedure yielding a white solid (3.2 g, 95 
%); mp 158 – 162 °C. 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.23 – 1.35 (m, 2H, Im-2-CH2-
CH2), 2.05 (t, 2H, 3J = 7.5 Hz, Im-2-CH2), 2.85 (t, 2H, 3J = 7.1 Hz, Im-2-(CH2)2-CH2), 6.80 (d, 
1H, 3J = 1.6 Hz, Im-4-H), 6.95 (d, 1H, 3J = 1.6 Hz, Im-5-H), 7.09 – 7.19 (m, 6H, Ph-H), 7.32 – 
7.44 (m, 9H, Ph-H). 13C-NMR (75 MHz, CD3OD): δ [ppm] = 27.72, 28.60 (-, Im-2-CH2-CH2), 
41.77 (-, Im-2-(CH2)2-CH2), 76.50 (Cquat, CPh3), 122.68 (+, Im-C-5), 125.94 (+, Im-C-4), 
129.33 (+, 3 Ph-C), 129.39 (+, 6 Ph-C), 131.05 (+, 6 Ph-C), 143.67 (Cquat, 3 Ph-C-1), 150.71 
(Cquat, Im-C-2), 158.74 (Cquat, C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 410 (100) [M + 
H]+. HRMS (EI-MS) calcd. for C26H27N5 [M+•] 409.2267; found 409.2266. C26H27N5 (409.53). 
 
N-(3-(1-Trityl-1H-pyrazol-4-yl)propyl)guanidine (5.48) 
The title compound was prepared from 5.39 (5.5 g, 8.1 mmol) and Pd/C (10 %) (0.55 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a white solid (3.2 g, 96 %). 
1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.72 – 1.87 (m, 2H, Pyraz-4-CH2-CH2), 2.53 (t, 2H, 3J 
= 7.6 Hz, Pyraz-4-CH2), 3.14 (t, 2H, 3J = 7.0 Hz, Pyraz-4-(CH2)2-CH2), 7.05 – 7.17 (m, 6H, 
Ph-H), 7.24 – 7.38 (m, 10H, Ph-H + Pyraz-3-H), 7.49 (s, 1H, Pyraz-5-H). 13C-NMR (75 MHz, 
CD3OD): δ [ppm] = 22.08 (-, Pyraz-4-CH2), 31.20 (-, Pyraz-4-CH2-CH2), 41.85 (-, Pyraz-4-
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(CH2)2-CH2), 79.93 (Cquat, CPh3), 120.83 (Cquat, Pyraz-C-4), 128.90 (+, 6 Ph-C), 128.98 (+, 3 
Ph-C), 131.22 (+, 6 Ph-C), 132.31 (+, Pyraz-C-5), 140.31 (+, Pyraz-C-3), 144.56 (Cquat, 3 Ph-
C-1), 158.94 (Cquat, C=N). EI-MS (70 eV) m/z (%): 409 (16) [M+•], 243 (100) [CPh3+]. HRMS 
(EI-MS) calcd. for C26H27N5 [M+•] 409.2267; found 409.2265. C26H27N5 (409.53). 
 
N-[3-(1-Trityl-1H-1,2,4-triazol-5-yl)propyl]guanidine (5.49) 
The title compound was prepared from 5.40 (4.4 g, 6.5 mmol) and Pd/C (10 %) (0.44 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a colorless foam-like solid 
(2.6 g, 98 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.31 – 1.44 (m, 2H, Triaz-5-CH2-CH2), 
2.14 (t, 2H, 3J = 7.5 Hz, Triaz-5-CH2), 2.91 (t, 2H, 3J = 7.0 Hz, Triaz-5-(CH2)2-CH2), 7.06 – 
7.15 (m, 6H, Ph-H), 7.30 – 7.40 (m, 9H, Ph-H), 7.92 (s, 1H, Triaz-5-H). 13C-NMR (75 MHz, 
CD3OD): δ [ppm] = 27.22, 27.33 (-, Triaz-5-CH2-CH2), 41.53 (-, Triaz-5-(CH2)2-CH2), 79.53 
(Cquat, CPh3), 129.11 (+, 6 Ph-C), 129.15 (+, 3 Ph-C), 131.09 (+, 6 Ph-C), 143.21 (Cquat, 3 Ph-
C-1), 149.01 (+, Triaz-C-3), 158.55, 158.74 (Cquat, C=N + Triaz-C-5). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 411 (100) [M + H]+. HRMS (EI-MS) calcd. for C25H26N6 [M+•] 410.2219; 
found 410.2214. C25H26N6 (410.51).  
 
3-Phenylpropylguanidine (5.50)37 
The title compound was prepared from 5.41 (1.72 g, 3.9 mmol) and Pd/C (10 %) (0.17 g, 
cat.) in MeOH (80 mL) according to the general procedure yielding a colorless foam-like solid 
(0.65 g, 94 %); mp (5.50 · C6H3N3O7) 146 – 148 °C. 1H-NMR (300 MHz, DMSO-d6, picrate): δ 
[ppm] = 1.71 – 1.84 (m, 1H, Ph-CH2-CH2), 2.60 (t, 2H, 3J = 7.8 Hz, Ph-CH2), 3.06 – 3.16 (m, 
2H, Ph-(CH2)2-CH2), 7.00 (brs, 4H, N-H), 7.15 – 7.35 (m, 5H, Ph-H), 7.45 (t, 1H, 3J = 5.4 Hz, 
N-H), 8.59 (s, 2H, picrate-H). 13C-NMR (75 MHz, DMSO-d6, picrate): δ [ppm] = 30.09 (-, Ph-
CH2-CH2), 31.95 (-, Ph-CH2), 40.30 (-, Ph-CH2-CH2-CH2), 124.12 (Cquat, picrate-C-4), 125.13 
(+, picrate-C-3,5), 125.85 (+, 1 Ph-C), 128.14 (+, 2 Ph-C), 128.30 (+, 2 Ph-C), 141.00 (Cquat, 
Ph-C), 141.75 (Cquat, picrate-C-2,6), 156.57 (Cquat, C=N), 160.73 (Cquat, picrate-C-1). CI-MS 
(NH3) m/z (%): 178 (100) [M + H]+. Anal. (C10H15N3 · C6H3N3O7) C, H, N. C10H15N3 (177.25). 
 
3-(Pyridin-2-yl)propylguanidine (5.51)38 
The title compound was prepared from 5.42 (4.2 g, 9.4 mmol) and Pd/C (10 %) (0.42 g, cat.) 
in MeOH (150 mL) according to the general procedure yielding a colorless foam-like solid 
(1.6 g, 96 %); mp (5.51 · 2 C6H3N3O7) 194 – 195 °C. 1H-NMR (300 MHz, DMSO-d6, 
dipicrate): δ [ppm] = 1.85 – 1.99 (m, 2H, Pyr-2-CH2-CH2), 2.98 (t, 2H, 3J = 7.8 Hz, Pyr-2-
CH2), 3.12 – 3.24 (m, 2H, Pyr-2-(CH2)2-CH2), 7.05 (brs, 4H, N-H), 7.50 (t, 1H, 3J = 5.6 Hz, N-
H), 7.81 – 7.92 (m, 2H, Pyr-3,5-H), 8.40 – 8.49 (m, 1H, Pyr-4-H), 8.59 (s, 2H, picrate-H), 8.80 
(dd, 1H, 3J = 5.8 Hz, 4J = 1.6 Hz, Pyr-6-H). 13C-NMR (75 MHz, DMSO-d6, dipicrate): δ [ppm] 
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= 27.70 (-, Pyr-2-CH2-CH2), 30.35 (-, Pyr-2-CH2), 39.93 (-, Pyr-2-(CH2)2-CH2), 124.20 (Cquat, 
picrate-C-4), 124.43 (+, Pyr-C-5), 125.15 (+, picrate-C-3,5), 126.39 (+, Pyr-C-3), 141.73 
(Cquat, picrate-C-2,6), 142.29 (+, Pyr-C-6), 145.36 (+, Pyr-C-4), 156.30 (Cquat, Pyr-C-2), 
156.53 (Cquat, C=N), 160.71 (Cquat, picrate-C-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
179 (100) [M + H]+. Anal. (C9H14N4 · 2 C6H3N3O7) C, H, N. C9H14N4 (178.23). 
 
3-(Pyridin-3-yl)propylguanidine (5.52) 
The title compound was prepared from 5.43 (4.31 g, 9.7 mmol) and Pd/C (10 %) (0.43 g, 
cat.) in MeOH (150 mL) according to the general procedure yielding a colorless foam-like 
solid (1.7 g, 97 %); mp (5.52 · 2 C6H3N3O7) 186 – 187 °C. 1H-NMR (300 MHz, DMSO-d6, 
dipicrate): δ [ppm] = 1.76 – 1.94 (m, 2H, Pyr-3-CH2-CH2), 2.80 (t, 2H, 3J = 7.8 Hz, Pyr-3-
CH2), 3.08 – 3.22 (m, 2H, Pyr-3-(CH2)2-CH2), 7.03 (brs, 4H, N-H), 7.48 (t, 1H, 3J = 5.5 Hz, N-
H), 7.99 (dd, 1H, 3J = 8.0 Hz, 3J = 5.9 Hz, Pyr-5-H), 8.43 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.9 Hz, 
4J = 1.5 Hz, Pyr-4-H), 8.59 (s, 2H, picrate-H), 8.77 – 8.81 (m, 2H, Pyr-2,6-H). 13C-NMR (75 
MHz, DMSO-d6, dipicrate): δ [ppm] = 28.77 (-, Pyr-3-CH2-CH2), 29.09 (-, Pyr-3-CH2), 40.03 (-
, Pyr-3-(CH2)2-CH2), 124.16 (Cquat, picrate-C-4), 125.13 (+, picrate-C-3,5), 126.54 (+, Pyr-C-
5), 140.40 (+, Pyr-C-6), 140.62 (Cquat, Pyr-C-3), 141.74 (Cquat, picrate-C-2,6), 141.91 (+, Pyr-
C-2), 145.14 (+, Pyr-C-4), 156.53 (Cquat, C=N), 160.72 (Cquat, picrate-C-1). ES-MS 
(H2O/MeCN) m/z (%): 179 (100) [M + H]+. Anal. (C9H14N4 · 2 C6H3N3O7) C, H, N. C9H14N4 
(178.23). 
 
3-(Pyridin-4-yl)propylguanidine (5.53) 
The title compound was prepared from 5.44 (3.65 g, 8.2 mmol) and Pd/C (10 %) (0.37 g, 
cat.) in MeOH (150 mL) according to the general procedure yielding a colorless foam-like 
solid (1.4 g, 96 %); mp (5.53 · 2 C6H3N3O7) 205 – 207 °C. 1H-NMR (300 MHz, CDCl3): δ 
[ppm] = 1.78 – 1.95 (m, 2H, Pyr-4-CH2-CH2), 2.66 (t, 2H, 3J = 7.8 Hz, Pyr-4-CH2), 3.09 – 3.22 
(m, 2H, Pyr-4-(CH2)2-CH2), 7.03 (brs, 3H, N-H), 7.49 (t, 1H, 3J = 5.5 Hz, N-H), 7.92 (dd, 2H, 
3J = 6.7 Hz, 4J = 1.4 Hz, Pyr-3,5-H), 8.59 (s, 4H, picrate-H), 8.82 (d, 2H, 3J = 6.7 Hz, 4J = 1.4 
Hz, Pyr-2,6-H). 13C-NMR (75 MHz, DMSO-d6, dipicrate): δ [ppm] = 28.41 (-, Pyr-4-CH2-CH2), 
32.04 (-, Pyr-4-CH2), 40.14 (-, Pyr-4-(CH2)2-CH2), 124.15 (Cquat, picrate-C-4), 125.14 (+, 
picrate-C-3,5), 126.61 (+, Pyr-C-3,5), 141.75 (Cquat, picrate-C-2,6), 141.83 (+, Pyr-C-2,6), 
156.52 (Cquat, C=N), 160.72 (Cquat, picrate-C-1), 161.58 (Cquart, Pyr-C-4). ES-MS 
(H2O/MeCN) m/z (%): 179 (100) [M + H]+. Anal. (C9H14N4 · 2 C6H3N3O7) C, H, N. C9H14N4 
(178.23). 
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N-(3-(1H-Imidazol-1-yl)propyl)guanidine (5.54)39 
The title compound was prepared from 5.45 (5.3 g, 12.2 mmol) and Pd/C (10 %) (0.53 g, 
cat.) in MeOH (150 mL) according to the general procedure yielding a colorless foam-like 
solid (1.9 g, 95 %); mp (5.54 · 2 C6H3N3O7) 190 – 191 °C. 1H-NMR (300 MHz, DMSO-d6, 
dipicrate): δ [ppm] = 1.97 – 2.09 (m, 2H, Im-1-CH2-CH2), 3.08 – 3.18 (m, 2H, Im-1-(CH2)2-
CH2), 4.21 (t, 2H, 3J = 7.1 Hz, Im-1-CH2), 7.07 (brs, 4H, N-H), 7.48 (t, 1H, 3J = 5.7 Hz, N-H), 
7.70 – 7.73 (m, 1H, Im-4-H), 7.75 – 7.78 (m, 1H, Im-5-H), 8.60 (s, 4H, picrate-H), 9.08 – 9.11 
(m, 1H, Im-2-H). 13C-NMR (75 MHz, DMSO-d6, dipicrate): δ [ppm] = 28.81 (-, Im-1-CH2-CH2), 
37.79 (-, Im-1-(CH2)2-CH2), 46.02 (-, Im-1-CH2), 120.03, 121.03 (+, Im-C-4,5), 124.17 (Cquat, 
picrate-C-4), 125.14 (+, picrate-C-3,5), 135.35 (+, Im-C-2), 141.75 (Cquat, picrate-C-2,6), 
156.55 (Cquat, C=N), 160.73 (Cquat, picrate-C-1). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
168 (100) [M + H]+. Anal. (C7H13N5 · 2 C6H3N3O7) C, H, N. C7H13N5 (167.21). 
 
5.4.1.7 Preparation of the NG-acylated arylpropylguanidines 5.59-5.80 
General procedure 1 
A solution of the pertinent carboxylic acid (1 eq) and CDI (1.2 eq) in THFabs (15 mL) was 
stirred for 1 h under argon atmosphere at room temperature. In a separate vessel, NaH (60 
% dispersion in mineral oil) (2 eq) was added to a solution of the pertinent guanidine (1 eq) in 
THFabs (15 mL) under argon atmosphere, stirred for 45 min at 30 – 35 °C and allowed to cool 
to ambient temperature. Both mixtures were merged and stirred for 5 h under argon 
atmosphere. EtOAc (50 mL) was added and the organic phase was washed with H2O (3 x 20 
mL) and dried over Na2SO4. After evaporation of the solvent, the crude product was purified 
by flash chromatography or preparative HPLC. Compounds purified by preparative HPLC 
were dried by lyophilization and obtained as trifluoroacetates. 
 
General procedure 2 
A solution of the pertinent carboxylic acid (1 eq) and CDI (1.2 eq) in anhydrous DMF (10 mL) 
was stirred for 1 h under argon atmosphere at room temperature. In a separate vessel, NaH 
(60 % dispersion in mineral oil) (2 eq) was added to a solution of the pertinent guanidine (1 
eq) in anhydrous DMF (10 mL) under argon atmosphere, stirred for 45 min at 30 – 35 min 
and allowed to cool to ambient temperature. Both mixtures were merged and stirred for 5 h 
under argon atmosphere. After evaporation of the solvent, the crude product was subjected 
to flash chromatography or preparative HPLC. Compounds purified by preparative HPLC 
were dried by lyophilization and obtained as trifluoroacetic acid salts. 
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N1-(3-Phenylbutanoyl)-N2-(3-phenylpropyl)guanidine (5.59)  
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.50 (177 mg, 1.0 mmol) 
according to the general procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 50/50) yielded a white solid (92 mg, 21 %); mp 118 – 119 °C. 1H-NMR (300 MHz, 
(CD3)2CO, trifluoroacetate): δ [ppm] = 1.30 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.95 – 2.05 (m, 
2H, Ph-CH2-CH2), 2.73 (t, 2H, 3J = 7.8 Hz, Ph-CH2), 2.75 (dd, 1H, 2J = 15.0 Hz, 3J = 7.7 Hz, 
PhCH3CH-CH2), 2.87 (dd, 1H, 2J = 15.0 Hz, 3J = 7.5 Hz, PhCH3CH-CH2), 3.27 – 3.39 (m, 1H, 
PhCH), 3.40 (t, 2H, 3J = 7.1 Hz, Ph-CH2-CH2-CH2), 7.14 – 7.36 (m, 10H, Ph-H). 13C-NMR (75 
MHz, CD3OD, trifluoroacetate): δ [ppm] = 22.28 (+, PhCH3CH), 30.76, 33.66 (-, Ph-CH2-CH2), 
37.67 (+, PhCH3CH), 42.06 (-, Ph-CH2-CH2-CH2), 46.29 (-, PhCH3CH-CH2), 127.31 (+, Ph-C-
4), 127.77 (+, Ph-C-4), 127.93 (+, 2 Ph-C), 129.46 (+, 2 Ph-C), 129.65 (+, 2 Ph-C), 129.72 
(+, 2 Ph-C), 142.02 (Cquat, Ph-C-1), 146.41 (Cquat, Ph-C-1), 152.27 (Cquat, C=N), 175.91 (Cquat, 
C=O). IR (cm-1) = 3245, 2960, 1706, 1656, 1594, 1197, 1140. HRMS (EI-MS) calcd. for 
C20H25N3O [M+•] 323.1998; found 323.1995. C20H25N3O · TFA (437.46). 
 
N1-(3,3-Diphenylpropanoyl)-N2-(3-phenylpropyl)guanidine (5.60)  
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.50 (177 mg, 1.0 mmol) 
according to the general procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 55/45) yielded a white solid (141 mg, 28 %); mp 138 – 140 °C. 1H-NMR (300 MHz, 
(CD3)2CO, trifluoroacetate): δ [ppm] = 1.92 – 2.03 (m, 2H, Ph-CH2-CH2), 2.70 (t, 2H, 3J = 7.7 
Hz, Ph-CH2), 3.34 (d, 2H, 3J = 8.1 Hz, Ph2CH-CH2), 3.39 (t, 2H, 3J = 7.0 Hz, Ph-CH2-CH2-
CH2), 4.65 (t, 1H, 3J = 8.1 Hz, Ph2CH), 7.12 – 7.42 (m, 15H, Ph-H). 13C-NMR (75 MHz, 
(CD3)2CO, trifluoroacetate): δ [ppm] = 30.36, 33.40 (-, Ph-CH2-CH2), 41.60 (-, Ph-CH2-CH2-
CH2), 43.08 (-, Ph2CH-CH2), 47.67 (+, Ph2CH), 126.90 (+, 1 Ph-C-4), 127.44 (+, 2 Ph-C-4), 
128.64 (+, 4 Ph-C), 129.30 (+, 2 Ph-C), 129.32 (+, 2 Ph-C), 129.43 (+, 4 Ph-C), 142.00 (Cquat, 
1 Ph-C-1), 144.35 (Cquat, 2 Ph-C-1), 155.47 (Cquat, C=N), 175.81 (Cquat, C=O). IR (cm-1) = 
3247, 2971, 1704, 1661, 1598, 1193, 1142. HRMS (EI-MS) calcd. for C25H27N3O [M+•] 
385.2154; found 385.2168. C25H27N3O · TFA (499.52). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(pyridin-2-yl)propyl]guanidine (5.61) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.51 (178 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 15/85, 20 min: 35/65) yielded a colorless oil (421 mg, 76 %). 1H-NMR (400 MHz, 
CD3OD, trifluoroacetate): δ [ppm] = 1.31 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 2.07 – 2.16 (m, 2H, 
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Pyr-2-CH2-CH2), 2.73 (dd, 1H, 2J = 15.3 Hz, 3J = 7.3 Hz, PhCH3CH-CH2), 2.79 (dd, 1H, 2J = 
15.3 Hz, 3J = 7.8 Hz, PhCH3CH-CH2), 3.12 (t, 2H, 3J = 8.0 Hz, Pyr-2-CH2), 3.26 – 3.36 (m, 
1H, overlap with solvent, PhCH3CH), 3.39 (t, 2H, 3J = 6.8 Hz, Pyr-2-(CH2)2-CH2), 7.14 – 7.30 
(m, 5H, Ph-H), 7.86 (ddd, 1H, 3J = 7.7 Hz, 3J = 5.9 Hz, 4J = 1.2 Hz, Pyr-5-H), 7.94 (ddd, 1H, 
3J = 8.1 Hz, 4J = 1.2 Hz, 5J = 0.8 Hz, Pyr-3-H), 8.46 (ddd, 1H, 3J = 8.1 Hz, 3J = 7.7 Hz, 4J = 
1.6 Hz, Pyr-4-H), 8.71 (ddd, 1H, 3J = 5.9 Hz, 4J = 1.6 Hz, 5J = 0.8 Hz, Pyr-6-H). 13C-NMR 
(100 MHz, CD3OD, trifluoroacetate, HSQC, HMBC): δ [ppm] = 22.28 (+, PhCH3CH), 28.39 (-, 
Pyr-2-CH2-CH2), 31.84 (-, Pyr-2-CH2), 37.59 (+, PhCH3CH), 41.62 (-, Pyr-2-(CH2)2-CH2), 
46.07 (-, PhCH3CH-CH2), 126.09 (+, Pyr-C-5), 127.66 (+, Ph-C-4), 127.92 (+, 2 Ph-C), 
128.23 (+, Pyr-C-3), 129.63 (+, 2 Ph-C), 143.29 (+, Pyr-C-6), 146.43 (Cquat, Ph-C-1), 147.33 
(+, Pyr-C-4), 155.29 (Cquat, C=N), 157.88 (Cquat, Pyr-C-2), 175.91 (Cquat, C=O). IR (cm-1) = 
3066, 2964, 1668, 1602, 1178, 1127. HRMS (EI-MS) calcd. for C19H24N4O [M+•] 324.1950; 
found 324.1951. C19H24N4O · 2 TFA (552.47). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(pyridin-2-yl)propyl]guanidine (5.62) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.51 (178 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 25/75, 20 min: 45/55) yielded a semisolid compound (264 mg, 43 %). 1H-NMR 
(300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 2.02 – 2.16 (m, 2H, Pyr-2-CH2-CH2), 3.08 (t, 
2H, 3J = 7.9 Hz, Pyr-2-CH2), 3.26 (d, 2H, 3J = 8.0 Hz, Ph2CHCH2), 3.39 (t, 2H, 3J = 6.8 Hz, 
Pyr-2-(CH2)2-CH2), 4.59 (t, 1H, 3J = 8.0 Hz, Ph2CH), 7.14 – 7.33 (m, 10H, Ph-H), 7.82 (ddd, 
1H, 3J = 7.7 Hz, 3J = 5.8 Hz, 4J = 1.2 Hz, Pyr-5-H), 7.90 (ddd, 1H, 3J = 8.2 Hz, 4J = 1.2 Hz, 5J 
= 0.8 Hz, Pyr-3-H), 8.46 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.7 Hz, 4J = 1.7 Hz, Pyr-4-H), 8.71 (ddd, 
1H, 3J = 5.8 Hz, 4J = 1.6 Hz, 5J = 0.8 Hz, Pyr-6-H). 13C-NMR (75 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 28.41 (-, Pyr-2-CH2-CH2), 32.10 (-, Pyr-2-CH2), 41.71 (-, Pyr-2-
(CH2)2-CH2), 43.81 (-, Ph2CH-CH2), 48.00 (+, Ph2CH), 125.94 (+, Pyr-C-5), 127.82 (+, 2 Ph-
C-4), 128.03 (+, Pyr-C-3), 128.84 (+, 4 Ph-C), 129.73 (+, 4 Ph-C), 143.77 (-, Pyr-C-6), 144.56 
(Cquat, 2 Ph-C-1), 146.81 (+, Pyr-C-4), 155.21 (Cquat, C=N), 158.15 (Cquat, Pyr-C-2), 175.42 
(Cquat, C=O). IR (cm-1) = 3064, 2971, 2901, 1668, 1599, 1179, 1127. HRMS (EI-MS) calcd. 
for C24H26N4O [M+•] 386.2107; found 386.2105. C24H26N4O · 2 TFA (614.54). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(pyridin-3-yl)propyl]guanidine (5.63) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.52 (178 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 15/85, 20 min: 35/65) yielded a colorless oil (355 mg, 64 %). 1H-NMR (300 MHz, 
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CD3OD, trifluoroacetate): δ [ppm] = 1.32 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.95 – 2.09 (m, 2H, 
Pyr-3-CH2-CH2), 2.73 (dd, 1H, 2J = 15.3 Hz, 3J = 7.4 Hz, PhCH3CH-CH2), 2.80 (dd, 1H, 2J = 
15.3 Hz, 3J = 7.7 Hz, PhCH3CH-CH2), 2.90 (t, 2H, 3J = 8.0 Hz, Pyr-3-CH2), 3.24 – 3.33 (m, 
1H, overlap with solvent, PhCH3CH), 3.35 (t, 2H, 3J = 7.0 Hz, Pyr-3-(CH2)2-CH2), 7.12 – 7.32 
(m, 5H, Ph-H), 7.86 (dd, 1H, 3J = 8.0 Hz, 3J = 5.8 Hz, Pyr-5-H), 8.39 (d, 1H, 3J = 8.0 Hz, Pyr-
4-H), 8.56 – 8.80 (m, 2H, Pyr-2-H + Pyr-6-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 22.36 (+, PhCH3CH), 29.79 (-, Pyr-3-CH2-CH2), 30.61 (-, Pyr-3-CH2), 37.68 (+, 
PhCH3CH), 41.83 (-, Pyr-3-(CH2)2-CH2), 46.10 (-, PhCH3CH-CH2), 127.72 (+, Ph-C-4), 
127.97 (+, 2 Ph-C), 128.31 (+, Pyr-C-5), 129.68 (+, 2 Ph-C), 141.22 (+, Pyr-C-6), 142.88 (+, 
Pyr-C-2), 143.15 (Cquat, Pyr-C-3), 146.46 (Cquat, Ph-C-1), 147.62 (+, Pyr-C-4), 155.23 (Cquat, 
C=N), 176.05 (Cquat, C=O). IR (cm-1) = 2971, 2901, 1668, 1603, 1177, 1130. HRMS (EI-MS) 
calcd. for C19H24N4O [M+•] 324.1950; found 324.1946. C19H24N4O · 2 TFA (552.47). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(pyridin-3-yl)propyl]guanidine (5.64) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.52 (178 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 15/85, 20 min: 45/55) yielded a white solid (384 mg, 62 %); mp 48 – 52 °C. 1H-
NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 1.94 – 2.08 (m, 2H, Pyr-3-CH2-CH2), 
2.88 (t, 2H, 3J = 8.0 Hz, Pyr-3-CH2), 3.26 (d, 2H, 3J = 8.0 Hz, Ph2CHCH2), 3.33 (t, 2H, 
overlap with solvent, 3J = 6.9 Hz, Pyr-3-(CH2)2-CH2), 4.59 (t, 1H, 3J = 8.0 Hz, Ph2CH), 7.12 – 
7.34 (m, 10H, Ph-H), 7.87 (ddd, 1H, 3J = 8.0 Hz, 3J = 6.0 Hz, 5J = 0.7 Hz, Pyr-5-H), 8.37 
(ddd, 1H, 3J = 8.0 Hz, 4J = 2.0 Hz, 4J = 1.4 Hz, Pyr-4-H), 8.64 (dd, 1H, 3J = 6.0 Hz, 4J = 1.4 
Hz, Pyr-6-H), 8.71 (dd, 1H, 4J = 2.0 Hz, 5J = 0.7 Hz, Pyr-2-H). 13C-NMR (75 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 29.74 (-, Pyr-3-CH2-CH2), 30.60 (-, Pyr-3-CH2), 41.84 (-, Pyr-3-
(CH2)2-CH2), 43.79 (-, Ph2CH-CH2), 48.07 (+, Ph2CH), 127.81 (+, Ph-C-4), 128.27 (+, Pyr-C-
5), 128.85 (+, 2 Ph-C), 129.72 (+, 2 Ph-C), 141.30 (+, Pyr-C-6), 142.96 (+, Pyr-C-2), 143.07 
(Cquat, Pyr-C-3), 144.55 (Cquat, Ph-C-1), 147.51 (+, Pyr-C-4), 155.16 (Cquat, C=N), 175.52 
(Cquat, C=O). IR (cm-1) = 2973, 2901, 1668, 1599, 1180, 1128. HRMS (EI-MS) calcd. for 
C24H26N4O [M+•] 386.2107; found 386.2110. C24H26N4O · 2 TFA (614.54). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(pyridin-4-yl)propyl]guanidine (5.65) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.53 (178 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 15/85, 20 min: 35/65) yielded a colorless semisolid compound (312 mg, 56 %). 
1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 1.31 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 
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1.99 – 2.12 (m, 2H, Pyr-4-CH2-CH2), 2.73 (dd, 1H, 2J = 15.2 Hz, 3J = 7.4 Hz, PhCH3CH-CH2), 
2.80 (dd, 1H, 2J = 15.2 Hz, 3J = 7.7 Hz, PhCH3CH-CH2), 3.01 (t, 2H, 3J = 8.0 Hz, Pyr-4-CH2), 
3.20 – 3.33 (m, 1H, overlap with solvent, PhCH3CH), 3.37 (t, 2H, 3J = 7.0 Hz, Pyr-4-(CH2)2-
CH2), 7.13 – 7.31 (m, 5H, Ph-H), 7.98 (d, 2H, 3J = 6.8 Hz, Pyr-3,5-H), 8.74 (d, 2H, 3J = 6.8 
Hz, Pyr-2,6-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 22.34 (+, PhCH3CH), 
29.07 (-, Pyr-4-CH2-CH2), 33.97 (-, Pyr-4-CH2), 37.70 (+, PhCH3CH), 41.84 (-, Pyr-4-(CH2)2-
CH2), 46.11 (-, PhCH3CH-CH2), 127.71 (+, Ph-C-4), 127.99 (+, 2 Ph-C), 128.58 (+, Pyr-C-
3,5), 129.68 (+, 2 Ph-C), 142.53 (+, Pyr-C-2,6), 146.46 (Cquat, Ph-C-1), 155.28 (Cquat, C=N), 
164.69 (Cquat, Pyr-C-4), 176.11 (Cquat, C=O). IR (cm-1) = 2969, 2901, 1666, 1639, 1177, 1128. 
HRMS (EI-MS) calcd. for C19H24N4O [M+•] 324.1950; found 324.1960. C19H24N4O · 2 TFA 
(552.47). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(pyridin-4-yl)propyl]guanidine (5.66) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.53 (178 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 15/85, 20 min: 45/55) yielded a white solid (388 mg, 63 %); mp 93 – 94 °C. 1H-
NMR (300 MHz, CD3OD, trifluoroacetate): δ [ppm] = 1.95 – 2.10 (m, 2H, Pyr-4-CH2-CH2), 
2.95 (t, 2H, 3J = 8.0 Hz, Pyr-4-CH2), 3.26 (d, 2H, 3J = 8.0 Hz, Ph2CHCH2), 3.34 (t, 2H, 
overlap with solvent, 3J = 7.0 Hz, Pyr-4-(CH2)2-CH2), 4.59 (t, 1H, 3J = 8.0 Hz, Ph2CH), 7.13 – 
7.33 (m, 10H, Ph-H), 7.88 (d, 1H, 3J = 6.6 Hz, Pyr-3,5-H), 8.69 (d, 1H, 3J = 6.6 Hz, Pyr-2,6-
H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 29.09 (-, Pyr-4-CH2-CH2), 33.82 (-
, Pyr-4-CH2), 41.88 (-, Pyr-4-(CH2)2-CH2), 43.82 (-, Ph2CH-CH2), 48.08 (+, Ph2CH), 127.82 
(+, 2 Ph-C-4), 128.19 (+, Pyr-C-3,5), 128.85 (+, 4 Ph-C), 129.72 (+, 4 Ph-C), 143.50 (+, Pyr-
C-2,6), 145.54 (Cquat, 2 Ph-C-1), 155.17 (Cquat, C=N), 163.19 (Cquat, Pyr-C-4), 175.52 (Cquat, 
C=O). IR (cm-1) = 3091, 1677, 1596, 1594, 1199, 1133. HRMS (EI-MS) calcd. for C24H26N4O 
[M+•] 386.2107; found 386.2105. C24H26N4O · 2 TFA (614.54). 
 
N1-(3-{5-[(Dimethylamino)methyl]furan-2-yl}propyl)-N2-(3-phenylbutanoyl)guanidine 
(5.67) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.46 (224 mg, 1.0 mmol) 
according to the general procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 30/70) yielded a pale brownish oil (208 mg, 35 %). 1H-NMR (300 MHz, D2O, 
trifluoroacetate): δ [ppm] = 1.24 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.82 – 1.95 (m, 2H, Fur-2-
CH2-CH2), 2.63 (t, 2H, 3J = 7.4 Hz, Fur-2-CH2), 2.68 – 2.79 (m, 8H, N(CH3)2 + PhCH3CH-
CH2), 3.15 – 3.28 (m, 3H, Fur-2-(CH2)2-CH2 + PhCH3CH), 4.14 (d, 1H, 2J = 14.9 Hz, Fur-5-
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CH2), 4.19 (d, 1H, 2J = 14.9 Hz, Fur-5-CH2), 6.10 (d, 1H, 3J = 3.2 Hz, Fur-3-H), 6.50 (d, 1H, 3J 
= 3.2 Hz, Fur-4-H), 7.17 – 7.37 (m, 5H, Ph-H). 13C-NMR (75 MHz, D2O, trifluoroacetate): δ 
[ppm] = 21.29 (+, PhCH3CH), 24.53 (-, Fur-2-CH2), 25.43 (-, Fur-2-CH2-CH2), 36.61 (+, 
PhCH3CH), 40.66 (-, Fur-2-(CH2)2-CH2), 41.93 (+, N(CH3)2), 45.07 (-, PhCH3CH-CH2), 53.03 
(-, Fur-5-CH2), 107.23 (+, Fur-C-3), 115.59 (+, Fur-C-4), 126.98 (+ , 2 Ph-C), 127.06 (+, Ph-
C-4), 128.99 (+, 2 Ph-C), 142.04 (Cquat, Fur-C-5), 145.02 (Cquat, Ph-C-1), 152.76 (Cquat, C=N), 
157.65 (Cquat, Fur-C-2), 176.00 (Cquat, C=O). IR (cm-1) = 3032, 2964, 1669, 1602, 1594, 1177, 
1132. HRMS (EI-MS) calcd. for C21H30N4O2 [M+•] 370.2369; found 370.2370. C21H30N4O2 · 2 
TFA (598.54). 
 
N1-(3-{5-[(Dimethylamino)methyl]furan-2-yl}propyl)-N2-[3-(thiophen-2-yl)butanoyl]-
guanidine (5.68) 
The title compound was prepared from 5.563 (170 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.46 (224 mg, 1.0 mmol) 
according to the general procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 27.5/72.5) yielded a pale brownish oil (72 mg, 12 %). 1H-NMR (300 MHz, D2O, 
trifluoroacetate): δ [ppm] = 1.33 (d, 3H, 3J = 7.0 Hz, ThioCH3CH), 1.84 – 1.97 (m, 2H, Fur-2-
CH2-CH2), 2.69 – 2.87 (m, 10H, Fur-2-CH2 + + ThioCH3CH-CH2 + N(CH3)2), 3.36 (t, 2H, 3J = 
6.7 Hz, Fur-2-(CH2)2-CH2), 3.48 – 3.62 (m, 1H, ThioCH3CH), 4.17 (d, 1H, 2J = 14.7 Hz, Fur-5-
CH2), 4.22 (d, 1H, 2J = 14.7 Hz, Fur-5-CH2), 6.13 (d, 1H, 3J = 3.2 Hz, Fur-3-H), 6.52 (d, 1H, 3J 
= 3.2 Hz, Fur-4-H), 6.89 (ddd, 1H, 3J = 3.5 Hz, 4J = 1.3 Hz, 4J = 0.7 Hz, Thio-3-H), 6.94 (dd, 
1H, 3J = 5.0 Hz, 3J = 3.5 Hz, Thio-4-H), 7.24 (dd, 1H, 3J = 5.0 Hz, 4J = 1.3 Hz, Thio-5-H). 13C-
NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 22.28 (+, ThioCH3CH), 24.55 (-, Fur-2-CH2), 
25.44 (-, Fur-2-CH2-CH2), 31.96 (+, ThioCH3CH), 40.75 (-, Fur-2-(CH2)2-CH2), 41.92 (+, 
N(CH3)2), 46.02 (-, ThioCH3CH-CH2), 53.03 (-, Fur-5-CH2), 107.27 (+, Fur-C-3), 115.58 (+, 
Fur-C-4), 123.74, 123.97 (+, Thio-C-3,4), 127.25 (+, Thio-C-5), 142.04 (Cquat, Fur-C-5), 
148.87 (Cquat, Thio-C-2), 152.75 (Cquat, C=N), 157.64 (Cquat, Fur-C-2), 175.47 (Cquat, C=O). IR 
(cm-1) = 2989, 2901, 1663, 1178, 1130. HRMS (EI-MS) calcd. for C19H28N4O2S [M+•] 
376.1933; found 376.1930. C19H28N4O2S · 2 TFA (604.56). 
 
N1-(3-{5-[(Dimethylamino)methyl]furan-2-yl}propyl)-N2-(3,3-diphenylpropanoyl)-
guanidine (5.69) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.46 (224 mg, 1.0 mmol) 
according to the general procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 35/65) yielded a brownish oil (176 mg, 27 %). 1H-NMR (300 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 1.89 – 2.02 (m, 2H, Fur-2-CH2-CH2), 2.73 (t, 2H, 3J = 7.5 Hz, Fur-
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2-CH2), 2.83 (s, 6H, N(CH3)2), 3.22 – 3.33 (m, 4H, overlap with solvent, Fur-2-(CH2)2-CH2 + 
Ph2CH-CH2), 4.30 (s, 2H, Fur-5-CH2), 4.58 (t, 1H, 3J = 8.0 Hz, Ph2CH), 6.18 (d, 1H, 3J = 3.2 
Hz, Fur-3-H), 6.58 (d, 1H, 3J = 3.2 Hz, Fur-4-H), 7.13 – 7.34 (m, 10H, Ph-H). 13C-NMR (75 
MHz, CD3OD, trifluoroacetate): δ [ppm] = 25.97 (-, Fur-2-CH2), 27.34 (-, Fur-2-CH2-CH2), 
41.82 (-, Fur-2-(CH2)2-CH2), 42.76 (+, N(CH3)2), 43.86 (-, Ph2CHCH2), 48.08 (+, Ph2CH), 
54.09 (-, Fur-5-CH2), 108.48 (+, Fur-C-3), 116.61 (+, Fur-C-4), 127.83 (+ , 2 Ph-C-4), 128.84 
(+, 4 Ph-C), 129.73 (+, 4 Ph-C), 143.86 (Cquat, Fur-C-5), 144.53 (Cquat, 2 Ph-C-1), 155.09 
(Cquat, C=N), 158.84 (Cquat, Fur-C-2), 175.54 (Cquat, C=O). IR (cm-1) = 2989, 2901, 1663, 
1599, 1174, 1126. HRMS (EI-MS) calcd. for C26H32N4O2 [M+•] 432.2525; found 432.2531. 
C26H32N4O2 · 2 TFA (660.60). 
 
N1-(3-{5-[(Dimethylamino)methyl]furan-2-yl}propyl)-N2-[3-phenyl-3-(thiazol-2-yl)-
propanoyl]guanidine (5.70) 
The title compound was prepared from 5.583 (233 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.46 (224 mg, 1.0 mmol) 
according to the general procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 27.5/72.5) yielded a brownish semisolid compound (134 mg, 17 %). 1H-NMR (400 
MHz, D2O, trifluoroacetate): δ [ppm] = 1.82 – 1.93 (m, 2H, Fur-2-CH2-CH2), 2.63 (t, 2H, 3J = 
7.3 Hz, Fur-2-CH2), 2.73 (s, 6H, N(CH3)2), 3.23 (t, 2H, 3J = 6.8 Hz, Fur-2-(CH2)2-CH2), 3.34 
(dd, 1H, 2J = 16.6 Hz, 3J = 8.2 Hz, PhThiazCH-CH2), 3.48 (dd, 1H, 2J = 16.6 Hz, 3J = 7.2 Hz, 
PhThiazCH-CH2), 4.13 (d, 1H, 2J = 14.5 Hz, Fur-5-CH2), 4.17 (d, 1H, 2J = 14.5 Hz, Fur-5-
CH2), 5.05 (dd, 1H, 3J = 8.2 Hz, 3J = 7.2 Hz, PhThiazCH), 6.08 (d, 1H, 3J = 3.2 Hz, Fur-3-H), 
6.47 (d, 1H, 3J = 3.2 Hz, Fur-4-H), 7.29 – 7.40 (m, 5H, Ph-H), 7.64 (d, 1H, 3J = 3.6 Hz, Thiaz-
5-H), 7.80 (d, 1H, 3J = 3.6 Hz, Thiaz-4-H). 13C-NMR (100 MHz, D2O, trifluoroacetate, HSQC, 
HMBC): δ [ppm] = 24.44 (-, Fur-2-CH2), 25.33 (-, Fur-2-CH2-CH2), 40.75 (-, Fur-2-(CH2)2-
CH2), 41.57 (-, PhThiazCHCH2), 41.84 (+, N(CH3)2), 43.19 (+, PhThiazCH), 52.94 (-, Fur-5-
CH2), 107.17 (+, Fur-C-3), 115.48 (+, Fur-C-4), 122.05 (+, Thiaz-C-5), 127.86 (+ , 2 Ph-C), 
128.65 (+, Ph-C-4), 129.52 (+, 2 Ph-C), 138.19 (+, Thiaz-C-4), 138.62 (Cquat, Ph-C-1), 141.93 
(Cquat, Fur-C-5), 152.55 (Cquat, C=N), 157.54 (Cquat, Fur-C-2) 173.07 (Cquat, C=O), 175.11 
(Cquat, Thiaz-C-2). IR (cm-1) = 2989, 2901, 1669, 1173, 1130. HRMS (EI-MS) calcd. for 
C23H29N5O2S [M+•] 439.2042; found 439.2040. C23H29N5O2S · 3 TFA (781.64). 
 
N1-[3-(1H-Imidazol-1-yl)propyl]-N2-(3-phenylbutanoyl)guanidine (5.71) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.54 (167 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 15/85, 20 min: 35/65) yielded a colorless oil (275 mg, 51 %). 1H-NMR (600 MHz, 
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D2O, trifluoroacetate): δ [ppm] = 1.24 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 2.11 – 2.19 (m, 2H, Im-
1-CH2-CH2), 2.68 (dd, 1H, 2J = 15.0 Hz, 3J = 9.1 Hz, PhCH3CH-CH2), 2.75 (dd, 1H, 2J = 15.0 
Hz, 3J = 6.4 Hz, PhCH3CH-CH2), 3.18 – 3.25 (m, 1H, PhCH3CH), 3.28 (t, 2H, 3J = 6.7 Hz, Im-
1-(CH2)2-CH2), 4.22 (t, 2H, 3J = 7.2 Hz, Im-1-CH2), 7.20 – 7.34 (m, 5H, Ph-H), 7.35 – 7.36 (m, 
1H, Im-4-H), 7.41 – 7.43 (m, 1H, Im-5-H), 8.66 – 8.67 (m, 1H, Im-2-H). 13C-NMR (150 MHz, 
D2O, trifluoroacetate, HSQC, HMBC): δ [ppm] = 21.23 (+, PhCH3CH), 27.64 (-, Im-1-CH2-
CH2), 36.43 (+, PhCH3CH), 38.30 (-, Im-1-(CH2)2-CH2), 44.90 (-, PhCH3CH-CH2), 46.53 (-, 
Im-1-CH2), 120.01 (+, Im-C-4), 121.64 (+, Im-C-5), 126.88 (+, 2 Ph-C), 126.97 (+, Ph-C-4), 
128.90 (+, 2 Ph-C), 134.54 (+, Im-C-2), 144.97 (Cquat, Ph-C-1), 152.92 (Cquat, C=N), 175.91 
(Cquat, C=O). IR (cm-1) = 3138, 2989, 2901, 1667, 1601, 1174, 1132. HRMS (EI-MS) calcd. 
for C17H23N5O [M+•] 313.1903; found 313.1899. C17H23N5O · 2 TFA (541.44). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1H-imidazol-1-yl)propyl]guanidine (5.72) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.54 (224 mg, 1.0 mmol) 
according to the general procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA 
(aq.): 0 min: 20/80, 20 min: 40/60) yielded a white solid (162 mg, 27 %); mp 48 – 52 °C. 1H-
NMR (300 MHz, D2O, trifluoroacetate): δ [ppm] = 2.01 – 2.13 (m, 2H, Im-1-CH2-CH2), 3.19 (d, 
2H, 3J = 8.1 Hz, Ph2CHCH2), 3.21 (t, 2H, 3J = 6.8 Hz, Im-1-(CH2)2-CH2), 4.14 (t, 2H, 3J = 7.2 
Hz, Im-1-CH2), 4.45 (t, 1H, 3J = 8.1 Hz, Ph2CH), 7.12 – 7.29 (m, 11H, Ph-H + Im-4-H), 7.32 – 
7.35 (m, 1H, Im-5-H), 8.58 – 8.61 (m, 1H, Im-2-H). 13C-NMR (75 MHz, D2O, trifluoroacetate): 
δ [ppm] = 27.60 (-, Im-1-CH2-CH2), 38.32 (-, Im-1-(CH2)2-CH2), 42.10 (-, Ph2CH-CH2), 46.38 
(+, Ph2CH), 46.50 (-, Im-1-CH2), 119.98 (+, Im-C-4), 121.60 (+, Im-C-5), 127.16 (+, 2 Ph-C-
4), 127.45 (+, 4 Ph-C), 129.05 (+, 4 Ph-C), 134.51 (+, Im-C-2), 142.91 (Cquat, 2 Ph-C-1), 
152.87 (Cquat, C=N), 175.09 (Cquat, C=O). IR (cm-1) = 3149, 3068, 2969, 1665, 1603, 1178, 
1132. HRMS (EI-MS) calcd. for C22H25N5O [M+•] 375.2059; found 375.2055. C22H25N5O · 2 
TFA (603.51). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(1-trityl-1H-pyrazol-4-yl)propyl]guanidine (5.73) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.48 (409 mg, 1.0 mmol) 
according to the general procedure 2. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (410 mg, 74 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.27 (d, 3H, 3J = 6.9 Hz, PhCH3CH), 1.75 – 1.89 
(m, 2H, Pyraz-4-CH2-CH2), 2.43 – 2.56 (m, 3H, Pyraz-4-CH2 + PhCH3CH-CH2), 2.62 (dd, 1H, 
2J = 14.6 Hz, 3J = 6.2 Hz, PhCH3CH-CH2), 3.07 (t, 2H, 3J = 6.9 Hz, Pyraz-4-(CH2)2-CH2), 3.24 
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– 3.38 (m, 1H, PhCH3CH), 7.08 – 7.37 (m, 21H, Ph-H + Pyraz-3-H), 7.48 (s, 1H, Pyraz-5-H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 556 (66) [M + H]+, 466 (100). C36H37N5O (555.71). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1-trityl-1H-pyrazol-4-yl)propyl]guanidine (5.74) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.48 (409 mg, 1.0 mmol) 
according to the general procedure 2. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a colorless oil (430 mg, 70 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 1.69 – 1.86 (m, 2H, Pyraz-4-CH2-CH2), 2.48 (t, 2H, 3J = 7.4 Hz, 
Pyraz-4-CH2), 2.97 – 3.08 (m, 4H, Pyraz-4-(CH2)2-CH2 + Ph2CHCH2), 4.63 (t, 1H, 3J = 7.8 
Hz, Ph2CH), 7.05 – 7.37 (m, 26H, Ph-H + Pyraz-3-H), 7.46 (s, 1H, Pyraz-5-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 618 (83) [M + H]+, 528 (100). C41H39N5O (617.78). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(1-trityl-1H-imidazol-2-yl)propyl]guanidine (5.75) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.47 (409 mg, 1.0 mmol) 
according to the general procedure 1. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow oil (290 mg, 52 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 1.28 (d, 3H, 3J = 6.9 Hz, PhCH3CH), 1.36 – 1.52 (m, 2H, Im-2-
CH2-CH2), 1.84 (t, 2H, 3J = 5.7 Hz, Im-2-CH2), 2.55 (dd, 1H, 2J = 14.8 Hz, 3J = 8.2 Hz, 
PhCH3CH-CH2), 2.69 (dd, 1H, 2J = 14.8 Hz, 3J = 6.4 Hz, PhCH3CH-CH2), 3.07 (t, 2H, 3J = 7.4 
Hz, Im-2-(CH2)2-CH2), 3.26 – 3.38 (m, 1H, PhCH3CH), 6.78 (d, 1H, 3J = 1.5 Hz, Im-4-H), 6.89 
(d, 1H, 3J = 1.5 Hz, Im-5-H), 7.05 – 7.39 (m, 20H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 556 (100) [M + H]+. C36H37N5O (555.71). 
 
N1-[3-(Thiophen-2-yl)butanoyl]-N2-[3-(1-trityl-1H-Imidazol-2-yl)propyl]guanidine (5.76) 
The title compound was prepared from 5.563 (170 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.47 (409 mg, 1.0 mmol) 
according to the general procedure 1. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow foam-like solid (310 mg, 55 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.34 – 1.54 (m, 5H, ThioCH3CH + Im-2-CH2-CH2), 
1.85 (t, 2H, 3J = 7.1 Hz, Im-2-CH2), 2.60 (dd, 1H, 2J = 15.0 Hz, 3J = 8.4 Hz, ThioCH3CH-CH2), 
2.78 (dd, 1H, 2J = 15.0 Hz, 3J = 6.6 Hz, ThioCH3CH-CH2), 3.09 (t, 2H, 3J = 7.4 Hz, Im-2-
(CH2)2-CH2), 3.55 – 3.70 (m, 1H, ThioCH3CH), 6.77 – 6.94 (m, 4H, Thio-3,4-H + Im-4,5-H), 
7.04 – 7.16 (m, 7H, Ph-H, Thio-5-H), 7.27 – 7.39 (m, 9H, Ph-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 562 (100) [M + H]+. C34H35N5OS (561.74). 
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N1-(3,3-Diphenylpropanoyl)-N2-[3-(1-trityl-1H-imidazol-2-yl)propyl]guanidine (5.77) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.47 (409 mg, 1.0 mmol) 
according to the general procedure 1. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow foam-like solid (380 mg, 62 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.30 – 1.42 (m, 2H, Im-2-CH2-CH2), 1.81 (t, 2H, 3J 
= 5.6 Hz, Im-2-CH2), 3.03 (t, 2H, 3J = 7.1 Hz, Im-2-(CH2)2-CH2), 3.12 (d, 2H, 3J = 7.9 Hz, 
Ph2CHCH2), 4.62 (t, 1H, 3J = 7.9 Hz, Ph2CH), 6.77 (d, 1H, 3J = 1.5 Hz, Im-4-H), 6.85 (d, 1H, 
3J = 1.5 Hz, Im-5-H), 7.04 – 7.40 (m, 25H, Ph-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
618 (100) [M + H]+. C41H39N5O (617.78). 
 
N1-[3-Phenyl-3-(thiazol-2-yl)propanoyl]-N2-[3-(1-trityl-1H-imidazol-2-yl)propyl]guanidine 
(5.78) 
The title compound was prepared from 5.583 (233 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.47 (409 mg, 1.0 mmol) 
according to the general procedure 1. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a brownish oil (300 mg, 48 %). 1H-NMR 
(300 MHz, CDCl3): δ [ppm] = 1.35 – 1.50 (m, 2H, Im-2-CH2-CH2), 1.81 (t, 2H, 3J = 5.7 Hz, Im-
2-CH2), 2.96 – 3.10 (m, 3H, Im-2-(CH2)2-CH2 + PhThiazCH-CH2), 3.39 (dd, 1H, 2J = 16.0 Hz, 
3J = 8.2 Hz, PhThiazCH-CH2), 5.00 (dd, 1H, 3J = 8.2 Hz, 3J = 7.2 Hz, PhThiazCH), 6.76 (d, 
1H, 3J = 1.5 Hz, Im-4-H), 6.87 (d, 1H, 3J = 1.5 Hz, Im-5-H), 7.14 – 7.41 (m, 21H, Ph-H + 
Thiaz-5-H), 7.66 (d, 1H, 3J = 3.5 Hz, Thiaz-4-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
625 (100) [M + H]+. C38H36N6OS (624.80). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(1-trityl-1H-1,2,4-triazol-3-yl)propyl]guanidine (5.79) 
The title compound was prepared from 5.55 (164 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.49 (411 mg, 1.0 mmol) 
according to the general procedure 2. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (470 mg, 84 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.27 (d, 3H, 3J = 6.9 Hz, PhCH3CH), 1.41 – 1.57 
(m, 2H, Triaz-5-CH2-CH2), 1.95 (t, 2H, 3J = 5.9 Hz, Triaz-5-CH2), 2.48 (dd, 1H, 2J = 14.6 Hz, 
3J = 8.9 Hz, PhCH3CH-CH2), 2.62 (dd, 1H, 2J = 14.6 Hz, 3J = 8.5 Hz, PhCH3CH-CH2), 3.04 (t, 
2H, 3J = 7.5 Hz, Triaz-5-(CH2)2-CH2), 3.24 – 3.39 (m, 1H, PhCH3CH), 7.05 – 7.14 (m, 6H, Ph-
H), 7.23 – 7.38 (m, 14H, Ph-H), 7.88 (s, 1H, Triaz-3-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 557 (100) [M + H]+. C35H36N6O (556.70). 
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N1-(3,3-Diphenylpropanoyl)-N2-[3-(1-trityl-1H-1,2,4-triazol-3-yl)propyl]guanidine (5.80) 
The title compound was prepared from 5.57 (226 mg, 1.0 mmol), CDI (195 mg, 1.2 mmol), 
NaH (60 % dispersion in mineral oil) (80 mg, 2.0 mmol) and 5.49 (411 mg, 1.0 mmol) 
according to the general procedure 2. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (580 mg, 94 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.37 – 1.51 (m, 2H, Triaz-5-CH2-CH2), 2.88 (t, 2H, 
3J = 5.8 Hz, Triaz-5-CH2), 2.99 (t, 2H, 3J = 7.6 Hz, Triaz-5-(CH2)2-CH2), 3.04 (d, 2H, 3J = 7.8 
Hz, Ph2CHCH2), 4.63 (t, 1H, 3J = 7.8 Hz, Ph2CH), 7.00 – 7.40 (m, 25H, Ph-H), 7.86 (s, 1H, 
Triaz-3-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 619 (100) [M + H]+. C40H38N6O 
(618.77). 
 
5.4.1.8 Preparation of the NG-acylated arylpropylguanidines 5.81-5.88 
The pertinent trityl-protected NG-acylated arylpropylguanidine was stirred for 5 h in a mixture 
of TFA (5.0 mL) and DCM (20 mL). After removing the solvent in vacuo, the crude product 
was purified by preparative HPLC. All compounds were dried by lyophilization and obtained 
as trifluoroacetic acid salts. 
 
N1-[3-(1H-Imidazol-2-yl)propyl]-N2-(3-phenylbutanoyl)guanidine (5.81) 
The title compound was prepared from 5.75 (280 mg, 0.50 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
colorless semisolid compound (79 mg, 29 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.20 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.90 – 2.05 (m, 2H, Im-2-CH2-CH2), 2.64 (dd, 
1H, 2J = 15.0 Hz, 3J = 8.9 Hz, PhCH3CH-CH2), 2.71 (dd, 1H, 2J = 15.0 Hz, 3J = 6.4 Hz, 
PhCH3CH-CH2), 2.91 (t, 2H, 3J = 7.7 Hz, Im-2-CH2), 3.10 – 3.22 (m, 1H, PhCH3CH), 3.26 (t, 
2H, 3J = 6.7 Hz, Im-2-(CH2)2-CH2), 7.13 (s, 2H, Im-4,5-H), 7.14 – 7.33 (m, 5H, Ph-H). 13C-
NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 21.36 (+, PhCH3CH), 22.58 (-, Im-2-CH2), 
24.95 (-, Im-2-CH2-CH2), 36.41 (+, PhCH3CH), 40.33 (-, Im-2-(CH2)2-CH2), 44.88 (-, 
PhCH3CH-CH2), 118.59 (+, Im-C-4,5), 126.93 (+, 2 Ph-C), 127.01 (+, Ph-C-4), 128.95 (+, 2 
Ph-C), 145.04 (Cquat, Ph-C-1), 146.18 (Cquat, Im-C-2), 152.92 (Cquat, C=N), 175.95 (Cquat, 
C=O). IR (cm-1) = 3114, 2939, 2719, 1662, 1626, 1179, 1128. HRMS (EI-MS) calcd. for 
C17H23N5O [M+•] 313.1903; found 313.1906. C17H23N5O · 2 TFA (541.44). 
 
N1-[3-(1H-Imidazol-2-yl)propyl]-N2-[3-(thiophen-2-yl)butanoyl]guanidine (5.82) 
The title compound was prepared from 5.76 (280 mg, 0.50 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
beige semisolid compound (99 mg, 36 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ [ppm] 
= 1.28 (d, 3H, 3J = 7.0 Hz, ThioCH3CH), 1.94 – 2.07 (m, 2H, Im-2-CH2-CH2), 2.65 (dd, 1H, 2J 
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= 15.2 Hz, 3J = 8.8 Hz, ThioCH3CH-CH2), 2.74 (dd, 1H, 2J = 15.2 Hz, 3J = 6.3 Hz, 
ThioCH3CH-CH2), 2.94 (t, 2H, 3J = 7.7 Hz, Im-2-CH2), 3.29 (t, 2H, 3J = 6.8 Hz, Im-2-(CH2)2-
CH2), 3.44 – 3.58 (m, 1H, ThioCH3CH), 6.85 (ddd, 1H, 3J = 3.5 Hz, 4J = 1.2 Hz, 4J = 0.6 Hz, 
Thio-3-H), 6.90 (dd, 1H, 3J = 5.0 Hz, 3J = 3.5 Hz, Thio-4-H), 7.16 (s, 2H, Im-4,5-H), 7.19 (dd, 
1H, 3J = 5.0 Hz, 4J = 1.2 Hz, Thio-5-H). 13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 
22.26 (+, ThioCHCH3), 22.59 (-, Im-2-CH2), 24.96 (-, Im-2-CH2-CH2), 31.79 (+, ThioCH3CH), 
40.36 (-, Im-2-(CH2)2-CH2), 45.89 (-, ThioCH3CH-CH2), 118.59 (+, Im-C-4,5), 123.67, 123.90 
(+, Thio-C-3,4), 127.17 (+, Thio-C-5), 146.19 (Cquat, Im-C-2), 148.88 (Cquat, Thio-C-2), 152.94 
(Cquat, C=N), 175.42 (Cquat, C=O). IR (cm-1) = 3121, 2989, 2901, 1663, 1625, 1594, 1180, 
1128. HRMS (EI-MS) calcd. for C15H21N5OS [M+•] 319.1467; found 319.1472. C15H21N5OS · 2 
TFA (547.47). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1H-imidazol-2-yl)propyl]guanidine (5.83) 
The title compound was prepared from 5.77 (370 mg, 0.60 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 35/65) yielded a 
colorless semisolid compound (115 mg, 32 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.86 – 2.02 (m, 2H, Im-2-CH2-CH2), 2.88 (t, 2H, 3J = 7.7 Hz, Im-2-CH2), 3.17 (d, 2H, 
3J = 8.1 Hz, Ph2CHCH2), 3.23 (t, 2H, 3J = 6.7 Hz, Im-2-(CH2)2-CH2), 4.44 (t, 1H, 3J = 8.1 Hz, 
Ph2CH), 7.06 (s, 2H, Im-4,5-H), 7.10 – 7.30 (m, 10H, Ph-H). 13C-NMR (75 MHz, D2O, 
trifluoroacetate): δ [ppm] = 22.58 (-, Im-2-CH2), 24.90 (-, Im-2-CH2-CH2), 40.37 (-, Im-2-
(CH2)2-CH2), 42.09 (-, Ph2CH-CH2), 46.33 (+, Ph2CH), 118.54 (+, Im-C-4,5), 127.17 (+, 2 Ph-
C-4), 127.48 (+, 4 Ph-C), 129.07 (+, 4 Ph-C), 142.95 (Cquat, 2 Ph-C-1), 146.14 (Cquat, Im-C-2), 
152.85 (Cquat, C=N), 175.08 (Cquat, C=O). IR (cm-1) = 3114, 2990, 2902, 1663, 1623, 1180, 
1129. HRMS (EI-MS) calcd. for C22H25N5O [M+•] 375.2059; found 375.2059. C22H25N5O · 2 
TFA (603.51). 
 
N1-[3-(1H-Imidazol-2-yl)propyl]-N2-[3-phenyl-3-(thiazol-2-yl)propanoyl]guanidine (5.84) 
The title compound was prepared from 5.78 (270 mg, 0.43 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 27.5/72.5) yielded a 
pale yellow semisolid compound (140 mg, 45 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): 
δ [ppm] = 1.91 – 2.06 (m, 2H, Im-2-CH2-CH2), 2.92 (t, 2H, 3J = 7.7 Hz, Im-2-CH2), 3.24 – 3.37 
(m, 3H, Im-2-(CH2)2-CH2 + PhThiazCH-CH2), 3.45 (dd, 1H, 2J = 16.6 Hz, 3J = 7.4 Hz, 
PhThiazCH-CH2), 4.90 (dd, 1H, 3J = 7.7 Hz, 3J = 7.4 Hz, PhThiazCH), 7.11 (s, 2H, Im-4,5-H), 
7.24 – 7.37 (m, 5H, Ph-H), 7.52 (d, 1H, 3J = 3.5 Hz, Thiaz-5-H), 7.70 (d, 1H, 3J = 3.5 Hz, 
Thiaz-4-H). 13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 22.57 (-, Im-2-CH2), 24.92 (-, 
Im-2-CH2-CH2), 40.41 (-, Im-2-(CH2)2-CH2), 41.67 (-, PhThiazCH-CH2), 43.43 (+, 
PhThiazCH), 118.54 (+, Im-C-4,5), 121.49 (+, Thiaz-C-5), 127.83 (+, 2 Ph-C), 128.44 (+, Ph-
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C-4), 129.44 (+, 2 Ph-C), 139.31 (Cquat, Ph-C-1), 139.53 (+, Thiaz-C-4), 146.16 (Cquat, Im-C-
2), 152.81 (Cquat, C=N), 173.41, 174.37 (Cquat, Thiaz-C-2 + C=O). IR (cm-1) = 3117, 2902, 
1663, 1624, 1181, 1129. HRMS (EI-MS) calcd. for C19H22N6OS [M+•] 382.1576; found 
382.1577. C19H22N6OS · 2 TFA (724.55). 
 
N1-(3-Phenylbutanoyl)-N2-[3-(1H-pyrazol-4-yl)propyl]guanidine (5.85) 
The title compound was prepared from 5.73 (400 mg, 0.72 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 20/80, 20 min: 
45/65) yielded a pale yellow semisolid compound (210 mg, 54 %). 1H-NMR (300 MHz, 
CD3OD, trifluoroacetate): δ [ppm] = 1.32 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 1.82 – 1.97 (m, 2H, 
Pyraz-4-CH2-CH2), 2.60 (t, 2H, 3J = 7.6 Hz, Pyraz-4-CH2), 2.60 (dd, 2H, 2J = 15.1 Hz, 3J = 7.6 
Hz, PhCH3CH-CH2), 2.75 (dd, 1H, 2J = 15.1 Hz, 3J = 7.5 Hz, PhCH3CH-CH2), 3.23 – 3.37 (m, 
3H, overlap with solvent, PhCH3CH + Pyraz-4-(CH2)2-CH2), 7.13 – 7.33 (m, 5H, Ph-H), 7.62 
(s, 2H, Pyraz-3,5-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 21.87 (-, Pyraz-
4-CH2), 22.30 (+, PhCH3CH), 30.22 (-, Pyraz-4-CH2-CH2), 37.69 (+, PhCH3CH), 41.92 (-, 
Pyraz-4-(CH2)2-CH2), 46.21 (-, PhCH3CH-CH2), 121.22 (Cquat, Pyraz-C-4), 127.75 (+, Ph-C-
4), 127.95 (+, 2 Ph-C), 129.70 (+, 2 Ph-C), 133.85 (+, Pyraz-C-3,5), 146.43 (Cquat, Ph-C-1), 
155.08 (Cquat, C=N), 176.00 (Cquat, C=O). IR (cm-1) = 3092, 2968, 1662, 1594, 1176, 1133. 
HRMS (EI-MS) calcd. for C17H23N5O [M+•] 313.1903; found 313.1898. C17H23N5O · 2 TFA 
(541.44). 
  
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1H-pyrazol-4-yl)propyl]guanidine (5.86) 
The title compound was prepared from 5.74 (420 mg, 0.68 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 30/70, 20 min: 
50/50) yielded a pale yellow semisolid compound (205 mg, 50 %). 1H-NMR (300 MHz, 
CD3OD, trifluoroacetate): δ [ppm] = 1.80 – 1.94 (m, 2H, Pyraz-4-CH2-CH2), 2.56 (t, 2H, 3J = 
7.6 Hz, Pyraz-4-CH2), 3.24 (t, 2H, 3J = 7.0 Hz, Pyraz-4-(CH2)2-CH2), 3.25 (d, 2H, 3J = 8.0 Hz, 
Ph2CHCH2), 4.59 (t, 1H, 3J = 8.0 Hz, Ph2CH), 7.11 – 7.34 (m, 10H, Ph-H), 7.51 (s, 2H, Pyraz-
3,5-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 21.87 (-, Pyraz-4-CH2), 30.27 
(-, Pyraz-4-CH2-CH2), 41.94 (-, Pyraz-4-(CH2)2-CH2), 43.90 (-, Ph2CH-CH2), 48.06 (-, Ph2CH), 
120.76 (Cquat, Pyraz-C-4), 127.84 (+, 2 Ph-C-4), 128.84 (+, 4 Ph-C), 129.74 (+, 4 Ph-C), 
133.82 (+, Pyraz-C-3,5), 144.51 (Cquat, Ph-C-1), 154.98 (Cquat, C=N), 175.46 (Cquat, C=O). IR 
(cm-1) = 3026, 2923, 1663, 1599, 1183, 1129. HRMS (EI-MS) calcd. for C22H25N5O [M+•] 
375.2059; found 375.2049. C22H25N5O · 2 TFA (603.51). 
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N1-(3-Phenylbutanoyl)-N2-[3-(1H-1,2,4-triazol-3-yl)propyl]guanidine (5.87) 
The title compound was prepared from 5.79 (450 mg, 0.81 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 15/85, 20 min: 
40/60) yielded a white solid (220 mg, 50 %); mp 58 – 62 °C. 1H-NMR (400 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 1.32 (d, 3H, 3J = 7.0 Hz, PhCH3CH), 2.01 – 2.11 (m, 2H, Triaz-3-
CH2-CH2), 2.69 – 2.80 (m, 2H, PhCH3CH-CH2), 2.88 (t, 2H, 3J = 7.3 Hz, Triaz-3-CH2), 3.26 – 
3.36 (m, 1H, overlap with solvent, PhCH3CH), 3.37 (t, 2H, 3J = 7.1 Hz, Triaz-3-(CH2)2-CH2), 
7.14 – 7.31 (m, 5H, Ph-H), 8.39 (s, 1H, Triaz-5-H). 13C-NMR (75 MHz, CD3OD, 
trifluoroacetate, HSQC): δ [ppm] = 22.29 (+, PhCH3CH), 24.20 (-, Triaz-3-CH2), 26.94 (-, 
Triaz-3-CH2-CH2), 37.60 (+, PhCH3CH), 41.69 (-, Triaz-3-(CH2)2-CH2), 46.25 (-, PhCH3CH-
CH2), 127.75 (+, Ph-C-4), 127.92 (+, 2 Ph-C), 129.72 (+, 2 Ph-C), 146.45 (Cquat, Ph-C-1), 
146.91 (+, Triaz-C-5), 155.22 (Cquat, C=N), 159.51 (Cquat, Triaz-C-3), 175.80 (Cquat, C=O). IR 
(cm-1) = 3086, 2971, 2931, 1669, 1602, 1178, 1130. HRMS (EI-MS) calcd. for C16H22N6O 
[M+•] 314.1855; found 314.1853. C16H22N6O · 2 TFA (542.43). 
 
N1-(3,3-Diphenylpropanoyl)-N2-[3-(1H-1,2,4-triazol-3-yl)propyl]guanidine (5.88) 
The title compound was prepared from 5.80 (560 mg, 0.93 mmol) according to the general 
procedure. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 20/80, 20 min: 
50/50) yielded a white solid (228 mg, 41 %); mp 65 – 68 °C. 1H-NMR (300 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 1.98 – 2.12 (m, 2H, Triaz-3-CH2-CH2), 2.88 (t, 2H, 3J = 7.3 Hz, 
Triaz-3-CH2), 3.25 (d, 2H, 3J = 7.9 Hz, Ph2CHCH2), 3.36 (t, 2H, 3J = 7.1 Hz, Triaz-3-(CH2)2-
CH2), 4.59 (t, 1H, 3J = 7.9 Hz, Ph2CH), 7.11 – 7.32 (m, 10H, Ph-H), 8.42 (s, 1H, Triaz-5-H). 
13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 24.19 (-, Triaz-3-CH2), 26.89 (-, Triaz-
3-CH2-CH2), 41.70 (-, Triaz-3-(CH2)2-CH2), 43.92 (-, Ph2CH-CH2), 47.96 (+, Ph2CH), 127.83 
(+, 2 Ph-C-4), 128.82 (+, 4 Ph-C), 129.74 (+, 4 Ph-C), 144.54 (Cquat, 2 Ph-C-1), 146.87 (+, 
Triaz-C-5), 155.14 (Cquat, C=N), 159.50 (Cquat, Triaz-C-3), 175.28 (Cquat, C=O). IR (cm-1) = 
2970, 2901, 1662, 1598, 1183, 1129. HRMS (EI-MS) calcd. for C21H24N6O [M+•] 376.2012; 
found 376.2004. C21H24N6O · 2 TFA (604.50). 
 
5.4.2 Pharmacological methods 
5.4.2.1 Materials 
Histamine dihydrochloride was purchased from Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany). Thioperamide maleate was from Tocris Bioscience (Ellisville, USA). [γ-32P]GTP 
was synthesized according to a previously described method.40 [32P]Pi (8,500 – 
9,100 Ci/mmol orthophosphoric acid) was from PerkinElmer Life Sciences (Boston, MA). All 
unlabeled nucleotides, glycerol-3-phosphate dehydrogenase, triose phosphate isomerase, 
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glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase were from Roche 
(Mannheim, Germany). 3-Phosphoglycerate kinase and L-α-glycerol phosphate was from 
Sigma. 
 
5.4.2.2 Steady-state GTPase activity assay 
See section 3.4.2.2. 
 
5.4.2.3 Histamine H1R assay on guinea pig ileum3 
See section 3.4.2.4. 
 
5.4.2.4 Histamine H2R assay on the isolated spontaneously beating guinea pig 
right atrium3  
See section 3.4.2.5. 
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Chapter 6 
 
NG-Acylated imidazolylpropylguanidines as 
potent histamine H4 receptor agonists: 
selectivity by variation of the NG-substituent  
 
6.1 Introduction 
Among a series of NG-acylated imidazolylpropylguanidines1-3  originally developed by our 
group as potent H2R agonists, several compounds were serendipitously found to be even 
more potent at the hH3R and the hH4R (for example UR-AK24 (6.1), Figure 6.1).2, 3 Most of 
the investigated compounds displayed high efficacies at the hH4R, but low efficacies at the 
hH3R. Subsequent evaluation of the parent structure, 3-(1H-imidazol-4-yl)propylguanidine 
(6.2, SK&F 91486, Figure 6.1), a weak partial H2R agonist,4 surprisingly revealed this 
compound as a highly potent partial agonist at the hH3R and hH4R (Table 6.1).   
Starting from this model 
compound, the goal of the 
present study was to 
elaborate the possibility to 
develop more selective 
hH4R agonists by acylation 
of the guanidine group in 
SK&F 91486. One strategy 
was to introduce acyl 
residues containing 
structural motifs of the 
potent and selective hH4R 
antagonist JNJ 7777120 
 
Figure 6.1.  Structures of the acylguanidine UR-AK24 (6.1), SK&F 
91486 (6.2), the selective H4R antagonist JNJ 7777120 (6.3), and 
the novel NG-acylated imidazolylpropyl-guanidines (6.15-6.25) 
presented in this study.
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(6.3, Figure 6.1).5 The resulting hybrid molecules (6.15-6.21) consisting of an H4R agonistic 
and antagonistic moiety could be favorable for hH4R selectivity and activity, provided that the 
acyl residue can additionally interact with the binding site of JNJ 7777120. The second 
approach focused on the size of the acyl residues with respect to selectivity for H4R over 
H2R. The imidazolylpropylguanidine portion is considered to be responsible for H2R agonistic 
activity, whereas the NG-acyl residue is assumed to contribute to H2R affinity.3 However, the 
endogenous ligand histamine, lacking additional affinity conferring residues, is about 50 
times more potent at the hH3R and the hH4R relative to the hH2R (Table 6.1). As bulky NG-
acyl groups may be dispensable or unfavorable to obtain highly potent compounds at the 
hH3R and hH4R, acylation of SK&F 91486 with small alkanoyl groups (6.22-6.25) was 
explored to switch selectivity toward the hH3R and hH4R and to gain more insight into the 
structure-activity relationships of the NG-acylated imidazolylpropylguanidines at the distinct 
histamine receptor subtypes.  
 
6.2 Chemistry 
The NG-acylated imidazolylpropylguanidines 6.4, 6.6 and 6.8 were synthesized by acylation 
of the guanidine base 6.29 with CDI-activated carboxylic acids6, 7 according to the method 
described by Ghorai et al. (Scheme 6.1).3 However, preparation of the acylguanidines via this 
route showed drawbacks. The synthesis of 6.7 failed since under the strongly basic 
conditions (NaH) required for the deprotonation of the guanidine moiety an intramolecular 
cyclization of the carboxylic acid 6.47 (Scheme 6.4) occurred (acylation of the indole nitrogen 
giving a six-membered ring; analysed by mass spectrometry). Therefore, a modified 
synthetic pathway was employed. To avoid the strongly basic conditions, instead of the free 
guanidine (pKa ≈ 13)8 the Boc-protected derivatives (pKa ≈ 5)8 6.30 or 6.34 (6.30: mixture of 
isomers I and II, 6.34: single isomer; c.f. Scheme 6.2) were used,9 yielding the trityl- and Boc-
protected intermediates 6.5, 6.7 and 6.9-6.14. This procedure can be performed in a one-pot 
reaction without pre-activation of the carboxylic acids. Moreover, the isolation and purification 
of the less polar and less basic twofold acylated intermediates was facilitated, fewer side 
reactions were observed and excessive acylation of the guanidine moiety was prevented. 
Nevertheless, as marked cleavage of one acyl-group was detectable by NMR after storage in 
solution for few days, the intermediates 6.5, 6.7, 6.9-6.14 should be deprotected timely. 
Detritylation of the imidazole ring was routinely performed in a mixture of 20 % TFA in 
dichloromethane (6.15, 6.17, 6.19).3 However, under these conditions the deprotection of 
compound 6.8 gave 6.19 in only 3 % yield and produced a large number of side products, 
whereas refluxing in hydrochloric acid resulted in 10 to 20 times higher yields. In contrast to 
the TFA/dichloromethane mixture, side reactions were reduced in aqueous medium, 
presumably, because the intermediate trityl cation was trapped and precipitated as 
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triphenylmethanol. This procedure was applied for the preparation of the NG-acylated 
imidazolylpropylguanidines 6.16, 6.18, 6.20-6.25 and for 6.2 (SK&F 91486).35  
In theory, acylation of the Boc-protected guanidine is possible at the nitrogen adjacent to the 
carbon chain or at the unsubstituted nitrogen. However, 2D-NMR experiments (HMBC, 
NOESY) with compound 6.24, synthesized from building block 6.34, i. e. isomer I, bearing 
the Boc-group at the terminal nitrogen, confirmed the acylation at the designated third 
guanidine nitrogen. 
The trityl-protected imidazolylpropylguanidine 6.29 was synthesized via Mitsunobu reaction10 
followed by hydrogenation over Pd/C as previously described.3 The Boc-protected 
guanidines 6.30 (mixture of isomers I and II) and 6.34 (isomer I, Scheme 6.1), respectively, 
were obtained depending on the employed procedure (Scheme 6.2). Condensation of trityl-
protected imidazolylpropanol 6.263, 11 with Cbz/Boc-diprotected guanidine 6.37 under 
Mitsunobu conditions10 yielded the diurethane-protected guanidine 6.28. Hydrogenolytic 
cleavage of the Cbz group provided the Boc-protected imidazolylpropylguanidine 6.30. As 
the alkylation of the substituted guanidine 6.37 (Scheme 6.3) can occur alternatively at the 
nitrogens bearing electron-withdrawing groups (Cbz or Boc), 6.28 and 6.30 were obtained as 
mixtures of regioisomers. The formation of isomers was avoided by an alternative convenient 
route: guanidinylation of the amine 6.32 with Boc/Cbz/triflyl-protected guanidine (6.38) gave 
6.33, and subsequent hydrogenation afforded the designated Boc-protected 
imidazolylpropylguanidine 6.34 (Scheme 6.2). 
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Scheme 6.1. Synthesis of the NG-acylated imidazolylpropylguanidines 6.15-6.25 and 6.2 (SK&F 
91486). Reagents and conditions: (i) for 6.4, 6.6, 6.8: CDI (1.2 eq), NaH (60 % dispersion in mineral 
oil) (2 eq), THF, 5 h, rt; (ii) for 6.5, 6.7, 6.9-6.14: EDC · HCl (1.2 eq), DMAP (1.1 eq), DCM, 24 h, 0 °C 
 rt; (iii) for 6.15, 6.17, 6.19: TFA (20 %), DCM, 5 h, rt; (iv) for 6.2, 6.16, 6.18, 6.20-6.25: HCl 1 M, 30 
min, reflux. b c.f. Scheme 6.2. c mixture of I and II. d isomer I. e UR-PI288. f UR-PI294. g UR-PI295. h 
UR-PI287. 
 
 
No. R1 R2  No. R1 R2 
6.4, 6.15 H 
 
 6.10c, 6.21 Boc 
6.5c, 6.16 Boc 
 
 6.11d, 6.22e Boc CH3 
6.6, 6.17 H 
 
 6.12d, 6.23f Boc CH2CH3 
6.7c, 6.18 Boc 
N
H
O
NH
 
 6.13d, 6.24g Boc CH2CH2CH3 
6.8, 6.19 H 
 
 6.14d, 6.25h Boc 
 
6.9c, 6.20 Boc     
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Scheme 6.2. Preparation of the imidazolylpropylguanidines 6.29, 6.30, 6.34. Reagents and conditions: 
(i) 6.35 or 6.37 (1.75 eq), PPh3 (1.5 eq), DIAD (1.5 eq), THF, overnight, 0 °C  rt; (ii) H2, Pd/C (10 %) 
(cat.), MeOH, 3 h, rt; (iii) phthalimide (1.5 eq), PPh3 (1.5 eq), DIAD (2 eq), THF, 1 h, 0 °C  rt; (iv) 
N2H4 · H2O (6.4 eq), n-BuOH, 1 h, reflux; (v) 6.38 (0.9 eq), NEt3 (1 eq), DCM, overnight, rt.   
 
Preparation of the guanidinylation reagents employed in Scheme 6.2 was achieved by 
successive introduction of the protective groups starting from guanidine as described by 
Feichtinger et al. (Scheme 6.3).12 
 
 
 
Scheme 6.3. Preparation of the guanidinylation reagents 6.35-6.38. Reagents and conditions: (i) 
benzyl chloroformate (3 eq), NaOH (5 eq), H2O/DCM, 20 h, 0 °C; (ii) NaOH (2 eq), Boc2O (0.8 eq), 
1,4-dioxane/H2O, overnight, 0 °C  rt; (iii) benzyl succinimidyl carbonate (1 eq), DMF, overnight, rt; 
(iv) Tf2O (1 eq), NaH (60 % dispersion in mineral oil) (2 eq), chlorobenzene, overnight, - 45 °C  rt.  
 
Not commercially available carboxylic acids (6.47-6.50) were synthesized as outlined in 
Scheme 6.4. EDC-activated 1H-indole-2-carboxylic acid was coupled to the pertinent amino 
acid methyl ester followed by saponification of the ester with LiOH in EtOH. Treatment of 3-
(methylamino)propanenitrile with HCl in MeOH provided the corresponding methyl ester 
6.36.13 
 
Scheme 6.4. Preparation of the carboxylic acids 6.47-6.50. Reagents and conditions: (i) HCl (gas), 
Na2SO4, MeOH, 5 h, rt; (ii) EDC · HCl (1.2 eq), DMAP (1.3 eq), DCM, 24 h, 0 °C  rt; (iii) LiOH · H2O 
(2 eq), EtOH, 20 h, rt.   
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6.3 Pharmacological results and discussion 
The synthesized compounds were investigated for agonism and antagonism at the four 
human histamine receptor subtypes in steady-state GTPase assays using membrane 
preparations of Sf9 insect cells expressing the hH1R plus RGS4 (regulator of G-protein 
signaling), the hH2R-GsαS fusion protein, the hH3R plus Giα2 plus Gβ1γ2 plus RGS4, or the 
hH4R-RGS19 fusion protein plus Giα2 plus Gβ1γ2 (Table 6.1).3, 14, 15 In addition, selected 
compounds were investigated at the guinea pig ileum and the guinea pig right atrium, 
respectively, for activity at gpH1R and gpH2R. 
 
6.3.1 Potencies and efficacies of the prepared compounds at the hH1R, hH2R, 
hH3R and hH4R in the steady-state GTPase activity assay 
The reference acylguanidine UR-AK24 was similarly potent as histamine at the hH4R,3 had 
high affinity but low efficacy at the hH3R, was about 35 times more potent than histamine at 
the hH2R and a weak antagonist at the hH1R. SK&F 91486, which is considered as essential 
moiety for agonistic activity of such acylguanidine-type H2R agonists,3 was about half as 
potent as histamine at the hH2R and acted as partial agonist (EC50 = 2,600 nM, Emax = 0.66). 
This is in accordance with previous findings at the guinea pig right atrium (H2R).4 At the hH3R 
and hH4R, SK&F 91486 showed similarly high potencies (EC50 ≈ 8 nM) and efficacies of 
≈ 0.7 to 0.8, whereas the compound was almost ineffective at the hH1R. These results 
suggest the imidazolylpropylguanidine moiety to be a suitable agonist structure not just at the 
hH2R, but also at the hH3R and hH4R.  
Most of the new acylguanidines (6.15-6.25) listed in Table 6.1, except compounds 6.17 and 
6.21, which had negligible efficacy if any, proved to be hH4R agonists achieving low 
nanomolar potencies. However, the two groups of compounds, 6.15-6.21 and 6.22-6.25, 
differed in particular in terms of efficacy and hH4R selectivity. In compounds 6.15-6.21, the 
guanidine group of SK&F 91486 was acylated with an indole-3-alkanoyl or indole-2-carbonyl 
residue reminiscent of the core structure of the selective hH4R antagonist JNJ 7777120.5 
Compared to SK&F 91486, the acylation of the guanidine group with indole-3-acetic or 
-propanoic acid (6.15, 6.16) substantially increased potency at the hH2R and thereby 
produced diminished discrimination between the hH2R and hH4R. Agonistic efficacy at the 
hH3R was abolished. In compounds 6.17-6.21, indole-2-carboxylic acid is attached to the 
imidazolylpropylguanidine portion either directly (6.17) or via amino acid linkers (6.18-6.21). 
The amino acid spacers were considered as “ring-opened equivalents” to the piperazine ring 
in JNJ 7777120, and the basic tertiary amine, which is regarded as crucial for H4R affinity of 
JNJ 7777120,16 may be mimicked by the acylguanidine group. Direct attachment of the 
indole-2-carboxylic acid (6.17) significantly changed the pharmacological profile at HxRs 
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relative to the reference compound SK&F 91486. Compound 6.17 showed moderate partial 
agonism at hH1R (EC50 = 1,700 nM, Emax = 0.42). At hH2R, 6.17 was about 10 times more 
potent than SK&F 91486 and showed slightly elevated efficacy (EC50 = 290 nM, Emax = 0.87). 
In contrast, at the hH3R and hH4R, 6.17 was > 10 times less potent and efficacy substantially 
decreased. The incorporation of a glycine spacer (6.18) was not tolerated in terms of hH2R 
activity; compared to 6.17 efficacy and potency remarkably dropped (EC50 = 950 nM, Emax = 
0.51). At the hH3R and hH4R, 6.18 was more potent than compound 6.17 and displayed 
partial agonistic activity at both receptors. Replacing the glycine spacer with β-alanine (6.19) 
and 4-aminobutyric acid (6.21) increased potency at the hH2R by a factor of 10 (EC50 = 83 
nM) and 30 (EC50 = 30 nM), respectively. Obviously, the increased flexibility of the higher 
homologs favored high hH2R potency. The hH3R and hH4R affinities remained largely 
unaffected, whereas the efficacies at these receptors were significantly reduced. At all hHxR, 
especially at the hH2R, N-methylation of the amide nitrogen (6.20) increased efficacies, but 
the potencies at the hH2R and hH4R (EC50 values: 350 nM and 150 nM) were reduced, 
suggesting the amide NH group to contribute to hH2R and hH4R binding, although steric 
factors may also play a role. In contrast, at the hH3R, 6.20 was more potent as a partial 
agonist than the unmethylated analog 6.19. Taken together, the hybrid approach, combining 
hH4R agonistic (SK&F 91486) and antagonistic (JNJ 7777120) structural elements, was 
unsuccessful with respect to improving the hH4R selectivity.  
The second approach to increase selectivity for the hH4R, in particular over the hH2R, was 
focused on the introduction of small NG-alkanoyl residues instead of the larger arylalkanoyl 
groups found to be useful in H2R agonists.3 This idea was stimulated by the fact that the 
natural agonist, histamine, is 100 times more potent at hH4R than hH2R (EC50 values: 12 nM 
vs. 1200 nM). Obviously, additional affinity-conferring substituents are not required to 
achieve low nanomolar hH4R potencies. Acetylation of the guanidine group yielding 6.22 
(UR-PI288) provided a moderate increase in potency and efficacy (EC50 = 730 nM, Emax = 
0.76) relative to SK&F 91486 at the hH2R. As expected, the potencies of the acylguanidines 
at the hH2R further increased (EC50 = 730 nM  EC50 = 110 nM) with the extension of the 
alkanoyl residue (6.23, UR-PI294; 6.24, UR-PI295; 6.25, UR-PI287), whereas the efficacy 
remained unaffected. However, with the small NG-alkanoyl residues in 6.22-6.25 the hH2R 
agonistic potency was kept considerably lower than with larger arylalkanoyl groups.3 The NG-
alkanoylguanidines 6.22-6.25 were very weak partial agonists at the hH1R. Regarding the 
hH3R, acetylation of the guanidine group in SK&F 91486 slightly increased potency, but 
substantially decreased efficacy (EC50 = 3.6 nM, Emax = 0.27). Likewise, substitution of the 
guanidine group with larger alkanoyl residues was poorly tolerated in terms of hH3R efficacy. 
Obviously, acylation of the guanidine group modifies the interaction of the imidazolylpropyl-
guanidine moiety with the hH3R in a manner that impedes the stabilization of an active 
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receptor conformation. Contrary to the structure-activity relationships at the hH3R, the 
alkanoyl residue was beneficial for the activation of the hH4R. The NG-alkanoyl imidazolyl-
propylguanidines 6.22-6.25 were highly potent and (almost) full agonists at the hH4R (EC50 
values: 3.0 – 4.9 nM, Emax: 0.90 – 1.00). This demonstrates that acylation of the guanidine 
group in SK&F 91486 is a successful way to shift the efficacy to the hH4R at the expense of 
the hH3R agonism.  
To visualize the impact of the size and lipophilicity of the acyl group on the potency at the 
different HR subtypes, the clogP values of the compounds bearing small alkanoyl residues 
(6.22-6.25) were calculated and plotted against their pEC50 values. As shown in Figure 6.2, 
concerning the hH2R, the potencies of the compounds tended to increase with their 
lipophilicity, suggesting hydrophobic interactions of the alkyl chains with amino acid residues 
of the hH2R. Contrary to the potencies, the efficacies at the hH2R were not remarkably 
affected (Emax: 0.76 – 0.86). A similar H2R structure-activity relationship was observed for 
6.22-6.25 in functional studies using isolated, spontaneously beating guinea pig right atria 
(c.f. 6.3.2). This confirms the observation from guanidine-type H2R agonists that the 
imidazolylpropylguanidine part is crucial for agonistic activity, whereas the second 
substituent at the guanidine moiety is necessary as affinity-conferring moiety.17, 18 The 
potencies at the hH3R and hH4R were almost independent of compound lipophilicity. 
Obviously, in contrast to the hH2R, larger NG-acyl substituents are not required for gaining 
additional affinity for the hH3/4Rs.  Therefore, acylation of the guanidine moiety with small 
residues enables a shift of selectivity from the hH2R toward the hH3R and hH4R.  
 
 
Figure 6.2. Relation between the pEC50 
values of the NG-alkanoyl imidazolyl-
propylguanidines 6.22-6.25 at the hH2R, 
hH3R and hH4R and their clogP values 
(calculated with ChemDraw Ultra 10.0, 
CambridgeSoft, Cambridge, UK). The lines, 
representing the trend, were obtained from 
linear regression (hH2R: slope, 0.783 ± 
0.208; r2, 0.877; p = 0.0636. hH3R: slope, 
0.364 ± 0.139; r2, 0.774; p = 0.120. hH4R: 
slope, 0.219 ± 0.104; r2, 0.688; p = 0.170). 
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6.3.2 Potencies and efficacies of selected compounds at the guinea pig ileum 
(gpH1R) and guinea pig right atrium (gpH2R) 
Table 6.2. Pharmacological activities of selected compounds at the guinea pig ileum (gpH1R) and the 
guinea pig right atrium (gpH2R). 
 
 
a number of experiments, b pEC50 was calculated from the mean shift ∆pEC50 of the agonist curve 
relative to the histamine reference curve by equation: pEC50 = 6.00 + 0.13 + ∆pEC50. Summand 0.13 
represents the mean desensitization observed for control organs when two successive curves for 
histamine were performed (0.13 ± 0.02, n = 16). The SEM given for pEC50 is the SEM calculated for ∆pEC50, c efficacy, maximal response (%), relative to the maximal increase in heart rate induced by the 
reference compound histamine, d pA2 of cimetidine (10 µM), n = 3: 6.44 ± 0.04 (agonist 6.22), 6.46 ± 
0.02 (6.23), 6.39 ± 0.09 (6.24), 6.52 ± 0.02 (6.25), n = 2: 6.36 ± 0.20 (6.16).  
 
The investigated NG-acylated imidazolylpropylguanidines usually acted as weak to moderate 
H1R antagonists at the guinea pig ileum (Table 6.2). Species-dependent differences were 
most striking for compound 6.15, which turned out to be a fairly potent gpH1R antagonist with 
a pA2 value of 7.41, but displayed just poor antagonistic activity at the hH1R in the GTPase 
assay.  
At the guinea pig right atrium, all evaluated compounds bearing an indole residue (6.15, 
6.16, 6.20, 6.21) turned out to be partial to full H2R agonists. However, in comparison to the 
parent compound UR-AK24 the potencies of the compounds were reduced as also found in 
the hH2R GTPase assay. In particular for 6.20, containing an indole-2-carboxylic acid, linked 
to the guanidine group via an N-methylated β-alanine spacer, potency dropped by more than 
two orders of magnitude. Otherwise, 6.21 demonstrates that a rather extended acyl residue 
is also tolerated in terms of gpH2R agonistic activity. The alkanoyl analogs 6.22-6.25 exerted 
a similar structure-activity relationship at the gpH2R as at the human isoform, i.e., the 
potency increased with size and lipophilicity of the alkanoyl residue, confirming the 
observation that the NG-substituent in acylguanidine-type and guanidine-type H2R agonists is 
gpH1R gpH2R 
compound 
pA2 na pEC50b Emaxc na 
histamine - -  6.00 ± 0.10 1.00 ± 0.02 > 50 
6.1 (UR-AK24)3 5.87 ± 0.14  4  7.80 ± 0.07 0.99 ± 0.02 4 
6.15 7.41 ± 0.04 39  6.74 ± 0.13 0.91 ± 0.04 4 
6.16 6.40 ± 0.05 11  7.11 ± 0.10d 1.01 ± 0.01 3 
6.20 5.52 ± 0.07 12  5.45 ± 0.18 0.84 ± 0.04 4 
6.21 6.13 ± 0.03 8  6.31 ± 0.16 0.90 ± 0.04 3 
6.22 (UR-PI288) 5.07 ± 0.09 6  6.09 ± 0.09d 0.83 ± 0.01 3 
6.23 (UR-PI294) 5.29 ± 0.09 12  6.52 ± 0.09d 0.94 ± 0.03 3 
6.24 (UR-PI295) 5.45 ± 0.07 10  6.73 ± 0.17d 0.97 ± 0.01 4 
6.25 (UR-PI287) 5.11 ± 0.08 12  6.96 ± 0.04d 0.98 ± 0.04 3 
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crucial for gaining gpH2R affinity.3, 17, 18 In the presence of the H2R antagonist cimetidine the 
concentration-response curves of the compounds 6.22-6.25 were shifted rightward and the 
calculated pA2 values for cimetidine (pA2 ≈ 6.4) were in accordance with reference data for 
antagonism of cimetidine against histamine at the gpH2R.21 
 
6.3.3 Summary and conclusion 
Starting from the potent nonselective acylguanidine-type hH4R agonist UR-AK24, which was 
initially designed and synthesized as an H2R agonist, the parent compound SK&F 91486 
(weak partial agonist at the H2R4) was identified as a highly potent hH3R and hH4R partial 
agonist. With the aim to increase the selectivity of the acylguanidine-type compounds for the 
hH4R, two distinct strategies were explored. 
In the first approach the guanidine group in SK&F 91486 was acylated with indolealkanoic 
and indole-2-carboxylic acid moieties as structural motifs derived from the selective and 
potent hH4R antagonist JNJ 7777120. Depending on the residues and amino acid spacers, 
compounds with varying potencies and efficacies (GTPase assay) at the different histamine 
receptor subtypes were obtained. Obviously, the indole substructures were not suitable to 
confer additional affinity by interaction with the binding site of JNJ 7777120, as neither 
potency nor selectivity for the hH4R were substantially improved. An explanation therefore 
may be provided by an hH4R homology model, suggesting both histamine and JNJ 7777120 
to mainly interact with Asp-94 of TM3 and Glu-182 of TM5.16 Presumably, as previously 
described for the H2R,3, 22 histamine and NG-acylated imidazolylpropylguanidines also 
predominantly interact with identical amino acid residues at the hH4R, resulting in 
overlapping binding sites of the imidazolylpropylguanidine group and JNJ 7777120.  
In the second approach small alkanoyl residues were attached to SK&F 91486 (6.22-6.25). 
With increasing lipophilicity of the alkanoyl residues, potencies at the hH2R increased, too, 
confirming the importance of the acyl group as an affinity-conferring moiety at the hH2R. At 
the hH3R, acylation drastically lowered efficacy, whereas the same compounds turned out to 
be potent and full (or nearly full) hH4R agonists. Thus, although the imidazolylpropyl-
guanidine portion is capable of stimulating hH2R, hH3R and hH4R, selectivity can be achieved 
by appropriate NG-acylation.  
A major advantage of the test systems applied in this study is that for any given HxR subtype, 
we used an identical read-out, namely steady-state GTP hydrolysis. This is a very proximal 
read-out in G-protein-mediated signal transduction, reducing bias of agonist evaluation 
usually introduced by downstream measurements of second messenger generation, changes 
in cell function or gene transcription. Thus, the receptor profiles described herein for 
acylguanidines reflect true differences in pharmacology and not differences in read-out 
between various receptors.  
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The hH4R agonists 6.22-6.25 belong to the most potent hH4R agonists reported up to now 
and may become useful experimental tools in addition to selective hH4R antagonists like JNJ 
7777120 to analyze the as yet incompletely understood (patho)physiological functions of the 
H4R. In most immune cells like mast cells or eosinophils, where the H4R is mainly located, 
H3Rs are not expressed.23-25 Therefore, based on the > 100-fold selectivity over the hH1R 
and hH2R subtypes, NG-alkanoyl imidazolylpropylguanidines like 6.22 may also be applicable 
for investigating the function of the hH4R in hH3R deficient immune cells. Moreover, these 
potent hH4R agonists may be suitable pharmacological probes for desensitization studies 
with the hH4R.  
Taken together, as previously observed, from the medicinal chemistry point of view, the 
imidazolylpropylguanidine scaffold may be considered a “privileged structure” providing 
ligands for several histamine receptor subtypes.3 However, as demonstrated in the present 
study, potencies, efficacies and receptor selectivities of the imidazolylpropylguanidines can 
be triggered by variation of the NG-acyl substituent. 
 
6.4 Experimental section 
6.4.1 Chemistry 
6.4.1.1 General conditions 
Commercial reagents and chemicals were purchased from Acros Organics (Geel, Belgium), 
IRIS Biotech GmbH (Marktredwitz, Germany), Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany), Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Munich, 
Germany), TCI Europe (Zwijndrecht, Belgium) and used without further purification. 
Deuterated solvents for NMR spectroscopy were from Deutero GmbH (Kastellaun, 
Germany). All solvents were of analytical grade or distilled prior to use. If moisture-free 
conditions were required, reactions were performed in dried glassware under inert 
atmosphere (argon or nitrogen). Anhydrous DMF was purchased from Sigma-Aldrich Chemie 
GmbH. Flash chromatography was performed on silica gel (Merck silica gel 60, 40 - 63 µM). 
Reactions were monitored by TLC on aluminum plates coated with silica gel (Merck silica 
gel 60 F254, thickness 0.2 mm). The compounds were detected by UV light (254 nm), a 0.3 % 
solution of ninhydrine in n-butanol (amines) or a 1.0 % solution of Fast Blue B salt (Sigma-
Aldrich Chemie GmbH) in EtOH/H2O = 30/70 (v/v). All melting points are uncorrected and 
were measured on a Büchi 530 apparatus (Büchi GmbH, Essen, Germany).  
Nuclear Magnetic Resonance spectra (1H-NMR and 13C-NMR) were recorded with Bruker 
Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz) or Bruker Avance 600 (1H: 600.1 MHz; 
13C: 150.9 MHz) NMR spectrometers (Bruker BioSpin GmbH, Rheinstetten, Germany). 
Chemical shifts are given in δ (ppm) relative to external standards. Abbreviations for the 
NG-Acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists 221
multiplicities of the signals: s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), sep 
(septet), m (multiplet), brs (for broad singlet) and combinations thereof. In certain cases 2D-
NMR techniques (HSQC, HMBC, NOESY) were used to assign 1H and 13C chemical shifts. 
Infrared spectra (IR) were measured on a Bruker Tensor 27 spectrometer equipped with an 
ATR (attenuated total reflexion) unit from Harrick Scientific Products Inc. (Ossining/NY, US). 
Mass spectra (MS) were recorded on a Finnigan MAT 95 (EI-MS 70 eV, HR-MS), Finnigan 
SSQ 710A (CI-MS (NH3)) and on a Finnigan ThermoQuest TSQ 7000 (ES-MS) 
spectrometer. The peak-intensity in % relative to the strongest signal is indicated in 
parenthesis. Elemental analysis (C, H, N, Elementar Vario EL, Hanau, Germany) were 
performed by the Analytical Department of the University Regensburg and are listed in the 
appendix (Chapter 9). 
Preparative HPLC was performed with a pump model K-1800 (Knauer, Berlin, Germany), the 
column was Eurosphere 100 (250 x 32 mm) (Knauer), which was attached to a UV-detector 
model K-2000 (Knauer). UV detection of the compounds was performed at 210 nm. The 
temperature was 25 °C and the flow rate 37 ml/min. The mobile phase was 0.1 % TFA in 
millipore water and MeCN. Analytical HPLC was performed on a system from Thermo 
Separation Products (TSP, Egelsbach, Germany) equipped with an SN 400 controller, P4000 
pump, an AS3000 autosampler and a Spectra Focus UV/VIS detector. Stationary phase was 
a Eurosphere-100 C-18 (250 x 4.0 mm, 5 µm) column (Knauer) thermostated at 30 °C. The 
flow rate was 0.8 ml/min and the dead time (t0) was 3.32 min. As mobile phase gradients of 
MeCN/0.05 % TFA (aq.) were used and the absorbance was detected at 210 nm. Compound 
purities were calculated as the percentage peak area of the analyzed compound by UV 
detection at 210 nm. HPLC conditions, retention times (tR), capacity factors (k’ = (tR – t0)/t0) 
and purities of the target compounds are listed in the appendix (Chapter 9). 
 
6.4.1.2 Preparation of 1-(3-(1H-imidazol-4-yl)propyl)guanidine 6.2 
(SK&F 91486)26 
A suspension of 6.34 (600 mg, 1.18 mmol) in HCl (1 M, 30 mL) was refluxed for 1 h. After 
removing insoluble material by filtration, the solvent was evaporated. The obtained residue 
was recrystallized from EtOAc/EtOH yielding a white solid (162 mg, 59 %). mp (6.2 · 2 HCl) 
149 – 150 °C. 1H-NMR (300 MHz, DMSO-d6, dihydrochloride): δ [ppm] = 1.76 – 1.91 (m, 2H), 
2.71 (t, 2H, 3J = 7.5 Hz), 3.09 – 3.21 (m, 2H), 7.33 (brs, 4H), 7.47 (d, 1H, 4J = 1.3 Hz), 8.12 (t, 
1H, 3J = 5.7 Hz), 9.03 (d, 1H, 4J = 1.3 Hz), 14.60 (brs, 2H). 13C-NMR (75 MHz, DMSO-d6, 
dihydrochloride): δ [ppm] = 20.94, 27.26, 39.57, 115.49, 132.24, 133.46, 157.07. IR (cm-1) = 
3112, 2989, 2901, 1662, 1616, 1096. ES-MS (DCM/MeOH + NH4OAc) m/z (%): 168 (100) [M 
+ H]+. HRMS (EI-MS) calcd. for C7H13N5 [M+•] 167.1171; found 167.1166. Anal. (C7H13N5 · 2 
HCl · 0.5 H2O) C, H, N. C7H13N5 · 2 HCl (240.13). 
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6.4.1.3 Preparation of the trityl-protected NG-acylated imidazolylpropyl-
guanidines 6.4, 6.6 and 6.8 
General procedure 
A solution of the pertinent carboxylic acid (1 eq) and CDI (1.2 eq) in THFabs (15 mL) was 
stirred for 1 h under argon atmosphere at room temperature. Parallel to this, NaH (60 % 
dispersion in mineral oil) (2 eq) was added to a solution of 6.29 (1 eq) in THFabs (15 mL) 
under argon atmosphere, stirred for 45 min at 30 – 35 °C and allowed to cool to ambient 
temperature. Both mixtures were united and stirred for 5 h under argon atmosphere. EtOAc 
(50 mL) was added and the organic phase was washed with H2O (3 x 20 mL) and dried over 
Na2SO4. After evaporation of the solvent, the crude product was purified by flash 
chromatography.     
 
N1-[2-(1H-Indol-3-yl)acetyl]-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (6.4) 
The title compound was prepared from 2-(1H-indol-3-yl)acetic acid (350 mg, 2.0 mmol), CDI 
(390 mg, 2.4 mmol), NaH (60 % dispersion in mineral oil) (160 mg, 4.0 mmol) and 6.29 (819 
mg, 2.0 mmol) according to the general procedure. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a pale yellow foam-like solid (530 mg, 47 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.74 – 1.90 (m, 2H, Im-4-CH2-CH2), 2.51 (t, 2H, 3J 
= 6.0 Hz, Im-4-CH2), 3.50 (t, 2H, 3J = 6.4 Hz, Im-4-(CH2)2-CH2), 3.92 (s, 2H, indole-4-CH2), 
6.56 (d, 1H, 4J = 1.2 Hz, Im-5-H), 7.00 – 7.46 (m, 20H, Ph-H + indole-H + Im-2-H), 7.66 (d, 
1H, 3J = 7.7 Hz, indole-4-H), 11.57 (indole-N-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
567 (100) [M + H]+. C36H34N6O (566.69). 
 
N1-(1H-Indole-2-carbonyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (6.6) 
The title compound was prepared from 1H-indole-2-carboxylic acid (322 mg, 2.0 mmol), CDI 
(390 mg, 2.4 mmol), NaH (60 % dispersion in mineral oil) (160 mg, 4.0 mmol) and 6.29 (819 
mg, 2.0 mmol) according to the general procedure. Purification by flash chromatography 
(CHCl3/MeOH/NH3 (aq.) 32 % 95/3/2 v/v/v) yielded a colorless foam-like solid (600 mg, 54 
%). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.83 – 2.00 (m, 2H, Im-4-CH2-CH2), 2.79 (t, 2H, 3J 
= 5.9 Hz, Im-4-CH2), 3.51 (t, 2H, 3J = 6.5 Hz, Im-4-(CH2)2-CH2), 6.59 (d, 1H, 4J = 1.1 Hz, Im-
5-H), 7.04 – 7.17 (m, 7H, Ar-H), 7.20 – 7.42 (m, 13H, Ar-H), 7.66 (d, 1H, 3J = 8.3 Hz, indole-
H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 553 (100) [M + H]+. C35H32N6O (552.67). 
 
N1-[3-(1H-Indole-2-carbonylamino)propanoyl]-N2-[3-(1-trityl-1H-imidazol-4-
yl)propyl]guanidine (6.8) 
The title compound was prepared from 6.48 (464 mg, 2.0 mmol), CDI (390 mg, 2.4 mmol), 
NaH (60 % dispersion in mineral oil) (160 mg, 4.0 mmol) and 6.29 (819 mg, 2.0 mmol) 
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according to the general procedure. The precipitated product was filtered, washed with THF 
(2 x 5 mL) and used without further purification (white solid, 842 mg, 67 %); mp 214 – 215 
°C. 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 1.62 – 1.83 (m, 2H, Im-4-CH2-CH2), 2.32 – 2.55 
(m, 4H, overlap with solvent, Im-4-CH2 + indole-2-CO-NH-CH2-CH2), 3.01 – 3.27 (m, 2H, 
indole-2-CO-NH-CH2), 3.42 – 3.56 (m, 2H, Im-4-(CH2)2-CH2), 6.63 (s, 1H, Im-5-H), 6.95 – 
7.49 (m, 20H, Ph-H + Im-2-H, indole-H), 7.57 (d, 1H, 3J = 7.9 Hz, indole-H), 11.57 (s, 1H, 
indole-N-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 624 (100) [M + H]+. C38H37N7O2 
(623.75). 
 
6.4.1.4 Preparation of the Boc/trityl-protected NG-acylated imidazolylpropyl-
guanidines 6.5, 6.7 and 6.9-6.14 
General procedure 
To a solution of the pertinent carboxylic acid (1 eq) and Boc-protected guanidine 6.30 or 6.34 
(1 eq) in DCM (20 mL), EDC · HCl (1.2 eq) and DMAP (1.1 eq) were added at 0 °C. After 
stirring for 4 h at 0 °C, the solution was allowed to warm to ambient temperature and stirred 
for additional 20 h. DCM (20 mL) was added and the organic phase was washed with water 
and brine and dried over Na2SO4. The solvent was evaporated and the crude product purified 
by flash chromatography. 
 
N1-(tert-Butoxycarbonyl)-N2-[3-(1H-indol-3-yl)propanoyl]-N1-[3-(1-trityl-1H-imidazol-4-
yl)propyl]guanidine (6.5) 
The title compound was prepared from 3-(1H-indol-3-yl)propanoic acid (189 mg, 1.0 mmol), 
6.30 (510 mg, 1.0 mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) 
according to the general procedure. Purification by flash chromatography (CHCl3/MeOH 
97.5/2.5 v/v) yielded a colorless foam-like solid (350 mg, 51 %). 1H-NMR (600 MHz, CDCl3): 
δ [ppm] = 1.42 (s, 9H, C(CH3)3), 1.72 – 1.89 (m, 2H, Im-4-CH2-CH2), 2.45 (t, 2H, 3J = 7.1 Hz, 
Im-4-CH2), 2.56 (t, 2H, 3J = 7.5 Hz, indole-3-CH2-CH2), 2.92 (t, 2H, 3J = 7.5 Hz, indole-3-
CH2), 3.86 (t, 2H, 3J = 7.1 Hz, Im-4-(CH2)2-CH2), 6.60 (s, 1H, Im-5-H), 6.83 – 7.55 (m, 21H, 
Ph-H + indole-H + Im-2-H), 10.72 (indole-N-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
681 (100) [M + H]+. C42H44N6O3 (680.84). 
  
N1-(tert-Butoxycarbonyl)-N2-[2-(1H-indole-2-carbonylamino)acetyl]-N1-[3-(1-trityl-1H-
imidazol-4-yl)propyl]guanidine (6.7) 
The title compound was prepared from 6.47 (164 mg, 0.75 mmol), 6.30 (382 mg, 0.75 mmol), 
EDC · HCl (173 mg, 0.9 mmol) and DMAP (101 mg, 0.83 mmol) according to the general 
procedure. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 v/v) yielded a 
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colorless oil (200 mg, 38 %). 1H-NMR (300 MHz, CDCl3) isomers: δ [ppm] = 1.48 (s, 9H, 
C(CH3)3), 1.91 – 2.04 (m, 2H, Im-4-CH2-CH2), 2.41 – 2.65 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 3.42 
– 3.52 (m, 2H, Im-4-(CH2)2-CH2), 4.18 (d, 1.6H, 3J = 4.7 Hz, indole-2-CO-NH-CH2), 4.28 (d, 
0.4H, 3J = 5.2 Hz, indole-2-CO-NH-CH2), 6.57 (d, 1H, 4J = 1.3 Hz, Im-5-H), 6.93 – 6.96 (m, 
1H, indole-H), 7.06 – 7.48 (m, 20H, Ph-H + indole-H + Im-2-H + N-H), 7.58 – 7.70 (m, 1H, 
indole-7-H), 8.66 (t, 1H, 3J = 5.6 Hz, N-H), 9.61 (brs, 1H, N-H), 11.86 (s, 1H, indole-N-H). ES-
MS (DCM/MeOH + NH4OAc) m/z (%): 710 (100) [M + H]+. C42H43N7O4 (709.84). 
 
N1-(tert-Butoxycarbonyl)-N2-[3-(N-methyl-1H-indole-2-carboxamido)propanoyl]-N1-[3-(1-
trityl-1H-imidazol-4-yl)propyl]guanidine (6.9) 
The title compound was prepared from 6.49 (246 mg, 1.0 mmol), 6.30 (510 mg, 1.0 mmol), 
EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) according to the general 
procedure. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 v/v) yielded a 
colorless foam-like solid (440 mg, 60 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.42 (s, 9H, 
C(CH3)3), 1.85 – 2.07 (m, 2H, Im-4-CH2-CH2), 2.46 – 3.51 (m, 9H, Im-4-CH2 + indole-2-CO-
NCH3CH2-CH2), 3.95 (t, 2H, 3J = 7.3 Hz, Im-4-(CH2)2-CH2), 6.60 (s, 1H, Im-5-H), 7.01 – 7.71 
(m, 21H, Ph-H + indole-H + Im-2-H), 10.33 (brs, 1H, indole-N-H). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 738 (100) [M + H]+. C44H47N7O4 (737.89). 
 
N1-(tert-Butoxycarbonyl)-N2-[4-(1H-indole-2-carboxamido)butanoyl]-N1-[3-(1-trityl-1H-
imidazol-4-yl)propyl]guanidine (6.10) 
The title compound was prepared from 6.50 (185 mg, 0.75 mmol), 6.30 (382 mg, 0.75 mmol), 
EDC · HCl (173 mg, 0.9 mmol) and DMAP (101 mg, 0.83 mmol) according to the general 
procedure. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 v/v) yielded a 
colorless oil (280 mg, 51 %). 1H-NMR (300 MHz, CDCl3) isomers: δ [ppm] = 1.47 (s, 5.3H, 
C(CH3)3), 1.47 (s, 3.7H, C(CH3)3), 1.82 – 2.08 (m, 4H, Im-4-CH2-CH2 + indole-2-CO-NH-CH2-
CH2), 2.41 – 2.65 (m, 4H, Im-4-CH2 + indole-2-CO-NH-(CH2)2-CH2), 3.36 – 3.60 (m, 4H, Im-4-
(CH2)2-CH2 + indole-2-CO-NH-CH2), 6.54 (d, 0.4H, 4J = 1.3 Hz, Im-5-H), 6.58 (d, 0.6 H, 4J = 
1.3 Hz, Im-5-H), 6.63 (t, 0.4H, 3J = 5.7 Hz, NH), 6.85 – 6.92 (m, 1H, indole-H), 7.03 – 7.70 
(m, 20.6H, Ph-H + indole-H + Im-2-H + N-H), 8.49 (t, 0.6H, 3J = 5.6 Hz, CON-H), 8.92 (t, 
0.4H, 3J = 5.3 Hz, CON-H), 9.25 (brs, 0.6H, N-H), 9.69 (brs, 0.4H, N-H), 12.22 (s, 0.6H, 
indole-N-H), 12.50 (s, 0.4H, indole-N-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 738 (100) 
[M + H]+. C44H47N7O4 (737.89). 
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N1-Acetyl-N2-(tert-butoxycarbonyl)-N3-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(6.11) 
The title compound was prepared from acetic acid (60 mg, 1.0 mmol), 6.34 (510 mg, 1.00 
mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) according to the 
general procedure. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 v/v) yielded 
a colorless oil (360 mg, 65 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.50 (s, 9H, C(CH3)3), 
1.85 – 1.99 (m, 2H, Im-4-CH2-CH2), 2.16 (s, 3H, CH3), 2.59 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 
3.39 – 3.49 (m, 2H, Im-4-(CH2)2-CH2), 6.53 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.08 – 7.17 (m, 6H, 
Ph-H), 7.29 – 7.39 (m, 10H, Ph-H + Im-2-H), 8.96 (t, 1H, 3J = 5.2 Hz, N-H), 12.41 (brs, 1H, N-
H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 552 (100) [M + H]+. C33H37N5O3 (551.68). 
 
N1-(tert-Butoxycarbonyl)-N2-propionyl-N3-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(6.12) 
The title compound was prepared from propanoic acid (74 mg, 1.0 mmol), 6.34 (510 mg, 
1.00 mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) according to the 
general procedure. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 v/v) yielded 
a colorless oil (320 mg, 57 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.18 (t, 3H, 3J = 7.5 Hz, 
CH3), 1.50 (s, 9H, C(CH3)3), 1.85 – 1.98 (m, 2H, Im-4-CH2-CH2), 2.41 (q, 2H, 3J = 7.5 Hz, 
CH2CH3), 2.60 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 3.39 – 3.50 (m, 2H, Im-4-(CH2)2-CH2), 6.53 (d, 
1H, 4J = 1.3 Hz, Im-5-H), 7.09 – 7.18 (m, 6H, Ph-H), 7.29 – 7.38 (m, 10H, Ph-H + Im-2-H), 
9.01 (t, 1H, 3J = 5.0 Hz, N-H), 12.42 (brs, 1H, N-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 566 (100) [M + H]+. C34H39N5O3 (565.71). 
 
N1-(tert-Butoxycarbonyl)-N2-butyryl-N3-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(6.13) 
The title compound was prepared from butyric acid (88 mg, 1.0 mmol), 6.34 (510 mg, 1.00 
mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) according to the 
general procedure. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 v/v) yielded 
a colorless oil (320 mg, 55 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 0.97 (t, 3H, 3J = 7.4 Hz, 
CH3), 1.50 (s, 9H, C(CH3)3), 1.59 – 1.76 (m, 2H, CH2CH3), 1.85 – 1.98 (m, 2H, Im-4-CH2-
CH2), 2.35 (t, 2H, 3J = 7.5 Hz, CH2CH2CH3), 2.60 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 3.39 – 3.50 
(m, 2H, Im-4-(CH2)2-CH2), 6.53 (d, 1H, 4J = 1.3 Hz, Im-5-H), 7.09 – 7.17 (m, 6H, Ph-H), 7.29 
– 7.39 (m, 10H, Ph-H + Im-2-H), 9.01 (t, 1H, 3J = 5.0 Hz, N-H), 12.40 (brs, 1H, N-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 580 (100) [M + H]+. C35H41N5O3 (579.73). 
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N1-(tert-Butoxycarbonyl)-N2-isobutyryl-N3-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine 
(6.14) 
The title compound was prepared from isobutyric acid (88 mg, 1.0 mmol), 6.34 (510 mg, 1.00 
mmol), EDC · HCl (230 mg, 1.2 mmol) and DMAP (134 mg, 1.1 mmol) according to the 
general procedure. Purification by flash chromatography (CHCl3/MeOH 97.5/2.5 v/v) yielded 
a colorless oil (320 mg, 55 %). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.21 (d, 6H, 3J = 6.9 
Hz, CH(CH3)2), 1.50 (s, 9H, C(CH3)3), 1.85 – 1.99 (m, 2H, Im-4-CH2-CH2), 2.42 – 2.66 (m, 
3H, CH + Im-4-CH2), 3.39 – 3.50 (m, 2H, Im-4-(CH2)2-CH2), 6.53 (d, 1H, 4J = 1.3 Hz, Im-5-H), 
7.09 – 7.17 (m, 6H, Ph-H), 7.29 – 7.38 (m, 10H, Ph-H + Im-2-H), 9.03 (t, 1H, 3J = 5.0 Hz, N-
H), 12.50 (brs, 1H, N-H). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 580 (100) [M + H]+. 
C35H41N5O3 (579.73). 
 
6.4.1.5 Preparation of the NG-acylated imidazolylpropylguanidines 6.15-6.25 
General procedure 1 
The pertinent trityl-protected NG-acylated imidazolylpropylguanidine was stirred for 5 h in a 
mixture of TFA (5.0 mL) and DCM (20 mL). After removing the solvent in vacuo, the crude 
product was purified by preparative HPLC. The solvent was removed by lyophilization and 
the compounds were obtained as trifluoroacetates. 
 
General procedure 2 
The pertinent Boc-trityl-protected NG-acylated imidazolylpropylguanidine was refluxed for 30 
min in HCl (1 M, 20 mL). After removing the precipitated trityl alcohol by filtration, the solvent 
was removed in vacuo. Purification of the crude product was performed by preparative 
HPLC. The solvent was removed by lyophilization and the compounds obtained as 
trifluoroacetates. 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[2-(1H-indol-3-yl)acetyl]guanidine (6.15) 
The title compound was prepared from 6.4 (520 mg, 0.92 mmol) according to the general 
procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 20/80) yielded a pale 
yellow solid (80 mg, 16 %); mp 69 – 73 °C. 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 1.91 – 2.06 (m, 2H, Im-4-CH2-CH2), 2.79 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 3.34 (t, 2H, 
3J = 6.9 Hz, Im-4-(CH2)2-CH2), 3.93 (s, 2H, indole-4-CH2), 7.03 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 
Hz, 4J = 1.0 Hz, indole-5-H), 7.12 (ddd, 1H, 3J = 8.1 Hz, 3J = 7.0 Hz, 4J = 1.2 Hz, indole-6-H), 
7.28 (s, 1H, indole-2-H), 7.33 (s, 1H, Im-5-H), 7.37 (ddd, 1H, 3J = 8.1 Hz, 4J = 1.0 Hz, 5J = 0.8 
Hz, indole-7-H), 7.55 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.2 Hz, 5J = 0.8 Hz, indole-4-H), 8.76 (d, 1H, 
4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, trifluoroacetate): δ [ppm] = 22.58 (-, Im-4-
CH2), 27.93 (-, Im-4-CH2-CH2), 35.31 (-, indole-4-CH2), 41.63 (-, Im-4-(CH2)2-CH2), 106.84 
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(Cquat, indole-C-3), 112.58 (+, indole-C-7), 117.11 (+, Im-C-5), 119.36 (+, indole-C-4), 120.33 
(+, indole-C-5), 122.91 (+, indole-C-6), 125.81 (+, indole-C-2), 128.40 (Cquat, indole-C-3a), 
134.30 (Cquat, Im-C-4), 134.98 (+, Im-C-2), 138.20 (Cquat, indole-C-7a), 155.52 (Cquat, C=N), 
175.87 (Cquat, C=O). IR (cm-1) = 3133, 3028, 2814, 1662, 1628, 1181, 1125. HRMS (EI-MS) 
calcd. for C17H20N6O [M+•] 324.1699; found 324.1696. C17H20N6O · 2 TFA (552.43). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[3-(1H-indol-3-yl)propanoyl]guanidine (6.16) 
The title compound was prepared from 6.5 (330 mg, 0.48 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a 
white solid (147 mg, 54 %); mp 54 – 57 °C. 1H-NMR (600 MHz, NOESY, CD3OD, 
trifluoroacetate): δ [ppm] = 1.95 – 2.05 (m, 2H, Im-4-CH2-CH2), 2.80 (t, 2H, 3J = 7.7 Hz, Im-4-
CH2), 2.84 (t, 2H, 3J = 7.4 Hz, indole-3-CH2-CH2), 3.12 (t, 2H, 3J = 7.4 Hz, indole-3-CH2), 
3.34 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)2-CH2), 6.98 (ddd, 1H, 3J = 7.9 Hz, 3J = 7.1 Hz, 4J = 1.0 
Hz, indole-5-H), 7.05 – 7.09 (m, 2H, indole-6-H + indole-2-H), 7.31 (ddd, 1H, 3J = 8.1 Hz, 4J = 
1.0 Hz , 5J = 0.9 Hz, indole-7-H), 7.34 (s, 1H, Im-5-H), 7.54 (ddd, 1H, 1H, 3J = 7.9 Hz, 4J = 1.2 
Hz , 5J = 0.9 Hz, indole-4-H), 8.78 (d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (150 MHz, HMBC, 
CD3OD, trifluoroacetate): δC [ppm] = 21.34 (-, indole-3-CH2), 22.54 (-, Im-4-CH2), 27.93 (-, 
Im-4-CH2-CH2), 39.18 (-, indole-3-CH2-CH2), 41.56 (-, Im-4-(CH2)2-CH2), 112.30 (+, indole-C-
7), 114.14 (Cquat, indole-C-3), 117.13 (+, Im-C-5), 119.19 (+, indole-C-4), 119.69 (+, indole-C-
5), 122.44 (+, indole-C-6), 123.34 (+, indole-C-2), 128.40 (Cquat, indole-C-3a), 134.30 (Cquat, 
Im-C-4), 134.95 (+, Im-C-2), 138.16 (Cquat, indole-C-7a), 155.27 (Cquat, C=N), 177.14 (Cquat, 
C=O). IR (cm-1) = 3142, 3034, 2962, 1662, 1628, 1182, 1127. HRMS (EI-MS) calcd. for 
C18H22N6O [M+•] 338.1855; found 338.1852. C18H22N6O · 2 TFA (566.45). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-(1H-indole-2-carbonyl)guanidine (6.17) 
The title compound was prepared from 6.6 (500 mg, 0.90 mmol) according to the general 
procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 20/80) yielded a 
white solid (120 mg, 25 %); mp 62 – 65 °C. 1H-NMR (300 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 2.02 – 2.16 (m, 2H, Im-4-CH2-CH2), 2.88 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 3.47 (t, 2H, 
3J = 7.0 Hz, Im-4-(CH2)2-CH2), 7.13 (ddd, 1H, 3J = 8.1 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-5-
H), 7.33 (ddd, 1H, 3J = 8.3 Hz, 3J = 7.0 Hz, 4J = 1.2 Hz, indole-6-H), 7.39 (d, 1H, 4J = 1.3 Hz, 
Im-5-H), 7.45 – 7.52 (m, 2H, indole-3-H + indole-7-H), 7.68 (ddd, 1H, 3J = 8.1 Hz, 4J = 1.2 
Hz, 4J = 1.0 Hz, indole-4-H), 8.82 (d, 1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, CD3OD, 
trifluoroacetate): δ [ppm] = 22.65 (-, Im-4-CH2), 28.11 (-, Im-4-CH2-CH2), 41.83 (-, Im-4-
(CH2)2-CH2), 109.06 (+, indole-C-3), 113.51 (+, indole-C-7), 117.16 (+, Im-C-5), 122.15 (+, 
indole-C-5), 123.81 (+, indole-C-4), 127.34 (+, indole-C-6), 128.65 (Cquat, indole-C-3a), 
129.10 (Cquat, indole-C-2), 134.37 (Cquat, Im-C-4), 135.07 (+, Im-C-2), 139.92 (Cquat, indole-C-
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7a), 155.79 (Cquat, C=N), 163.33 (Cquat, C=O). IR (cm-1) = 3132, 2989, 1665, 1635, 1199, 
1131. HRMS (EI-MS) calcd. for C16H18N6O [M+•] 310.1542; found 310.1541. C16H18N6O · 2 
TFA (538.40). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[2-(1H-indole-2-carbonylamino)acetyl]guanidine 
(6.18) 
The title compound was prepared from 6.7 (190 mg, 0.27 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a 
white solid (53 mg, 33 %); mp 85 – 89 °C. 1H-NMR (300 MHz, D2O, trifluoroacetate): δ [ppm] 
= 1.78 – 1.93 (m, 2H, Im-4-CH2-CH2), 2.65 (t, 2H, 3J = 7.6 Hz, Im-4-CH2), 3.20 (t, 2H, 3J = 6.9 
Hz, Im-4-(CH2)2-CH2), 4.14 (s, 2H, indole-2-CO-NH-CH2), 7.05 – 7.13 (m, 3H, Im-5-H + 
indole-3-H + indole-5-H), 7.25 (ddd, 1H, 3J = 8.2 Hz ,3J = 7.0 Hz , 4J = 1.1 Hz, indole-6-H), 
7.43 (d, 1H, 3J = 8.2 Hz, indole-7-H), 7.64 (d, 1H, 3J = 8.1 Hz, indole-4-H), 8.44 (s, 1H, Im-2-
H). 13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 21.04 (-, Im-4-CH2), 25.94 (-, Im-4-
CH2-CH2), 40.54 (-, Im-4-(CH2)2-CH2), 43.53 (-, indole-2-CO-NH-CH2), 105.12 (+, indole-C-3), 
112.38 (+, indole-C-7), 115.45 (+, Im-C-5), 120.84 (+, indole-C-5), 122.30 (+, indole-C-4), 
125.16 (+, indole-C-6), 127.09 (Cquat, indole-C-3a), 129.42 (Cquat, indole-C-2), 132.36 (Cquat, 
Im-C-4), 133.02 (+, Im-C-2), 136.89 (Cquat, indole-C-7a), 152.72 (Cquat, C=N), 164.35 (indole-
2-CO), 172.37 (Cquat, guanidine-CO). IR (cm-1) = 3235, 3142, 3034, 2869, 1664, 1634, 1554, 
1197, 1128. HRMS (LSI-MS) calcd. for C18H22N7O2 [M + H]+ 368.1829; found 368.1831. 
C18H21N7O2 · 2 TFA (595.45). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[3-(1H-indole-2-carbonylamino)propanoyl]guanidine 
(6.19) 
The title compound was prepared from 6.8 (480 mg, 0.77 mmol) according to the general 
procedure 1. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a 
beige solid (15 mg, 3 %); mp 63 – 67 °C. 1H-NMR (600 MHz, CD3OD, trifluoroacetate): δ 
[ppm] = 1.98 – 2.06 (m, 2H, Im-4-CH2-CH2), 2.80 (t, 2H, 3J = 7.7 Hz, Im-4-CH2), 2.85 (t, 2H, 
3J = 6.4 Hz, indole-2-CO-NH-CH2-CH2), 3.39 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)2-CH2), 3.75 (t, 
2H, 3J = 6.4 Hz, indole-2-CO-NH-CH2), 7.05 (d, 1H, 4J = 0.8 Hz, indole-3-H), 7.06 (ddd, 1H, 
3J = 8.0 Hz, 3J = 7.2 Hz, 4J = 0.9 Hz, indole-5-H), 7.22 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.2 Hz, 4J = 
1.1 Hz, indole-6-H), 7.33 (s, 1H, Im-5-H), 7.43 (dd, 1H, 3J = 8.2 Hz, 4J = 0.9 Hz, indole-7-H), 
7.59 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.1 Hz, 4J = 0.8 Hz, indole-4-H), 8.79 (d, 1H, 4J = 1.2 Hz, Im-
2-H). 13C-NMR (150 MHz, HSQC, HMBC, CD3OD, trifluoroacetate): δ [ppm] = 22.51 (-, Im-4-
CH2), 27.97 (-, Im-4-CH2-CH2), 36.07 (-, indole-2-CO-NH-CH2), 38.08 (-, indole-2-CO-NH-
CH2-CH2), 41.65 (-, Im-4-(CH2)2-CH2), 104.64 (+, indole-C-3), 113.08 (+, indole-C-7), 117.10 
(+, Im-C-5), 121.26 (+, indole-C-5), 122.79 (+, indole-C-4), 125.20 (+, indole-C-6), 128.97 
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(Cquat, indole-C-3a), 131.94 (Cquat, indole-C-2), 134.29 (Cquat, Im-C-4), 134.94 (+, Im-C-2), 
138.37 (Cquat, indole-C-7a), 155.24 (Cquat, C=N), 164.42 (Cquat, indole-2-CO), 175.48 (Cquat, 
guanidine-CO). IR (cm-1) = 3274, 3152, 2986, 1668, 1623, 1557, 1181, 1126. HRMS (LSI-
MS) calcd. for C19H24N7O2 [M+•] 382.1986; found 382.1993. C19H23N7O2 · 2 TFA (609.48). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[3-(N-methyl-1H-indole-2-
carbonylamino)propanoyl]guanidine (6.20) 
The title compound was prepared from 6.9 (400 mg, 0.54 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a pale 
pink solid (215 mg, 64 %); mp 89 – 93 °C. 1H-NMR (600 MHz, COSY, NOESY, CD3OD, 
trifluoroacetate): δ [ppm] = 1.91 – 2.00 (m, 2H, Im-4-CH2-CH2), 2.73 (t, 2H, 3J = 7.7 Hz, Im-4-
CH2), 2.87 (t, 2H, 3J = 6.6 Hz, indole-2-CO-NCH3CH2-CH2), 3.24 – 3.55 (m, 5H, Im-4-(CH2)2-
CH2 + CH3), 3.93 (brs, 2H, indole-2-CO-NCH3CH2), 6.89 (s, 1H, indole-3-H), 7.04 (ddd, 1H, 3J 
= 8.0 Hz, 3J = 7.0 Hz, 4J =0.9 Hz, indole-5-H), 7.19 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.0 Hz, 4J =1.1 
Hz, indole-6-H), 7.28 (s, 1H, Im-5-H), 7.40 (dd, 1H, 3J = 8.2 Hz, 4J = 0.9 Hz, indole-7-H), 7.59 
(ddd, 1H, 3J = 8.0 Hz, 4J = 1.1 Hz, 4J = 0.9 Hz, indole-4-H), 8.75 (d, 1H, 4J = 1.2 Hz, Im-2-H). 
13C-NMR (150 MHz, HSQC, HMBC, CD3OD, trifluoroacetate): δ [ppm] = 22.45 (-, Im-4-CH2), 
27.89 (-, Im-4-CH2-CH2), 36.28 (-, indole-2-CO-NCH3CH2-CH2), 38.35 (+, CH3), 41.51 (-, Im-
4-(CH2)2-CH2), 46.26 (-, indole-2-CO-NCH3CH2), 107.15 (+, indole-C-3), 112.82 (+, indole-C-
7), 117.07 (+, Im-C-5), 121.20 (+, indole-C-5), 122.79 (+, indole-C-4), 125.17 (+, indole-C-6), 
128.81 (Cquat, indole-C-3a), 130.66 (Cquat, indole-C-2), 134.24 (Cquat, Im-C-4), 134.86 (+, Im-
C-2), 137.66 (Cquat, indole-C-7a), 155.23 (Cquat, C=N), 166.01 (indole-2-CO), 175.43 (Cquat, 
guanidine-CO). IR (cm-1) = 3278, 2989, 1658, 1609, 1181, 1133. HRMS (EI-MS) calcd. for 
C20H25N7O2 [M+•] 395.2070; found 395.2070. C20H25N7O2 · 2 TFA (623.50). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-[4-(1H-indole-2-carbonylamino)butanoyl]guanidine 
(6.21) 
The title compound was prepared from 6.10 (270 mg, 0.37 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 25/75) yielded a pale 
pink solid (103 mg, 45 %); mp 102 – 105 °C. 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.28 – 1.43 (m, 2H, indole-2-CO-NH-CH2-CH2), 1.89 – 2.01 (m, 2H, Im-4-CH2-CH2), 
2.26 (t, 2H, 3J = 7.7 Hz, CH2), 2.41 (t, 2H, 3J = 6.2 Hz, CH2), 2.63 (t, 2H, 3J = 7.2 Hz, Im-4-
CH2), 3.35 (t, 2H, 3J = 6.0 Hz, Im-4-(CH2)2-CH2), 6.88 (d, 1H, 4J = 0.8 Hz, indole-3-H), 6.92 
(d, 1H, 4J = 1.4 Hz, Im-5-H), 6.97 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.1 Hz, 4J = 1.0 Hz, indole-5-H), 
7.12 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.1 Hz, 4J = 1.2 Hz, indole-6-H), 7.31 (dd, 1H, 3J = 8.2 Hz, 4J 
= 1.0 Hz, indole-7-H), 7.52 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.2 Hz, 4J = 0.8 Hz, indole-4-H), 8.43 
(d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 20.78 (-, Im-
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4-CH2), 23.90 (-, indole-2-CO-NH-CH2-CH2), 25.75 (-, Im-4-CH2-CH2), 34.93, 38.92 (-, indole-
2-CO-NH-CH2-CH2-CH2), 40.19 (-, Im-(CH2)2-CH2), 103.88 (+, indole-C-3), 112.14 (+, indole-
C-7), 115.35 (+, Im-C-5), 120.61 (+, indole-C-5), 121.99 (+, indole-C-4), 124.69 (+, indole-C-
6), 127.09 (Cquat, indole-C-3a), 130.18 (Cquat, indole-C-2), 132.12 (Cquat, Im-C-4), 132.87 (+, 
Im-C-2), 136.62 (Cquat, indole-C-7a), 152.55 (Cquat, C=N), 163.54 (Cquat, indole-2-CO), 177.14 
(Cquat, guanidine-CO). IR (cm-1) = 3232, 3134, 2988, 1684, 1620, 1558, 1178, 1132. HRMS 
(LSI-MS) calcd. for C20H26N7O2 [M + H]+ 396.2142; found 396.2141. C20H25N7O2 · 2 TFA 
(623.50). 
 
N1-Acetyl-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (6.22) 
The title compound was prepared from 6.11 (350 mg, 0.63 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 4/96) yielded a 
colorless semisolid compound (150 mg, 54 %). 1H-NMR (300 MHz, D2O, trifluoroacetate): δ 
[ppm] = 1.84 – 1.97 (m, 2H, Im-4-CH2-CH2), 2.08 (s, 3H, CH3), 2.69 (t, 2H, 3J = 7.6 Hz, Im-4-
CH2), 3.26 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)2-CH2), 7.12 (d, 1H, 4J = 1.3 Hz, Im-5-H), 8.46 (d, 
1H, 4J = 1.3 Hz, Im-2-H). 13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 21.06 (-, Im-4-
CH2), 23.69 (+, CH3), 26.04 (-, Im-4-CH2-CH2), 40.38 (-, Im-4-(CH2)2-CH2), 115.48 (+, Im-C-
5), 132.44 (Cquat, Im-C-4), 133.03 (+, Im-C-2), 152.98 (Cquat, C=N), 174.73 (Cquat, C=O). IR 
(cm-1) = 3139, 3035, 2854, 1662, 1629, 1179, 1124. HRMS (EI-MS) calcd. for C9H15N5O [M+•] 
209.1277; found 209.1275. C9H15N5O · 2 TFA (437.30). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-propionylguanidine (6.23) 
The title compound was prepared from 6.12 (310 mg, 0.55 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 5/95, 20 min: 
15/85) yielded a colorless semisolid compound (144 mg, 58 %). 1H-NMR (300 MHz, D2O, 
trifluoroacetate): δ [ppm] = 0.98 (t, 3H, 3J = 7.5 Hz, CH3), 1.84 – 1.97 (m, 2H, Im-4-CH2-CH2), 
2.36 (q, 2H, 3J = 7.5 Hz, CH2CH3), 2.69 (t, 2H, 3J = 7.5 Hz, Im-4-CH2), 3.26 (t, 2H, 3J = 6.9 
Hz, Im-4-(CH2)2-CH2), 7.11 (d, 1H, 4J = 1.4 Hz, Im-5-H), 8.45 (d, 1H, 4J = 1.4 Hz, Im-2-H). 
13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 7.70 (+, CH3), 21.07 (-, Im-4-CH2), 26.06 
(-, Im-4-CH2-CH2), 30.16 (-, CH2CH3), 40.37 (-, Im-4-(CH2)2-CH2), 115.48 (+, Im-C-5), 132.44 
(Cquat, Im-C-4), 133.04 (+, Im-C-2), 153.07 (Cquat, C=N), 178.27 (Cquat, C=O). IR (cm-1) = 
3133, 2989, 2901, 1662, 1628, 1180, 1128. HRMS (EI-MS) calcd. for C10H17N5O [M+•] 
233.1433; found 233.1430. C10H17N5O · 2 TFA (451.32).  
 
N1-Butyryl-N2-[3-(1H-imidazol-4-yl)propyl]guanidine (6.24) 
The title compound was prepared from 6.13 (310 mg, 0.55 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 5/95, 20 min: 
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20/80) yielded a colorless semisolid compound (156 mg, 61 %). 1H-NMR (600 MHz, D2O, 
trifluoroacetate): δ [ppm] = 0.86 (t, 3H, 3J = 7.5 Hz, CH3), 1.54 – 1.62 (m, 2H, CH2CH3), 1.94 
– 2.01 (m, 2H, Im-4-CH2-CH2), 2.38 (t, 2H, 3J = 7.3 Hz, CH2CH2CH3), 2.76 (t, 2H, 3J = 7.5 Hz, 
Im-4-CH2), 3.33 (t, 2H, 3J = 6.9 Hz, Im-4-(CH2)2-CH2), 7.19 (d, 1H, 4J = 1.4 Hz, Im-5-H), 8.52 
(d, 1H, 4J = 1.4 Hz, Im-2-H). 13C-NMR (150 MHz, D2O, trifluoroacetate): δ [ppm] = 12.60 (+, 
CH3), 17.68 (-, CH2CH3), 21.07 (-, Im-4-CH2), 26.04 (-, Im-4-CH2-CH2), 38.58 (-, 
CH2CH2CH3), 40.41 (-, Im-4-(CH2)2-CH2), 115.48 (+, Im-C-5), 132.44 (Cquat, Im-C-4), 133.04 
(+, Im-C-2), 153.04 (Cquat, C=N), 177.59 (Cquat, C=O). IR (cm-1) = 3109, 2973, 2901, 1662, 
1629, 1172, 1125. HRMS (EI-MS) calcd. for C11H19N5O [M+•] 237.1590; found 237.1592. 
C11H19N5O · 2 TFA (465.35). 
 
N1-[3-(1H-Imidazol-4-yl)propyl]-N2-isobutyrylguanidine (6.25) 
The title compound was prepared from 6.14 (310 mg, 0.53 mmol) according to the general 
procedure 2. Purification by preparative HPLC (MeCN/0.1 % TFA (aq.): 0 min: 10/90, 20 min: 
20/80) yielded a colorless semisolid compound (166 mg, 67 %). 1H-NMR (300 MHz, D2O, 
trifluoroacetate): δ [ppm] = 1.03 (d, 6H, 3J = 6.9 Hz, 2 CH3), 1.85 – 1.98 (m, 2H, Im-4-CH2-
CH2), 2.53 (sep, 1H, 3J = 6.9 Hz, CH), 2.70 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 3.27 (t, 2H, 3J = 
6.8 Hz, Im-4-(CH2)2-CH2), 7.12 (d, 1H, 4J = 1.4 Hz, Im-5-H), 8.46 (d, 1H, 4J = 1.4 Hz, Im-2-H). 
13C-NMR (75 MHz, D2O, trifluoroacetate): δ [ppm] = 17.87 (+, CH3), 21.10 (-, Im-4-CH2), 
26.05 (-, Im-4-CH2-CH2), 36.20 (+, CH), 40.42 (-, Im-4-(CH2)2-CH2), 115.48 (+, Im-C-5), 
132.45 (Cquat, Im-C-4), 133.06 (+, Im-C-2), 153.31 (Cquat, C=N), 181.44 (Cquat, C=O). IR (cm-1) 
= 3129, 2989, 2901, 1662, 1628, 1180, 1127. HRMS (EI-MS) calcd. for C11H19N5O [M+•] 
237.1590; found 237.1589. C11H19N5O · 2 TFA (465.35). 
 
6.4.1.6 Preparation of the diurethane-protected 3-(1-trityl-1H-imidazol-4-yl)-
propylguanidines 6.27 and 6.28 
General procedure 
To a solution of 6.263, 11 (1 eq), the diurethane-protected guanidine 6.35 or 6.37 (1.75 eq) 
and PPh3 (1.5 eq) in THFabs, DIAD (1.5 eq) in THFabs was added dropwise at 0 °C. After the 
addition was complete, the solution was allowed to warm to room temperature and stirred 
overnight. The solvent was removed in vacuo and the crude product purified by flash 
chromatography. 
 
N1,N2-Bis(benzyloxycarbonyl)-N1-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (6.27)3 
The title compound was prepared from a solution of 6.263, 11 (4.4 g, 11.9 mmol), 6.35 (6.82 g, 
20.8 mmol), PPh3 (4.68 g, 17.9 mmol) in THFabs (100 mL) and a solution of DIAD (3.6 mL, 
3.62 g, 17.9 mmol) in THFabs (30 mL) according to the general procedure. Purification by 
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flash chromatography (PE/EtOAc 80/20 v/v) yielded a colorless foam-like solid. (7.3 g, 91 %). 
1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.89 – 2.04 (m, 2H, Im-4-CH2-CH2), 2.60 (t, 2H, 3J = 
7.7 Hz, Im-4-CH2), 4.02 (t, 2H, 3J = 7.3 Hz, Im-4-(CH2)2-CH2), 5.07 (s, 2H, PhCH2), 5.21 (s, 
2H, PhCH2), 6.59 (d, 1H, 4J = 1.2 Hz, Im-5-H), 7.03 – 7.17 (m, 6H, Ph-H), 7.21 – 7.40 (m, 
19H, Ph-H), 7.43 (d, 1H, 4J = 1.2 Hz, Im-2-H), 9.26 (s, 1H, N-H), 9.42 (brs, 1H, N-H). ES-MS 
(DCM/MeOH + NH4OAc) m/z (%): 678 (100) [M + H]+. C42H39N5O4 (677.79). 
 
N1-(Benzyloxycarbonyl)-N2-(tert-butoxycarbonyl)-N1-[3-(1-trityl-1H-imidazol-4-
yl)propyl]guanidine (6.28) 
The title compound was prepared from a solution of 6.263, 11 (4.42 g, 12.0 mmol), 6.37 (6.16 
g, 21.0 mmol), PPh3 (4.72 g, 18.0 mmol) in THFabs (100 mL) and a solution of DIAD (3.6 mL, 
3.64 g, 18.0 mmol) in THFabs (25 mL) according to the general procedure. Purification by 
flash chromatography (PE/EtOAc 80/20 v/v) yielded a colorless foam-like solid. (5.8 g, 75 %). 
1H-NMR (300 MHz, CDCl3) isomers: δ [ppm] = 1.47 (s, 2.8H, CH3), 1.48 (s, 6.2H, CH3), 1.85 
– 1.99 (m, 2H, Im-4-CH2-CH2), 2.51 – 2.61 (m, 2H, Im-4-CH2), 3.92 – 4.06 (m, 2H, Im-4-
(CH2)2-CH2), 5.10 (s, 1.4H, PhCH2), 5.17 (s, 0.6H, PhCH2), 6.49 (d, 0.3H, 4J = 1.1 Hz, Im-5-
H), 6.54 (d, 0.7H, 4J = 1.1 Hz, Im-5-H), 7.07 – 7.17 (m, 6H, Ph-H), 7.23 – 7.39 (m, 15H, Ph-H 
+ Im-2-H), 9.35 (brs, 1H, N-H), 9.40 (brs, 1H, N-H). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 644 (100) [M + H]+. C39H41N5O4 (643.77). 
 
6.4.1.7 Preparation of the diurethane-protected 3-(1-trityl-1H-imidazol-4-yl)-
propylguanidine 6.33 
2-[3-(1-Trityl-1H-imidazol-4-yl)propyl]isoindoline-1,3-dione (6.31)  
To a cold solution (0 °C) of 6.263, 11 (10.00 g, 27.1 mmol) in THFabs (250 mL), phthalimide 
(6.00 g, 40.8 mmol) and triphenylphosphine (10.7 g, 40.8 mmol) were added. Under external 
ice cooling DIAD (11.00 g, 54.2 mmol) in THFabs (200 mL) was added dropwise. The mixture 
was allowed to warm to ambient temperature, stirred for 1lh and concentrated in vacuo. The 
precipitated product was filtered, washed twice with cold THF (20 mL) and recrystallized from 
THF/MeCN yielding the title compound as white solid (13.0 g, 96 %); mp 212 °C (ref.27: 217 – 
219 °C). 1H-NMR (300 MHz, CDCl3): δ [ppm] = 1.93 – 2.09 (m, 2H, Im-4-CH2-CH2), 2.60 (t, 
2H, 3J = 7.7 Hz, Im-4-CH2), 3.73 (t, 2H, 3J = 7.2 Hz, Im-4-(CH2)2-CH2), 6.57 (d, 1H, 4J = 1.3 
Hz, Im-5-H), 7.09 – 7.18 (m, 6H, Ph-H), 7.28 – 7.37 (m, 10H, Ph-H + Im-2-H), 7.64 – 7.72 (m, 
2H, Phth-H), 7.77 – 7.85 (m, 2H, Phth-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 26.03 (-, Im-
4-CH2-CH2), 28.34 (-, Im-4-CH2), 37.70 (-, Im-4-(CH2)2-CH2), 75.11 (Cquat, CPh3), 118.04 (+, 
Im-C-5), 123.15 (+, Phth-C-4, 7), 127.95 (+, 3 Ph-C-4), 128.02 (+, 6 Ph-C), 129.84 (+, 6 Ph-
C), 132.23 (Cquat, Im-C-4), 133.82 (+, Phth-C-5, 6), 138.39 (+, Im-C-2), 140.65 (Cquat, Phth-C-
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3a, 7a), 142.61 (Cquat, 3 Ph-C-1), 168.39 (Cquat, 2 C=O). ES-MS (DCM/MeOH + NH4OAc) m/z 
(%): 498 (100) [M + H]+. Anal. (C33H27N3O2) C, H, N. C33H27N3O2 (497.59). 
 
3-(1-Trityl-1H-imidazol-4-yl)propan-1-amine (6.32)27 
A mixture of 6.31 (12.80 g, 25.7 mmol) and hydrazine monohydrate (8.0 mL, 164.6 mmol) in 
n-butanol was refluxed for 1 h. After removal of insoluble material, the filtrate was evaporated 
giving a pale brownish oil that solidified (9.11 g, 96 %); mp 106 – 108 °C. 1H-NMR (300 MHz, 
CDCl3): δ [ppm] = 1.70 – 1.82 (m, 2H, Im-4-CH2-CH2), 2.57 (t, 2H, 3J = 7.5 Hz, Im-4-CH2), 
2.70 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)2-CH2), 6.52 (d, 1H, 4J = 1.4 Hz, Im-5-H), 7.08 – 7.18 (m, 
6H, Ph-H), 7.27 – 7.37 (m, 10H, Ph-H + Im-2-H). 13C-NMR (75 MHz, CDCl3): δ [ppm] = 25.83 
(-, Im-4-CH2), 33.42 (-, Im-4-CH2-CH2), 41.85 (-, Im-4-(CH2)2-CH2), 75.09 (Cquat, CPh3), 
117.79 (+, Im-C-5), 127.97 (+, 3 Ph-C-4), 128.00 (+, 6 Ph-C), 129.81 (+, 6 Ph-C), 138.35 (+, 
Im-C-2), 141.45 (Cquat, Im-C-4), 142.63 (Cquat, 3 Ph-C-1). ES-MS (DCM/MeOH + NH4OAc) 
m/z (%): 368 (100) [M + H]+. Anal. (C25H25N3 · 0.5 H2O) C, H, N. C25H25N3 (367.49). 
 
N1-(Benzyloxycarbonyl)-N2-(tert-butoxycarbonyl)-N3-[3-(1-trityl-1H-imidazol-4-yl)-
propyl]guanidine (6.33) 
To a solution of 6.38 (10.17 g, 23.9 mmol) and 6.32 (9.78 g, 26.6 mmol) in DCM (200 mL) 
NEt3 (3.7 mL, 2.69 g, 26.6 mmol) was added. After stirring overnight at room temperature, 
the organic layer was washed with saturated NaHCO3 solution, water and brine and dried 
over Na2SO4. The solvent was removed in vacuo and the crude product was purified by flash 
chromatography (PE/EtOAc 60/40 v/v) yielding a colorless foam-like solid (13.6 g, 88 %). 1H-
NMR (300 MHz, CDCl3): δ [ppm] = 1.46 (s, 9H, C(CH3)3), 1.84 – 1.98 (m, 2H, Im-4-CH2-CH2), 
2.59 (t, 2H, 3J = 7.5 Hz, Im-4-CH2), 3.43 (t, 2H, 3J = 7.2 Hz, Im-4-(CH2)2-CH2), 5.13 (s, 2H, 
PhCH2), 6.54 (d, 1H, 4J = 1.2 Hz, Im-5-H), 7.08 – 7.17 (m, 6H, Ph-H), 7.24 – 7.43 (m, 15H, 
Ph-H + Im-2-H), 8.46 (brs, 1H, N-H), 11.36 (brs, 1H, N-H). 13C-NMR (75 MHz, CDCl3): δ 
[ppm] = 25.61 (-, CH2), 28.07 (+, CH3), 28.58 (-, CH2), 40.71 (-, Im-4-(CH2)2-CH2), 67.00 (-, 
PhCH2), 75.22 (Cquat, CPh3), 83.32 (Cquat, C(CH3)3), 118.10 (+, Im-C-5), 127.85 (+, 1 Ph-C), 
128.07 (+, 11 Ph-C), 128.42 (+, 2 Ph-C), 129.79 (+, 6 Ph-C), 137.07 (Cquat, 1 Ph-C-1), 138.50 
(+, Im-C-2), 140.30 (Cquat, Im-C-4), 142.46 (Cquat, 3 Ph-C-1), 153.11, 156.49, 163.65 (Cquat, 2 
C=O + C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 644 (100) [M + H]+. C39H41N5O4 
(643.77). 
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6.4.1.8 Preparation of the trityl protected imidazolylpropylguanidines 6.29, 6.30 
and 6.34 
General procedure 
A mixture of the pertinent diurethane-protected guanidine and catalytical amounts of Pd/C 
(10 %) in MeOH was stirred under a hydrogen atmosphere at room temperature for 
approximately 3 h (TLC control). After the Cbz-groups were quantitatively cleaved, the 
catalyst was removed by filtration over Celite and the solvent was evaporated. 
 
N-[3-(1-Trityl-1H-imidazol-4-yl)propyl]guanidine (6.29)3 
The title compound was prepared from 6.27 (7.0 g, 10.3 mmol) and Pd/C (10 %) (0.7 g, cat.) 
in MeOH (200 mL) according to the general procedure yielding a colorless foam-like solid 
(4.1 g, 97 %). 1H-NMR (300 MHz, CD3OD): δ [ppm] = 1.80 – 1.92 (m, 2H, Im-4-CH2-CH2), 
2.58 (t, 2H, 3J = 7.4 Hz, Im-4-CH2), 3.17 (t, 2H, 3J = 7.0 Hz, Im-4-(CH2)2-CH2), 6.70 (d, 1H, 4J 
= 1.3 Hz, Im-5-H), 7.10 – 7.19 (m, 6H, Ph-H), 7.33 – 7.43 (m, 10H, Im-2-H + Ph-H). 13C-NMR 
(75 MHz, CD3OD): δ [ppm] = 25.66 (-, Im-4-CH2), 29.76 (-, Im-4-CH2-CH2), 41.83 (-, Im-4-
(CH2)2-CH2), 76.87 (Cquat, CPh3), 119.93 (+, Im-C-5), 129.32 (+, 6 Ph-C), 128.42 (+, 3 Ph-C-
4), 130.90 (+, 6 Ph-C), 139.53 (+, Im-C-2), 141.21 (Cquat, Im-C-4), 143.75 (Cquat, 3 Ph-C-1), 
158.89 (Cquat, C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 410 (100) [M + H]+. C26H27N5 
(409.53). 
 
N1-(tert-Butoxycarbonyl)-N1-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (6.30) 
The title compound was prepared from 6.28 (5.6 g, 8.7 mmol) and Pd/C (10 %) (0.56 g, cat.) 
in MeOH (200 mL) according to the general procedure yielding a colorless foam-like solid 
(4.3 g, 97 %). 1H-NMR (300 MHz, CDCl3) isomers: δ [ppm] = 1.47 (s, 2.8H, CH3), 1.50 (s, 
6.2H, CH3), 1.80 – 2.04 (m, 2H, Im-4-CH2-CH2), 2.48 – 2.63 (m, 2H, Im-4-CH2), 3.34 (t, 0.6H, 
3J = 6.7 Hz, Im-4-(CH2)2-CH2), 3.85 (t, 1.4H, 3J = 7.7 Hz, Im-4-(CH2)2-CH2), 6.53 – 6.58 (d, 
1H, 4J = 1.3 Hz, Im-5-H), 7.07 – 7.16 (m, 6H, Ph-H), 7.28 – 7.39 (m, 10H, Ph-H + Im-2-H). 
ES-MS (DCM/MeOH + NH4OAc) m/z (%): 510 (100) [M + H]+. C31H35N5O2 (509.64). 
 
N1-(tert-Butoxycarbonyl)-N2-[3-(1-trityl-1H-imidazol-4-yl)propyl]guanidine (6.34) 
The title compound was prepared from 6.33 (13.5 g, 21.0 mmol) and Pd/C (10 %) (1.35 g, 
cat.) in MeOH (200 mL) according to the general procedure. Purification by flash 
chromatography yielded a colorless foam-like solid (10.6 g, 93 %). 1H-NMR (300 MHz, 
CDCl3): δ [ppm] = 1.47 (s, 9H, C(CH3)3), 1.80 – 1.93 (m, 2H, Im-4-CH2-CH2), 2.57 (t, 2H, 3J = 
6.1 Hz, Im-4-CH2), 3.35 (t, 2H, 3J = 6.7 Hz, Im-4-(CH2)2-CH2), 6.55 (d, 1H, 4J = 1.2 Hz, Im-5-
H), 7.07 – 7.16 (m, 6H, Ph-H), 7.30 – 7.38 (m, 10H, Ph-H + Im-2-H). 13C-NMR (75 MHz, 
CDCl3): δ [ppm] = 23.30 (-, CH2), 28.54 (+, CH3), 29.50 (-, CH2), 40.27 (-, Im-4-(CH2)2-CH2), 
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75.28 (Cquat, CPh3), 77.60 (Cquat, C(CH3)3), 118.31 (+, Im-C-5), 128.11 (+, 9 Ph-C), 129.76 (+, 
6 Ph-C), 138.06 (+, Im-C-2), 140.48 (Cquat, Im-C-4), 142.38 (Cquat, 3 Ph-C-1), 162.56, 163.98 
(Cquat, C=O + C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 510 (100) [M + H]+. HRMS 
(EI-MS) calcd. for C31H35N5O2 [M+•] 509.2791; found 509.2786. Anal. (C31H35N5O2 · 0.5 H2O) 
C, H, N. C31H35N5O2 (509.64). 
 
6.4.1.9 Preparation of the guanidinylation reagents 6.35-6.38 
N1,N2-Bis(benzyloxycarbonyl)guanidine (6.35)12 
For the preparation of 6.35 see section 4.4.1.6 (compound 4.28). 
 
N1-(tert-Butoxycarbonyl)guanidine (6.36)28 
For the preparation of 6.36 see section 4.4.1.6 (compound 4.26). 
 
N1-(Benzyloxycarbonyl)-N2-(tert-butoxycarbonyl)guanidine (6.37) 
For the preparation of 6.37 see section 4.4.1.6 (compound 4.27). 
 
N1-Benzyloxycarbonyl-N2-(tert-butoxycarbonyl)-N3-trifluoromethanesulfonylguanidine 
(6.38)  
To a solution of 6.37 (10.0 g, 34.1 mmol) in anhydrous chlorobenzene (250 mL) NaH (60 % 
dispersion in mineral oil) (2.73 g, 68.2 mmol) was added in portions at 0 °C (argon 
atmosphere). After stirring for 1 h at 0 °C, the mixture was cooled to –45 °C and 
trifluoromethanesulfonic anhydride (5.7 mL, 9.62 g, 34.1 mmol) was added. The mixture was 
allowed to warm to ambient temperature and stirred overnight. After evaporation of the 
solvent, a 2 M solution of KHSO4 (60 mL) was added to the residue and extracted with 
EtOAc (250 mL). The organic layer was washed with H2O and brine, dried over MgSO4 and 
removed in vacuo. Purification was performed by flash chromatography (PE/EtOAc 80/20 
v/v) yielding a colorless semisolid compound (10.9 g, 75 %). 1H-NMR (600 MHz, DMSO-d6): 
δ [ppm] = 1.45 (s, 9H, CH3), 5.22 (s, 2H, CH2), 7.33 – 7.47 (m, 5H, Ph-H), 11.13 (brs, 1H, N-
H), 11.42 (brs, 1H, N-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 27.40 (+, CH3), 67.74 (-, 
CH2), 83.37 (Cquat, C(CH3)3), 118.99 (Cquat, 1J = 320.6 Hz, CF3), 128.21 (+, 2 Ph-C), 128.38 
(+, Ph-C), 128.41 (+, 2 Ph-C), 134.97 (Cquat, Ph-C), 149.85, 151.46, 152.12 (Cquat, 2 C=O + 
C=N). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 443 (100) [M + NH4]+, 426 (78) [M + H]+. 
C15H18F3N3O6S (425.38). 
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6.4.1.10 Preparation of methyl 3-(methylamino)propanoate 6.41 
Methyl 3-(methylamino)propanoate (6.41)13 
To a solution of 3-(methylamino)propanenitrile (3.36 g, 40.0 mmol) in anhydrous MeOH (40 
mL), Na2SO4 (1.0 g) was added. HCl gas was bubbled through the solution for 5 h. After 
concentration of the solvent to approximately 20 mL, the residue was cooled to – 78 °C and 
filtered to remove precipitated NH4Cl. The filtrate was evaporated to dryness yielding a pale 
yellow oil that was used without further purification (2.8 g, 60 %). 1H-NMR (300 MHz, D2O): δ 
[ppm] = 2.62 (s, 3H, NHCH3), 2.73 (t, 2H, 3J = 6.5 Hz, CH2CO), 3.20 (t, 2H, 3J = 6.5 Hz, 
NHCH2), 3.61 (s, 3H, OCH3). 13C-NMR (75 MHz, D2O): δ [ppm] = 30.04 (-, CH2CO), 33.04 (+, 
NHCH3), 44.38 (-, NHCH2), 52.65 (+, OCH3), 172.88 (Cquat, C=O). CI-MS (NH3) m/z (%): 118 
(100) [M + H]+. C5H11NO2 · HCl (153.61). 
 
6.4.1.11 Preparation of the methyl esters 6.43-6.46  
General procedure 
To a solution of 1H-indole-2-carboxylic acid (1 eq) and the methyl ester of the amino acid 
(hydrochloride) (1.2 eq) in DCM, EDC · HCl (1.2 eq) and DMAP (1.6 eq) were added at 0 °C. 
After stirring for 4 h at 0 °C, the solution was allowed to warm to ambient temperature and 
stirred for additional 20 h. The organic layer was washed with H2O and 10 % HCl, dried over 
Na2SO4 and evaporated in vacuo. 
 
Methyl 2-(1H-indole-2-carbonylamino)acetate (6.43) 
The title compound was prepared from 1H-indole-2-carboxylic acid (1.61 g, 10.0 mmol), 
methyl 2-aminoacetate · HCl (1.51 g, 12.0 mmol), EDC · HCl (2.30 g, 12.0 mmol) and DMAP 
(1.95 g, 16.0 mmol) in DCM (100 mL) according to the general procedure. Recrystallization 
from MeOH yielded a white solid (1.7 g, 73 %); mp 209 – 211 °C (dec.). 1H-NMR (300 MHz, 
DMSO-d6): δ [ppm] = 3.67 (s, 3H, CH3), 4.06 (d, 2H, 3J = 6.0 Hz, CH2), 7.04 (ddd, 1H, 3J = 
8.0 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-5-H), 7.16 (dd, 1H, 4J = 2.0 Hz, 4J = 1.0 Hz, indole-3-
H), 7.19 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.0 Hz, 4J = 1.1 Hz, indole-6-H), 7.44 (ddd, 1H, 3J = 8.2 
Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, indole-7-H), 7.63 (ddd, 1H, 3J = 8.0 Hz, 4J = 2.0 Hz, 4J = 1.1 Hz, 
indole-4-H), 8.96 (t, 1H, 3J = 6.0 Hz, CONH), 11.63 (brs, 1H, indole-N-H). 13C-NMR (75 MHz, 
DMSO-d6): δ [ppm] = 40.72 (+, CH3), 51.72 (-, CH2), 102.92 (+, indole-C-3), 112.26 (+, 
indole-C-7), 119.72 (+, indole-C-5), 121.54 (+, indole-C-4), 123.42 (+, indole-C-6), 126.93 
(Cquat, indole-C-3), 130.93 (Cquat, indole-C-2), 136.43 (Cquat, indole-C-7), 161.45 (Cquat, indole-
2-CO), 170.37 (Cquat, COOCH3). EI-MS (70 eV) m/z (%): 232 (100) [M+•]. Anal. (C12H12N2O3) 
C, H, N. C12H12N2O3 (232.24). 
 
NG-Acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists 237
Methyl 3-(1H-indole-2-carboxamido)propanoate (6.44) 
The title compound was prepared from 1H-indole-2-carboxylic acid (0.81 g, 5.0 mmol), 
methyl 3-aminopropanoate · HCl (0.84 g, 6.0 mmol), EDC · HCl (1.15 g, 6.0 mmol) and 
DMAP (0.98 g, 8.0 mmol) in DCM (50 mL) according to the general procedure. 
Recrystallization from MeOH yielded a white solid (0.78 g, 63 %); mp 148 – 150 °C. 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 2.62 (t, 2H, 3J = 7.0 Hz, CH2CO), 3.48 – 3.57 (m, 2H, 
NHCH2), 3.62 (s, 3H, CH3), 7.02 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-5-H), 
7.09 (dd, 1H, 4J = 2.1 Hz, 4J = 0.9 Hz, indole-3-H), 7.17 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.0 Hz, 4J 
= 1.1 Hz, indole-6-H), 7.42 (ddd, 1H, 3J = 8.2 Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, indole-7-H), 7.60 
(ddd, 1H, 3J = 8.0 Hz, 4J = 2.1 Hz, 4J = 1.1 Hz, indole-4-H), 8.59 (t, 1H, 3J = 5.6 Hz, CONH), 
11.59 (brs, 1H, indole-N-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 33.61 (-, CH2), 35.03 (-
, CH2), 51.35 (+, CH3), 102.40 (+, indole-C-3), 112.19 (+, indole-C-7), 119.61 (+, indole-C-5), 
121.39 (+, indole-C-4), 123.18 (+, indole-C-6), 126.94 (Cquat, indole-C-3), 131.45 (Cquat, 
indole-C-2), 136.29 (Cquat, indole-C-7), 161.10 (Cquat, indole-2-CO), 171.68 (Cquat, COOCH3). 
CI-MS (NH3) m/z (%): 247 (100) [M + H]+. Anal. (C13H14N2O3) C, H, N. C13H14N2O3 (246.26). 
 
Methyl 3-(N-methyl-1H-indole-2-carbonylamino)propanoate (6.45) 
The title compound was prepared from 1H-indole-2-carboxylic acid (1.61 g, 10.0 mmol), 
6.41 · HCl (1.84 g, 12.0 mmol), EDC · HCl (2.30 g, 12.0 mmol) and DMAP (1.95 g, 16.0 
mmol) in DCM (100 mL) according to the general procedure. Recrystallization from MeOH 
yielded a white solid (1.24 g, 73 %); mp 119 – 121 °C. 1H-NMR (300 MHz, DMSO-d6): δ 
[ppm] = 2.70 (t, 2H, 3J = 7.2 Hz, CH2CO), 3.28 (brs, 3H, NCH3), 3.61 (s, 3H, COOCH3), 3.78 
(brs, 2H, NCH2), 6.87 (s, 1H, indole-3-H), 7.04 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.1 Hz, 
indole-5-H), 7.19 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-6-H), 7.43 (ddd, 1H, 
3J = 8.2 Hz, 4J = 1.9 Hz, 4J = 1.1 Hz, indole-7-H), 7.60 (ddd, 1H, 3J = 8.0 Hz, 4J = 1.9 Hz, 4J = 
1.0 Hz, indole-4-H), 11.56 (brs, 1H, indole-N-H). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 
31.85 (-, CH2CO), 37.07 (+, NCH3), 44.78 (-, NCH2), 51.44 (+, OCH3), 104.74 (+, indole-C-3), 
111.98 (+, indole-C-7), 119.59 (+, indole-C-5), 121.40 (+, indole-C-4), 123.26 (+, indole-C-6), 
126.92 (Cquat, indole-C-3), 129.91 (Cquat, indole-C-2), 135.68 (Cquat, indole-C-7), 162.48 (Cquat, 
indole-2-CO), 171.61 (Cquat, COOCH3). CI-MS (NH3) m/z (%): 261 (100) [M + H]+. Anal 
(C14H16N2O3) C, H, N. C14H16N2O3 (260.29). 
 
Methyl 4-(1H-indole-2-carbonylamino)butanoate (6.46) 
The title compound was prepared from 1H-indole-2-carboxylic acid (1.61 g, 10.0 mmol), 
methyl 4-aminobutanoate · HCl (1.84 g, 12.0 mmol), EDC · HCl (2.30 g, 12.0 mmol) and 
DMAP (1.95 g, 16.0 mmol) in DCM (100 mL) according to the general procedure. 
Recrystallization from MeOH yielded a white solid (1.63 g, 63 %); mp 140 – 141 °C. 1H-NMR 
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(300 MHz, DMSO-d6): δ [ppm] = 1.74 – 1.87 (m, 2H, CH2CH2CO), 2.39 (t, 2H, 3J = 7.4 Hz, 
CH2CO), 3.26 – 3.36 (m, 2H, NHCH2), 3.62 (s, 3H, CH3), 7.02 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 
Hz, 4J = 1.1 Hz, indole-5-H), 7.10 (dd, 1H, 4J = 2.0 Hz, 4J = 0.9 Hz, indole-3-H), 7.17 (ddd, 
1H, 3J = 8.2 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-6-H), 7.42 (ddd, 1H, 3J = 8.2 Hz, 4J = 1.9 Hz, 
4J = 1.1 Hz, indole-7-H), 7.60 (ddd, 1H, 3J = 8.0 Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, indole-4-H), 
8.49 (t, 1H, 3J = 5.7 Hz, CONH), 11.55 (brs, 1H, indole-N-H). 13C-NMR (75 MHz, DMSO-d6): 
δ [ppm] = 24.54 (-, CH2CH2CO), 30.66 (-, CH2CO), 37.98 (-, NHCH2), 51.19 (+, CH3), 102.19 
(+, indole-C-3), 112.18 (+, indole-C-7), 119.56 (+, indole-C-5), 121.34 (+, indole-C-4), 123.08 
(+, indole-C-6), 126.99 (Cquat, indole-C-3), 131.67 (Cquat, indole-C-2), 136.27 (Cquat, indole-C-
7), 161.05 (Cquat, indole-2-CO), 173.05 (Cquat, COOCH3). CI-MS (NH3) m/z (%): 261 (100) [M 
+ H]+. Anal. (C14H16N2O3) C, H, N. C14H16N2O3 (260.29).   
 
6.4.1.12 Preparation of the carboxylic acids 6.47-6.50 
General procedure 
A solution of the pertinent methyl ester (1 eq) and LiOH · H2O (2 eq) in EtOH was stirred for 
20 h at ambient temperature. The solvent was removed in vacuo, the residue taken up in 
H2O and adjusted to pH = 2 with concentrated HCl. After extraction of the precipitated 
product with EtOAc, washing with H2O and drying over Na2SO4, the solvent was evaporated 
giving the respective carboxylic acid. 
 
2-(1H-Indole-2-carbonylamino)acetic acid (6.47)  
The title product was prepared from 6.43 (1.65 g, 7.1 mmol) and LiOH · H2O (0.60 g, 14.2 
mmol) in EtOH (80 mL) according to the general procedure. Extraction with EtOAc (3 x 
80 mL). Recrystallization from MeOH yielded a white solid (0.76 g, 49 %); mp 220 – 222 °C 
(dec.) (ref.29: 158 – 159 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 3.97 (d, 2H, 3J = 6.0 
Hz, CH2), 7.04 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-5-H), 7.15 (dd, 1H, 4J = 
2.0 Hz, 4J = 0.9 Hz, indole-3-H), 7.19 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-6-
H), 7.44 (ddd, 1H, 3J = 8.2 Hz, 4J = 1.9 Hz, 4J = 1.0 Hz, indole-7-H), 7.63 (ddd, 1H, 3J = 8.0 
Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, indole-4-H), 8.84 (t, 1H, 3J = 6.0 Hz, CONH), 11.61 (brs, 1H, 
indole-N-H), 12.65 (brs, 1H, COOH). 13C-NMR (75 MHz, DMSO-d6): δ [ppm] = 40.72 (-, CH2), 
102.75 (+, indole-C-3), 112.24 (+, indole-C-7), 119.67 (+, indole-C-5), 121.49 (+, indole-C-4), 
123.32 (+, indole-C-6), 126.96 (Cquat, indole-C-3), 131.16 (Cquat, indole-C-2), 136.40 (Cquat, 
indole-C-7), 161.35 (Cquat, indole-2-CO), 171.30 (Cquat, COOH). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 219 (100) [M + H]+. Anal. (C11H10N2O3) C, H, N. C11H10N2O3 (218.21). 
 
 
 
NG-Acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists 239
3-(1H-Indole-2-carbonylamino)propanoic acid (6.48) 
The title product was prepared from 6.44 (0.76 g, 3.1 mmol) and LiOH · H2O (0.26 g, 6.2 
mmol) in EtOH (100 mL) according to the general procedure. Extraction with EtOAc (3 x 50 
mL). Recrystallization from MeOH yielded a white solid (0.54 g, 75 %); mp 163 – 164 °C. 
(ref.30: 163 – 165 °C). 1H-NMR (300 MHz, DMSO-d6): δ [ppm] = 2.55 (t, 2H, 3J = 7.0 Hz, 
CH2CO), 3.44 – 3.55 (m, 2H, NHCH2), 7.02 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, 
indole-5-H), 7.10 (dd, 1H, 4J = 2.1 Hz, 4J = 0.9 Hz, indole-3-H), 7.17 (ddd, 1H, 3J = 8.2 Hz, 3J 
= 7.0 Hz, 4J = 1.1 Hz, indole-6-H), 7.42 (ddd, 1H, 3J = 8.2 Hz, 4J = 1.9 Hz, 4J = 1.0 Hz, indole-
7-H), 7.60 (ddd, 1H, 3J = 8.0 Hz, 4J = 2.1 Hz, 4J = 1.1 Hz, indole-4-H), 8.55 (t, 1H, 3J = 5.6 
Hz, CONH), 11.57 (brs, 1H, indole-N-H), 12.28 (brs, 1H, COOH). 13C-NMR (75 MHz, DMSO-
d6): δ [ppm] = 33.81 (-, CH2), 35.11 (-, CH2), 102.37 (+, indole-C-3), 112.19 (+, indole-C-7), 
119.60 (+, indole-C-5), 121.38 (+, indole-C-4), 123.16 (+, indole-C-6), 126.96 (Cquat, indole-C-
3), 131.54 (Cquat, indole-C-2), 136.28 (Cquat, indole-C-7), 161.06 (Cquat, indole-2-CO), 172.81 
(Cquat, COOH). CI-MS (NH3) m/z (%): 233 (100) [M + H]+. Anal. (C12H12N2O3) C, H, N. 
C12H12N2O3 (232.24). 
 
Methyl 3-(N-methyl-1H-indole-2-carbonylamino)propanoate (6.49) 
The title product was prepared from 6.45 (1.17 g, 4.5 mmol) and LiOH · H2O (0.38 g, 9.0 
mmol) in EtOH (80 mL) according to the general procedure. Extraction with EtOAc (3 x 60 
mL). Evaporation of the solvent gave a white solid (1.0 g, 90 %); mp 155 – 157 °C. 1H-NMR 
(300 MHz, DMSO-d6): δ [ppm] = 2.55 – 2.72 (m, 2H, CH2CO), 3.36 (brs, 3H, NCH3), 3.62 – 
3.95 (brs, 2H, NCH2), 6.86 (s, 1H, indole-3-H), 7.04 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 
1.0 Hz, indole-5-H), 7.19 (ddd, 1H, 3J = 8.2 Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-6-H), 7.43 
(ddd, 1H, 3J = 8.2 Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, indole-7-H), 7.60 (ddd, 1H, 3J = 8.0 Hz, 4J = 
1.9 Hz, 4J = 1.0 Hz, indole-4-H), 11.56 (brs, 1H, indole-N-H), 12.39 (brs, 1H, COOH). 13C-
NMR (75 MHz, DMSO-d6): δ [ppm] = 32.36 (-, CH2CO), 37.85 (+, NCH3), 44.85 (-, NCH2), 
104.79 (+, indole-C-3), 111.98 (+, indole-C-7), 119.58 (+, indole-C-5), 121.39 (+, indole-C-4), 
123.24 (+, indole-C-6), 126.93 (Cquat, indole-C-3), 129.99 (Cquat, indole-C-2), 135.67 (Cquat, 
indole-C-7), 162.44 (Cquat, indole-2-CO), 172.81 (Cquat, COOH). ES-MS (DCM/MeOH + 
NH4OAc) m/z (%): 247 (100) [M + H]+. Anal. (C14H16N2O3) C, H, N. C14H16N2O3 (260.29). 
 
4-(1H-Indole-2-carbonylamino)butanoic acid (6.50) 
The title product was prepared from 6.46 (1.5 g, 5.8 mmol) and LiOH · H2O (0.49 g, 11.6 
mmol) in EtOH (100 mL) according to the general procedure. Extraction with EtOAc (3 x 80 
mL). Recrystallization from MeOH yielded a white solid (0.78 g, 58 %); mp 148 – 150 °C. 1H-
NMR (300 MHz, DMSO-d6): δ [ppm] = 1.70 – 1.85 (m, 2H, CH2CH2CO) 2.30 (t, 2H, 3J = 7.4 
Hz, CH2CO), 3.25 – 3.36 (m, 2H, NHCH2), 7.02 (ddd, 1H, 3J = 8.0 Hz, 3J = 7.0 Hz, 4J = 1.1 
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Hz, indole-5-H), 7.11 (dd, 1H, 4J = 2.0 Hz, 4J = 0.9 Hz, indole-3-H), 7.17 (ddd, 1H, 3J = 8.2 
Hz, 3J = 7.0 Hz, 4J = 1.0 Hz, indole-6-H), 7.42 (ddd, 1H, 3J = 8.2 Hz, 4J = 1.9 Hz, 4J = 1.1 Hz, 
indole-7-H), 7.60 (ddd, 1H, 3J = 8.0 Hz, 4J = 2.0 Hz, 4J = 1.0 Hz, indole-4-H), 8.50 (t, 1H, 3J = 
5.7 Hz, CONH), 11.55 (brs, 1H, indole-N-H), 12.17 (brs, 1H, COOH). 13C-NMR (75 MHz, 
DMSO-d6): δ [ppm] = 24.61 (-, CH2CH2CO), 31.07 (-, CH2CO), 38.14 (-, NHCH2), 102.20 (+, 
indole-C-3), 112.18 (+, indole-C-7), 119.56 (+, indole-C-5), 121.33 (+, indole-C-4), 123.07 (+, 
indole-C-6), 127.00 (Cquat, indole-C-3), 131.72 (Cquat, indole-C-2), 136.27 (Cquat, indole-C-7), 
161.02 (Cquat, indole-2-CO), 174.19 (Cquat, COOH). ES-MS (DCM/MeOH + NH4OAc) m/z (%): 
247 (100) [M + H]+. Anal. (C13H14N2O3 · 0.1 H2O) C, H, N. C13H14N2O3 (246.26). 
 
6.4.2 Pharmacological methods 
6.4.2.1 Materials 
Histamine dihydrochloride was purchased from Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany). Thioperamide maleate was from Tocris Bioscience (Ellisville, USA). [γ-32P]GTP 
was synthesized according to a previously described method.31 [32P]Pi (8,500 – 9,100 
Ci/mmol orthophosphoric acid) was from PerkinElmer Life Sciences (Boston, MA). All 
unlabeled nucleotides, glycerol-3-phosphate dehydrogenase, triose phosphate isomerase, 
glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase were from Roche 
(Mannheim, Germany). 3-Phosphoglycerate kinase and L-α-glycerol phosphate was from 
Sigma. 
 
6.4.2.2 Steady-state GTPase activity assay 
See section 3.4.2.2. 
 
6.4.2.3 Histamine H1R assay on guinea pig ileum3 
See section 3.4.2.4. 
 
6.4.2.4 Histamine H2R assay on the isolated spontaneously beating guinea pig 
right atrium3 
See section 3.4.2.5. 
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Chapter 7 
 
Tritium-labeled N1-[3-(1H-imidazol-4-yl)propyl]-
N2-propionylguanidine ([3H]UR-PI294), a high 
affinity histamine H3 and H4 receptor 
radioligand 
 
7.1 Introduction 
To investigate the biological role of the human (h) H3R, and in particular that of the hH4R, 
selective agonists and antagonists as well as special ligands including radioligands are 
required as pharmacological tools. The NG-alkanoylimidazolylpropylguanidines described in 
Chapter 6 are high affinity hH3R antagonists (partial agonists) and highly potent full hH4R 
agonists, which belong to the most potent hH4R agonists described so far. For example, UR-
PI294 (7.1), bearing an NG-propionyl group (Figure 7.1), possesses more than 1000- and 
100-fold selectivity for the hH3,4Rs relative to the hH1R and hH2R, respectively. 
The propionyl group in UR-PI294 is 
of special interest, as it offers the 
possibility to introduce a 
commercially available tritiated 
propionyl residue. The resulting 
radioligand, [3H]UR-PI294 (7.10), 
may be a valuable pharmacological 
tool for the labeling of the hH3R and 
in particular of the hH4R. With 
respect to the hH3R, the low efficacy of UR-PI294 at this histamine receptor subtype may be 
of interest, because partial agonistic radioligands with low intrinsic activities have been 
shown to behave as antagonists.1-3 Therefore, [3H]UR-PI294 may complement the 
commercially available and preferably used full hH3R agonists [3H](R)-α-methylhistamine4 
and [3H]Nα-methylhistamine5, 6 (Figure 7.2) in pharmacological studies at the hH3R. 
 
Figure 7.1. The acylguanidine 7.1 (UR-PI294): structure 
and pharmacological profile at the four histamine 
receptors, determined in steady-state GTPase assays 
using membrane preparations of Sf9 cells expressing the 
respective human histamine receptor. Agonistic activity 
expressed as EC50; Emax = efficacy relative to histamine = 
1.00.
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Concerning the hH4R, only 
three radioligands have 
been reported: 
[3H]histamine,7-10 
[3H]JNJ 77771207, 11 and 
[125I]iodophenpropit (Figure 
7.2).7 The low specific 
activity (10 - 25 Ci/mmol),7, 9, 
11-14 of the commonly 
commercially available H4R 
radioligand [3H]histamine 
brings about low sensitivity and requires high concentrations of either the radioligand or the 
receptor protein. The use of iodinated compounds is compromised by potential chemical 
instability,15 the shorter half-life of 125I-labeled (59.4 days) compared to 3H-labeled ligands 
(12.4 years) and the need for special safety precautions (shielding) during preparation and 
handling. By contrast, tritium-labeled UR-PI294 is considered a valuable novel radioligand in 
particular for the hH4R. 
This study presents the synthesis and pharmacological characterization of [3H]UR-PI294, a 
new high-affinity hH3R and hH4R radioligand. 
 
7.2 Chemistry 
The radioligand 7.10 ([3H]UR-PI294) was prepared as depicted in Scheme 7.1. Acylation of 
Boc-guanidine 7.7 (c.f. Chapter 6)  with tritiated propionic acid was achieved by employing 
the commercially 
available reactive 
succinimidyl ester (7.8). 
Intermediate 7.9 was not 
isolated and directly 
deprotected under acidic 
conditions. After 
purification by HPLC, the 
designated radioligand 
7.10 ([3H]UR-PI294) was 
obtained in high 
radiochemical purity 
 
Figure 7.2. Structures of hH3R and hH4R ligands reported as 
radioligands.
 
Scheme 7.1. Synthesis of the radioligand [3H]UR-PI294 (7.10). 
Reagents and conditions: (i) NEt3, CHCl3, 16 h, rt; (ii) TFA 23 %, 
CHCl3, 5 h, rt.
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(97.8 %) with a specific activity of 41.8 Ci/mmol. The identity of the radioligand was 
confirmed by HPLC analysis of the labeled (7.10) and unlabeled (7.1) UR-PI294 by identical 
retention times (Figure 7.3). 
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Figure 7.3. Identity and purity control of [3H]UR-PI294 (7.10). A, radiochromatogram of the prepared 
radioligand [3H]UR-PI294 (7.10), c: 0.8 µM. B, UV (λ = 210 nm) chromatogram of unlabeled UR-PI294 
(7.1), c: 100 µM. Conditions: injection volume: 100 µL, gradient: 0.05 % TFA in MeCN (v/v) / 0.05 % 
TFA in H2O (v/v): 0 min: 5/95, 13 min: 11.5/88.5, 25 min: 95/5, 40 min: 95/5), flow: 0.8 mL/min. The 
minor difference in tR (13.68 vs. 13.93 min) results from the setup of UV and radiodetector in series. 
 
7.3 Results and discussion 
7.3.1 Saturation binding analysis of [3H]UR-PI294 at the hH3R and hH4R 
The specific binding of [3H]UR-PI294 to membranes of Sf9 insect cells co-expressing hH3R 
plus Giα2 plus Gβ1γ2 plus RGS4 (regulator of G-protein signaling 4) was saturable (Figure 7.4 
A). Up to a radioligand concentration of 5 nM, nonspecific binding, determined in the 
presence of thioperamide (10 µM) 
was low, amounting to 5 to 10 % of 
total binding. Specific binding versus 
[3H]UR-PI294 concentrations was 
best fitted by nonlinear regression to 
a one-site binding model (Figure 7.4 
A). The determined KD value of 1.1 
nM (Table 7.1) is consistent with the 
EC50 value determined in functional 
GTPase assays (EC50 = 1.6 nM, Figure 7.1) confirming that [3H]UR-PI294 acts as a high-
Table 7.1. Saturation binding parameters of [3H]UR-
PI294 at the hH3R and hH4R.a 
 
 KD Bmax 
 [nM] [pmol · mg protein-1] 
hH3R 1.1 ± 0.2 1.4 ± 0.3 
hH4R 5.1 ± 1.9 2.0 ± 0.1 
 
a Data are the means of five independent experiments 
each performed in duplicate. 
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affinity radioligand at the hH3R. The estimated Bmax value was 1.4 pmol per mg of membrane 
protein. Within the investigated concentration range, the Scatchard plot was linear, which is 
in agreement with the binding of [3H]UR-PI294 to a single binding site (Figure 7.4 B). 
Binding of [3H]UR-PI294 to the hH4R was determined in Sf9 insect cell membranes co-
expressing the hH4R-RGS19 fusion protein plus Giα2 plus Gβ1γ2. Nonspecific binding was 
determined in the presence of an excess of thioperamide (10 µM ). Similar to its binding to 
the hH3R, [3H]UR-PI294 bound specifically to the hH4R (Figure 7.4 C) in a saturable manner. 
Specific binding versus the concentration of [3H]UR-PI294 was best described by a one-site 
model and afforded a KD value of 5.1 nM (Table 7.1). This fits very well to the potency 
determined in the functional GTPase assay (EC50 = 3.0 nM, Figure 7.1). The calculated Bmax 
value of 2.0 pmol per mg membrane protein reveals similar expression levels of the hH3R 
and hH4R in the Sf9 insect cell membranes. The corresponding Scatchard plot of the ratio 
bound/free versus bound [3H]UR-PI294 revealed a straight line indicating that the radioligand 
binds to a single binding site (Figure 7.4 D). 
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Figure 7.4. Representative [3H]UR-PI294 saturation binding experiments in Sf9 insect cell membranes 
expressing the hH3R plus Giα2 plus Gβ1γ2 plus RGS4 (A, B) or the hH4R-RGS19 fusion protein plus Giα2 
plus Gβ1γ2 (C, D) performed in duplicate. Membranes were incubated with increasing concentrations of 
[3H]UR-PI294 as described in the Pharmacological methods section. Nonspecific binding was 
determined in the presence of 10 µmol/L of thioperamide. Specific binding is the difference between 
the total and nonspecific binding of [3H]UR-PI294 at a given concentration. A, C, data were best fitted 
by nonlinear regression to a one-site model. B, D, corresponding Scatchard plots of saturation binding 
data, best fitted by linear regression. 
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7.3.2 Analysis of the association and dissociation kinetic of [3H]UR-PI294 at the hH3R 
and hH4R 
Association and dissociation experiments were carried out with Sf9 insect cell membranes 
expressing the hH3R at a [3H]UR-PI294 concentration of 2 nM at 22 °C. As already observed 
for other hH3R radioligands,16, 17 the association and dissociation kinetics of [3H]UR-PI294 at 
the hH3R were very rapid (Figure 7.5 A). The specific binding of [3H]UR-PI294 achieved 
equilibrium after approximately 10 minutes corresponding to an association half-life (t½) of 1.4 
min. Displacement of [3H]UR-PI294 by thioperamide (10 µM) was complete within 20 min, 
indicating that [3H]UR-PI294 binds reversibly to the receptor (t½ = 3.2 min). The resulting 
association rate constant (kon) was 0.14 min-1 nM-1, and the dissociation rate constant (koff) 
was 0.21 min-1. The KD value calculated from the ratio of the koff and kon values (1.5 nM) is in 
very good agreement with the KD value determined from the saturation binding isotherms 
(Table 7.2).  
Due to the lower affinity of [3H]UR-PI294 for the hH4R, a concentration of 10 nM was 
employed for recording the association and dissociation rates of the radioligand at Sf9 insect 
cell membranes, expressing the hH4R-RGS19 fusion protein (22 °C). Compared to the hH3R, 
[3H]UR-PI294 showed remarkably slower association and dissociation kinetics at the hH4R 
(Figure 7.5 C, D). The specific binding of [3H]UR-PI294 reached equilibrium within 60 min. 
Association kinetics of [3H]UR-PI294 was almost 10 times slower compared to the hH3R (t½ = 
11.4 min). Likewise, the dissociation of [3H]UR-PI294 from the hH4R, initiated by 
thioperamide (10 µM), was slow, and not terminated after 1 h. The resulting kon for [3H]UR-
PI294 was 0.0027 min-1 nM-1 and the koff 0.033 min-1 yielding a KD value of 12 nM, which is 
consistent with the KD value from the saturation binding studies (Table 7.2). The rather slow 
association rate of the radioligand at the hH4R required an incubation period of the 
membranes with [3H]UR-PI294 of at least 60 min for saturation and competition experiments 
to ensure measurements at equilibrium. 
 
Table 7.2. Parameters of the kinetic analysis of [3H]UR-PI294 binding in Sf9 insect cell membranes 
expressing the hH3R plus Giα2 plus β1γ2 plus RGS4 or the hH4R-GAIP plus Giα2 plus β1γ2. 
 
a the dissociation constants taken from Table 7.1 determined in saturation binding experiments are listet for 
comparison. 
 kob 
t½ 
(association) 
kon koff 
t½ 
(dissociation) 
KD 
(kinetic) 
KD 
(saturation)a 
 [min-1] [min] [min-1·nM-1] [min-1] [min] [nM] [nM] 
hH3R 0.50 1.4 0.14 0.21 3.2 1.5 1.1 
hH4R 0.06 11.5 0.0027 0.033 20.7 12 5.1 
Chapter 7 250 
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
2.5
3.0
time (min)
bo
un
d 
[3
H
]-
U
R
-P
I2
94
(p
m
ol
 m
g-
1 )
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
2.5
time (min)
[3
H
]U
R
-P
I2
94
 b
ou
nd
(p
m
ol
 m
g-
1 )
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
2.5
time (min)
[3
H
]U
R
-P
I2
94
 b
ou
nd
(p
m
ol
 m
g-
1 )
0 10 20 30 40 50 60
0.0
0.5
1.0
1.5
2.0
2.5
time (min)
[3
H
]U
R
-P
I2
94
 b
ou
nd
(p
m
ol
 m
g-
1 )
A
B
C
D
hH3R
hH3R
hH4R
hH4R
bo
un
d 
[3
H
]-
U
R
-P
I2
94
(p
m
ol
 m
g-
1 )
[3
H
]U
R
-P
I2
94
 b
ou
nd
(p
m
ol
 m
g-
1 )
[3
H
]U
R
-P
I2
94
 b
ou
nd
(p
m
ol
 m
g-
1 )
[3
H
]U
R
-P
I2
94
 b
ou
nd
(p
m
ol
 m
g-
1 )
 
Figure 7.5. Specific binding kinetics of [3H]UR-PI294 to Sf9 insect cell membranes expressing the 
hH3R plus Giα2 plus Gβ1γ2 plus RGS4 (A, B) or the hH4R-RGS19 fusion protein plus Giα2 plus Gβ1γ2 (C, 
D) were measured as described under Pharmacological methods. A, C, association kinetics for 2 nM 
(A) and 10 nM (C) of [3H]UR-PI294, respectively. Nonspecific binding was determined for each time 
point in the presence of thioperamide (10 µM). Specific binding is the difference between the total 
[3H]UR-PI294 and nonspecific [3H]UR-PI294 binding for a given time point. Data were best fitted by 
nonlinear regression to a one-phase exponential association model. B, D, dissociation kinetics for 2 
nM (B) and 10 nM (D) of [3H]UR-PI294, respectively. Displacement of [3H]UR-PI294 was induced by 
thioperamide (10 µM). Nonspecific binding was determined by incubation of [3H]UR-PI294 for 60 min 
with the respective membrane in the presence of thioperamide (10 µM). Specific binding is the 
difference between the total and nonspecific [3H]UR-PI294 binding. Data were best fitted by nonlinear 
regression to a one-phase exponential decay model. All experiments were performed in duplicate at 
22 °C. 
 
7.3.3 Competition binding experiments of [3H]UR-PI294 with reference ligands 
at the hH3R and hH4R  
A number of standard ligands for the hH3R and hH4R were evaluated for their ability to inhibit 
specific binding of [3H]UR-PI294 to Sf9 insect cell membranes expressing the hH3R or hH4R-
RGS19 fusion protein. The resulting KI values were determined and compared with affinities 
reported from competition binding experiments using other radioligands for the hH3R and 
hH4R. All obtained competition curves were monophasic and best described by a one-site 
competition model. 
[3H]UR-PI294 was displaced from the hH3R by the H3R agonists histamine and (R)-α-
methylhistamine as well as by the H3R antagonists (inverse agonists) thioperamide and 
clobenpropit (Figure 7.6 A). All resulting KI values were in good agreement with reported KI 
values determined with established H3R radioligands (Table 7.3). 
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The H4R ligands histamine, thioperamide, clobenpropit and JNJ 7777120 inhibited specific 
binding of [3H]UR-PI294 to the hH4R in a concentration-dependent manner (Figure 7.6 B). As 
for the hH3R, the determined KI values for hH4R binding were in good agreement with KI 
values from literature (Table 7.3). 
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Figure 7.6. Competition of [3H]UR-PI294 binding by reference H3R and H4R ligands in Sf9 insect cell 
membranes expressing the hH3R plus Giα2 plus Gβ1γ2 plus RGS4 (A) or the hH4R-RGS19 fusion 
protein plus Giα2 plus Gβ1γ2 (B). [3H]UR-PI294 concentrations were 2 nM for membranes expressing 
the hH3R and 5 nM for membranes expressing the hH4R. Data were analyzed by nonlinear regression 
and best fitted to one-site (monophasic) competition curves. Data points shown are the mean of three 
independent experiments, each performed in duplicate. (HIS: histamine, THIO: thioperamide, CLO: 
clobenpropit, RAMH: (R)-α-methylhistamine, JNJ: JNJ 7777120). 
 
 
Table 7.3. KI values of reference H3R and H4R ligands from competition binding experiments using 
[3H]UR-PI294 in Sf9 insect cell membranes expressing the hH3R plus Giα2 plus Gβ1γ2 plus RGS4 or the 
hH4R-RGS19 fusion protein plus Giα2 plus Gβ1γ2 in comparison to KI values reported in literature. 
 
a Mean KI values determined in three independent experiments, each performed in duplicate. b ref.7, 18-
23 c ref.7, 12, 14, 21, 24-27 
 
 
 
hH3R hH4R 
KI KI KI KI compound 
[3H]UR-PI294a reportedb [3H]UR-PI294a reportedc 
 [nM] [nM]  [nM] [nM] 
Histamine 11 ± 3.0 2.8 - 15  15.0 ± 2.0 8.1 ± 17 
(R)-α-Methyl-
histamine 
4.5 ± 1.1 0.56 - 6.3  - - 
Thioperamide 38 ± 2.0 25 - 76  45 ± 1.9 27 - 210 
Clobenpropit 0.46 ± 0.02 0.34 - 3.8  18 ± 2.2 7.2 - 13 
JNJ 7777120 - -  30 ± 3.8 4.0 - 32 
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7.3.4 Summary and conclusions 
Binding of [3H]UR-PI294 to Sf9 insect cell membranes expressing the hH3R or the hH4R-
RGS19 fusion protein was saturable and highly specific. [3H]UR-PI294 showed high affinities 
for both receptors. However, affinity for the hH3R was five times higher relative to the hH4R 
(KD = 1.1 nM (hH3R), KD = 5.1 nM (hH4R)). The saturation binding curves were best 
described by a one-site model and the Scatchard plots appeared to be linear, suggesting 
[3H]UR-PI294 to bind to a single binding site both at membranes expressing the hH3R and 
the hH4R, respectively. Kinetic experiments showed a rapid association and dissociation of 
the radioligand from the hH3R, whereas these processes were about 10 times slower for the 
hH4R. The resulting dissociation constants agreed very well with the KD values obtained from 
the saturation binding studies for both histamine receptor subtypes. Binding constants 
determined for H3R and H4R reference ligands were consistent with data reported in 
literature, confirming [3H]UR-PI294 to be a suitable radioligand for the determination of 
affinities of unlabeled H3R and H4R ligands. 
Due to the lack of selectivity between the hH3R and hH4R, the radioligand is primarily 
valuable for application in recombinant systems expressing only one histamine receptor 
subtype. However, in most immune cells such as mast cells or eosinophils, where the H4R is 
mainly located, H3Rs are not expressed.28-30 Therefore, due to the more than 100-fold 
selectivity over the hH1R and hH2R subtypes, [3H]UR-PI294 may also be applicable for 
labeling the hH4R in these native cells devoid of hH3Rs. 
Taken together, [3H]UR-PI294 is a new highly potent acylguanidine-type radioligand for both 
the hH3R and hH4R. The facile preparation and rather low costs employing commercially 
available tritiated succinimidyl propionate make [3H]UR-PI294 readily accessible under 
common laboratory conditions. The low efficacy of [3H]UR-PI294 at the hH3R may result in 
similar affinities for both the high-affinity and low-affinity binding site of the receptor. Such 
radioligands are required for studying constitutive activity of GPCRs.31 Therefore, [3H]UR-
PI294 may be a promising tool for investigating constitutive activity of the hH3R. The high 
specific activity of [3H]UR-PI294 (41.8 Ci/mmol) compared to commonly available 
[3H]histamine combined with high affinity and low nonspecific binding at the hH4R evidence 
this radioligand in particular as promising pharmacological probe for the hH4R, which is a 
promising new target, for instance, for the development of anti-inflammatory drugs.28 
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7.4 Experimental section 
7.4.1 Synthesis 
7.4.1.1 General conditions 
Commercial reagents and chemicals were purchased from Acros Organics (Geel, Belgium), 
Merck KGaA (Darmstadt, Germany), Sigma-Aldrich Chemie GmbH (Munich, Germany) and 
used without further purification. Succinimidyl [2,3-3H2]propionate solution in ethyl acetate (60 
Ci/mmol, 5 mCi/mL) was from Biotrend, American Radiolabeled Chemicals, Inc. (St. Louis, 
MO, USA). All solvents were of analytical grade or distilled prior to use. Scintillation cocktail 
was from Carl Roth GmbH (Rotiszint eco plus, Karlsruhe, Germany). Analytical HPLC was 
performed on a system from Waters (Waters GmbH, Eschborn, Germany) equipped with a 
Waters pump control module, Waters 510 HPLC pump, a Waters 486 UV/VIS detector and a 
Packard radiomatic Flo-one beta series A-500 radiodetector. Stationary phase was an 
Agilent Scalar C18 (250 x 4.6 mm, 5 µm) column. The flow rate was 0.8 mL/min. As mobile 
phase gradients of MeCN/TFA 0.05 % (v/v) and H2O/TFA 0.05 % (v/v) were used. The 
absorbance was detected at 210 nm or the radioactivity was measured with the radiodetector 
by liquid scintillation counting. Radiochemical purity of [3H]UR-PI294 was calculated as the 
percentage peak area from the radiochromatogram. 
 
7.4.1.2 Preparation of N1-[3-(1H-imidazol-4-yl)propyl]-N2-[2,3-3H2]propionyl-
guanidine ([3H]UR-PI294, 7.10) 
To a solution of 7.7 (preparation c.f. Chapter 6, compound 6.34) (2.0 µmol, 1.02 mg, 40 eq) 
and NEt3 (4.0 µmol, 0.405 mg, 80 eq) in CHCl3 (300 µL), a solution of succinimidyl 
[2,3-3H2]propionate in ethyl acetate (600 µL, 50 nmol, 1 eq, 8.76 µg, 3 mCi) was added. The 
solvent was removed by a rotary evaporator and the residue taken up in CHCl3 (100 µL). 
After the mixture was stirred for 16 h at room temperature, TFA (30 µL) was added and 
stirring was continued for additional 5 h. The solvent was removed under reduced pressure 
and the residue taken up in 500 µL of a mixture of MeCN/H2O/TFA 5/94.9/0.1 (v/v/v). 
Insoluble material was removed by centrifugation for 10 min at 13,000 rpm and aliquots (5 x 
100 µL) of the supernatant purified by HPLC. The fractions containing the radioligand were 
collected at approximately 14 min (gradient: 0.05 % TFA in MeCN/0.05 % TFA in H2O: 0 min: 
5/95 (v/v), 13 min: 11.5/88.5 (v/v), 25 min: 95/5 (v/v), 40 min: 95/5 (v/v)). The solvent of the 
combined fractions was evaporated and the residue was taken up in 450 µL of a mixture of 
EtOH/H2O 1/1 (v/v). The concentration of the radioligand in this stock solution was 
determined after recording a calibration curve with the unlabeled ligand UR-PI294 (HPLC, 
λ = 210 nm) from the peak area (11.89 µM, 5.35 nmol, yield: 10.7 %). The total activity of 
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[3H]UR-PI294 was determined by dilution of 1.5 µL of the stock solution with 448.5 µL 
MeCN/TFA (aq.) 0.1 % 5/95 (v/v) and counting 9 µL of this dilution (three times in duplicate) 
in 3 mL scintillation cocktail (total activity in 450 µL stock solution: 223.6 µCi). This results in 
a specific activity for [3H]UR-PI294 of 41.8 Ci/mmol. The activity concentration of the stock 
solution was adjusted to 250 µCi/mL with a mixture of EtOH/H2O 1/1 (v/v) (5.98 µM). HPLC 
analysis showed a radiochemical purity of 97.8 %. The identity of the radioligand was 
confirmed by HPLC analysis of the labeled and unlabeled UR-PI294 under same conditions 
resulting in nearly identical retention times (Figure 7.3). 
 
7.4.2 Pharmacological methods 
7.4.2.1 General 
Histamine dihydrochloride was purchased from Alfa Aesar GmbH & Co. KG (Karlsruhe, 
Germany). Thioperamide maleate, (R)-α-methylhistamine dihydrobromide and clobenpropit 
dihydrobromide were from Tocris Bioscience (Ellisville, MO, USA). The H4R antagonist JNJ 
7777120 was a gift from Dr. R. Thurmond (Department of Immunology, Johnson & Johnson 
Pharmaceutical R&D, San Diego, CA, USA). GF/C filters were from Whatman (Maidstone, 
UK). Radioactivity was determined by liquid scintillation counting in a Beckman LS-6500 
device. 
 
7.4.2.2 [3H]UR-PI294 binding assay 
Radioligand binding experiments were performed with a similar procedure described for the 
H1R and H2R by Seifert et al. and Kelley et al.32, 33 For [3H]UR-PI294 binding experiments Sf9 
insect cell membranes co-expressing the hH3R, mammalian Giα2, Gβ1γ2 and RGS4 or the 
hH4R-GAIP fusion protein, mammalian Giα2 and Gβ1γ2 were employed. The respective 
membranes were thawed and sedimented by a 10 min centrifugation at 4 °C and 13,000 g. 
Membranes were resuspended in binding buffer (12.5 mM MgCl2, 1 mM EDTA and 75 mM 
Tris/HCl, pH 7.4). Each tube (total volume 250 µL) contained 25 – 50 µg (hH3R) or 50 µg 
(hH4R) of membrane protein. Saturation binding experiments were performed in a 
concentration range from 0.125 – 20 nM (hH3R) and 0.5 – 50 nM (hH4R) of [3H]UR-PI294. 
Nonspecific binding was determined in the presence of 10 µM thioperamide. Competition 
binding experiments were performed with 2 nM [3H]UR-PI294 (hH3R) or 5 nM [3H]UR-PI294 
(hH4R) and increasing concentrations of unlabeled ligands. Incubations were conducted for 
60 min (hH3R) or 60 – 90 min (hH4R) at 22 °C and shaking at 250 rpm. Bound radioligand 
was separated from free radioligand by filtration through 0.3 % (m/v) polyethyleneimine-
pretreated GF/C filters followed by three washes with 2 mL of cold binding buffer (4 °C) using 
a Brandel Harvester. Pretreating the filter with polyethyleneimine reduced filter binding of 
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[3H]UR-PI294 to 0.14 %. Filter-bound radioactivity was determined after an equilibration 
phase of at least 12 h by liquid scintillation counting.  
 
7.4.2.3 [3H]UR-PI294 kinetic studies 
For the kinetic experiments the membranes were prepared as described for the [3H]UR-
PI294 binding assays. Tubes containing [3H]UR-PI294 at a concentration of 2 nM (hH3R) or 
10 nM (hH4R) and the respective hH3R or hH4R membrane at a concentration of 200 µg/mL 
(hH3R and hH4R) in binding buffer (12.5 mM MgCl2, 1 mM EDTA and 75 mM Tris/HCl, pH 
7.4) were employed. The reaction mixtures were agitated with a magnetic stir bar and 
incubated at ambient temperature (22 °C). Association kinetic experiments were started by 
addition of membrane suspension to the tube. At each time point 250 µL aliquots (50 µg 
membrane protein) were withdrawn from the tube. Nonspecific binding was determined for 
each time point in the presence of thioperamide (10 µM). Bound [3H]UR-PI294 was 
separated from free [3H]UR-PI294 by filtration through GF/C filters (pretreated with 0.3 % 
polyethyleneimine solution) using a Millipore 1225 vacuum sampling manifold followed by 
three washes with 2 mL binding buffer (4 °C). Filter-bound radioactivity was determined after 
an equilibration phase of at least 12 h by liquid scintillation counting. For the dissociation 
kinetics the tubes containing [3H]UR-PI294 and the respective membrane were incubated for 
60 min (hH3R) or 90 min (hH4R), respectively before starting dissociation by addition of 
thioperamide (10 µM final concentration). By analogy with the association kinetics, for each 
time point, a 250 µL aliquot was removed. Nonspecific binding was determined by incubation 
[3H]UR-PI294 for 60 min in the presence of thioperamide (10 µM). Bound [3H]UR-PI294 was 
measured as described for the association kinetics. 
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Chapter 8  
 
Summary 
 
In previous studies NG-acylated imidazolylpropylguanidines, originally developed as 
histamine H2 receptor (H2R) agonists with reduced basicity relative to guanidine-type H2R 
agonists, turned out to be also highly potent at the histamine H3 receptor (H3R) and histamine 
H4 receptor (H4R). Particularly at the H4R, the compounds showed high agonistic efficacies. 
This thesis aimed at the design, synthesis and pharmacological characterization of novel 
acylguanidine-type compounds and analogs to evaluate structure-activity relationships (SAR) 
at the histamine receptors (HRs) and to obtain HR subtype selective ligands. As the 
biological role of the recently discovered H4R is far from being understood, a major interest 
was the development of potent and selective H4R agonists as pharmacological tools. 
The prepared compounds were investigated for their pharmacological activities at the human 
(h) H1R, H2R, H3R and H4R in steady-state GTPase assays, employing membrane 
preparations of Sf9 insect cells expressing the distinct HR subtype. In addition, selected 
compounds were evaluated at the guinea pig (gp) ileum for H1R activity and at the guinea pig 
right atrium for H2R activity (in cooperation with Prof. Seifert (Medical School Hannover) and 
Prof. Elz (University of Regensburg)). 
In the first series of compounds the basic central group of the NG-acylated imidazolylpropyl-
guanidines was replaced with a non-basic cyanoguanidine moiety resulting in moderate 
partial agonists at the hH4R. As efforts to improve potency and efficacy by modifying the 
second alkyl substituent besides the imidazolylpropyl group were unsuccessful, the focus 
was turned on the carbon chain connecting the imidazole ring and the cyanoguanidine group. 
Elongation of the spacer length by one methylene group was the key step toward potent and 
selective hH4R agonists. Out of these cyanoguanidines, 2-cyano-1-[4-(1H-imidazol-4-
yl)butyl]-3-[(2-phenylthio)ethyl]guanidine (UR-PI376) was the most potent hH4R agonist 
(hH4R: EC50 = 34 nM, Emax = 0.93). Additionally, UR-PI376 showed a more than 25-fold 
selectivity over the hH3R in the GTPase assay and negligible activities at the hH1R and 
hH2R. In contrast to other reported selective H4R agonists, UR-PI376 exerted no agonistic 
activity at the other HR subtypes which makes this compound a promising pharmacological 
tool for studying the biological function of the hH4R. In addition, the carbamoylguanidine-type 
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compound 2-carbamoyl-1-[2-(1H-imidazol-4-yl)ethyl]-3-(3-phenylpropyl)guanidine (UR-PI97) 
was identified as highly potent hH3R inverse agonist (KB = 3.8 nM, Emax = -0.97) showing a 
more than 300-fold selectivity over the hH4R. 
The next series was focused on the imidazolylpropylguanidine portion of the acylguanidines. 
Minor structural modifications of this group essentially changed the pharmacological activities 
at the HR subtypes. For example, all performed modifications abolished hH4R agonistic 
activity, whereas introduction of a methyl group in position 5 of the imidazole ring remarkably 
improved efficacy at the hH3R. The study showed the imidazolylalkylguanidine part to be a 
promising structural motif for the development of HR ligands with new pharmacological 
profiles. 
Substitution of the 4-imidazolyl ring with isomers and other heterocycles was critical for the 
activity at all HRs. The most promising compounds in this series were the 1H-1,2,4-triazol-3-
yl analogs that showed (partial) agonistic activity at the hH2R and gpH2R and negligible 
activities at the other HR subtypes. This suggests the triazole ring to be promising 
bioisosteric imidazole replacement for the generation of new selective H2R agonists. 
Attaching small NG-alkanoyl residues to the imidazolylpropylguanidine moiety turned out to 
be favorable for hH4R activity. Potent (partial) hH4R agonists with up to 1000- and 100-fold 
selectivity relative to hH1R and hH2R, respectively, and only low efficacy at the hH3R were 
obtained. 
Due to the high potency of N1-[3-(1H-imidazol-4-yl)propyl]-N2-propionylguanidine at the hH3R 
and hH4R, this ligand was prepared as tritiated radioligand ([3H]UR-PI294). This readily 
available new radioligand specifically bound to the hH3R and hH4R with high affinities 
(KD (hH3R) = 1.1 nM, KD (hH4R) = 5.1 nM) and proved to be a valuable pharmacological tool 
for the determination of binding constants of H3R and H4R ligands. 
In conclusion, the structural modifications of NG-acylated imidazolylpropylguanidines yielded 
valuable information about SAR and structure-selectivity relationships and revealed new 
promising pharmacological tools for HR. The imidazolylbutylcyanoguanidines represent a 
new class of potent and selective hH4R agonists. Moreover, the carbamoylguanidine 
UR-PI97 was identified as a highly potent and selective hH3R inverse agonist. The 
synthesized NG-alkanoyl imidazolylpropylguanidines are among the most potent hH4R 
agonists and paved the way to the new high affinity hH3R and hH4R radioligand 
[3H]UR-PI294. 
 
Chapter 9  
Appendix 
 
9.1 Data analysis and pharmacological parameters 
All data are presented as mean of n independent experiments ± SEM. Agonist potencies 
were given as EC50 values (molar concentration of the agonist causing 50 % of the maximal 
response) or as pEC50 values (negative decadic logarithm of the EC50 value). pEC50 values 
obtained from the guinea pig right atrium were corrected according to the long term mean 
value of the reference agonist histamine in our laboratory (guinea pig atrium (gpH2R): pEC50 
= 6.00 for histamine). Maximal responses were expressed as Emax values. The Emax value of 
histamine was set to 1.00, Emax values of other compounds were referred to this value. 
IC50 values were converted to KI and KB values using the Cheng-Prussoff equation.1 KI 
values were analyzed by nonlinear regression and best fit to one-site (monophasic) 
competition curves. EC50/KB values from the functional GTPase assays were analyzed by 
nonlinear regression and best fit to sigmoidal dose-response curves (GraphPad Prism 4.02 
software, San Diego, CA). 
Antagonist potencies determined on isolated organs were expressed as apparent pA2. The 
apparent pA2 value was calculated according to following equation: pA2 = log (r – 1) – log [B], 
where [B] is the molar concentration of antagonist and r the ratio of agonist EC50 measured in 
the presence and absence of antagonist.2 Noncompetitive antagonists were characterized at 
the guinea pig ileum and atrium by estimation of a pD’2 value according to the equation: 
pD’2 = −log c(B) + log(100/Emax − 1).3  
Observed rate constants (kob) were analyzed by nonlinear regression and best fit to one-
phase exponential association curves. Dissociation constants (koff) were analyzed by 
nonlinear regression and best fit to one-phase exponential decay curves. (GraphPad Prism 
4.02 software, San Diego, CA, USA). kob is the observed association rate constant. 
Association rate constants (kon) were calculated according to following equation: kon = (kob – 
koff)/[radioligand].4 Dissociation constants (KD) from the kinetic experiments were calculated 
according to following equation: KD = koff/kon.4 
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9.2 Elemental analysis data 
calculated found 
No. formula 
C H N C H N 
3.11 C9H19N · HCl · 0.25 H2O 
59.32 11.34 7.69 59.64 11.25 7.93 
3.12 C8H11NS · HCl 50.65 6.38 7.38 50.49 6.36 7.30 
3.14 C9H12FN · HCl 57.00 6.91 7.39 56.96 6.95 7.26 
3.15 C8H12N2 · 2 C6H3N3O7 
40.41 3.05 18.85 40.42 3.15 19.20 
3.16 C8H12N2 · 2 C6H3N3O7 
40.41 3.05 18.85 40.23 2.91 19.08 
3.17 C8H12N2 · 2 C6H3N3O7 
40.41 3.05 18.85 40.37 2.91 19.19 
3.18 C10H15N · HCl 64.68 8.68 7.54 64.81 8.86 7.23 
3.24 C17H17N3O 73.10 6.13 15.04 73.02 6.07 15.12 
3.25 C16H15N3O 72.43 5.70 15.84 72.37 5.67 15.95 
3.26 C18H19N3O 73.69 6.53 14.32 73.41 6.57 14.25 
3.27 C23H21N3O 77.72 5.96 11.82 77.83 5.99 11.91 
3.28 C17H23N3O 71.55 8.12 14.72 71.56 7.95 14.89 
3.29 C16H15N3OS 64.62 5.08 14.13 64.57 5.07 14.16 
3.30 C18H16N4O 71.04 5.30 18.41 70.81 5.39 18.40 
3.31 C17H16FN3O 68.67 5.42 14.13 68.49 5.17 14.04 
3.32 C16H16N4O 68.55 5.75 19.99 68.51 5.69 20.29 
3.33 C16H16N4O 68.55 5.75 19.99 68.31 5.84 20.19 
3.34 C16H16N4O 68.55 5.75 19.99 68.32 5.43 20.39 
3.35 C18H19N3O 73.69 6.53 14.32 73.67 6.76 14.39 
3.36 C8H7N3O 59.62 4.38 26.07 59.68 4.34 26.32 
3.37 C9H9N3O 61.70 5.18 23.99 61.53 5.08 24.09 
3.38 C10H11N3O 63.48 5.86 22.21 63.37 5.82 22.35 
3.39 C11H13N3O 65.01 6.45 20.68 65.17 6.21 20.97 
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Elemental analysis data (continued) 
3.40 C12H15N3O 66.34 6.96 19.34 66.11 7.00 19.63 
3.41 C6H11N3 · 2 HCl 36.38 6.61 21.21 36.09 6.65 21.39 
3.42 C17H22N6 · 0.25 H2O 
64.84 7.20 26.69 64.93 7.50 26.85 
3.43 C16H20N6 · 0.7 C2H2O4 · 0.5 H2O 
56.73 6.13 22.81 56.97 6.45 22.50 
3.44 C18H24N6 · 0.85 C2H2O4 
59.01 6.46 20.96 58.98 6.81 21.30 
3.45 C23H26N6 · 0.25 H2O 
70.65 6.83 21.49 70.33 6.89 21.64 
3.46 C17H28N6 · 0.8 C2H2O4 
57.51 7.68 21.63 57.18 7.45 21.40 
3.47 C16H20N6S · 0.75 C2H2O4 · 0.25 H2O 
52.49 5.54 20.99 52.20 5.61 21.14 
3.48 C18H21N7 · C2H2O4 56.46 5.45 23.05 56.51 5.20 22.82 
3.52 C16H20N6 · 0.9 C2H2O4 · 0.25 H2O 
55.98 5.89 22.01 55.71 5.72 22.39 
3.53 C15H18N6 · 0.8 C2H2O4 · 0.25 H2O 
55.56 5.65 23.42 55.23 5.76 23.68 
3.54 C17H22N6 · C2H2O4 · 0.25 H2O 
56.36 6.10 20.75 56.28 6.05 20.93 
3.55 C22H24N6 · 0.25 H2O 
70.09 6.55 22.29 70.39 6.85 22.68 
3.56 C16H26N6 · C2H2O4 55.09 7.19 21.41 55.34 7.29 21.67 
3.57 C15H18N6S · C2H2O4 50.48 4.98 20.78 50.51 5.20 20.89 
3.58 C17H22N6 · 0.25 H2O 
62.65 6.03 30.09 62.58 6.31 29.91 
3.60 C7H13N3 · 2 HBr 27.93 5.02 13.96 27.83 5.24 13.81 
3.61 C18H24N6 · 0.9 C2H2O4 
58.65 6.41 20.73 58.73 6.64 20.83 
3.62 C17H22N6 · 0.75 C2H2O4 · 0.5 H2O 
57.45 6.08 21.95 57.43 6.38 21.72 
3.63 C19H26N6 · 0.85 C2H2O4 
59.91 6.73 20.25 59.71 6.90 20.44 
3.64 C24H28N6 · 0.25 H2O 
71.17 7.09 20.75 70.89 7.24 20.94 
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Elemental analysis data (continued) 
3.65 C18H30N6 · 0.8 C2H2O4 · 0.25 H2O 
57.84 7.95 20.65 58.20 8.27 20.45 
3.66 C17H22N6S · 0.75 C2H2O4 
54.20 5.78 20.50 53.94 6.16 20.75 
3.67 C19H23N7 · C2H2O4 57.39 5.73 22.31 56.50 6.37 21.57 
3.68 C18H23FN6 · C2H2O4 · H2O 
53.33 6.04 18.66 53.07 6.10 18.28 
3.69 C17H23N7 · 2 C2H2O4 · H2O 
48.18 5.58 18.73 48.30 5.92 18.49 
3.70 C17H23N7 · 2 C2H2O4 · 1.3 H2O 
47.69 5.64 18.54 47.94 5.95 18.14 
3.71 C17H23N7 · 2 C2H2O4 · 2 H2O 
46.58 5.77 18.11 46.97 5.94 17.92 
3.72 C19H26N6 · 0.85 C2H2O4 
59.91 6.73 20.25 59.58 7.04 20.39 
3.73 C9H14N6 · C2H2O4 · 0.1 H2O 
44.32 5.48 28.19 44.08 5.76 28.36 
3.74 C10H16N6 · C2H2O4 · 0.4 H2O 
45.39 5.97 26.47 45.66 6.22 26.28 
3.75 C11H18N6 · 0.75 C2H2O4 
49.74 6.51 27.84 49.79 6.87 27.64 
3.76 C12H20N6 · 0.75 C2H2O4 · 0.25 H2O 
50.61 6.92 26.23 50.26 7.17 26.16 
3.77 C13H22N6 · 0.75 C2H2O4 · 0.25 H2O 
52.08 7.23 25.13 51.88 7.60 25.47 
3.80 C18H24N6S · 0.85 C2H2O4 · 0.25 H2O 
54.08 6.04 19.21 53.76 6.21 19.58 
3.81 C24H28N6S · C2H2O4 · 0.5 H2O 
58.74 5.88 15.81 59.01 6.24 15.62 
3.83 C30H42N4O8 61.42 7.22 9.55 61.35 7.51 9.48 
3.88 C30H38N8O6 · 0.5 H2O 
58.52 6.38 18.20 58.65 6.58 18.36 
3.89 C22H24N6O2 · 0.25 H2O 
64.61 6.04 20.55 64.37 5.92 20.56 
3.90 C24H28N6O2 66.65 6.53 19.43 66.35 6.45 19.13 
3.91 C26H32N6O2 67.80 7.00 18.25 67.49 7.10 18.09 
3.105 C33H27N3O2 79.66 5.47 8.44 79.35 5.31 8.10 
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Elemental analysis data (continued) 
3.106 C25H25N3 · 0.5 H2O 79.75 6.96 11.16 80.15 6.67 11.06 
3.108 C14H15NO3 68.56 6.16 5.71 68.63 6.25 5.61 
3.109 C14H14BrNO3 51.87 4.35 4.32 51.86 4.38 4.32 
3.112 C9H6FN 73.46 4.11 9.52 73.41 3.92 9.57 
3.113 C9H8FN · 0.1 H2O 71.60 5.47 9.28 71.77 5.22 9.17 
3.116 C10H13N · HCl 65.39 7.68 7.63 65.39 7.82 7.38 
3.120 C16H14N2O2 · C6H3N3O7 
53.34 3.46 14.14 53.10 3.20 14.28 
3.121 C16H14N2O2 · C6H3N3O7 
53.34 3.46 14.14 53.24 3.12 14.42 
3.122 C16H14N2O2 · C6H3N3O7 
53.34 3.46 14.14 53.21 3.42 14.22 
4.7 C23H18N2O 81.63 5.36 8.28 81.56 5.25 8.18 
4.8 C24H20N2O 81.79 5.72 7.95 81.80 5.46 7.78 
4.9 C24H19N3O2 75.57 5.02 11.02 75.47 5.23 10.86 
4.10 C25H21N3O2 75.93 5.35 10.63 75.78 5.60 10.33 
4.11 C24H21N3O · 0.25 H2O 
77.50 5.83 11.30 77.80 5.91 10.98 
4.12 C25H23N3O · 0.75 H2O 
76.02 6.25 10.64 76.16 6.27 10.62 
4.15 C28H26N2O2 79.59 6.20 6.63 79.40 6.28 6.36 
4.16 C28H26N2O2 79.59 6.20 6.63 79.59 6.37 6.47 
4.17 C28H28N2O2 79.22 6.65 6.60 78.99 6.95 6.39 
4.18 C28H26N2O2 79.22 6.65 6.60 79.17 6.71 6.43 
4.19 C26H26N2O 81.64 6.85 7.32 81.46 6.93 7.34 
4.20 C26H26N2O 81.64 6.85 7.32 81.36 7.01 7.10 
4.21 C25H23ClN2 · HCl 70.92 5.71 6.62 70.85 5.87 6.54 
4.22 C26H23N3 82.73 6.14 11.13 82.68 6.19 10.94 
4.24 C26H25N3O 78.96 6.37 10.62 79.01 6.44 10.69 
4.26 C6H13N3O2 45.27 8.23 26.40 45.12 8.52 26.31 
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Elemental analysis data (continued) 
4.27 C14H19N3O4 57.33 6.53 14.33 57.06 6.80 14.29 
4.28 C17H17N3O4 62.38 5.23 12.84 62.40 5.57 13.03 
5.12 C25H24N2O 81.49 6.57 7.60 81.54 6.71 7.40 
5.14 C22H17IN2 60.56 3.93 6.42 60.49 3.92 6.41 
5.15 C25H20N2O · 0.25 H2O 
81.39 5.60 7.59 81.34 5.67 7.34 
5.16 C25H24N2O 81.49 6.57 7.60 81.31 6.80 7.70 
5.18 C21H17N3 81.00 5.50 13.49 80.60 5.68 13.46 
5.19 C22H17N3O 77.86 5.05 12.38 77.69 5.12 12.22 
5.20 
(E) C26H23N3O2 76.26 5.66 10.26 76.04 5.65 10.03 
5.20 
(Z) C26H23N3O2 76.26 5.66 10.26 76.08 5.97 10.03 
5.21 C26H25N3O2 75.89 6.12 10.21 75.98 5.95 10.11 
5.22 C24H23N3O 78.02 6.27 11.37 77.79 6.41 11.39 
5.39 C42H39N5O4 74.43 5.80 10.33 74.27 5.93 10.13 
5.40 C41H38N6O4 72.55 5.64 12.38 72.47 5.56 12.42 
5.46 C11H20N4O · 2 C6H3N3O7 
40.47 3.84 20.52 40.52 3.81 20.59 
5.50 C10H15N3 · C6H3N3O7 
47.29 4.46 20.68 47.01 4.38 20.65 
5.51 C9H14N4 · 2 C6H3N3O7 
39.63 3.17 22.01 39.46 2.83 22.40 
5.52 C9H14N4 · 2 C6H3N3O7 
39.63 3.17 22.01 39.45 2.81 22.41 
5.53 C9H14N4 · 2 C6H3N3O7 
39.63 3.17 22.01 39.36 2.79 22.30 
5.54 C7H13N5 · 2 C6H3N3O7 
36.49 3.06 24.64 36.51 2.84 24.81 
6.2 C7H13N5 · 2 HCl · 0.5 H2O 
33.75 6.47 28.46 33.36 6.72 28.52 
6.31 C33H27N3O2 79.66 5.47 8.44 79.35 5.31 8.10 
6.32 C25H25N3 · 0.5 H2O 79.75 6.96 11.16 80.15 6.67 11.06 
 
Appendix 267
Elemental analysis data (continued) 
 
6.34 C31H35N5O2 · 0.5 H2O 
71.79 7.00 13.50 71.72 6.95 13.44 
6.43 C12H12N2O3 62.06 5.21 12.06 62.09 5.03 12.09 
6.44 C13H14N2O3 63.40 5.73 11.38 63.45 5.87 11.30 
6.45 C14H16N2O3 64.60 6.20 10.76 64.64 6.46 11.04 
6.46 C14H16N2O3 64.60 6.20 10.76 64.67 6.16 10.68 
6.47 C11H10N2O3 60.55 4.62 12.84 60.34 4.72 12.83 
6.48 C12H12N2O3 62.06 5.21 12.06 61.87 5.56 11.95 
6.49 C14H16N2O3 63.40 5.73 11.38 63.25 5.90 11.23 
6.50 C13H14N2O3 · 0.1 H2O 
62.94 5.77 11.29 62.79 5.64 11.10 
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9.3 HPLC purity data 
No. tR (min) k' 
purity 
(%) No. tR (min) k' 
purity 
(%) 
3.49b 14.58 3.39 99.5 5.60e 19.82 4.97 97.0 
3.50b 16.10 3.85 99.7 5.61c 10.14 2.05 99.9 
3.59b 13.60 3.10 100 5.62c 15.04 3.53 98.7 
3.78b 14.73 3.44 99.6 5.63c 10.07 2.03 99.4 
3.92f 6.84 1.69 99.7 5.64c 14.82 3.46 96.5 
3.93f 10.61 3.18 98.1 5.65c 9.94 1.99 99.6 
3.94f 13.44 4.29 97.6 5.66c 14.60 3.40 99.8 
3.95f 16.43 5.47 94.4 5.67b 17.65 4.32 99.6 
3.102a 15.08 3.54 99.7 5.68b 17.12 4.16 99.2 
3.103b 15.42 3.64 97.8 5.69b 21.02 5.33 99.0 
4.63b 15.28 3.60 99.3 5.70b 17.68 4.33 99.8 
4.64b 14.48 3.36 99.7 5.71b 15.95 3.80 99.4 
4.65b 18.84 4.67 99.8 5.72b 19.32 4.82 98.9 
4.66b 16.31 3.91 99.8 5.81b 15.72 3.73 99.9 
4.67b 15.36 3.63 99.0 5.82b 15.17 3.57 98.4 
4.68b 19.72 4.94 99.9 5.83b 19.18 4.78 98.4 
4.69b 16.67 4.02 100 5.84b 16.15 3.86 100 
4.70b 16.58 3.99 99.8 5.85c 13.70 3.13 97.6 
4.71b 15.94 3.80 98.5 5.86c 18.74 4.64 94.3 
4.72b 19.78 4.96 100 5.87c 11.39 2.43 99.7 
4.73b 16.63 4.01 100 5.88c 16.67 4.02 96.4 
4.74b 16.59 4.00 100 6.15a 14.71 3.43 95.4 
4.75b 15.69 3.73 98.5 6.16a 16.23 3.89 99.8 
4.76b 19.79 4.96 99.6 6.17a 15.61 3.70 99.7 
4.77b 16.58 3.99 97.8 6.18b 14.44 3.35 98.7 
4.78a 16.64 4.01 99.7 6.19a 15.43 3.65 100 
4.79a 16.07 3.84 98.0 6.20a 16.52 3.98 99.1 
4.80a 20.63 5.21 99.2 6.21b 14.55 3.38 96.2 
4.81b 15.91 3.79 100 6.22d 6.12 0.84 100 
4.82b 15.20 3.58 99.7 6.23d 9.44 1.84 99.8 
4.83b 18.81 4.67 100 6.24d 14.18 3.27 99.9 
5.59e 14.23 3.29 98.1 6.25d 13.46 3.05 99.9 
a TSP-system, gradient mode: MeCN/0.05 % TFA (aq.): 0 min: 5/95, 25 min: 50/50, 30 min: 95/5, 35 
min: 95/5. b TSP-system, gradient mode: MeCN/0.05 % TFA (aq.): 0 min: 5/95, 25 min: 55/45, 30 min: 
90/10, 40 min: 90/10. c TSP-system, gradient mode: MeCN/0.05 % TFA (aq.): 0 min: 20/80, 25 min: 
55/45, 30 min: 90/10, 40 min: 90/10. d TSP-system, gradient mode: MeCN/0.05 % TFA (aq.): 0 min: 
5/95, 25 min: 20/80, 30 min: 90/10, 40 min: 90/10. e TSP-system, gradient mode: MeCN/0.05 % TFA 
(aq.): 0 min: 40/60, 25 min: 60/40, 30 min: 90/10, 40 min: 90/10. f Merck-Hitachi-system, gradient 
mode: 0.025 % TFA in MeCN/0.025 % TFA (aq.): 0 min: 20/80, 25 min: 65/35, 30 min: 90/10, 40 min: 
90/10. 
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9.5 Publications 
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